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Abstract 
 
Effective treatment for HIV has led to a reduction in AIDS-related morbidity and mortality.  
Consequently, other co-morbidities experienced by HIV-positive people may have a significant 
impact on their health.  Hepatitis B (HBV) and hepatitis C virus (HCV) are transmitted via the 
same routes as HIV, thus HIV-positive individuals are at risk of these infections.   
 
The UK Collaborative HIV Cohort (UK CHIC) study is an observational study of HIV-positive 
individuals attending for care at HIV centres in the UK.  This thesis takes a pragmatic approach 
to defining co-infection within HIV cohort studies using methods that could be implemented in 
other HIV cohorts where similar data are known to exist.  For those individuals defined as co-
infected at 11 centres, a new set of data was collected including information on liver disease 
progression and treatment for HBV and HCV. This novel dataset was used to examine the 
epidemiology of HIV and hepatitis co-infection and clinical outcomes of co-infected individuals. 
 
From 2004 to 2011, the proportion of individuals in this cohort who had been tested for HBV 
and/or HCV had increased.  The prevalence of HBV and HCV was 6.7% and 10.7%, respectively 
with ongoing incidence of both infections.  The majority of HIV/HBV co-infected individuals 
(86%) received HBV-active treatment, usually with more than 1 HBV-active drug, as 
recommended in clinical guidelines.  A smaller proportion (38%) had received treatment for 
HCV with 33% known to have failed treatment within one year.  The risk of liver-related death 
was 9.0 times higher among HIV/HBV co-infected individuals and 5.7 times higher among 
HIV/HCV co-infected individuals than among HIV mono-infected individuals.  Mortality rates 
were particularly high after the first liver decompensation event. 
 
Understanding the current burden of HIV and hepatitis co-infection and the clinical outcomes 
of co-infected individuals allows effective planning of services and monitoring of the impact of 
interventions. 
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Chapter 1 Introduction 
This thesis will focus on hepatitis B virus (HBV) and hepatitis C virus (HCV) infections among 
individuals who are human immunodeficiency virus (HIV) positive.  In this chapter I will give an 
overview of the features of these three infections, which are relevant to the research 
presented in subsequent chapters. I will also outline the aims of this thesis. 
 
1.1 HIV 
1.1.1 A brief history of the HIV epidemic 
The first reports of the disease which became known as Acquired Immunodeficiency Syndrome 
(AIDS) came from the USA in 1981.  Five previously healthy, young, gay men had been 
hospitalised with Pneumocystis carinii pneumonia (PCP) in California (1).  This was unusual 
since PCP is usually only observed in patients known to have severe immunosuppression.  
Further reports of PCP, as well as other conditions usually found only in immunocompromised 
patients, quickly followed (2, 3) and a case definition for AIDS was established in 1982 to allow 
surveillance (4).  At this stage, no etiologic agent had been identified for the syndrome but 
evidence was building that the condition was caused by an agent which was transmitted 
through heterosexual sex (5), sex between men (3), through blood and blood products (6, 7) 
and from mother to child (8).   
 
The viral cause of this syndrome, now known as human immunodeficiency virus (HIV), was 
identified in 1983 (9, 10). This significant advance allowed the development of diagnostic tests 
(11, 12).  These could be used to diagnose those presenting with immunodeficiency, to screen 
therapeutically used blood and blood products, to conduct high quality surveillance and to 
study the natural history of the disease which, in turn, could aid the development of 
treatment.  Since the first reports of unusual immunodeficiency in the USA, HIV has been 
reported in most countries in the world.  There are now an estimated 35.3 million people living 
with HIV-infection across the globe(13) and 39 million people have died from AIDS (14).  Sub-
Saharan Africa has experienced the highest number of HIV infections and deaths from AIDS 
(15).  
 
One of the most important changes in the epidemic occurred in 1995-1996 with the advent of 
highly active antiretroviral therapy (HAART) (described in detail in 1.1.4) (16).  At an 
international level, access to effective HIV treatment is improving and the number of people 
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dying from AIDS has fallen with 1.6 million AIDS deaths in 2012 compared to 2.3 million in 
2005 (13).  People with HIV may now be expected to live a near normal life-span if they are 
diagnosed early and receive treatment (17, 18).  
 
1.1.2 Epidemiology of HIV in the UK 
1.1.2.1 Prevalence of HIV in the UK 
In the UK, national estimates of HIV prevalence are made using a statistical model which 
incorporates data from HIV surveillance systems as well as survey data on risk behaviours (19).  
At the end of 2013, an estimated 107,800 people were living with HIV in the UK; a prevalence 
of 2 per 1000 population.  A quarter of people living with HIV in the UK are thought to be 
unaware of their infection (20).  Men who have sex with men (MSM) and black African 
heterosexuals are the population groups with the highest prevalence of HIV: 59 infections per 
1000 amongst MSM; 41 per 1000 amongst black African men; and 71 per 1000 amongst black 
African women  (21).  Unlike many other countries, prevalence of HIV among injecting drug 
users (IDU) in the UK is low (22).  The most recent estimates of the number of people living 
with HIV in the UK are shown in Figure 1.1.  Prevalence of HIV is highest in London where, for 
example, one in eight MSM are living with HIV compared to 1 in 26 outside of London. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1From Public Health England. HIV in the UK, 2014 slide set 
 
Figure 1.1 Estimated number of people living with HIV in the UK, 2013 
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1.1.2.2 Trends in HIV infection in the UK 
The number of people living with HIV in the UK, both diagnosed and undiagnosed, has risen 
year-on-year since the start of the epidemic.  This is partly due to ongoing transmission (23) 
and partly the increased survival (24) and decreased mortality (25) of people living with HIV.  
The increase has been seen across all sub-populations.  However, there have been changes to 
the patterns of HIV infection over time.  The number of new diagnoses of HIV infection 
continues to rise among MSM but among heterosexuals new diagnoses fell by 13% between 
2012 and 2013.  Another important change in the UK epidemic regards the country where an 
individual was most probably infected.  Among heterosexual men and women, the number of 
newly diagnosed infections which were likely to have been acquired abroad has fallen over the 
last 10 years while the number that were probably acquired in the UK has risen (26).  This 
marked a switch in 2010, from a situation where the majority of newly diagnosed heterosexual 
infections were probably acquired abroad, to a situation where the majority of heterosexual 
infections were probably acquired within the UK. Finally, over the last 10 years, the proportion 
of diagnosed HIV-positive individuals who are aged >50 has increased from 13% in 2004 to 27% 
in 2013. Increased survival has led to an aging cohort of HIV-positive individuals who have 
been diagnosed for a number of years, but there is also evidence of increasing numbers of new 
diagnosis among individuals aged >50 (27). 
 
1.1.3 Natural history of HIV 
1.1.3.1 The life cycle of HIV and pathogenesis of HIV  
HIV is a retrovirus. This family of viruses is distinguished from other viruses by having their 
genetic code stored as single-stranded ribonucleic acid (RNA) and through their mechanism of 
replication which involves reverse transcription of the genetic material and integration into the 
host cell’s genome.  HIV primarily infects CD4 T-cells which, ordinarily, play an important role 
in co-ordinating the body’s immune response to pathogens.   However, HIV can also infect 
other cells such as macrophages and dendritic cells; both of which are also involved in the 
body’s defence against infection (28). 
 
A representation of the life cycle of HIV is shown in Figure 1.2.  The virus attaches to a host cell 
via the CD4 receptor and fuses with the host cell membrane using the co-receptors CCR5 or 
CXCR4, resulting in the release of the viral RNA into the cytoplasm of the host cell.  The viral 
enzyme, reverse transcriptase, makes a copy of the viral RNA in the form of deoxyribonucleic 
acid (DNA) which enters the host cell nucleus.  Using another viral enzyme, integrase, this DNA 
copy of the viral genome is integrated into the host cell DNA. In latent HIV this integrated viral 
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DNA may remain here without any further action until the cell is activated.  In an activated cell 
the viral DNA is transcribed back into messenger-RNA, which is transported back to the 
cytoplasm and translated into viral polyproteins.  These are packaged into immature virus 
particles along with copies of the viral RNA which bud off from the cell.  The final stage in the 
replication cycle is the cleavage of the viral polyproteins into the proteins which are present in 
the mature viral particle.  This mature virus is then available to infect further cells (28). 
Antiretroviral drugs used to treat HIV act at various stages of the viral life cycle (Figure 1.2) as 
described in section 1.1.4.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
From Volberding & Deeks, 2010.  Antiretroviral therapy and management of HIV infection (29) 
1 Point of action of nucleoside reverse transcriptase inhibitors  
2 Point of action of non-nucleoside reverse transcriptase inhibitors 
3 Point of action of protease inhibitors 
4 Point of action of fusion inhibitors 
5 Point of action of integrase inhibitors 
Figure 1.2 HIV life cycle and antiretroviral drug targets 
1&2 
3 
4
5
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1.1.3.2 The course of HIV infection and markers of disease progression 
It has been clear since the early stages of the epidemic that HIV infection depletes the number 
of CD4 cells within the immune system of an infected person.  While the direct destruction of 
CD4 cells by HIV clearly plays a role in the pathogenesis of the infection, the exact mechanisms 
by which the virus destroys the CD4 cell population to such a great extent remains unclear 
(30). 
 
HIV becomes detectable in the blood between 4 and 11 days after infection (31).  The 
appearance of antibodies to HIV in the blood, known as seroconversion, occurs within weeks 
of the infection (32, 33).  In the acute period, defined as the time between infection and 
seroconversion, some individuals may experience generic symptoms of viremia (34), such as 
fever, fatigue and rash.  The acute period of infection is characterised by high levels of virus 
(35, 36) and a sudden fall in the number of CD4 cells in the blood (37). However, following this 
period, as the immune system begins to respond (38), the levels of virus fall and there is a 
partial recovery of the CD4 cell population.  This initial period of acute infection is followed by 
a long asymptomatic period during which the levels of virus in the blood slowly rise (39) and 
the number of CD4 cells falls at a rate of 30-60 cells/mm3 per year (40).  Even in the absence of 
treatment the asymptomatic period may last at least 10 years (41, 42).  However, when an 
individual’s CD4 count drops to levels of 200 cells/mm3, that individual is at high risk of 
opportunistic infections which the body is unable to fight effectively (43).  Individuals with CD4 
counts <200cells/mm3 or opportunistic infections are considered to have AIDS (44). Typical 
changes in HIV viral load and CD4 count in the absence of treatment are shown in Figure 1.3. 
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From Fauci, 1993.  Multifactorial nature of human immunodeficiency virus disease: 
implications for therapy (37) 
 
Both CD4 cell count and HIV viral load are used in monitoring people with HIV infection.  
Clinical guidelines from the British HIV Association (BHIVA) recommend that an HIV-positive 
individual has their CD4 count monitored every 3-6 months (45).  In healthy HIV-negative 
individuals CD4 cell count ranges from 600 to 1500 cells/mm3 (46, 47).  The change in CD4 cell 
count over the course of HIV infection has been shown to be a good marker of disease 
progression (48-51).   In particular, a fall in CD4 cell count to levels of 350 cells/mm3 or less is 
used as an indication for treatment in the UK (52).  
 
HIV viral load has also been shown to predict progression of HIV disease and those with higher 
HIV viral loads have higher rates of AIDS and AIDS-related mortality (39, 53).  Current 
laboratory assays can measure HIV virus to levels as low as 50 copies/ml.  Below this level an 
individual may still have virus in their blood but it is unquantifiable using standard assays.  
Therefore, in analyses of clinical outcomes which include HIV viral load as a covariate, viral 
load is often categorised as < 50 copies/ml or >50 copies/ml.   A rise in HIV viral load while an 
individual is on treatment is used as indication that an individual may be experiencing 
treatment failure (52). 
 
Figure 1.3 Changes in HIV viral load and CD4 cell count after infection with HIV 
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1.1.4 HIV treatment and management 
The drugs used to treat HIV are divided into classes depending on the point at which they act 
within the virus life cycle (Figure 1.2).  The first drug used to treat HIV infection was 
zidovudine, a drug belonging to the class known as nucleoside reverse transcriptase inhibitors 
(NRTI) (54). Other NRTIs were soon developed and were used in combination with zidovudine 
(55).  These drugs all acted at the same point of the viral life cycle, by preventing the reverse 
transcription of the viral RNA into DNA (stage 1, Figure 1.2).  When treatment is commenced 
there is a decrease in the level of HIV in the blood and a recovery in the number of CD4 cells. 
 
The first protease inhibitors (PI) were licensed for use in 1995.  These drugs act at the point at 
which the new viral particles mature and become a fully able to infect further cells (stage 3, 
Figure 1.2). These were the first drugs to result in long lasting suppression of viral replication 
when used in combination with NRTIs (16, 56).  The first non-nucleoside reverse transcriptase 
inhibitors (NNRTI) were licensed for use in 1996 and also led to improvements in 
immunological and virological response when used in combination with NRTIs (57, 58).  The 
NNRTIs act at the same point of the viral life cycle as the NRTIs (stage 2, Figure 1.2).  More 
recently, two new classes of drugs have been developed. Fusion inhibitors act at the point 
when the virus enters the host cell (59) (stage 4, Figure 1.2).  Integrase inhibitors prevent the 
integration of viral genome into the host cell DNA (60) (stage 5, Figure 1.2). 
 
Combinations of these drugs, often referred to as HAART, are now used routinely.  Cohort 
studies have shown that since the introduction of HAART, time from HIV infection to either 
AIDS or death has increased (61) and mortality rates and rates of AIDS among HIV-positive 
populations have fallen (62).  In the HAART era, the key determinant of AIDS and/or death is 
the CD4.  Low mortality rates are observed among individuals who start HAART with a CD4 
count of >200 cells/mm3 irrespective of the drugs included in their HAART regimen (63) and 
the highest mortality rates among those who start HAART at CD4 count <200 cells/mm3 (64). 
 
In the UK, most individuals are successfully linked into care once they are diagnosed with HIV; 
90% have a CD4 count within one month of receiving a diagnosis.  This means they are closely 
monitored and start treatment as necessary, which generally leads to good outcomes.  
However, challenges remain to ensure that HIV-positive individuals receive a diagnosis before 
their CD4 counts fall to levels where they experience symptoms of infection (20).  Currently, 
first-line treatment recommended by BHIVA is 2 NRTIs plus one of: a PI boosted with ritonavir; 
an NNRTI; or an integrase inhibitor (65). 
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1.2 HBV 
1.2.1 Global epidemiology and prevention of HBV infection 
Worldwide it is estimated that 240 million people are chronically infected with HBV and every 
year 780,000 people die of HBV (66). The greatest prevalence of HBV is seen in sub-Saharan 
Africa, Asia and the Pacific region (67).  HBV infection causes liver disease; half of all deaths 
from liver cancer and a third of all deaths from cirrhosis are attributable to HBV infection (68). 
HBV is carried in the blood and other body fluids of infected individuals. In areas of high 
prevalence HBV is usually transmitted perinatally, from mother to child, or early in childhood.  
In lower prevalence areas it may be transmitted via receipt of infected blood products, 
injecting drug use,  through sex, and by close household contact with infected individuals (69). 
 
A number of prevention strategies can be implemented to reduce transmission of HBV.  As 
with other blood borne viruses, screening of blood and blood products has been shown to 
significantly reduce the risk of HBV transmission via blood transfusion (70-72).  Importantly, 
unlike HIV and HCV, HBV infection can be effectively prevented through vaccination.  In high 
prevalence countries, where universal HBV immunisation of new-born infants and children has 
been introduced, the strategy has decreased the prevalence of HBV infection (73, 74) and has 
been credited with a decrease in the rates of liver cancer (75, 76).  A decline in HBV incidence 
has also been seen after introduction of universal immunisation in lower prevalence countries 
(77).  In addition to vaccination, which aims to induce immunity to HBV infection, passive 
immunisation with HBV antibodies is effective in preventing an infection occurring after an 
exposure has occurred.  This strategy is used in the context of children born to HBV-positive 
mothers as well as for healthcare workers who have an occupational exposure (78). 
 
1.2.2 HBV in the UK 
In the UK, clinicians and laboratories are required, by law, to notify public health authorities of 
newly diagnosed cases of viral hepatitis (79) and minimum datasets for reporting have been 
developed.  These notifications allow examination of trends in new HBV infection, HBV 
transmission patterns and evaluation of HBV prevention strategies (80).   
 
While laboratory reports of acute HBV have been shown to accurately describe the number of 
symptomatic cases, they may underestimate incidence as asymptomatic cases might not be 
identified (81).  Therefore laboratory reports are adjusted to estimate incidence of HBV 
infection.  In 2013, the estimated incidence of HBV in England was 0.77 per 100,000 population 
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(414 notifications).  This figure had fallen from 1.04 per 100,000 population in 2012.  At a 
regional level, the highest incidence was seen in London.  The population group with the 
highest incidence was men aged 45-54.  Where reported, the most common mode of 
transmission was sex between men and women (57% of incident cases).  In addition, 16% of 
cases were thought to be acquired through sex between men, 4% through injecting drug use 
and 8% through healthcare related exposures (82).  Although the proportion of cases acquired 
through sex between men is smaller than the proportion acquired through sex between men 
and women, the population of MSM is substantially smaller and therefore MSM are 
considered at high risk of infection. 
 
Estimates of HBV incidence are vital for monitoring ongoing transmission.  However, in order 
to assess the true extent of the HBV burden, and therefore the numbers of individuals at risk 
of HBV-related liver disease, estimates of HBV prevalence are required.   There are a number 
of available sources of information on HBV prevalence.  Women in antenatal care are all 
offered screening for HBV infection; the prevalence in this population, in 2013, was 0.4% (83).  
In addition, 22 sentinel surveillance centres report data on non-antenatal HBV testing; in 2013 
prevalence in this population was 1.1% (83). This higher prevalence from sentinel surveillance 
compared to that in the antenatal population reflects the fact that a quarter of the tests were 
conducted in sexual health clinics and therefore the population tested can be considered to be 
of increased risk of infection.  Finally, an ongoing unlinked anonymous seroprevalence survey 
provides estimates of HBV prevalence among IDU.  In 2013, 16% of this population had 
evidence of ever having had HBV but only 0.6% of IDU were currently infected with HBV (84).  
 
HBV infection is concentrated among certain ethnic groups.  Among antenatal women 
prevalence is highest in women of black ethnicity (2.4%) and women of other or mixed 
ethnicity (2.2%) compared to women of Asian ethnicity (0.5%) and women of white ethnicity 
(0.2%).  Black and other/mixed ethnic groups also had the highest prevalence in sentinel 
surveillance from non-antenatal sites; 6.8% among individuals of other/mixed ethnicity and 
4.8% among individuals of black ethnicity, compared to 1.5% in people of Asian ethnicity and 
0.6% among people of white ethnicity (83).  
 
There is no population level HBV vaccination programme in the UK.  However, high risk 
individuals are offered vaccination.  In particular, IDU, MSM, sex workers, close contacts of 
known HBV cases, people who regularly receive blood products, prisoners and people who 
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have an occupational risk of infection are among groups who are offered HBV vaccination (85).  
In addition, BHIVA recommends that all newly diagnosed HIV-positive individuals are screened 
for HBV infection and those who have no prior evidence of exposure or immunity to HBV are 
vaccinated (65). 
 
1.2.3 Natural history of HBV infection 
1.2.3.1 Life cycle of HBV 
HBV belongs to the Hepadnavirus family and was first identified in the 1960s (86). Viruses from 
this family preferentially infect liver cells (hepatocytes). Unlike HIV, the HBV genome is stored 
as DNA.  However, like HIV, one of the key features of HBV replication is the use of the enzyme 
reverse transcriptase (87).  The cell receptor for HBV virus is unknown.  After entry into the 
cell, the viral DNA is transcribed into RNA in the nucleus of the cell.  These RNA transcripts are 
translated into viral core and surface proteins in the host cell cytoplasm and reverse 
transcription takes place to create copies of the viral genome inside the core.  The replication 
is completed when the core particles, including the DNA genome, bud off from the surface of 
the cell and acquire their envelope proteins.    At this stage the mature virus is able to infect 
another hepatocyte (88).  The HBV-DNA is also able to integrate into the host cell DNA and 
while this does not form part of the replication cycle it is thought to be important in the ability 
of HBV to cause hepatocellular carcinoma (HCC) (89).  Neither the replication of HBV within 
hepatocytes, nor the release of the virus from these cells, directly kills the infected cells.  
Instead it is believed that damage to the liver is caused by the immune systems response to 
the infection (86). 
 
1.2.3.2 HBV disease progression and markers of infection 
After HBV infection takes place the disease can take a number of courses.  Among healthy 
individuals, who are infected as adults, around 95% will mount an immune response, clear the 
infection and develop lasting immunity to the virus. Only 5% will go on to develop chronic 
infection (90).  However, individuals who are infected as children are much less likely to 
resolve infection and are more likely to become chronically infected (91).  
 
The different courses of infection are characterised by the appearance and disappearance of 
several markers in the blood of the infected individual (Figure 1.4).  In all infections, the first 
marker to become detectable in the blood is HBV-DNA.  This is followed quickly by the 
appearance of hepatitis B surface antigen (HBsAg) and hepatitis B envelope antigen (HBeAg).  
An immune response to the infection is detectable in the blood only after a few weeks when 
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antibodies to hepatitis B core antigen (anti-HBc) appear.  As it is the immune response to the 
virus which causes damage to the liver cells, it is at this stage that clinical manifestations  of 
liver disease are first evidenced in the blood, in the form of raised liver enzymes; alanine 
aminotransferases (ALTs).  Among those individuals who clear the infection, the levels of 
HBsAg, HBeAg and HBV-DNA then fall until they are all undetectable. ALT levels also fall back 
to normal levels and the individual is left with anti-HBc, antibodies to the surface antigen (anti-
HBs) and antibodies to the envelope antigen (anti-HBe).  The development of antibodies 
protects the individual from any further infection.  Among those individuals in whom infection 
persists, levels of HBV-DNA and HBsAg remain high and anti-HBs does not become detectable, 
although anti-HBc remains present in the blood.   
 
From Ganem, 2004.  Hepatitis B Virus Infection – Natural History and Clinical Consequences 
(88) 
 
Once an individual is chronically infected the course of the infection is dynamic.  The stage of 
infection that chronically infected individuals enter is dependent on the interplay between the 
immune system and the virus.  An important distinction in chronic disease is between those 
Figure 1.4 Patterns of serological markers in acute (A) and chronic (B) HBV infection 
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individuals who remain HBeAg-positive and those who lose HBeAg and become positive for 
anti-HBe (known as seroconversion).  Those who remain HBeAg-positive have high levels of 
replication, evidenced by high HBV-DNA titres in the blood.  These individuals may have low or 
high ALTs depending on the response of the immune system (Table 1.1).  In individuals who 
lose HBeAg and develop anti-HBe, HBV-DNA levels are low or undetectable and ALTs are 
normal (Table 1.2).  This inactive state may persist throughout the lifetime, or individuals may 
experience a reactivation.  In the case of reactivation, HBV-DNA levels will rise again and 
HBeAg may or may not re-appear in the blood.  Among a small group of individuals, a variant 
with a mutation in the pre-core region is selected for during anti-HBe seroconversion.  This 
mutation allows the virus to continue to replicate and so these individuals remain HBV-DNA 
positive.  Infection among these individuals is distinguishable from chronic inactive infection 
only through the high levels of DNA present among those infected with pre-core mutants (92).  
A very small proportion of chronically infected individuals (0.1-2%) clear HBsAg in the natural 
course of infection (93).  Diagnosis of HBV infection is usually made through the identification 
of HBsAg and chronic HBV infection is defined as the presence of two positive HBsAg tests at 
least 6 months apart (94).  Further testing for other markers of infection is used when 
determining the need for treatment. 
 
Table 1.1 Markers of chronic HBV in HBeAg-positive individuals 
Disease 
stage 
HBsAg HBeAg Anti-HBe Anti-HBc HBV-DNA ALTs 
Immune 
tolerant 
+ + - + ++ Normal 
Immune 
active 
+ + - + + Increased 
     
Table 1.2 Markers of chronic HBV in HBeAg-negative individuals 
Disease 
stage 
HBsAg HBeAg Anti-HBe Anti-HBc HBV-DNA ALTs 
Chronic 
inactive 
+ - + + - Normal 
Pre-core 
mutant 
+ - + + + Increased 
 
As previously mentioned, damage to the liver which results from HBV infection is due to the 
destruction of infected hepatocytes by the host’s immune system.  This occurs during the 
immune active stage of the infection.  Around 65% of chronically infected individuals will 
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eventually undergo seroconversion from HBeAg positivity to anti-HBe positivity and this is 
associated with a decreased risk of disease progression (95, 96).  
 
Incidence of cirrhosis in HBV-infected populations in European countries has been estimated 
as 3.8 per 100 person years among HBeAg-positive individuals and 9.7 per 100 person years 
among HBeAg-negative individuals.  These equate to 5 year cumulative incidences of 17% and 
38% in HBeAg-positive and HBeAg-negative individuals, respectively (97).  Conversely, HBeAg is 
associated with increased rates of HCC in chronically infected individuals (98).  Among 
individuals in Europe with cirrhosis, the incidence of HCC is 2.2 per 100 person years and for 
those without cirrhosis it is 0.3 per 100 person years, giving a 5 year cumulative incidence of 
1% for non-cirrhotic individuals and 10% for cirrhotic individuals.  The rate of HCC in HBV 
chronically infected individuals is around 100 times higher than among HBV-negative 
populations and, as such, HBV is considered the main cause of HCC (99).  HBV-DNA has also 
been shown to be predictive of HCC, independent of presence of cirrhosis (100).  Therefore in 
chronically infected individuals HBV-DNA levels are closely monitored and are used as an 
indication for treatment (94).  
 
1.2.4 Treatment for HBV 
European guidelines recommend that treatment is considered when an individual has HBV-
DNA >2000 IU/ml, raised ALTs and liver disease which is classed as at least moderate (94).  Two 
different types of drugs are active against HBV.  Interferon and pegylated-interferon act by 
inducing an immune response to clear the virus.  In contrast 6 NRTIs act against HBV by 
interfering with the reverse transcription process involved in the viral replication cycle:  
lamivudine; tenofovir; emtricitabine; adefovir; telbivudine; and entecavir.  Three of these 
NRTIs are also active against HIV (lamivudine, tenofovir and emtricitabine).  The interferon 
treatments are usually given for a finite period of time, whereas the NRTI treatments are long 
term therapies (101). 
 
Cirrhosis is known to be associated with higher levels of HBV-DNA (102) and changes in HBV-
DNA as a result of treatment have been shown to correlate to changes in histological activity 
(103).  Therefore HBV-DNA levels are used to assess treatment efficacy.  The aim of HBV 
treatment is to reduce HBV-DNA to <2000 IU/ml and to facilitate seroconversion among 
HBeAg-positive individuals.  The ideal end point for treatment is loss of HBsAg, but this is rarely 
achieved (94). The different drugs available to treat HBV have different levels of efficacy with 
regard to each endpoint as shown in Table 1.3. Therefore the choice of treatment is 
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dependent on the type of disease present, any other co-existing morbidities (including HIV), 
potential drug interactions and the preferences of the patient. 
 
Table 1.3 Proportion of individuals achieving various treatment outcomes after 12 months of 
treatment for HBV-infection 
 Pegylated 
interferon 
NRTI 
Peg-
IFN-
2a 
Peg-
IFN-
2b 
Lamivudin
e 
Telbivudin
e 
Entecavi
r 
Adefovi
r 
Tenofovi
r 
Drug dose 180µ
g 
100µ
g 
100mg 600mg 0.5mg 10mg 245mg 
Anti-HBe 
seroconversio
n  
32% 29% 16-18% 22% 21% 12-18% 21% 
HBV-DNA <60-
80 IU/ml 
14% 7% 36-44% 60% 67% 12-21% 76% 
ALT 
normalisation 
41% 32% 41-72% 77% 68% 48% 68% 
HBsAg loss 3% 7% 0-1% 0.5% 2% 0% 3% 
Adapted from EASL, 2012.  EASL Clinical Practice Guidelines: Management of chronic hepatitis 
B virus infection (94) 
 
Choices of treatment regimens are complicated by the potential for development of resistance 
to the NRTIs.  High levels of resistance to lamivudine have been observed, with 24% of patients 
showing mutations which conferred resistance to lamivudine after one year of treatment and 
up to 70% of patients showing mutations which conferred resistance to lamivudine after 4 
years of treatment (104).  Lower levels of resistance to other NRTIs have been recorded.  For 
example, at one year of treatment with telbivudine, resistance was observed among 5% of 
HBeAg-positive individuals and 2.3% of HBeAg-negative individuals (105); at 2 years the 
proportions of patients with resistance had risen to 25.1% among HBeAg-positive individuals 
and 10.8% among HBeAg-negative individuals (106).  Resistance to adefovir also emerges 
slowly with 29% HBeAg-negative of individuals (107) and 20% of HBeAg-positive individuals 
having developed resistance after 5 years of adefovir treatment (108).  The prevalence of 
resistance to entecavir after 5 years of treatment remains low at 1.2% (109).  Resistance to 
tenofovir has not been demonstrated (110).   Mutations that confer resistance to lamivudine 
also confer a level of cross-resistance to telbivudine, adefovir and entecavir so higher rates of 
resistance to these drugs are observed among individuals who are known to be lamivudine 
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resistant (110).  At present, tenofovir and entecavir are considered first-line NRTIs for 
treatment of chronic HBV (94). 
 
1.3 HCV 
1.3.1 Global epidemiology and risk factors for HCV infection 
The World Health Organisation estimates that between 130 and 150 million people are 
chronically infected with HCV globally with the highest prevalence found in Central and East 
Asia and North Africa.  It is estimated that every year 350,000-500,000 people die of liver 
disease related to HCV infection (111).  Like both HIV and HBV, HCV prevalence estimates are 
complicated by a long asymptomatic period of infection which may lead to under-
ascertainment of cases through surveillance.  In Europe, the prevalence of HCV in the general 
population has been reported as ranging from 0.1% to 5.6%, depending on the country (112).  
However, these general population estimates should be treated with caution as high risk 
populations, such as those in prisons, hospitals, the military and individuals who are homeless, 
may be excluded leading to an underestimate of the true population prevalence  (113).  In 
general, prevalence is higher in Southern and Eastern Europe (>1.2%) than in Northern Europe 
(<0.1%) (114). 
 
HCV is carried within the blood of an infected individual and is usually transmitted parenterally 
(115).  The contribution of different routes of transmission to the overall epidemic differs by 
country and geographical region. Iatrogenic and nosocomial infections are those acquired as 
the result of a medical procedure or in hospital, for example infection as a result of a blood 
transfusion or from use of contaminated syringes or needles used in healthcare facilities.  This 
is a major transmission route for HCV in the developing world (116-120).  There is also 
evidence that this route of transmission has contributed to prevalent HCV infection in rural 
areas with particularly high prevalence in some European countries, for example Greece and 
Italy (121, 122).   
 
In most developed countries in Europe, North America and in Australia, where blood is 
routinely screened and levels of hygiene in hospitals are good, nosocomial infections as less 
common.  National surveillance data and research studies indicate that the main risk factor for 
new HCV infection in developed countries  is now injecting drug use (116, 123, 124).  For 
example, a study conducted in six sentinel county health departments in the USA showed that 
47% of acute HCV infections  between 1994 and 2006 were due to injecting drug use  (124) 
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and between 1990 and 2000 in Australia 80% of people living with HCV infection were thought 
to have been infected through injecting drug use (125). 
 
Evidence to date shows that sexual transmission of HCV is rare among heterosexuals with very 
low levels of incidence reported among the negative partners of HCV-infected individuals (126-
128).  Similarly, among HIV-negative MSM the prevalence of HCV is comparable to that among 
the general population and incidence is low, indicating that among this population sexual 
transmission is not a major route of transmission for HCV (129).  However, there is now 
evidence that HCV is carried in the seminal fluid, irrespective of HIV status (130).  In contrast to 
the low level of sexual transmission among HIV-negative MSM, among HIV-positive MSM there 
is now evidence that sexual transmission of HCV does occur with reports of outbreaks in 
Europe, USA and Australia and reports of increasing prevalence of HCV where sexual exposure 
is the predominant risk factor  (131). This increase in sexual transmission of HCV among MSM 
will be described in the literature review (section 2.1.1). 
 
1.3.2 HCV in the UK 
In the UK, prevalence of HCV antibodies is estimated using a statistical model which brings 
together a variety of data sources.  The size of the IDU population is estimated from drug 
treatment and intervention services in the community and within probation services and 
prisons.  Prevalence of HCV among IDU is estimated from an unlinked anonymous survey of 
those IDU in contact with treatment services.  Prevalence estimates among sexual health clinic 
attendees, women in antenatal care, blood donors and community surveys among the south 
Asian population are also included in the model (132).  The most recent estimate is that there 
were 214,000 chronically HCV-infected individuals in the UK in 2013.  In England, the figure is 
160,000; an overall prevalence of 0.4% in the population.  There were 11,051 new laboratory-
confirmed cases of HCV in England in 2013 (133). The majority of newly identified cases were 
among men, 47% were among individuals aged 25-39 and more than 90% were among IDU.   
 
Since injecting drug use remains the dominant risk factor for HCV infection, there are specific 
systems in place for monitoring infection in this group.  Among IDU who use psychoactive 
drugs, in 2013, 50% had antibodies to HCV and it is estimated that 40% of IDU were chronically 
infected with HCV.  Over the last 10 years this prevalence has remained steady (84).   The same 
survey provides evidence of increased risk for HCV infection among individuals who inject 
performance enhancing drugs among whom prevalence of HCV antibodies is 3.6% (84).   
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The incidence of HCV among IDU is estimated in order to assess the impact of prevention 
strategies.  Previously, the incidence had been estimated using a proxy measure of the 
prevalence of HCV among young injectors, since HCV is acquired at a young age in this 
population.  However, more recently, methodology has been developed which allows 
incidence to be estimated using laboratory techniques performed on blood samples taken as 
part of an unlinked anonymous survey of IDU.  This methodology has estimated incidence 
among HIV-negative IDU as 6-18 infections per 100 person years.  A comparison of this 
estimate to that from previous years using the proxy method suggests that the incidence 
among this group has remained stable over the last 10 years (133).    
 
1.3.3 Natural history of HCV infection 
1.3.3.1 Life cycle of HCV 
HCV belongs to the virus family Flaviviridae.  The virus itself was first identified in 1989 (134), 
but it had been clear for some time prior to this that there was a viral cause for a post-
transfusion hepatitis which was distinct from the other known viral causes of hepatitis (non-A 
non-B hepatitis) (115).  The identification of the virus allowed the development of diagnostic 
tests (135, 136). However, full investigation of the life cycle of the virus was not possible until 
2005 when in vitro models of the infection were developed (137, 138).   
 
The primary targets of HCV are hepatocytes (115).  The viral genome is stored as RNA.  
However, unlike both HIV and HBV, replication does not require the reverse transcriptase 
enzyme.  The cellular receptors for the virus are thought to be low density lipoproteins and 
glycoaminoglycans but a number of other co-receptors are also involved in allowing the virus 
to enter the cell (139).  Once the virus has entered the cell’s cytoplasm, primary translation of 
the RNA genome into protein occurs, resulting in production of an HCV polyprotein.  This 
polyprotein is cleaved by cellular and viral enzymes (proteases) to form 10 viral proteins 
required to complete the replication cycle.  One of these proteins is the viral RNA-polymerase, 
NS5B, which is the major enzyme responsible for replication of the RNA genome.  The virus 
utilises cellular machinery to complete assembly and release of mature viral particles (140).  
Detailed understanding of the replication cycle has aided recent development of effective 
treatments against HCV (see section 1.3.4). 
 
There are 7 main HCV genotypes, named 1-7.  These genotypes are divided into a number of 
subtypes, each assigned a letter, starting with ‘a’ (141).  In the UK, sentinel surveillance data 
has indicated that the large majority of prevalent HCV infection (~90%) is genotype 1 or 
40 
 
genotype 3 (133). The importance of different genotypes is in predicting response to 
treatment. 
 
1.3.3.2 HCV disease progression and markers of infection 
After infection with HCV, HCV-RNA quickly becomes detectable in the blood of the infected 
individual. The acute phase of infection can be divided into 3 distinct phases. In the first phase, 
early acute infection, the levels of HCV-RNA in the blood increase rapidly, doubling every 10.8 
hours (142). In the second phase, which starts around 5 days after HCV-RNA first becomes 
detectable in the blood, the levels of HCV-RNA plateau (142). Finally, from two months post-
infection the levels of HCV-RNA begin to fall and between 4-6 months after infection two 
different patterns of HCV-RNA emerge.  Among those individuals who go on to clear infection, 
HCV-RNA continues to fall and the virus is cleared from the system within 6 months of the 
initial infection.  Therefore the acute phase of HCV infection is considered to be this first 6 
months of infection.  Among those who develop chronic infection, HCV-RNA ceases to fall, may 
rise to some extent and then stabilises.  These individuals remain positive for HCV-RNA (143) 
(Figure 1.5).  Infection leads to stimulation of the immune system which includes production of 
antibodies against HCV (anti-HCV) within one to two months after initial infection (144, 145).  
These antibodies persist among patients who clear infection and among those in whom 
infection becomes chronic. 
 
As HCV-RNA levels rise and plateau during the first two stages of acute infection, ALT levels 
also rise indicating a degree of inflammation within the liver (146).  Similarly, as HCV-RNA 
levels fall in the later stages of acute infection, ALTs also decline (Figure 1.5).  Raised ALTs 
during acute infection may often lead to initial diagnosis of acute infection.  During the early 
acute phase of infection, where an individual is HCV-RNA positive but anti-HCV negative, only a 
minority of infected individuals will experience symptoms of hepatitis such as jaundice (144, 
146).   
 
It is estimated that around 25% of individuals will spontaneously clear infection, while the rest 
will remain chronically infected (147).  A number of host factors are associated with whether 
an individual clears infection or becomes chronically infected.  Female sex  has been associated 
with spontaneous clearance (147).  Importantly the extent of the immune response to the 
infection is key in determining clearance or persistence of infection.  In particular, the action of 
CD8+ T-cells (148, 149) and CD4+ T-cells (150) has been shown to protect against persistent 
infection.  One of the strongest measurable predictors of spontaneous clearance of acute HCV 
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infection is the host genotype with regard to IL-28B gene.  This gene encodes a particular 
interferon involved in the immune response to infection and those individuals who have the C-
C genotype are significantly more likely to clear HCV infection than individuals who have other 
genotypes (151, 152).  
 
From  Hajarizadeh et al, 2013.  Epidemiology and natural history of HCV infection (153) 
 
Since the majority of HCV-infected individuals go on to develop chronic infection, and all 
individuals who are exposed to HCV develop anti-HCV, testing for anti-HCV is the first-line test 
used to diagnose HCV infection.  However, where a negative anti-HCV test results and there is 
strong clinical suspicion of acute HCV infection, HCV-RNA testing is used to confirm or exclude 
Figure 1.5 HCV-RNA and ALT level from 2 months after initial infection, split by infection 
outcome 
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HCV infection.  In addition, among those individuals who test positive for anti-HCV, an HCV-
RNA test is conducted to assess whether the individual has active infection or has cleared the 
infection (154). 
 
Among individuals who become chronically infected with HCV, damage to the liver is caused by 
infiltration of inflammatory cells and death of liver cells.  This can lead to liver fibrosis and 
eventually to severe fibrosis and cirrhosis of the liver (155).  The median time from HCV 
infection to the development of cirrhosis is estimated to be around 30 years (156).  At 20 years 
after infection  around 15% of chronically HCV-infected individuals will have developed 
cirrhosis; by 30 years post-infection this proportion has increased to around 35% (157).  
However, some individuals never develop cirrhosis (156).  Male sex, high daily alcohol intake 
and longer duration of infection are all associated with increased levels of liver disease (156, 
157). Complications of liver disease caused by HCV are observed almost exclusively among 
individuals who have developed cirrhosis and include HCC, ascites (fluid around the liver), 
oesophageal varices (upper gastrointestinal bleeding), jaundice (yellowing of the skin and eye 
caused by raised bilirubin levels) and encephalopathy (damage to the brain) (158, 159). These 
complications are known as decompensation events.   Among HCV-infected individuals with 
cirrhosis, the estimated five year risk of HCC is 7% (an incidence of 1-3% per year) and the five 
year risk of any decompensation event is 18% (159). After development of complications, five 
year probability of survival is 50% (159). 
 
1.3.4 Treatment for HCV 
The aim of treatment for HCV is a sustained virological response (SVR) defined as a negative 
HCV-RNA test at least 6 months after stopping treatment.  This result is considered to be a 
permanent cure (160) and treatment for HCV is associated with a decreased risk of all-cause 
and liver-related mortality (161-163) and improved liver histology (164, 165).  
 
From 2001 until 2011 standard treatment for all HCV infection has been a combination of 
pegylated-interferon plus ribavirin (166). Prior to this, standard interferon (without the 
pegylation) was used. Clinical trials showed that the pegylated-interferon and ribavirin 
combination had higher efficacy in treating chronic HCV infection than the previously used 
interferon plus ribavirin combination (167-169). Use of pegylated-interferon and ribavirin has 
also been shown to be effective among 20-22% of individuals who have previously failed 
treatment with standard interferon and ribavirin (170, 171). Interferon and pegylated-
interferon do not act directly on the virus itself but instead stimulate the infected individual’s 
43 
 
immune system to induce antiviral activity. The method of action of ribavirin is less clear but 
also involves stimulation of the immune system (115).  The pegylated-interferon component of 
the treatment is given, by injection, once a week while the ribavirin is taken orally on a daily 
basis (169). 
 
The strongest predictor of SVR to pegylated-interferon and ribavirin treatment is HCV 
genotype. In clinical trials, 40-45% of individuals infected with genotype 1 HCV achieve SVR 
compared to 70-80% of individuals infected with genotype 2 or 3 HCV (167-169). SVR rates 
among individuals infected with genotype 4 HCV are less well defined but are thought to be 
between those for genotype 1 and genotypes 2 and 3 (172). Therefore genotypes 1 and 4 are 
considered difficult to treat while genotypes 2 and 3 are considered easier to treat.  IL28-B 
genotype of the infected individual is also strongly associated with SVR, with the same 
genotype which is associated with clearing acute infection begin associated with higher rates 
of SVR (173, 174). Other factors which are known to be associated with treatment response 
include low baseline HCV viral load (175-177), younger age of the infected individual (167, 
169), lower body weight (167, 177) and an absence of severe fibrosis or cirrhosis (169, 177).  
 
Treatment of acute HCV is associated with high rates of SVR (178-181)  and it is recommended 
that when an individual is diagnosed with acute HCV, treatment is considered in order to 
prevent the complications associated with chronic infection (154).  In the case of acute 
infection pegylated-interferon may be used as monotherapy.   
 
The duration of treatment for HCV is finite but long.  The time that an individual should remain 
on treatment is guided by their on-treatment response but in many cases of genotype 1 
infection treatment may last up to 48 weeks and in the case of genotype 2 or 3 infections may 
last up to 24 weeks (166).  In addition, the treatment may induce side effects such as flu-like 
illness, altered moods, depression, neutropenia and anaemia (182).  These side effects, 
combined with the long duration of infection mean that high proportions of infected 
individuals are not considered eligible for treatment (183-185) and among those who do 
commence treatment, high rates of early discontinuation of treatment have been observed 
(186-188). 
 
Since 2001 there has been rapid development of new drugs to treat genotype 1 HCV infection.  
These newer treatments are known as directly acting agents (DAAs) as, in contrast to 
44 
 
interferon-based treatments, they act at specific points of the viral lifecycle.  The first two 
DAAs to become available, in 2011, were boceprevir and telaprevir.  These drugs both act as 
protease inhibitors, preventing the cleavage of the HCV polyprotein and therefore stopping 
the production of mature virus particles.  
 
In clinical trials among treatment-naive patients, addition of boceprevir to a pegylated-
interferon and ribavirin regimen resulted in SVR rates ranging from 42% to 75% (depending on 
the ethnicity of the patient and on the dose given); a significant increase compared to the 
control groups who received only pegylated-interferon and ribavirin (189, 190). Addition of 
telaprevir to a pegylated-interferon and ribavirin regimen resulted in SVR rates ranging from 
60% to 79% compared to 40-46% in control groups who received only pegylated-interferon 
and ribavirin (191-193). Additionally, it has been shown that if patients are monitored 
throughout treatment and are known to have responded rapidly to treatment (undetectable 
HCV-RNA at both 4 and 12 weeks of treatment), duration of treatment can be reduced to 24 
weeks without affecting the proportion of patients who achieve SVR (194). Impressive results 
are also seen for these drugs among individuals who have previously failed treatment with 
pegylated-interferon and ribavirin.  Addition of boceprevir to a pegylated-interferon and 
ribavirin regimen resulted in SVR in 59-66% of individuals compared to 21% in those who 
received a second pegylated-interferon and ribavirin regimen without a DAA (195).  
 
Subsequent to the licensing of boceprevir and telaprevir, in 2014, 3 new DAAs were licensed 
for use in Europe:  sofosbuvir, simeprevir and daclatasvir.  Sofosbuvir inhibits the viral RNA-
polymerase, simeprevir is another protease inhibitor and daclatasvir inhibits the viral protein 
NS5A which is involved in a number of stages of the viral life cycle (154). A large number of 
trials have been conducted which have shown that addition of these agents to a pegylated-
interferon regimen achieves SVR rates of up to 90% for individuals infected with all HCV 
genotypes, including the harder to treat genotype 1 and genotype 4 infections (196-199).  
Importantly, clinical trials have also shown high rates of SVR when these drugs are used 
without interferon (200-202).  The newest European guidelines recommend a range of options 
including new DAAs to treat HCV based on genotype of infection, other co-morbidities present 
and stage of liver disease (154).  Studies assessing the ability of DAAs to treat acute HCV have 
not yet been published.  
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1.4  Investigating the stages of liver disease 
1.4.1 Techniques for monitoring liver disease progression 
The earlier stages of HBV or HCV infection are asymptomatic.  Therefore, by the time 
individuals are diagnosed with infection, some degree of liver damage may have already 
occurred.  The degree of liver damage guides treatment decisions and also gives an indication 
of an individual’s prognosis  (203).  Therefore once an individual is diagnosed with HBV or HCV 
infection, the degree of liver damage is evaluated.  UK guidelines for the assessment of liver 
disease in HIV-positive individuals, recommend that initial investigations include a full history 
including questions about past or present intravenous drug use, prior vaccination for hepatitis 
A and B, travel history and any associated exposure risks, past and current alcohol use, family 
history of any kind of liver disease and any prior investigations for liver disease. Clinical 
examination should investigate the presence of external signs of chronic liver disease such as 
splenomegaly (enlargement of the spleen) and ascites (204). The full extent of liver disease 
then can be assessed using a number of techniques. 
 
Liver biopsy is the gold-standard for assessing liver disease (205).  The degree of liver disease 
seen on biopsy is commonly graded, by pathologists, using a scoring system.  Various scoring 
systems are in use.  The Histological Activity Index (HAI or Knodell score) gives patients a total 
score out of 18 for the level of necrosis (cell death) and inflammation, based on the sum of 4 
separate scores, each of which results to a different type of inflammation or cell death .  A 
separate score between 0 and 4  is given for the degree of  fibrosis (206).  
 
Modifications of the HAI score have resulted in the development of the Ishak score (203) 
which also gives a necro-inflammatory score out of 18, but provides a more detailed 
breakdown of the level of fibrosis, scoring the degree of fibrosis between 0  (no fibrosis) and 6 
(probable or definite cirrhosis).  More recently the METAVIR score has been developed which 
grades the degree of fibrosis on a 5 point scale from F0 (no fibrosis) to F4 (cirrhosis) (207) and 
the level of inflammatory activity on a 4 point scale from A0 (no activity) to A3 (severe activity) 
(208).  Full details of the Ishak and METAVIR scoring systems are given in Appendix I.  Other 
grading systems which are less commonly used are the Ludwig, Desmet, Brunt and Scheuer 
scores (209). 
 
Although liver biopsy remains the gold-standard for assessing the extent of liver disease, its 
use has some disadvantages.  It is invasive and may be prone to sampling error as fibrosis 
46 
 
occurs unevenly throughout the liver.  It may not be an appropriate method of investigation in 
cases where the patient does not want an invasive procedure, when the procedure will be 
repeated a number of times to monitor the patient, or when the patient may be at risk of 
bleeding (for example, patients with haemophilia).  Therefore a number of non-invasive 
methods of assessing the degree of liver damage have been developed.    
 
Patients with, or at risk of, cirrhosis are monitored for signs of HCC and other complications of 
liver disease through liver imaging.  Liver scans can be conducted using ultrasound (US), 
computerised tomography (CT) or  magnetic resonance imaging (MRI) (210) .  The results of 
these imaging techniques are usually interpreted in the context of changes in levels of various 
markers in the blood. 
 
Liver function tests usually include testing for blood levels of total protein, albumin, globulins, 
bilirubin, ALT, aspartate aminotransferase (AST), alkaline phosphatase, gamma glutamyl 
transferase, alpha-feto protein (AFP) and prothrombin time (a measure of the ability of the 
blood to clot) as well as conducting a full blood count.  In patients who are not known to be 
infected with HBV or HCV these tests may provide an indication of the first signs of liver 
disease.  In those diagnosed with viral hepatitis, biochemical markers may be used to give an 
indication of the degree of liver disease.   
 
A number of indices have been developed which combine levels of biochemical markers to 
give a score which indicates the degree of fibrosis within the liver.  One example in patients 
with HCV is the AST to platelet ratio index (APRI) which was developed to predict the presence 
(APRI>1.5) or absence (APRI<0.05) of significant fibrosis and the presence (APRI>2.0) or 
absence (APRI<1.0) of cirrhosis (211).  However, a meta-analysis of studies assessing the 
diagnostic accuracy of the APRI score found only moderate accuracy for prediction of 
significant fibrosis, severe fibrosis and cirrhosis at the previously recommended above cut-offs 
and a suggestion that sensitivity and specificity were further lowered in the case of HIV/HCV 
co-infection (212).  Modified cut-offs for the exclusion or presence of fibrosis and the presence 
of significant fibrosis in HIV/HCV co-infection have been suggested: <0.6 indicating no 
significant fibrosis; and >1.8 indicating significant fibrosis (213). Variable results are seen 
where APRI is used to predict fibrosis and cirrhosis in patients with chronic HBV infection (214, 
215) and other ratios such as the age-spleen-platelet ratio index (ASPRI) may be of more use 
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when assessing patients with HBV (216).  Other non-invasive scoring systems which may be 
used are Fibrotest (217) and FIB4 which has a similar sensitivity and specify to APRI  (217). 
 
Hepatic elastography (FibroScan®) is another non-invasive method currently used to assess 
liver damage in individuals who are chronically infected with HBV or HCV.  This measures the 
elasticity of the liver using the velocity at which a low frequency elastic shear wave travels 
through the liver.  The faster the wave travels the stiffer the liver tissue and therefore the 
greater the degree of liver fibrosis (218).  FibroScan® has been shown to discriminate well 
between patients with cirrhosis (METAVIR=F4) and those without cirrhosis (METAVIR<F4). The 
performance of FibroScan® is more variable for identifying patients with presence of significant 
fibrosis (METAVIR>F2) compared to those with no or mild fibrosis (METAVIR<F2) (209) and 
therefore the results are usually considered in the context of the results of blood tests.  (219). 
1.4.2 Assessing end-stage liver disease 
In individuals with HCV or HBV, severe fibrosis of the liver, without treatment, may eventually 
lead to cirrhosis.  In patients with cirrhosis the liver architecture is, irreversibly, structurally 
abnormal.  The damage to the liver results in the liver being unable to carry out its functions 
and a number of complications may result.  These complications, associated with cirrhosis, are 
known as decompensation events.  One of the most common complications of cirrhosis is 
portal hypertension: an increase in the pressure in the portal vein which results in blood being 
diverted away from the portal vein and bypassing the liver (220).  Portal hypertension can lead 
to ascites which is defined as the build-up of fluid within the abdomen and occurs in particular 
around the liver. This fluid accumulation carries a risk of bacterial infection (221).  Portal 
hypertension can also lead to oesophageal varices: extremely dilated veins in the lower 
portion of the oesophagus.  These veins can rupture leading to variceal haemorrhage(222).  In 
addition to these complications resulting from portal hypertension, severe damage to the liver 
can lead to hepatic encephalopathy.  This can manifest as a wide range of neurological and 
psychiatric abnormalities (223). 
 
For individuals with decompensated cirrhosis or HCC, as a result of HBV and/or HCV infection, 
survival is limited and liver transplantation may be the only therapeutic option.  There are two 
methods available for predicting survival of patients with cirrhosis, a task that is required when 
assessing patients for liver transplant.  The Child-Pugh score is based on a combination of total 
bilirubin, serum albumin, prothrombin time and the presence and severity of ascites and 
hepatic encephalopathy.  The score is used to categorise the patients into one of three classes 
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which predict survival rates (see Table 1.4) (224).  From 2002 onwards, evaluation for liver 
transplant has been carried out using the Model for End-Stage Liver Disease (MELD) score.  
This uses a combination of bilirubin, serum creatinine and prothrombin time to give a score 
which is closely correlated with survival rates (see Table 1.5) (225, 226).  
 
Table 1.4 Child-Pugh score for patients with cirrhosis and corresponding probability of 
survival 
Class One year survival rate Two year survival rate 
A 100% 85% 
B 81% 57% 
C 45% 35% 
 
 
 
Table 1.5 MELD score and 3 month mortality rates among hospitalised patients 
MELD score Three month mortality rate 
<9 1.9% 
10-19 6.0% 
20-29 19.6% 
30-39 52.6% 
>40 71.3% 
 
 
1.5 Aim of this thesis and specific objectives 
The reduction in the rate of AIDS events and AIDS-related mortality among HIV-positive 
individuals since the introduction of HAART has made the effective management of other co-
morbidities an important area for research.  HIV, HBV and HCV share common modes of 
transmission and therefore high levels of co-infection might be expected.  The overall aim of 
this thesis is to identify a UK cohort of HIV-positive individuals who are co-infected with HBV 
and/or HCV and to describe the outcomes of these patients. Specifically, in the subsequent 
chapters, I will present: 
 
i. A review of the published literature on HIV and HBV and/or HCV co-infection.   
The literature review focuses on the epidemiology of HBV and HCV among HIV-positive 
populations and clinical outcomes for those HIV-positive individuals who are HBV 
and/or HCV co-infected. The literature review (Chapter 2) was conducted at the time 
49 
 
of commencing my research.  As such, it represents the state of the scientific 
knowledge at that time.  Some additional studies have been subsequently reported.  In 
certain circumstances, where these newly published studies provided new insight into 
a particular research question, they have been added to the literature review.  
However, those newer studies which simply confirm findings of previous research have 
not been included. 
 
ii. Methods used to identify a cohort of HIV and HBV and/or HCV co-infected individual 
(Chapter 3, Chapter 4, Chapter 5) 
This includes a description of the methods used in, and cohort characteristics of, the 
UK Collaborative HIV Cohort (UK CHIC) study (Chapter 3) which was used as the basis 
for this thesis.  I also present a description of the methods used to identify those 
individuals who were HBV and/or HCV co-infected within UK CHIC and the collection of 
a novel dataset including data on hepatitis treatment and outcomes of hepatitis 
infection for those individuals who are confirmed as being HBV and/or HCV co-infected 
(Chapter 4).  Finally, I present the methods which I developed to overcome missing and 
inconsistent hepatitis data within HIV cohort studies (Chapter 5). 
 
iii. Analyses  of epidemiology of HIV and HBV and/or HCV co-infection (Chapter 6) 
I present an analysis of patterns of testing for HBV and HCV. I assess how testing has 
changed over time and identify independent predictors of testing for each of HBV and 
HCV.  Subsequently, among those individuals who have tested for HBV and/or HCV, I 
identify independent predictors of co-infection.  I also estimate incidence of HBV and 
HCV co-infection within this HIV-positive cohort and identify factors associated with 
newly identified infection. 
 
iv. Analyses of hepatitis treatment among HIV-positive individuals (Chapter 7 and 
Chapter 8) 
These analyses are presented in two chapters; the first focussing on HCV (Chapter 7) 
and the second focussing on HBV (Chapter 8).  For each infection, I assess the 
proportion of co-infected individuals who have received any treatment and factors 
associated with having received treatment.  I then present an assessment of response 
to treatment, in the context of limited data, which includes estimating the proportion 
of individuals who respond to treatment and identifying predictors of different 
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treatment responses. I also describe the characteristics of those individuals who have 
not received treatment for their HBV/HCV infection and comment on the need for 
treatment of these individuals. 
 
v. Analyses of clinical outcomes of HIV and HBV and/or HCV co-infected individuals 
(Chapter 9) 
In this final analysis chapter I estimate the effect of HBV and or/HCV co-infection on 
mortality rates among this HIV-positive cohort.  I identify predictors of mortality 
among HBV and/or HCV co-infected individuals.  I also present an investigation into the 
prevalence of cirrhosis among the co-infected cohort, factors associated with cirrhosis 
and the rate of developing decompensated liver disease.  Finally, among those 
individuals with decompensated liver I describe survival after first decompensation 
event.  
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Chapter 2  Literature review on co-infection of HIV with HBV 
and/or HCV 
 
2.1 Epidemiology of HIV and HBV/HCV co-infection 
HIV and hepatitis share transmission routes and risk factors.  The sub-populations most 
affected by each of the infections and the predominant risk factor for each infection differs by 
geographical region.  Therefore the patterns of HIV/HBV and HIV/HCV co-infection differ by 
country and are dependent on patterns of HIV and hepatitis mono-infection within the 
geographical region.  Internationally, a meta-analysis of 22 studies found higher rates of 
HIV/HCV co-infection than HIV/HBV co-infection.  However, subgroup analysis showed that 
while this remained the case for studies conducted in Europe it was not the case for studies 
conducted in Africa or Asia due to the high background prevalence of HBV in many parts of 
Africa and Asia (227).   
 
Since the beginning of the HIV epidemic, researchers have studied the clinical course of HIV 
infection in large ongoing cohort studies.  In this section I present a summary of those studies 
which have investigated the extent of hepatitis co-infection in HIV-positive cohorts. 
 
2.1.1 HCV infection in HIV-positive populations 
The importance of local epidemiology of co-infection is highlighted by the finding that in a 
large multicentre international clinical trial, country of recruitment was shown to be an 
important predictor of HCV infection.  The prevalence of HCV co-infection among individuals 
recruited in Spain and Italy was more than double that among individuals recruited from 
northern European countries, Canada, Australia or South Africa (228).   
 
Injecting drug use is strongly associated with HCV infection (228-231).  Therefore the 
proportion of IDU within a cohort is an important consideration in interpreting HCV prevalence 
estimates.  Estimates of HCV co-infection reported from HIV cohort studies are summarised in 
Table 2.1. In European cohorts of HIV-positive individuals prevalence of HCV varies widely from 
a high of 69%, in a Spanish cohort where almost two thirds of the cohort were IDU, to as low 
as 8.9% in the UK, where only 3.3% of the cohort were IDU. 
 
In recent years, outbreaks of acute HCV have been recognised among HIV-positive MSM (232-
234).  In the UK, between 2002 and 2006, at 20 clinics in London and Brighton, incidence of 
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HCV among HIV-positive MSM increased by 20% per year from 6.86 per 1000 person-years in 
2002 to  11.58 per 1000 person-years  in 2006 (234). This estimate was based on case reports 
and therefore the observed increase may represent a combination of true increased incidence 
as well as increased identification of infections as a result of more awareness of the risk of 
infection among this population.   In Amsterdam, a 10-fold increase in HCV incidence was seen 
when comparing those men under follow-up in the period 1984-1999 (incidence of 0.08 per 
100 person-years) and those men followed-up in 2000-2003 (incidence of 0.87 per 100 person-
years)  (235).  This study used stored serum samples to test for anti-HCV and therefore the 
incidence estimates are not affected by any increased testing for or awareness of HCV in this 
population.    UK surveillance data has been used to estimate incidence among HIV-positive 
MSM at national level.  This was estimated as 2.14 per 1000 person-years in 2012.  This 
represented a significant decrease in incidence over in the past 4 years from 7.3 per 1000 
person-years in 2008 (133).  
 
In a number of outbreaks of HCV among MSM, infection through injecting drug use or other 
parenteral routes has been excluded (235-237).  High-risk sexual behaviour, including sexual 
practices which may increase the risk or mucosal trauma such as fisting, use of sex toys and 
group sex, have been found to be associated with HCV infection (131, 232, 237).   
 
Phylogenetic analysis of HCV infections among MSM in Amsterdam revealed 4 clusters of HCV 
strains which are specific to MSM and unrelated to those strains circulating among IDU.  This 
finding supports the hypothesis that there is a network of transmission among MSM in 
Amsterdam.  Among this group of MSM independent risk factors for HCV infection were HIV 
infection, prior IDU and recent fisting.   However, only 17.9% of HIV/HCV co-infected men 
reported injecting drug use supporting  the hypothesis that within this network HCV is sexually 
transmitted (238).  A larger phylogenetic study which included  MSM from England, the 
Netherlands Germany, France and Australia, found 11 clusters of HCV strains and concluded 
that there is evidence of a large international network of transmission across the European 
countries included (131).   
 
There have also been case reports of HCV incidence in HIV-negative MSM however the 
incidence of HCV in HIV-negative MSM is thought to be much lower than among HIV-positive 
MSM.  A recent meta-analysis of studies investigating incidence of HCV infection in HIV-
positive MSM compared to HIV-negative MSM pooled data on new HCV infections from 9 
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studies of HIV-negative and 20 studies of HIV-positive MSM (239).  The authors found that 
there was a 4.1 times higher risk of acquiring HCV for HIV-positive MSM compared to HIV-
negative MSM.  In addition, 4 studies included in the meta-analysis made direct comparisons 
of HCV incidence rates in HIV-positive and HIV-negative MSM.  Pooling the data from these 
four studies resulted in a risk difference of 3.45/1000 person-years with incidence ranging 
from 0 to 1.7 in HIV-negative MSM and from 0 to 11.8 in HIV-positive MSM (239). It should be 
noted, however, that the comparison conducted in this meta-analysis did not allow for 
inclusion of confounding factors.  In particular, differences in sexual behaviour between the 
HIV positive and HIV negative groups were not adjusted for.  Therefore, while it is clear that 
there is a higher incidence of HCV among HIV-positive MSM, compared to HIV-negative MSM, 
it is not possible to ascertain from this analysis whether this is due to differences in sexual 
behaviour between the two groups.  It is possible that the increased incidence among HIV-
positive MSM is due to greater exposure occurring within a sexual network of HIV-positive 
MSM who practice particular sexual behaviour. 
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Table 2.1 Prevalence of HCV infection in HIV-positive cohorts 
Cohort name Reference Country in which study was 
conducted 
Proportion of IDU within the 
cohort 
Prevalence of HCV infection 
HIV Outpatient Study (HOPS) Spradling et al, 2010 (240) USA 13.6% 24.2% 
(1115/4606) 
HIV Atlanta Veterans’ Affairs 
Cohort Study (HAVACS) 
Anderson et al, 2004(241) USA 22.4% 31.6% 
(306/970) 
VACH cohort (HIV aplicacio´n 
de control hospitalario) 
Roca et al, 2003 (242) Spain 63.8% 69% 
(3259/4709) 
Australian HIV Observational 
database 
Lincoln et al, 2003 (231) Australia 8.1% 13.1% 
(223/1704) 
Italian Cohort Naïve Anti-
retrovirals (ICONA) 
De Luca et al, 2002 (230) Italy 38.6% 45.5% 
(600/1320) 
Swiss HIV cohort study Greub et al, 2000 (243) Switzerland 35.6% 37.12% 
(1157/3111) 
UK Collaborative HIV Cohort 
(UK CHIC) 
Turner et al, 2010 (244) UK 3.3% 8.9% 
(1807/20365) 
Adult AIDS Clinical Trial 
Group (AACTG) cohort 
Sherman et al, 2002 (245) USA 18.2% 16.1%1 
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Cohort name Reference Country in which study was 
conducted 
Proportion of IDU within the 
cohort 
Prevalence of HCV infection 
Johns Hopkins HIV 
Observational cohort 
Sulkowski et al, 2002 (246) USA 45.2% 44.7% 
(873/1955) 
Adolescent/Adult Spectrum 
of HIV Disease Project (ASD) 
Buskin et al, 2011 (229) USA 18.0% 19.0% 
(5463/29400) 
Spanish cohort of adult HIV-
infected patients (CoRIS) 
Serrano-Villar et al, 2014 
(247) 
Spain 11.3% 15.6% 
(1099/7045) 
China National Free Anti-
retroviral Treatment 
Programme  
Zhang et al, 2014 (248) China 22.0% 18.2% 
(6149/33861) 
RESINA Reuter et al, 2011 (249) Germany 7.1% 10.6% 
(97/918) 
European Collaborative 
Study (ECS) 2 
Landes et al, 2008 (250) Pan-Europe 19.3% 12.3% 
(129/1050) 
Immunology Case Registry 
(ICR).  Department of 
Veterans Affairs  
Backus et al, 2005 (251) USA Unknown 3 37.0% 
(6782/18349) 
EuroSIDA Rockstroh et al, 2005 (252) Pan-Europe, plus Argentina 
and Israel 
27.7% 33.0% 
(1960/ 5957) 
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Cohort name Reference Country in which study was 
conducted 
Proportion of IDU within the 
cohort 
Prevalence of HCV infection 
Danish HIV cohort Weis et al, 2006 (253) Denmark 10.2% 16.0% 
(443/2734) 
Canadian Observational 
cohort collaboration 
(CANOC) 
Raboud et al, 2012 (254) Canada Unknown 28.0% 
(768/2706) 
Women and Infants 
Transmission Study (WITS) 
Hershow et al, 2005 (255) USA Unknown 3 29.0% 
(190/652) 
 
1 Weighed estimated prevalence among 1687 individuals 
2 Cohort includes pregnant women only 
3 Although the proportion of individuals who have injected drugs is not reported, a high prevalence of any drug use within the cohort is reported 
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2.1.2 HBV infection in HIV-positive populations  
Like HCV, the prevalence of and factors associated with HBV infection have been studied in 
HIV-positive cohorts (Table 2.2).  Prevalence is usually measured using the presence of HBsAg 
(a marker for current infection) and chronic infection is usually defined as having two or more 
positive HBsAg test results at least 6 months apart. 
   
In the USA, the prevalence of HBV has been reported as between 4.2% (256)  and 11.7% (257).  
The reported prevalence in European cohorts is similar, ranging from 4.5% among a cohort of 
pregnant woman screened in antenatal care (250) to 8.7% in the pan-European EuroSIDA 
cohort (258).  In the UK, a previous analysis of the UK CHIC cohort estimated a prevalence of 
6.9% among 25973 individuals who had ever been tested for HBsAg.  However, in this earlier 
analysis of data from UK CHIC, conducted prior to the analyses presented in this thesis, more 
than a quarter of individuals had never been tested for HBsAg which may have introduced bias 
in the results (259).    
 
Factors associated with HBV infection among HIV-positive individuals are HCV infection (231, 
260), being male and having higher alcohol intake (229, 260).  Specifically in the UK, HBV 
infection was associated with non-white ethnicity, having acquired HIV through sex between 
men or being a woman who has acquired HIV through heterosexual sex and entering the 
cohort in earlier years (259) .   
 
The incidence of HBV infection has been reported in both the USA and UK.  Compared to the 
pre-HAART era, incidence of HBV infection (after diagnosis of HIV) has decreased from 4.0 per 
100 person-years to 1.1 per 100 person-years (256).  However, the generalisability of this this 
study is limited as the cohort contains a limited number of IDU and a limited number of female 
patients, and prevalence may differ in these groups.  HBV incidence estimates for the pre-
HAART era are not available for the UK.  However, from 1996 onwards HBV incidence was 
estimated as 1.7 per 100 person-years.  Incidence was significantly associated with acquiring 
HIV through sex between men (259). 
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Table 2.2 Prevalence of HBV in HIV-positive cohorts 
Cohort name Reference Country in which study was 
conducted 
Definition of HBV infection Prevalence of HBV infection 
Australian HIV Observational 
database 
Lincoln et al, 2003 (231) Australia Positive HBsAg test at any 
time during follow-up 
6.3% 
(101/1605) 
Italian Cohort Naïve Anti-
retrovirals (ICONA) 
De Luca et al, 2002 (230) Italy Positive HBsAg test at any 
time during follow-up 
6.8% 
(90/1320) 
UK Collaborative HIV Cohort (UK 
CHIC) 
Price et al, 2012 (259) UK Positive HBsAg test at any 
time during follow-up 
6.9% 
(1781/25973) 
Muticenter AIDS cohort study 
(MACS) 
Thio et al, 2002 (261) USA Positive HBsAg test at any 
time during follow-up 
8.3% 
(231/2559) 
Adolescent/Adult Spectrum of HIV 
Disease Project (ASD) 
Kellerman et al, 2003 (262) USA Chronic HBV infection – 
HBsAg positivity for 6 
months or more 
7.6% 
(1506/19904) 
EuroSIDA Konopnicki et al, 2005 (258) Pan-Europe, plus Argentina 
and Israel 
Positive HBsAg test at any 
time during follow-up 
8.7% 
(498/5230) 
US Military HIV Natural History 
Study (DoD NHS) 
Chun et al, 2010 (256) USA Chronic HBV infection – 
HBsAg positivity for 6 
months or more 
4.2% 
(117/2769) 
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Cohort name Reference Country in which study was 
conducted 
Definition of HBV infection Prevalence of HBV infection 
Adolescent/Adult Spectrum of HIV 
Disease Project (ASD 
Buskin et al, 2011 (229) USA Chronic HBV infection – 
clinical diagnosis or HBsAg 
and IgG anti-HBc 
8.0% 
(2332/29490) 
EuroSIDA Soriano et al, 2010 (263) Pan-Europe, plus Argentina 
and Israel 
Positive HBsAg test at any 
time during follow-up 
7.1% 
(1179/16505) 
China National Free Anti-retroviral 
Programme 
Zhang et al, 2014 (248) China Positive HBsAg test at any 
time during follow-up 
8.7% 
(2958/33861) 
RESINA Reuter et al, 2011 (249) Germany Positive HBsAg test at any 
time during follow-up 
4.5% 
(41/918) 
European Collaborative Study 
(ECS) 1 
Landes et al, 2008 (250) Pan -Europe Positive HBsAg test at 
antenatal screening 
4.9% 
(51/1050) 
Danish HIV cohort study Omland et al, 2008 (264) Denmark Chronic HBV infection – 
HBsAg positivity for 6 
months or more 
6.0% 
 (178/2781) 
HIV Atlanta Veterans’ Affairs 
Cohort Study (HAVACS) 
Osborn et al, 2007 (257) USA Positive HBsAg test at any 
time during follow-up 
11.7% 
(157/1346) 
Swiss HIV cohort study Wandeler et al, 2013 (265) Switzerland Positive HBsAg test at any 
time during follow-up 
6.0% 
(287/4773) 
  
 
6
0
 
Cohort name Reference Country in which study was 
conducted 
Definition of HBV infection Prevalence of HBV infection 
Chilean AIDS cohort Otto-Knapp et al, 2013 
(266) 
Chile Positive HBsAg test at any 
time during follow-up 
8.4% 
(161/1907) 
HIV Outpatient Study (HOPS) Spradling et al, 2010 (267) USA Positive HBsAg or HBV-
DNA test at any time 
during follow-up 
8.4% 
(376/4467) 
 
1 Cohort includes pregnant women only 
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2.1.3 The importance of liver disease as a cause of death 
As the HIV epidemic has evolved, with the advent of HAART, HIV-positive individuals are living 
longer and progression to AIDS-defining events has become less common (62, 268).   
Consequently, there has been a change in the leading causes of death among HIV-positive 
populations. In particular, the proportion of individuals who die from liver disease has 
increased.  Mocroft et al examined cause of death among 1826 HIV-positive individuals who 
died between 1994 and 2001 in the EuroSIDA cohort.  While the incidence of death had 
decreased from 21.6 per 100 person-years in 1995 to 2.7 per 100 person-years in 2001/2002, 
the proportion of individuals who died from liver-related problems has increased from 19% of 
deaths in 1994 to 25% of the total deaths in 2001/2002 (269).  Similarly, in a large cohort of 
4214 HIV-positive individuals in the USA, 1224 deaths occurred among 4241 individuals 
between January 1990 and December 2003.  Overall there was an 80% decrease in the annual 
death rate over the study period.  However, at the same time, liver disease had become 
increasingly important: whereas it was the primary cause of death in only 0.2% of individuals in 
the pre-HAART era, it was the primary cause of death in 3.7% of individuals in the post HAART 
era (1997-2003) (270).   
 
In a smaller Spanish study, mortality and causes of death were compared in the pre-HAART era 
and the HAART era.  As expected there was a significant decline in overall mortality and in 
AIDS-related mortality in the HAART era while mortality from other causes had significantly 
increased.  In particular, death as a result of liver disease rose from 0.37 per 100 person-years 
follow-up in the pre-HAART era to 0.6 per 100 person-years follow-up in the HAART era.  
Importantly, despite the decreases in AIDS-related mortality, in the HAART era AIDS remains 
the predominant cause of death in this cohort, in the HAART era (271). 
 
As the proportion of all deaths among HIV-positive individuals from liver disease has increased, 
the importance of HBV or HCV infection as an aetiology of liver disease has also been shown. 
In France, a review in 2005 of deaths among HIV-positive individuals showed that of deaths all 
deaths that were related to end-stage liver disease, 64% of had an aetiology of viral hepatitis 
(272).  Among patients in the HIV Outpatients Study in the USA causes of death between 1996 
and 2004 were known for 554 individuals.  Among those individuals who died with at least one 
non-AIDS defining condition reported as the primary or secondary cause of death,  the rates of 
death from neurological, cardiovascular and pulmonary causes had decreased but the rate of 
liver-related death increased (from 1.3 per 100 person-years in 1996 to 12.5 per 100 person-
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years in 2004).  In the final year of the study 80% of individuals who died from liver-related 
diseases were co-infected with HBV or HCV (273).     
 
2.2 The impact of co-infection with HCV on HIV-infection 
In this section I will discuss how co-infection with HCV affects progression of HIV with regard to 
CD4 cell decline, HIV viral load increases and development of AIDS.   
 
2.2.1 The effect of HCV on progression of HIV to AIDS 
There is conflicting evidence from cohort studies regarding the effect of HCV co-infection on 
HIV progression.  Some studies show an increased progression to AIDS in patients who are co-
infected with HCV compared to those are HIV mono-infected, and others showing that there is 
no difference in progression to AIDS between the two groups.   In the pre-HAART era, 251 HCV 
co-infected individuals were compared to 1353 HIV mono-infected patients enrolled in the 
CAESAR study (in Canada, Australia, Europe and South Africa).  All patients were treated with 
zidovudine monotherapy or zidovudine plus one of didanosine or zalcitabine at baseline.  Over 
a 52 week period, there was no effect of HCV on CD4 count and HCV status did not impact on 
progression of HIV to a new AIDS event or death; 13% of HIV mono-infected patients 
experienced a new AIDS event or died compared to 11% of HCV co-infected patients (p=0.37).  
However, some aspects of this study limit the extent to which results can be generalised. For 
example, the study included only patients with very low initial CD4 counts (25-250 cells/mm3) 
and excluded patients with very high liver enzyme elevation.  Therefore the impact of HCV co-
infection may have underestimated (228). 
 
The Women and Infants Transmission Study focussed on women who were recruited in the 
pre-HAART era.  A total of 652 HIV-positive women with known HCV status were recruited in 
pregnancy and followed-up for a median of 43.2 months.  Of these women 29% were HCV co-
infected.  In multivariable mixed-effects regression analysis HCV co-infection was not 
associated with differences in mean HIV viral load, but it was associated with a slightly higher 
(1.9% higher) CD4 percentage compared to HIV-mono-infected individuals.  There did not 
appear to be any clinical impact of this difference as no association was found between HCV 
status and progression to AIDS (255). 
 
In the HAART era, a number of studies have suggested that co-infection with HCV may be 
associated with an increased progression of HIV.  However, many of these studies did not 
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distinguish between progression to AIDS and mortality.  Therefore the impact of HCV co-
infection on HIV progression alone is difficult to elucidate.   Data from the Swiss HIV Cohort 
Study of 3111 HIV-positive individuals (1157 co-infected with HCV) showed that there was an 
increased HIV progression rate among HCV co-infected persons compared to HIV mono-
infected individuals (Hazard ratio (HR) 1.7, 95% CI 1.26-2.30).  However, this analysis did not 
distinguish between AIDS events and deaths as an end point and therefore this increased risk 
of progression may be due to increased mortality (which might be expected in those with HCV 
co-infection) and not an increased risk of HIV progression.  In addition, this sample contained a 
high proportion of IDU (4.8% of HIV mono-infected and 87.7% of HCV co-infected individuals).  
IDU may have a poorer adherence to HAART and increased mortality (not related to HIV).  A 
subgroup analysis was conducted including only those individuals with well controlled HIV in 
order to limit the potential confounding effect of poor adherence to HAART.  There was an 
increased progression in HCV co-infected individuals (HR 3.54, 95% CI 2.0-6.25) even in this 
subgroup. (243). 
 
Likewise, an Italian study which recruited antiretroviral-naive patients who were initiating 
HAART compared clinical progression among 600 HCV co-infected individuals and 720 HIV 
mono-infected patients and found an increased risk of progression (HR 1.55, 95% confidence 
interval (CI) 1.0-2.41).  However, this study also did not distinguish between AIDS events and 
death and the higher risk seen may be due to an increased death rate in the co-infected group. 
This cohort also included a very high proportion of IDU in the co-infected group (93.4%) which 
may increase the mortality rates seen (230).  Finally, in the Australian HIV Observational 
Database, neither HBV nor HCV were associated with an increased risk of AIDS or death after 
the commencement of HAART, although this study also did not distinguish between rates of 
AIDS or rates of death (231). 
 
In studies in which AIDS and death are considered as separate outcomes (or where only AIDS 
events were considered), in the HAART era, HCV co-infection has not been shown to be 
associated with an increased rate of HIV progression.   Among 1955 HIV-positive patients in 
the Johns Hopkins’ HIV Observational Cohort study, in the USA, there was no difference in the 
risk of progression to AIDS between the 44.6% who were co-infected with HCV and the mono-
infected group (246).  Analysis of data from the EuroSIDA cohort (comprising 5957 HIV-positive 
individuals with known HCV status from 6 countries across Europe and Argentina) found no 
difference in clinical progression when progression was defined as a new AIDS event or death.  
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However, when AIDS and death were considered as separate end points, the progression to a 
new AIDS event, was less frequent among HCV co-infected individuals than among those 
infected with HIV only (Incident rate ratio(IRR) 0.78, 95% CI 0.62-0.98), although this may be 
due to other causes of mortality acting as a competing risk in the analysis (252).  One study has 
investigated HIV progression with regard to the development of an AIDS-related opportunistic 
infection.  In both the pre-HAART and HAART eras there was no difference in the hazard of 
developing an opportunistic infection in HCV co-infected patients compared to HIV mono-
infected patients (274). 
 
2.2.2 The effect of HCV on mortality in HIV-positive individuals 
In this section, I will describe studies which have investigated the impact of HCV on mortality in 
HIV-positive populations.  Some studies report on all-cause mortality and do not include cause 
of death.  This should not be interpreted as an increase in progression of HIV to death since 
the deaths may be due entirely to HCV disease or lifestyles associated with HCV infection.  
Therefore studies which report all-cause mortality but also differentiate between liver-related 
mortality, HIV-related mortality and other causes of mortality are most meaningful when 
assessing the impact of hepatitis co-infection on HIV progression.   
 
A summary of studies which compared mortality in HIV mono-infected and HIV/HCV co-
infected individuals is shown in Table 2.3.   A meta-analysis of publications up to end of April 
2008 was conducted by Chen et al.  This showed that in the pre-HAART era, HCV co-infection 
did not increase mortality compared to HIV mono-infection.  However, after the introduction 
of HAART, overall mortality was increased in co-infected patients compared to HIV mono-
infected patients (with a risk ratio (RR) of 1.35, 95% CI 1.11-1.63) (275). Subgroup analysis 
revealed the importance of the length of follow-up when comparing mortality rates as the 
strength of the effect increased with longer follow-up time. 
 
A number of studies conducted in the HAART era (and included in the above meta-analysis) 
showed no difference in all-cause mortality between HCV co-infected and HIV mono-infected 
individuals (246, 276-281). Some of these studies included high numbers of individuals who are 
likely to be at high risk of mortality irrespective of HCV infection, for example, individuals with 
AIDS (277), homeless individuals and IDU (279).  Higher rates of mortality among these groups 
as a whole may reduce the effect of HCV infection on mortality.  This was also seen among 
hospitalised patients in the USA, where there was no difference in mortality between HCV co-
infected and HIV mono-infected patients (282).  However, hospitalised HIV patients are likely 
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to be at very late stages of HIV disease and thus very sick.  These results may not, therefore, be 
generalisable to a setting where patients are not hospitalised.  In the Aquitaine cohort, France, 
which included HIV-positive patients recruited from 18 infectious disease units in the South 
West of France, among 576 HCV co-infected patients and 419 HIV mono-infected patients, HCV 
co-infection was not associated with decreased survival.  However, in this cohort, and in 
contrast to other cohorts, HCV co-infection was more prevalent in women; women have been 
demonstrated to have better survival from HCV overall (283).    
 
Among studies which showed no difference in mortality between HIV mono-infected and HCV 
co-infected individuals, higher rates of mortality were often observed among co-infected 
individuals, however the association of mortality with co-infection was lost after adjusting for 
demographic factors and other factors such as HAART, CD4 counts and alcohol (277, 278, 280, 
281). 
 
In agreement with the overall findings from the meta-analysis, significant increases in all-cause 
mortality were observed in co-infected individuals compared to HIV mono-infected individuals, 
even after adjustment for HAART, in a number of studies (241, 252, 253, 274, 284-287).  In 
addition to those studies included in the meta-analysis, two more recent studies have found 
increased all-cause mortality rates in co-infected compared to mono-infected individuals (288, 
289).  These two studies were also able to adjust for additional co-morbidities.   
 
As well as studies showing an increase in all-cause mortality in HCV co-infected persons 
compared to mono-infected individuals, a number of studies have shown increased liver-
related mortality among HCV co-infected individuals (252, 253, 287, 290, 291).  For example, in 
the D:A:D study (a collaborative study of 11 cohorts in Europe, the USA and Australia), where 
23,441 individuals were followed for a median of 3.5 years, HCV co-infection was 
independently associated with liver-related death in HIV-positive individuals (291).  Similarly, 
in the EuroSIDA cohort, despite not finding an increased progression to AIDS (see section 
2.2.1), there was a significantly higher incidence of death among co-infected individuals 
compared to HIV mono-infected individuals.  This was due to a 10 fold higher increase in liver-
related deaths in the co-infected group than in the HIV mono-infected group (252) 
 
The differences in findings highlight the importance of the particular setting in which a study 
has taken place, the make-up of the study, the co-variates included in the analyses and the 
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length of follow-up.   It is important to note that very few studies include a measurement of 
whether patients had been or were currently being treated for HCV infection and HCV viral 
load is not reported in most studies.  As treatment for HCV evolves (see section 2.7.2), it will 
be important to consider the impact of treatment on mortality and HIV progression.
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Table 2.3 Studies comparing mortality rates in HIV mono-infected and HIV/HCV co-infected individuals in the era of HAART 
Reference Study setting Number included in 
analysis (HIV mono-
infected, HCV co-
infected) 
Relevant analysis Relevant results2 
Ananthakrishan et al, 
2010 (282) 
Nationwide Inpatient 
Study, USA 
263062 (206758, 56304) Multivariable logistic regression of 
factors associated with hospital 
inpatient mortality  
AOR for mortality in co-infected 
compared to mono-infected  1.11 
(95% CI, 0.97-1.29) 
Anderson et al, 20041 
(241) 
HIV Atlanta VA Cohort 
study (HAVACS), USA 
970 (664,306) Multivariable Cox regression of factors 
associated with survival from HIV 
diagnosis to all-cause mortality 
AHR for mortality among co-infected 
compared to mono-infected 2.47  
(95% CI 1.26-4.82) 
Backus et al1(284) HIV-infected veterans 
on HAART, USA 
12216 (7548, 4668) Multivariable Cox regression of 
survival from first HAART to all-cause 
mortality 
AHR for mortality among co-infected 
compared to mono-infected 1.56 
(95% CI 1.42-1.70) 
Bonacini et al1 (290) University clinic 
cohort, USA 
382 (126,256) Unadjusted all-cause  and liver-related 
mortality 
 
25%(65/256) HIV/HCV co-infected 
individuals died compared to 33% 
(41/126) HIV mono-infected  
 
13% 32/256 HIV/HCV co-infected 
individuals had a liver-related death 
compared to 6% (7/126) HIV mono-
infected (p=0.05)  
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Reference Study setting Number included in 
analysis (HIV mono-
infected, HCV co-
infected) 
Relevant analysis Relevant results2 
Braitstein et al1 (285) HIV/AIDS drug 
treatment 
programme, British 
Columbia, Canada 
1186 (580, 6060) Multivariable Cox regression of 
survival from first HAART to death 
from natural causes 
AHR for mortality among co-infected 
compared to mono-infected 2.20  
(95% CI 1.50-3.21) 
Bruno et al, 2007 
(292) 
Single HIV centre, Italy (140, 183) Unadjusted mortality rates in HIV 
mono-infected and HCV co-infected 
individuals without  cirrhosis 
Mortality rate 8 per 1000 person-
years in co-infected individuals 
without cirrhosis (95% CI 4-16) 
 
Mortality rate 6.5 per 1000 person-
years in HIV mono-infected (95% CI 
2.7-15.5) 
Chen et al, 2009 (275) Meta-analysis of 27  
studies in HAART era 
comparing outcomes 
in HIV mono-infected 
and HIV/HCV co-
infected individuals 
 
20 studies Pooled risk ratio from random effects 
model  for all-cause mortality in HCV 
co-infected compared to HIV mono-
infected individuals 
Risk ratio for mortality among co-
infected individuals compared to 
mono-infected individuals  1.35 (95% 
CI 1.11-1.63) 
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Reference Study setting Number included in 
analysis (HIV mono-
infected, HCV co-
infected) 
Relevant analysis Relevant results2 
Crane et al1(286) University of 
Washington HIV 
cohort, USA 
694 (550, 144) Multivariable Cox regression of 
survival from starting HAART to all-
cause mortality 
AHR for mortality among co-infected 
compared to mono-infected 
individuals  1.6 (95% CI 1.0-2.6) 
E-Serag et al1 (293) Hospitalised patients, 
USA 
18018 (12761, 5320) Multivariable Cox regression of 
survival from hospitalisation to all-
cause mortality 
AHR for mortality among co-infected 
compared to mono-infected 
individuals  0.55 (0.51-0.58) 
Fischer et al, 2010 
(288) 
Veterans aging cohort 
study, USA 
23155 (13825, 9330) Multivariable Poisson regression of 
factors associated with all-cause 
mortality 
AHR for mortality among co-infected 
compared to mono-infected 
individuals  1.23, 95% CI 1.17-1.29 
Hung et al1 (276) National Taiwan 
University Hospital 
cohort, Taiwan 
440 (387, 53) Multivariable Cox regression of 
survival from cohort entry to all-cause 
mortality 
AHR for mortality among co-infected 
compared to mono-infected 
individuals  0.50 95% CI 0.20-1.26 
Jaggy et al1 (294) Swiss HIV cohort 
study, Switzerland 
3963 (2318, 1645) Excess death rate compared to the 
general Swiss population in HCV co-
infected and  to HIV mono-infected 
 
EDR 14.0, 95% CI 11.3-17.2 among 
HIV mono-infected 
 
EDR 38.1 95% CI 33.2-43.7 among 
HCV co-infected 
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Reference Study setting Number included in 
analysis (HIV mono-
infected, HCV co-
infected) 
Relevant analysis Relevant results2 
Klein et al1(274) Patients attending 
large HIV clinic in 
Montreal, Canada 
539 (456, 83) Multivariable Cox regression of 
survival from cohort entry to all-cause 
mortality 
AHR for mortality among co-infected 
compared to mono-infected 
individuals  3.37 95% CI 1.58-7.17 
Lohse et al, 2011 
(289) 
Danish HIV cohort 
study. 8 clinics, 
Denmark 
1638 (1427, 211) Multivariable Cox regression of 
survival from cohort entry to all-cause 
mortality (adjusting for additional pre-
existing co-morbidities) 
AHR for mortality among co-infected 
compared to mono-infected 
individuals  2.04, 95% CI 1.19-3.51 
Marins et al1 (277) Nationally 
representative sample 
of AIDS patients, Brazil 
833 (554, 279) Multivariable Cox regression of 
survival from cohort entry to all-cause 
mortality 
AHR for mortality among co-infected 
compared to mono-infected 
individuals  0.94, 95% CI 0.75-1.18 
Mayor et al1(278) Retrovirus research 
centre cohort, Puerto 
Rico 
356 (163, 193) Multivariable Cox regression of 
survival from cohort entry to all-cause 
mortality 
 
AHR for mortality among co-infected 
compared to mono-infected 
individuals  1.17, 95% CI 0.79- 1.72 
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Reference Study setting Number included in 
analysis (HIV mono-
infected, HCV co-
infected) 
Relevant analysis Relevant results2 
Monga et al1(287) Veteran Affairs 
Medical Center, 
Houston, USA 
429 (263, 166) Unadjusted all-cause and liver-related 
mortality rates 
 
7% HIV mono-infected individuals 
died compared to 11% of co-infected 
individuals (p=0.02) 
 
9 liver-related deaths among co-
infected and none in HIV mono-
infected 
Riley et al1(279) Homeless and 
marginally housed 
individuals, San 
Francisco, USA 
330 (118, 212) Univariable Cox regression of survival 
from cohort entry to all-cause 
mortality 
CHR for mortality among co-infected 
compared to mono-infected 
individuals  0.88 (95% CI 0.51-1.50) 
Rancinin et al, 2002 
(283) 
Aquitaine cohort, 
France 
995 (419, 576) Multivariable Cox regression of 
survival from cohort entry to all-cause 
mortality 
AHR for mortality among co-infected 
compared to mono-infected 
individuals  1.20 (95% CI 0.75-1.92) 
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Reference Study setting Number included in 
analysis (HIV mono-
infected, HCV co-
infected) 
Relevant analysis Relevant results2 
Rockstroh et al, 
20051(252) 
EuroSIDA cohort, 
including individuals 
from 89 centres in 
Europe, Israel and 
Argentina 
5757 (3997, 1960) Poisson regression of factors 
associated with all-cause and liver-
related mortality 
 
ARR for mortality among co-infected 
compared to mono-infected 1.80 
(95% CI 1.44-2.25) 
 
ARR for liver-mortality among co-
infected compared to mono-infected 
12.31, 95% CI 6.77-22.41 
Sulkowski et al1(246) John Hopkins HIV 
cohort study.  A 
university based HIV 
clinic cohort, USA 
1955 (1082, 873) Multivariable Cox regression of 
survival from cohort entry to all-cause 
mortality 
AHR for mortality among co-infected 
compared to mono-infected 
individuals  1.05, 95% CI 0.85-1.30  
Sullivan et al1(280) Adult and adolescent 
spectrum of HIV 
disease project.  
Including 100 HIV 
inpatient and 
outpatient facilities, 
USA 
10481 (8457, 2024) Multivariable Cox regression of 
survival from cohort entry until all-
cause mortality 
AHR for mortality among co-infected 
compared to mono-infected 
individuals  1.1 (95% CI 0.9-1.2) 
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Reference Study setting Number included in 
analysis (HIV mono-
infected, HCV co-
infected) 
Relevant analysis Relevant results2 
Tedaldi et al1 (281) HIV outpatients study.  
Three  clinics, USA 
823 (556, 267) Multivariable Cox regression of 
survival from cohort entry until all-
cause mortality 
AHR for mortality among co-infected 
compared to mono-infected 
individuals  0.91 (95% CI 0.55-1.51) 
Voirin et al1 (295) French Hospital 
database of HIV-
positive individuals, 
Lyon, France 
1490 (1285, 205) Multivariable Cox regression of 
survival from cohort entry until all-
cause mortality comparing HIV mono-
infected individuals who do not inject 
drugs  
AHR for mortality among co-infected 
non-IDU compared to mono-infected 
individuals non-IDU 0.76 (95% CI 
0.28-2.08) 
 
AHR for mortality among co-infected 
IDU compared to mono-infected 
non- IDU 2.90 (95% CI 1.62-5.20) 
Weber et al1(291) Data Collection on 
Adverse Events of 
Anti-HIV Drugs (D:A:D) 
Study, Europe, USA, 
Australia 
23441 (18167, 5274) Poisson regression of factors 
associated with liver-related mortality 
ARR  for 6.7 for co-infected 
compared to mono-infected 
individuals, 95% CI 4.0-11.2 
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Reference Study setting Number included in 
analysis (HIV mono-
infected, HCV co-
infected) 
Relevant analysis Relevant results2 
Weis et al1 (253) Danish HIV cohort, 
nationwide cohort 
study, Denmark 
1726 (1283, 443) Multivariable Cox regression of 
survival from cohort entry to all-cause 
and liver-related  mortality 
AHR for all-cause mortality among 
co-infected compared to mono-
infected individuals  2.4, 95% CI 1.3-
2.6 
 
AHR for liver-mortality among co-
infected compared to mono-infected 
individuals  15, 95% CI 7.1-34.0 
 
 
1 Study included in meta-analysis from Chen et al (275) 
2 AOR – adjusted odds ratio; AHR – adjusted hazards ratio; 95% CI – 95% confidence interval; EDR – excess death rate; CHR – crude hazards ratio; ARR – 
adjusted rate ratio
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2.2.3 The effect of HCV infection on the immunological and virological response to 
HAART 
An individual’s response to HAART can be described in terms of suppression of HIV replication 
(decreased HIV viral load) or in terms of recovery of immune restoration, measured as 
increases in CD4 cell count and maintenance of high levels of CD4 cells. Co-infection with HCV 
may affect the response to HAART.  In this section I will describe the currently available 
knowledge on the extent to which co-infection with HCV does or does not affect an individual’s 
response to treatment with HAART.  The biological mechanisms by which HCV may affect the 
response to HAART are beyond the scope of this literature review.   
 
A meta-analysis of studies published by May 2004 used median change in CD4 count after 
starting HAART as a measure of response to treatment.  The analysis included results from 8 
cohorts of HIV-positive individuals with follow up ranging from 48 months to 4 years.  After at 
least 48 weeks of HAART the increase in CD4 cells among HCV co-infected individuals was 33.4 
cells/mm3 (95% CI -43.3-23.5 cells/mm3) less than among HIV mono-infected individuals. This 
result proved to be insensitive to any one of the included studies and did not depend on year 
of HAART initiation (296).   
 
A number of the studies which were included in the meta-analysis also reported on the effect 
of HCV co-infection on the virological response to HAART: the decrease in HIV viral load and 
the ability to maintain an undetectable HIV viral load.  In general, these studies found that 
there was no difference in the virological response to HAART between HCV co-infected 
individuals and HIV mono-infected individuals (230, 231, 243, 274, 297).  However, one study 
did show a trend towards smaller decreases in HIV viral load in HCV co-infected individuals 
compared to HIV mono-infected individuals (283).  In addition to reporting on both the overall 
virological and immunological responses to HAART, Greub et al also conducted a nested study 
of 56 patients with well controlled viral load but differing CD4 responses. Although the 
numbers in this study were very small, the results indicated that there may be a link between 
decreased immunological response to HAART and infection with HCV genotype 3 (243). 
 
In more recent studies, there have been a range of results with some studies showing no effect 
of HCV co-infection on the response to HAART and others, like the meta-analysis, showing a 
decreased response to HAART in HCV co-infected individuals.  Among the Atlanta Veterans 
Affairs cohort study of 970 HIV-positive individuals, CD4 count was measured three times: 
within 6 months of HCV test; 6 months after initiation of HAART; and at last visit prior to study 
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end date (October 2001).  No difference was reported in recovery of CD4 counts after starting 
HAART between those who were co-infected with HCV and HIV mono-infected patients at six 
months post initiation of HAART.  The longer term model which considered difference in CD4 
count from initiation of HAART to last visit also showed no difference in CD4 changes between 
the two groups (241). 
 
Analysis of data from the EuroSIDA cohort also did not show any significant differences in the 
increase in CD4 count or the time taken to detect that increase.  However, this study did find 
that HCV co-infected individuals were less likely to commence HAART than HIV mono-infected 
individuals (252).  Similarly, in a previous analysis of data from the UK CHIC, there was no 
impact on either the virological or the immunological response to HAART in HCV co-infected 
compared to HIV mono-infected patients.  This analysis also investigated the possibility of 
discordant virological and immunological responses and found no evidence for an association 
between HCV co-infection and discordant responses to HAART (244). 
 
Among a cohort of individuals who were enrolled in randomised controlled trials for 
antiretroviral drugs in Thailand, there was no significant difference in virological response 
between HCV co-infected individuals and HIV mono-infected individuals.  There was a 
decreased immunological response to HAART at weeks 4 and 8 weeks but by 48 weeks of 
follow-up the increases in CD4 count were comparable between HCV co-infected and HIV 
mono-infected individuals (298).  Interestingly this study included very low proportions of 
individuals who were infected through injecting drug use unlike many other cohorts.  
 
Other recent studies have found that HCV co-infection does affect the response to HAART.  In a 
cohort of HIV-positive veterans in the USA, where there is a high prevalence of HCV, both HCV 
co-infected and HIV mono-infected individuals had similar virological responses to HAART.  
However, the immunological response to HAART was lower among HCV co-infected 
individuals, evidenced by lower maximum CD4 counts and lower median CD4 counts at 6 
months follow up (284) 
 
In the HAART Observational Medical Evaluation and Research study, outcomes were defined as 
an absolute CD4 event, defined as an increase of 75 or more cells/mm3, and CD4 fraction 
event, defined as an increase of 10% of CD4 cells out of the total T cell population.  HCV co-
infected patients took longer to experience each of these outcomes than HIV mono-infected 
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patients.  This cohort included a very high proportion of people with HCV infection (51%).  In 
an adjusted Cox regression analysis, HCV co-infected patients were less likely to experience an 
absolute CD4 response than HIV mono-infected individuals.  This study had the advantage of 
being able to account for adherence to HAART during the first year of HAART.  This was based 
on the proportion of time that dispensed antiretroviral drugs would last and was classified into 
a binary variable of ≥95% or <95% adherence allowing the analysis to be restricted to 
individuals with ≥95% adherence (299). 
 
The ICoNA study conducted an analysis of 1053 individuals with known HCV-RNA test results 
and compared the response in those who were HIV-positive and HCV-viremic with that among 
those who were HCV-negative.  HCV co-infected patients were significantly less likely to 
achieve an increase of greater than 100 CD4 cells during follow up (maximum follow up 80 
weeks).  However, the CD4 recovery post-HAART initiation did not appear to be dependent on 
HCV viral load and did not appear to be influenced by HCV genotype (300). 
 
There are a number of possible reasons for the contradictory results seen in published data.  
Firstly, most studies are unable to account for adherence to HAART.  Adherence may be worse 
among HCV co-infected patients and therefore result in an observed decreased immune 
response.  Secondly, many studies do not measure time on HAART and it is possible that the 
impact of HCV infection on response to HAART may be different at different stages of HAART 
treatment (i.e. decreased in earlier stages but the same over a longer period of follow-up).  
Similarly, the follow-up time for all the studies is different which may lead to different results.  
Thirdly, the prevalence of HCV within the cohorts studied and the profile of the HCV-infected 
cohort is different across the studies and this may affect results (for example IDU may have 
decreased responses to HAART and more co-infected patients may be IDU than HIV mono-
infected patients). Finally, there may be other co-morbidities which affect the response to 
HAART and these are not recorded in studies to date.   These possible reasons for conflicting 
results in the literature highlight the importance of forming treatment guidelines based on 
results of studies which are conducted in cohorts similar to the population needing treatment 
and also ensuring continual monitoring of individuals’ responses to treatment. 
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2.3 The impact of co-infection with HBV on HIV infection 
2.3.1 The effect of HBV on the progression of HIV to AIDS 
In this section I will describe the progression of HIV infection to AIDS which may be defined 
either as an AIDS-defining illness or a point at which an individual has very suppressed immune 
function – usually defined as a CD4 count of <200 cells/mm3. 
 
In the pre-HAART era a small study of 347 newly HIV-positive who did not have AIDS were 
enrolled into a prospective cohort study.  The median follow up was four years and 229 
individuals showed signs of past or current HBV infection at enrolment (197 past infections and 
32 current infections).  A further 15 individuals became positive for HBsAg during follow up.  
Both progression to AIDS and progression to a CD4 count <200 cells/mm3 from estimated date 
of HIV seroconversion were estimated.  There were no significant differences in the time to 
these end points between currently HBV co-infected, HBV past-infected or HIV mono-infected 
individuals (301). 
 
In the era of HAART, analysis of data from the EuroSIDA cohort showed that among 5728 
individuals with known HBsAg status at enrolment  there was no difference in the incidence of 
new AIDS-defining events between HBsAg-positive (8.7%) and HBsAg-negative individuals (ARR  
0.94, 95% CI 0.74-1.19)(258) . 
 
A large multicentre cohort study of MSM in the USA included men who initiated HAART while 
enrolled and who could be classified as HBV never infected, past infection, chronically infected 
or having isolated core antibody. Of 816 men, 350 had never been infected with HBV; 357 
showed evidence of a past HBV infection; 45 were chronically infected with HBV; and 64 had 
isolated anti-HBc.  Median follow up was 7 years and the large majority of patients (95%) 
received an HBV active drug as part of their HAART regimen.  There was no difference in the 
incidence of AIDS-defining events between chronically infected and never infected individuals 
(302).   
 
A retrospective study of 1792 HIV-positive individuals in Greece was conducted by testing 
stored serum samples for HBsAg where patients had 2 serum samples available.  Patients were 
then classified as HBsAg-negative for both their samples, HBsAg-positive for both their samples 
(these individuals were considered probably chronically infected), HBsAg-negative followed by 
positive (classified as HBsAg convertors) or HBsAg-positive followed by negative (classified as 
 79 
 
HBsAg revertors).  Overall 13.24% of individuals experienced their first AIDS-defining event 
during follow-up. However, there was no significant difference in the incidence of AIDS-
defining events by HBsAg status.  The authors also conducted a meta-analysis of 7 studies 
(including their own). Three of these studies were conducted in the pre-HAART era.  This also 
showed no effect of HBsAg status on the development of AIDS and there was no evidence of 
heterogeneity between the studies (p= 0.54, I2 statistic 0%) (303).  
 
The above studies were all conducted in geographic areas where HBV is not endemic and 
conclude that HBV infection does not increase progression of HIV to AIDS.  By contrast, in a 
secondary analysis of data from two antiretroviral trials (where all patients were screened for 
HBsAg at entry) individuals who were co-infected with HBV had lower CD4 counts than those 
who were HIV mono-infected.  This was a multinational study conducted in countries where 
HBV is endemic and infection was probably acquired in childhood. Similarly they had a higher 
prevalence of AIDS although this was not statistically significant, but HIV RNA levels did not 
differ (304).  Therefore, although the majority of the literature suggests not increased 
progression of HIV in the context of HBV co-infection it is possible that that the impact of HBV 
on HIV infection is different depending on the duration of the HBV infection.  
 
2.3.2 The effect of HBV on mortality in HIV-positive individuals 
A summary of those studies which assess the effect of HBV co-infection on mortality among 
HIV-positive individuals is shown in Table 2.4.  There are mixed results among studies with 
some showing a significantly increased risk of death among co-infected individuals compared 
to HIV mono-infected individuals and others showing no significant difference.  The results of 
many of these studies were included in the meta-analysis conducted by Nikolopolous et al.  In 
addition to reporting on progression to AIDS (see section 2.3), Nikolopoulos et al reported on 
mortality rates from a meta-analysis of 11 studies (involving 12382 individuals).  The overall 
mortality rate in this cohort was 2.12 per 100 person-years.  The incidence of death was 
slightly higher in the HBV chronically infected group (those with 2 positive HBsAg samples) 
compared to the never infected group (IRR 1.72, 95% CI 1.05-2.83). However, this difference 
was not maintained after adjusting for HIV viral load and CD4 count.  After adjustment, no 
difference was seen between the mortality rates in the four HBsAg groups (never infected, 
chronically infected, HBV convertors and HBV revertors) (303).  However, interpretation of 
these adjusted estimates is problematic since HBV infection may lead to difference in HIV viral 
load in CD4 count and these clinical factors are on the causal pathway to death.   
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The meta-analysis conducted by the authors included 11 studies.  Four of the studies included 
in the meta-analysis were conducted before the HAART era.  The studies did not show 
significant evidence of heterogeneity.  The random effects model showed a significantly 
increased rate of mortality in HBV co-infected individuals compared to HIV mono-infected 
individuals (RR 1.36, 95% CI 1.12-1.64).  This result appeared to be independent of any specific 
study (as assessed by omitting one study at a time) and the same effect was seen when 
conducting the analysis for studies in the pre-HAART era separately from those in the HAART 
era (303). The meta-analysis reported on all-cause mortality only and was not able to 
distinguish between liver-related deaths and other deaths.  Therefore this increased mortality 
may not be an indication of increased progression of HIV.  For example the study conducted by 
Thio et al showed that not only was all-cause mortality higher in co-infected individuals, but 
also that liver-related death was 8 times more likely among co-infected men compared to HIV 
mono-infected men. 
 
An additional study which was not included in the above meta-analysis in the pre-HAART era is 
a case control study nested within a cohort of HIV-positive individuals in Italy (305).  Being 
positive for HBsAg was significantly associated with death from liver disease compared to 
death from other causes.  However, a high proportion of the cohort was co-infected with 
either HCV or HDV and so it is not possible to look at the association of HBV alone on death 
from liver disease compared to other causes.   Other factors which were also associated with 
death from liver disease compared to death from other causes were alcohol abuse, higher CD4 
count and older age at enrolment. 
 
There are also a number of additional studies which were not included in the meta-analysis in 
the HAART era.   Although in the MACS there was no difference in the incidence of AIDS-
defining events between chronically infected and never-infected individuals (see section 2.3), 
both AIDS-related and non-AIDS-related mortality were higher among chronically HBV co-
infected individuals than among HIV mono-infected individuals who had never had HBV (302).  
Liver-related deaths were also investigated within the D:A:D study which included 23,114 
individuals followed for a median of 3.5 years.  This analysis indicated that active HBV infection 
was associated with liver-related death.  The authors also reported that liver-related disease 
was associated with immune-suppression as measured by decreased CD4 counts (a 2-fold 
lower CD4 count resulting in a 23% increased risk of liver-related death) (291). 
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In the US Military HIV Natural History Study, all included patients are known to have been 
infected with HIV for 3 years or less.  Therefore the effect of duration of HIV infection was 
minimised in this study.  Patients were classified according to their HBsAg status as negative 
(74%), resolved HBV infection (20%), isolated anti-HBc (3%) and chronically infected (3%).  
AIDS events and death were reported together in this analysis.  Before adjustment for 
potential confounders all categories of HBV infection were associated with an increased risk of 
AIDS or death.  After adjustment, in a multivariable model, only chronic HBV infection was 
associated with an increased risk of AIDS or death.  Other factors associated with AIDS or 
death were a low CD4 count, no receipt of HAART and HCV infection.  Therefore it is not 
possible to assess whether HBV is a surrogate marker of poor outcome or whether it has a 
direct harmful impact on HIV disease.  In addition, the cause of death is not reported and so it 
is not possible to assess whether these deaths were liver-related or not (306). 
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Table 2.4 Studies comparing mortality rates in HIV mono-infected and HIV/HBV co-infected individuals in the era of HAART 
Reference Study setting Number included in analysis 
(HIV mono-infected, HBV 
co-infected) 
Relevant analysis Relevant results2 
Bonacini et al, 2004 1 (290) University clinic cohort, USA 198 (126, 72) Unadjusted all-cause  and 
liver-related mortality 
 
26% (19/72) of individuals 
died in co-infected group 
compared to 33%  (41/126) 
in the HIV mono-infected 
group 
 
15% (11/720 of the co-
infected individuals had 
liver-related death  
compared to 6% (7/126) of 
mono-infected individuals 
had liver-related deaths 
(P=0.04) 
Chun et al, 2011 (306) HIV sero-convertors in the 
US Military HIV Natural 
History Study, USA 
2352 (2288, 64) Multivariable Cox regression 
of all-cause mortality/AIDS 
events combined 
AHR for mortality/AIDS 
event among co-infected 
compared to mono-infected 
1.80 (95% CI 1.20-2.69) 
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Reference Study setting Number included in analysis 
(HIV mono-infected, HBV 
co-infected) 
Relevant analysis Relevant results2 
Hoffman et al, 2009 (302) Multicentre AIDS cohort 
study (MACS), USA 
395 (350, 45) Multivariable Poisson 
regression of factors 
associated with AIDS-related 
mortality and non-AIDS 
mortality 
IRR for AIDS-related 
mortality among co-infected 
compared to mono-infected 
individuals 2.7 (95% CI 0.9-
8.2) 
 
IRR for non-AIDS mortality 
among co-infected 
compared to mono-infected 
individuals 4.1 (1.0-16) 
Konopnicki et al, 2005 1 (258) EuroSIDA cohort, including 
individuals from 72 centres 
in Europe, Israel and 
Argentina 
5728 (5230, 498) Poisson regression of factors 
associated with all-cause and 
liver-related mortality 
IRR for all-cause mortality 
among co-infected 
compared to mono-infected 
individuals 1.54 (1.19-1.98) 
 
IRR for liver-related 
mortality among co-infected 
compared to mono-infected 
individuals 3.31 (95% CI 
1.80-6.11) 
  
 
8
4
 
Reference Study setting Number included in analysis 
(HIV mono-infected, HBV 
co-infected) 
Relevant analysis Relevant results2 
Nikolopolous et al, 2009 1 
(303) 
Retrospective cohort study, 
Greece 
1729 (1528, 107) Poisson regression of factors 
associated with all-cause 
mortality 
Adjusted IRR for mortality 
among HBsAg-positive 
individuals compared to 
HBsAg-positive individuals 
1.72 (95% CI 1.05-2.83) 
Nikolopolous et al, 2009 
(303) 
Meta-analysis of studies 
comparing mortality among 
HBV co-infected and HIV 
mono-infected individuals 
6 studies in the post HAART 
era 
Pooled measure of random 
effects model 
Pooled effect estimate of co-
infection on mortality rates 
in post-HAART era 1.28 (95% 
CI 1.03-1.60)  
Osborn et al 2007 1 (257) HIV Atlanta Veterans Affairs 
Cohort Study (HAVACS), USA 
443 (286, 157) Multivariable Cox regression 
of all-cause mortality  
AHR for mortality among co-
infected compared to mono-
infected individuals 1.28 
(p=0.27) 
Sheng et al, 2004 1 (307) National Taiwan University 
Hospital cohort, Taiwan 
498 (387, 111) Multivariable Cox regression 
of all-cause mortality  
AHR for mortality among co-
infected compared to mono-
infected individuals 1.71  
(95% CI 1.19-2.47) 
  
 
8
5 
Reference Study setting Number included in analysis 
(HIV mono-infected, HBV 
co-infected) 
Relevant analysis Relevant results2 
Thio et al, 2002 (261) Multicentre AIDS cohort 
study (MACS), USA 
2559 (2346, 213) Poisson regression of liver-
related mortality 
ARR for mortality among 
HIV-positive, HBsAg-negative  
individuals and HIV-positive, 
HBsAg-positive individuals 
compared to HIV-negative 
HBsAg-negative individuals 
1.7 (p<0.0001) and 14.2 
(p<0.0001) respectively 
Weber et al1(291) Data Collection on Adverse 
Events of Anti-HIV Drugs 
(D:A:D) Study, Europe, USA, 
Australia 
23441 (21847, 1594) Poisson regression of factors 
associated with liver-related 
mortality 
ARR for liver-related 
mortality among co-infected 
compared to mono-infected 
individuals 3.7 (95% CI 2.4-
5.9) 
Zhou et al, 2007 1 (308) The TREAT Asia HIV 
Observational Database, a 
multicentre study at 15 sites 
in the Asia Pacific region 
1641 (1470,171) Multivariable Cox regression 
of all-cause mortality 
AHR of mortality among co-
infected compared to mono-
infected individuals 0.80 
(95% CI 0.24-2.64) 
1 Study included in meta-analysis from Nikolopolous et al (303) 
2 AOR – adjusted odds ratio; AHR – adjusted hazards ratio; 95% CI – 95% confidence interval; EDR – excess death rate; CHR – crude hazards ratio; ARR – 
adjusted rate ratio 
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2.3.3 The effect of HBV infection on the immunological and virological response to 
HAART 
A number of studies have investigated whether co-infection with HBV has an impact on the 
virological or immunological repose to HAART and there have been some conflicting results.  In 
general, studies which have assessed response to HAART by examining increases in CD4 count 
have found no difference in response to HAART between HBV co-infected and HIV mono-
infected persons.  This was shown in the EuroSIDA cohort (258), in the USA in the MACS cohort 
(302), in a nationwide Danish cohort study (264), in a South African cohort (309) and in a large 
Australian cohort (231).   A retrospective analysis of a cohort of HIV-positive individuals 
investigated the response to HAART in the context of HBV co-infection only by measuring the 
virological response.  This study also did not find any association between response to HAART 
and HBV co-infection (303).   
 
In contrast to these results, there have been some studies which have shown an impaired 
response to HAART associated with HBV co-infection.  In the Swiss cohort study patients were 
followed for three years after starting HAART.  Throughout these three years individuals who 
had current or resolved HBV infection had significantly lower CD4 counts than those who were 
HBV uninfected.  CD4 recovery was particularly impaired among those individuals who had 
detectable HBV-DNA one year after starting HAART (265).  In a cohort of individuals in Thailand 
an impaired response to HAART was observed in the first four weeks of treatment where those 
who were HBV co-infected had significantly lower mean increases in CD4 count than those 
who were HIV mono-infected.  However, this difference was not  sustained in the longer term 
and by 48 weeks of treatment the mean increases in CD4 count were similar (298).  
 
The reasons for the conflicting results described in the studies above are unclear.  However, it 
should be noted that in HBV co-infected patients HAART regimens will almost always include 
an agent which is active against HBV.  Few studies have included the components of HAART 
regimen as a covariate in the analyses performed and therefore the difference may in part be 
due to the impact of HAART on HBV infection as well as HIV infection.  For example, where no 
association is observed between HBV co-infection and response to HAART this may be, in part 
due to successful suppression of HBV by the HAART regimen, thus limiting the impact of HBV 
on the response to HAART. 
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2.4 Co-infections with hepatitis viruses and the development of anti-
retroviral induced hepatotoxicity 
Hepatotoxicity, usually expressed as liver enzyme elevation (LEE), can develop in HIV-positive 
patients in response to treatment with antiretroviral drugs.  Infection with hepatitis viruses can 
also lead to LEE.   In this section I will describe how co-infection with hepatitis viruses affects 
the development of hepatotoxicity in response to HAART.  This has been investigated in the 
literature by comparing the risk and rate of development of LEE in HIV mono-infected patients 
with that in hepatitis co-infected patients.  Analysis of co-infection and hepatotoxicity is 
complicated by the fact that in many cohorts co-infection is more prevalent among IDU than in 
those who do not inject drugs.  Since injecting drug use is also a risk factor for hepatotoxicity 
there is the possibility that this may affect results, particularly in smaller cohorts. 
 
Higher rates of LEE are seen among hepatitis co-infected individuals compared to HIV mono-
infected individuals.  This has been shown both in cohorts with high hepatitis prevalence (310, 
311) and in cohorts where hepatitis prevalence is lower (312, 313). However, these studies 
have not examined the effect of HBV and HCV on rates of LEE separately.  For example, one of 
the largest studies of hepatotoxicity in hepatitis co-infected and HIV mono-infected individuals 
used data from patients in the ICoNA study.  A total of 5272 patients were included.  A high 
prevalence of co-infection was present but this was mostly due to HCV co-infection:  47.6% of 
patients were co-infected, of whom 85.6% were HCV co-infected, 7.7% were HBV co-infected 
and 6.8% were HBV and HCV co-infected.  Co-infection with hepatitis viruses was significantly 
associated with increased risk of LEE (RR 5.07, p<0.0001).  This association with co-infection 
was not different between those on HAART and those not on HAART, indicating that the LEE 
was due to hepatitis infection rather than as a result of HAART (310).  
 
In some larger cohorts researchers have been able to examine the separate effects of HBV and 
HCV co-infections on the development of hepatotoxicity. For example, among a cohort of 560 
HIV-positive patients, the risk of developing LEE was 2.78 times greater among co-infected 
individuals than among HIV mono-infected individuals (314).  Specifically both chronic HBV 
(adjusted hazard ratio (AHR) 4.6, 95% CI 2.6-8.3) and chronic HCV (AHR 3.2, 95%CI 1.8-8.3) 
were associated with grade 3 or 4 LEE.  In this cohort although the hazards ratios are relatively 
high, it is worth noting that only a small proportion of individuals in the cohort actually 
experienced LEE (7.7% overall) and that the clinical impact of these episodes was small – a 
minority were symptomatic and all resolved (315).  The finding that the risk of LEE is higher 
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among hepatitis co-infected individuals than among HIV mono-infected individuals but the 
clinical impact of this is minimal has also been shown in a number of other studies (316, 317). 
 
Some researchers have investigated factors associated with LEE in co-infected individuals.  In 
the study previously described by Wit et al, neither absolute nor changes in CD4 count were 
associated with LEE (315).  In contrast, Aceti et al observed that at 12 months among HCV co-
infected individuals hepatotoxicity was more frequent in individuals with lower CD4 count and 
higher viral load and that patients with higher CD4 increases had faster decreases of ALTs than 
patients with lower CD4 counts (318). 
 
It is possible that the degree of liver damage in co-infected patients may affect the 
development of hepatotoxicity.  A significant correlation between liver fibrosis stage and 
incidence of hepatotoxicity has been observed with higher incidence in individuals with stage 3 
or 4 fibrosis.  Among only those with stage 3 or 4 fibrosis incidence of hepatotoxicity was 
higher in individuals who were on a NNRTI based regimen compared to those not exposed to 
NNRTIs.  The use of NNRTIs did not affect hepatotoxicity incidence in those with stage 1 or 2 
fibrosis (319).  This effect was not seen in a Spanish cohort of patients treated with PIs 
(atazanavir or ritonavir).  In this cohort almost all patients were co-infected with HCV (98%) 
(320). 
 
It is clear from the literature that those individuals on HAART and co-infected with hepatitis 
viruses, are at increased risk of developing LEE compared to HIV mono-infected individuals.  
However, these events may or may not have significant clinical impact.  Therefore in the 
context of hepatitis virus co-infection, clinicians should carefully consider the  choice of drugs 
included in a HAART regimen with regards to their liver toxicity profiles (65) and HIV and 
hepatitis co-infected individuals should be frequently monitored for liver damage caused not 
only by their hepatitis infection but also possibly by their HIV treatment.  
 
 
2.5 The impact co-infection with HIV on HCV infection 
In this section I will describe the current knowledge on how HIV affects the progression of HCV.  
This may be with regard to levels of virus present in the blood, progression from acute to 
chronic infection or with regard to clinical outcomes of HCV infection including risk of 
development of liver fibrosis and its progression to cirrhosis, steatosis, end-stage liver disease 
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and HCC.  I will also describe how the use of HAART may affect the progression of HCV 
infection in HIV co-infected individuals. 
 
2.5.1 The effect of HIV on HCV progression 
Evidence from studies conducted in the pre-HAART era suggests that co-infection with HIV is 
associated with higher levels of HCV-RNA.  A multi-centre cohort study of haemophilia patients 
was initiated in 1982.  In order to investigate the effect of HIV on HCV infection with regard to 
HCV-RNA levels data were analysed from a group of patients who were all positive for HCV 
before recruitment. Seventeen of these patients seroconverted to HIV during follow up and 17 
remained HIV-negative.  Over the total study period (up to 13 years), the mean HCV-RNA levels 
increased 58 fold in those who became HIV-positive, while the increase was much smaller (3-
fold) in those who remained HIV-negative.  There was a clear correlation between the degree 
of immunosuppression and the HCV-RNA level among the individuals who became HIV-positive 
during follow-up, with those with lower CD4 counts having higher mean HCV-RNA levels (321). 
 
These findings have been confirmed in larger studies.  HCV-RNA level was correlated with CD4 
count in a study of 116 HIV co-infected individuals and 431 HCV mono-infected individuals 
where in the HIV-positive group CD4 counts greater than 500 cells/mm3 were associated with 
lower HCV-RNA levels (322).  In 2 studies, HIV co-infected individuals were matched to HCV 
mono-infected individuals.  In 80 HCV mono-infected and 80 HIV co-infected patients, followed 
for 52 months,  HIV patients had significantly higher mean serum HCV-RNA levels than HIV-
negative controls and serum high HCV-RNA level was associated with low CD4 count (323).  
The same pattern was seen among 38 HIV co-infected and 38 HCV mono-infected individuals 
with a history of injecting drug use (324). 
 
Finally, in a more recent study of HCV-infected patients in China (25% of whom were HIV co-
infected), levels of HCV core antigen (indicating chronic infection) were shown to be negatively 
correlated with CD4 count among the co-infected group  (325).  
 
The long asymptomatic period in HCV infection means that many new infections are 
undetected and therefore studying the early phases of infection is difficult.  However, current 
evidence suggests that HIV-positive individuals are less likely to spontaneously clear acute HCV 
infection than HIV-negative individuals.  In a small cohort of 112 HIV-positive patients with 
acute HCV, followed for a median of 45 months, 15% of patients cleared the infection while 
the others progressed to chronic infection (326).  This compares to proportions of 36%-54% of 
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HCV mono-infected patients who have been reported as clearing HCV infection (327, 328). 
Among HIV-positive individuals clearance of acute infection was associated with higher CD4 
counts (above 650 cells/mm3), having a rapid HCV viral decline, elevated ALT and bilirubin 
levels and infection with HCV genotype 1 (326).  In addition, in a study of 43 HIV-positive 
individuals with acute HCV there was evidence for delayed development of anti-HCV with 37% 
of individuals remaining antibody negative at 3 months after diagnosis, 10% at 9 months and 5 
% at 1 year after diagnosis (329). 
 
The clinical impact of co-infection has also been investigated in a number of cohorts.  A meta-
analysis conducted predominantly in the pre-HAART era included 8 studies involving a total of 
1871 HCV-positive patients (601 were HIV co-infected and 1370 were HCV mono-infected).  
The authors assessed the development of cirrhosis or clinically identified decompensated liver 
disease in HIV co-infected patients compared to HCV mono-infected patients.  Two of the 
included studies assessed only decompensated liver disease, 4 assessed only cirrhosis and 2 
assessed both outcomes.  Overall, the populations studied were predominantly male.  Only 
one study included the role of HAART in their analysis (330).  Combined relative risk for 
development of decompensated liver disease or cirrhosis across the studies was 2.92 (95% CI 
1.70-5.01) for co-infected individuals compared to HCV mono-infected individuals.  When the 
analyses were conducted separately for decompensated liver disease and cirrhosis combined 
relative risks were 6.14 (95% CI 2.86-13.20) and 2.07 (95%CI 1.40-3.07), respectively. Three 
studies which investigated duration of HCV infection found that a higher proportion of HIV co-
infected patients developed severe liver disease <15 years after HCV exposure than HCV-
mono-infected patients.  Five of the included studies found an increased risk of liver disease in 
those patients with a lower CD4 count or AIDS.  Although alcohol consumption was described 
in 5 studies a range of measures were used and therefore this could not be included in the 
meta-analysis (331). 
 
In a further meta-analysis, conducted in the era of HAART, the authors estimated the rate of 
fibrosis progression and identified factors associated with higher or lower rates of progression 
as well as comparing fibrosis progression among HIV/HCV co-infected and HV mono-infected 
individuals. In 17 studies, involving 3567 HIV/HCV co-infected individuals, liver fibrosis 
progression was shown to be constant across all stages of fibrosis but was shown to be 
significantly influenced by duration of HCV infection with longer duration being associated 
with a slower rate of fibrosis progression. The estimated weighted proportions of co-infected 
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individuals with cirrhosis at 20 and 30 years after HCV infection were 21% and 49%, 
respectively.  Among 27 studies involving 7666 individuals (4970 with HCV mono-infection and 
2636 with HIV co-infection) there was a significantly higher risk of cirrhosis in HIV co-infected 
patients compared to HCV mono-infected patients (RR 2.11, 95% CI 1.51-2.96).  These effects 
were seen both in patients on and not on HAART.  In meta-regression analysis there was no 
significant association between HAART, or CD4 count, and risk of cirrhosis, indicating that 
HAART and recovery of the immune system do not fully limit the impact of HIV in HCV 
progression (332). 
 
It should be noted that selection bias may be present in a number of cohort studies included in 
the meta-analyses since recruitment of subjects is often dependent on referral for liver biopsy 
and those patients who have a liver biopsy may not be representative of all patients who are 
infected with HCV.  They may be more adherent to antiretroviral treatment, less likely to drink 
alcohol and more likely to have stable HIV disease and more likely to be symptomatic for HCV 
disease.  Factors associated with fibrosis progression in co-infected individuals have been 
reported as heavy alcohol intake, length of HCV infection, failure of HCV treatment and higher 
ALT levels (333), as reported in HCV mono-infected patients.  Difficulties with comparing 
results arise from the fact that many different measures are used for these outcomes 
(particularly for measuring degree of fibrosis present) and because HCV may be asymptomatic 
in the acute phase, the duration of the infection is often unknown. 
 
A number of studies, conducted after these meta-analyses, provide additional evidence of 
increased progression of HCV infection when individuals are co-infected with HIV. In particular, 
the studies examined how the degree of immunosuppression impacts on the development of 
cirrhosis and HCC.  Among a cohort of HIV co-infected individuals in France, HCC was strongly 
associated with a low CD4 count at the time of cancer diagnosis.  However, due to small 
numbers, this analysis was not conducted separately for HCC that resulted from HBV or HCV 
infection (334).  Similarly, a case control study of individuals with HCC compared to those 
without, nested within the Swiss HIV Cohort Study of HIV-positive individuals, found that a 
higher level of immunodeficiency was associated with HCC (with an odds ratio (OR) of 1.33 per 
100 CD4 cells/mm3 lower).  Again, it was not possible to distinguish between HBV and HCV 
infections in this analysis (335).  In a cross-sectional study of HIV-positive patients in Madrid, 
Spain, cirrhosis was also associated with lower CD4 counts and the main cause of cirrhosis was 
HCV (336). 
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In contrast to these results a large study in the USA of patients attending one Veterans’ Health 
Administration Hospital between 1991 and 2000 found no association between HIV co-
infection and risk of developing cirrhosis in the HAART era although there was an increased 
risk of cirrhosis for co-infected patients in the pre-HAART era.  The authors also found no 
association between HIV co-infection and HCC irrespective of whether patients were recruited 
in the HAART era or earlier (337).  Although higher rates of HCC were observed in the co-
infected group compared to the HCV mono-infected group, the association between co-
infection and HCC disappeared after controlling for confounding factors.   
 
Hepatic steatosis, or fatty liver, is important in HCV infection as it is associated with increased 
risk of fibrosis and HCC in HCV mono-infected individuals (338, 339).  A meta-analysis was 
conducted of 12 studies, involving 1989 individuals, which aimed to investigate the prevalence 
of steatosis in HCV/HIV co-infected individuals and risk factors for steatosis.  Four of the 
included studies also included data from a comparison group of HCV mono-infected patients (a 
total of 1540 individuals).  The study showed that HIV co-infection did not increase the risk of 
hepatic steatosis compared to the risk in HCV mono-infected patients (pooled OR 1.67, 95% CI 
0.84-2.10).  In the pooled data, steatosis was not associated with HIV viral load, HCV viral load, 
HCV genotype, CD4 count or patient demographic characteristics.  However, it was associated 
with body mass index, the presence of diabetes, elevated ALT levels and fibrosis (340).  There 
was significant heterogeneity between studies included in the meta-analysis and the overall 
findings differ from some of the individual results of the included studies.  Two of the included 
studies did find an association between higher HCV viral load and steatosis (341, 342) one 
included study found that individuals with a detectable HIV viral load had less steatosis than 
those with undetectable viral load (343).   
 
In summary, evidence from cohort studies of HIV/HCV co-infected individuals combined with 
and comparing the results of studies which examine progression of HCV among co-infected 
with studies which examine progression in HCV mono-infected individuals indicates that 
individuals who are co-infected with HCV and HIV are at increased risk of chronic infection as 
well as increased risk of progression of liver disease compared to individuals infected with HCV 
alone.  
  
2.5.2 The effect of HAART on liver outcomes of HCV infection 
In this section I will discuss how treatment for HIV with HAART can impact on liver outcomes in 
co-infected individuals.  This is complex since having a better immune system, as a result of 
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HAART, may improve liver outcomes while use of HAART may also contribute to increased liver 
damage in co-infected patients.   
 
Although liver disease has been shown to be an important cause of mortality in HIV-positive 
patients in the era of HAART, there is some evidence that HAART is protective against 
progressive liver disease.  For example, time from first liver decompensation event to death 
was increased in individuals who were treated with HAART.  This analysis did not distinguish 
between patients who were co-infected with HBV or HCV but the total number of individuals 
included who had HBV infection was small (292). In addition, longer duration on HAART has 
been shown to be associated with less severe fibrosis (344, 345) and in a study in Los Angeles, 
USA, HIV/HCV co-infected individuals on HAART were shown to have similar rates of fibrosis as 
HCV mono-infected patients (346, 347) indicating that HAART is protective against liver disease 
in the context of HCV co-infection.   
 
There may be some differences in the impact of different classes of HIV drug on liver 
outcomes.  A number of studies have found an association between the use of specific NRTIs 
and the development of liver fibrosis, cirrhosis and decompensated liver disease in HIV/HCV 
co-infected patients. These drugs are also known to cause liver damage in HIV-mono-infected 
patients.  In the ARNS HCO2 Ribaviric study, fibrosis was assessed over a two year period by 
comparing paired biopsy samples. A worsening in fibrosis was associated with use of 
didanosine as part of the HAART regimen (348). Similarly, in a case series of patients from the 
same trial, use of didanosine was associated with spontaneous hepatic decompensation (349).  
 
In a cross-sectional study of HIV-positive patients undergoing assessment for liver disease by 
FibroScan® there were 389 patients who were co-infected with HCV.  Among this co-infected 
subgroup, advanced liver fibrosis was more common in individuals who had never received 
HAART compared to all the others, indicating a protective effect of HAART in co-infection.  
However, those individuals with prolonged exposure to HAART (>6 years) had higher rates of 
advanced liver fibrosis than those with shorter term exposure to HAART, which may indicate 
some effect of HAART on fibrosis over time.  In multivariate analysis, use of NRTIs (didanosine 
and stavudine) as a component of HIV treatment was associated with advanced liver fibrosis; 
this analysis was conducted for both HIV mono-infected and HIV/HCV co-infected patients 
combined, however, and therefore it is not possible to assess the impact of these drugs 
specifically in HCV co-infected patients (350). 
 94 
 
A study of 201 co-infected patients assessed the effect of NNRTIs and PIs in fibrosis.  The 
authors found that a shorter duration of HAART was associated with advanced fibrosis and the 
level of fibrosis decreased significantly with each additional year of HAART.  This was shown to 
hold true for NNRTIs as a class and for nevirapine and efavirenz individually but not for PIs 
(351) 
 
In contrast, the use of PIs as part of a HAART regimen has been shown to be associated with a 
reduced risk of liver disease.   Among a cohort of 182 co-infected patients in France, 35% were 
on a PI and these patients showed significantly lower levels of liver fibrosis than patients who 
were not treated with a PI (352).  Likewise, in a cross-sectional study of 116 HIV/HCV co-
infected patients, the rate of fibrosis progression was slower among individuals who were on 
PIs compared to those who were not on PIs, with a trend towards higher fibrosis scores for 
patients who were on stavudine (353).  Among 152 HIV/HCV co-infected patients treated at an 
infectious disease unit in Spain, use of PIs was protective against high grade fibrosis whereas 
use of nevirapine was associated with more advanced fibrosis (354). 
 
The meta-analysis (described previously) of steatosis in co-infected individuals did not find any 
associations between antiretroviral classes and steatosis in the pooled data (340).  However, 
one of the included studies did find an association between NRTI use and steatosis (343) while 
another found NNRTI use to have a protective effect (355).  In a more recent study, of paired 
biopsies from 222 HIV/HCV co-infected individuals, a high CD4 count and HIV treatment was 
associated with a reduced progression of HCV to steatosis (356). 
 
Finally, the importance of continuity of treatment has been shown in a number of studies.  
Permanent HAART discontinuation was associated with hepatic decompensation in a 
prospective study of 248 co-infected patients in a multicentre study in Spain (357)  and in a 
multi-centre prospective study in Canada, treatment interruption was a risk factor for 
development of fibrosis among 541 HIV/HCV co-infected individuals (358). 
 
While the choice of appropriate drugs to be included in the HAART regimen is clearly 
important, it is clear that high CD4 count achieved through HAART is highly important in 
preventing the development of liver disease in HIV/HCV co-infected individuals.  
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2.5.3 Impact of HAART on HCV viral load 
A number of small studies have shown that in HIV/HCV co-infected patients after initiation of 
HAART, as HIV viral load decreases, there is an increase in HCV viral load (297, 359-361).  
Among co-infected patients in residential care homes in New York, this increase in serum HCV 
was maintained at 9 months.  However, it is worth noting that these patients were at a very 
late stage of HIV infection and had a mean baseline CD4 count of <200 cells/mm3 (360).  
 
Conversely in a cohort of 50 co-infected patients in Australia more than half (54%) experienced 
a significant increase in HCV levels after initiation of HAART but for most patients this increase 
peaked between 1 and 3 months and then declined.  Where particularly large increases in HCV 
viral load occurred they were associated with baseline CD4 counts of <200 cells/mm3 (361) .  
Similarly, in a cohort of 60 co-infected individuals, in the USA, larger increases in HCV viral load 
were seen in patients with lower CD4 counts at HAART initiation; those with higher CD4 counts 
had initial increases in HCV levels but these returned to normal by 48 weeks (297).  
 
 
2.6 The impact of co-infection with HIV on HBV infection 
2.6.1 The effect of HIV on the serological profile of HBV 
In this section I will describe the effect of HIV on the development of chronic HBV infection and 
the production of antibodies to HBV.  In mono-infected patients HBV-DNA levels are correlated 
to the degree of cirrhosis and risk of HCC.  Therefore while there may be few studies of the 
direct impact of HIV on progression of fibrosis, the studies which find differences in the course 
of HBV infection with regard to presence of antigens, antibodies and HBV-DNA are relevant to 
the clinical progression of infection.  
 
Evidence for the effect of HIV on the natural history of HBV infection is available from studies 
conducted in the pre-HAART era.  In a small study of 77 individuals acutely infected with HBV, 
HBsAg status was assessed at 6 months after the diagnosis of acute infection.   Where HBsAg 
was present at 6 months these individuals were considered to be chronically infected. In this 
cohort, 40% were HIV co-infected and a significantly higher proportion of co-infected 
individuals developed chronic infection (26%) compared to HBV mono-infected individuals 
(4%) (362). 
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In a larger study, conducted in the era of HAART, a total of 2037 patients were classified as 
chronically infected (ever having 2 or more reactive HBsAg tests at least 6 months apart)  
having isolated anti-HBc, or having resolved HBV infection (positive for anti-HBc and anti-HBs).  
There was an increased risk of chronic infection compared to resolved or isolated anti-HBc in 
individuals who acquired their HBV after HIV compared to those who did not definitely acquire 
their HBV after HIV infection.  The cohort was also stratified by CD4 count and this effect was 
seen in each of the strata (363). Taken together these results indicate an increased likelihood 
of progression to chronic infection after becoming infected in HIV-positive individuals 
compared to HIV-negative individuals. 
 
The rate of loss of HBeAg and the prevalence of HBV-DNA were also investigated in the pre-
HAART era.  In a study of 152 MSM diagnosed with HBV before the end of 1987 and 212 
HBsAg-negative controls, the HIV prevalence in the two groups was 41% and 70%, respectively. 
Patients were followed until April 1990. HIV/HBV co-infected individuals were more likely to be 
HBsAg positive and have higher HBV-DNA polymerase activity (indicating higher levels of 
replication) than HBV mono-infected individuals and the rate of loss of serum HBeAg was 
lower among HIV-positive individuals.  In this study, Gilson et al also showed evidence of 
increased rates of reactivation of HBV as evidenced by the reappearance of HBeAg after its 
initial disappearance (364).  These differences may have an impact on the clinical 
manifestations of HBV in HIV-positive compared to HIV-negative individuals (364). 
 
Similarly, among 150 MSM with chronic HBV infection, HIV-positive individuals were more 
likely to be positive for HBeAg and HBV-DNA and this was not dependent on CD4 count.  None 
of the individuals who were HBeAg-negative at the beginning of the study had a reactivation of 
HBeAg over the study period and thus the authors concluded that the higher prevalence of 
HBeAg and HBV-DNA among HIV co-infected individuals was not due to reactivation but due to 
slower clearance of HBeAg; this effect was not altered by the degree of immunosuppression 
(365). A study by Colin et al also found higher levels of HBV-DNA in co-infected patients, but 
like the study by Bodsworth et al, this was found in the context of lower ALT levels (366).  In a 
retrospective cohort study of 141 HBeAg-positive individuals, compared to HBV mono-infected 
patients, HIV co-infected patients had significantly higher HBV-DNA levels and this was 
independently associated with lower CD4 counts (367).   
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Among HBV co-infected patients recruited to two trials of antiretroviral therapy, high levels of 
HBV-DNA were associated with low CD4 counts.  The median CD4 count did not differ 
significantly between individuals who were HBeAg-positive and those who were HBeAg-
negative.  However, overall a higher proportion of individuals had low levels of HBV-DNA than 
had been seen in previous studies (16% of HBeAg-negative individuals and 75% of HBeAg-
positive individuals had undetectable HBV-DNA).  This may be due to the duration of HBV 
infection since most individuals in these trials were living in areas of high HBV prevalence and 
had probably acquired their HBV infection when they were children.  The authors postulated 
that the long-standing chronic nature of the HBV-infection in these patients may have led to 
immune activation and thus an increase in CD4 cell apoptosis (304). 
 
The finding of slower clearance of HBeAg in HIV-positive individuals has been confirmed in the 
HAART-era.  In a retrospective multicentre study in France (the GERMIVIC group), among 477 
individuals with past or present HBV infection, HIV-positive individuals were more likely to be 
HBeAg-positive and less likely to be anti-HBe and anti-HBc positive at baseline.  Over follow-up, 
a significantly lower proportion of HIV co-infected individuals cleared HBeAg and 
seroconverted to anti-HBe compared to HBV mono-infected individuals.  In this population, 
clearance of HBeAg was associated with histological improvement, indicating that in the 
presence of HIV, where HBeAg is less likely to be cleared, HBV-infected individuals may have 
poorer clinical outcomes than in the absence of HIV (260). 
 
Compared to the results of studies in the pre-HAART era, there are some conflicting findings 
with regard to the prevalence of HBV-DNA in HIV co-infected individuals in the HAART era.  A 
subsequent analysis of data from 451 patients seen at GERMIVIC sites showed that HIV status 
was not associated with HBV-DNA levels.  However, the authors of this study found that a 
higher proportion of HIV-positive individuals were on therapy for HBV which was likely to have 
controlled the levels of HBV replication (368).   
 
Occult HBV is defined as the presence of low levels of HBV-DNA measured in the serum in the 
absence of HBsAg after the period of acute HBV infection (369).  This phenomenon has been 
identified among HIV/HBV co-infected individuals (370-375), however other studies of HIV-
positive HBV-negative individuals have failed to identify presence of HBV-DNA (376, 377).  One 
study in South Africa has shown higher rates of occult HBV infection in HIV-positive individuals 
than in HIV-negative individuals (378).   The clinical implications of occult HBV infection in HIV-
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positive individuals remain unclear.   It has been suggested that it may play a role in 
reactivation of resolved HBV infection in HIV-positive individuals and in LEE (379, 380).  
However, this is not be confirmed by other studies (375, 381). 
 
In general, HIV/HBV co-infected individuals are more likely to become chronically infected, 
have higher levels of HBV replication, reduced loss of  HBeAg, reduced development of anti-
HBe and higher rate of reactivation of HBV virus than HIV uninfected individuals (382). As 
previously stated these findings are important as changes in the serological profile of HBV 
infection are predictive of clinical progression of the infection. 
 
2.6.2 The effect of HIV on clinical outcomes of HBV 
Evidence to date shows that HIV negatively impacts on the clinical outcomes of HBV infection.  
Studies to examine the effect of HIV on the clinical outcomes of HBV compare HIV/HBV co-
infected groups to HBV mono-infected groups.  The effect can be studied in terms of 
progression of fibrosis to cirrhosis, HCC or mortality.  A study in the pre-HAART era assessed 
HBV outcomes in a cohort of 132 non-drug-using, chronically HBV-infected MSM who had not 
previously been treated and were also not infected with HCV or HDV; 65 (49%) of those were 
HIV-positive.  A significantly higher proportion of HIV-positive individuals had cirrhosis 
compared to HBV mono-infected individuals and HIV positivity remained associated with 
cirrhosis  in a multivariate model after adjusting for age, alcoholism, duration of HBV infection 
and HBeAg positivity (366).  
 
In the HAART era, liver fibrosis was compared in 500 HIV-positive individuals and 500 HIV-
negative individuals in Uganda.  The prevalence of chronic HBV was similar between the two 
groups and in both cases was low (5% in HIV-positive and 3% in HIV-negative individuals).  The 
prevalence of fibrosis was significantly higher among HIV-positive individuals compared to HIV-
negative individuals (17% compared to 11%, p=0.008).  However, given the low prevalence of 
HBV in both these groups the increase in fibrosis cannot be attributed to HBV co-infection 
(383).  A more recent study of co-infected patients identified factors which were associated 
with fibrosis in a co-infected population.  These were shown to be HBV genotype G (the 
strongest independent predictor), efavirenz exposure and longer duration of HIV infection 
(384).   
 
Whether HIV co-infection increases the risk of HCC in co-infected patients compared to that in 
HBV mono-infected patients is less clear.  As previously described in section 2.5.1, Clifford et al 
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reported an increased risk of HCC in co-infected persons in the context of HIV-related 
immunosuppression (lower CD4 counts) but it was not possible to attribute these cases of HCC 
to either HBV or HCV specifically (335).  In the MACS cohort in the USA, 326 individuals were 
HBsAg-positive and 65% of those individuals were HIV co-infected.  Liver mortality was 
significantly higher among the co-infected individuals compared to the HBV mono-infected 
individuals, indicating that HIV may accelerate progression of HBV infection (261).  
 
Linkage of data from HBV and HCV notifications, HIV notifications and death registrations in 
New South Wales, Australia, has also shown higher all-cause mortality among HIV/HBV co-
infected individuals ( 378.6/10,000 person-years) compared to HBV mono-infected individuals 
(37.6/10,000 person-years).  However, the authors of this study also noted that a high 
proportion (70%) of these deaths were HIV-related and therefore may not represent an impact 
of HIV infection on HBV (385). 
  
2.6.3 The effect of HAART on liver outcomes in HBV 
A number of drugs used to treat HIV are also effective against HBV and in particular 
lamivudine, tenofovir and emtricitabine are approved for use against HBV.  Therefore patients 
who are co-infected with HBV and HIV are usually commenced on HAART with a regimen that 
includes one of these drugs.  In this section I will focus on how treatment for HIV with HAART 
affects the outcomes of HBV infection as a result of immune restoration.  I will not consider 
the effects of particular anti-HBV drugs or their combinations on HBV or the development of 
resistance to these drugs as this will be covered in a section 2.8.  Studies have assessed the 
effect of HAART by considering mortality, levels of HBV-DNA, clearance of HBV antigens and 
development and persistence of HBV-specific antibodies (seroconversion) in patients on 
HAART compared to patients who were not on HAART or in patients with differing 
immunological responses to HAART. 
 
In a Cox regression model considering the end point of liver-related mortality among  HIV/HBV 
co-infected individuals, being treated with two or less than two anti-HIV drugs was significantly 
associated with increased liver-related mortality.  The authors conclude that individuals 
treated with fewer than three anti-HIV drugs had commenced treatment before the 
widespread use of HAART.  This study indicates that use of HAART is protective against liver-
related mortality among HIV/HBV co-infected individuals (290).   
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In a small study of HIV/HBV co-infected individuals in Spain, liver fibrosis stage was measured 
in 72 individuals followed for a median of 35 months.  Of these 17% showed an improvement 
in their liver disease stage over the follow-up period while they were on treatment (386).  
Similarly, a slightly larger study followed 148 HIV/HBV co-infected individuals starting 
treatment with tenofovir for 36 months.  Over this time period, a significant decrease in liver 
disease was observed among those individuals who had F3 or F4 fibrosis at the start of 
treatment. This decrease occurred predominantly in the first 12 months of treatment (387).  
However, since these studies are small it was not possible to adjust for CD4 count and 
therefore it is unclear whether the observed effects are related to immune restoration or to 
the direct effect of the drugs on HBV infection. 
 
Greater increases in CD4 count and undetectable HIV viral load have been associated with 
undetectable HBV-DNA in a small cohort of 79 co-infected patients in Madrid (388).  A cohort 
study of 92 HIV/HBV co-infected patients at a single reference centre in France followed 
patients for a median of five years; in this study having an sustained virological response to 
HAART (defined as < 50copies/ml for at least 80% of the treatment duration) was correlated 
with seroconversion from HBsAg to anti-HBs and seroconversion from HBeAg to anti-HBe 
(389).  The loss of HBV antigens and the development of HBV-specific antibodies have also 
been associated with better immunological response to HAART.  In a larger cohort of 538 HIV-
positive patients who tested positive for at least one HBV marker at baseline, individuals were 
followed for a median of 4.96 years.  Of those patients who were anti-HBs positive at baseline, 
loss of anti-HBs was more likely for those with lower levels of immune restoration after the 
initiation of HAART.  Those patients in the cohort who had isolated anti-HBc at baseline, who 
then developed anti-HBs also had significantly greater increases in CD4 than those who did 
not.  Two years after the initiation of HAART an increase in CD4 count of greater than 100 
cells/mm3 was the only factor which was associated with the presence of anti-HBs in both 
these groups (390). 
 
The effect of duration of HAART on HBV infection was assessed in 72 HIV/HBV co-infected 
individuals in the USA.  Longer duration of HAART was associated with both HBsAg and HBeAg 
clearance.  However, since this study did not include the changes in CD4 count in response to 
HAART, it is not possible to determine whether the clearance of these antigens is due to 
immune restoration as a result of HAART or due to the direct action of the HBV-active drugs 
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which formed a component of the HAART regimen (391).  This study does, however, highlight 
the importance of HAART in the management of co-infected patients.   
 
Data from the SMART trial also showed the importance of sustained HAART in co-infected 
patients.  Participants were assigned to receive either continuous HAART or HAART with 
interruptions (the drug conservation arm) and plasma HBV-DNA was measured every 2 months 
for a year.  Individuals in the drug-conservation arm were more likely to experience HBV-DNA 
rebound than those in the continuous-treatment arm (392). 
 
Most studies have considered the effect of HAART on HBV irrespective of whether HBV was 
acquired before or after HAART.  However in one study,  previously described in section 2.5.1 , 
among those infected with HBV after HIV, use of HAART prior to HBV diagnosis was associated 
with a decreased risk of chronic infection; this was the case in patients both with high and low 
CD4 counts at the time of HBV diagnosis (363). 
 
 
2.7 Treatment and management of HCV in HIV co-infected patients 
Only a very small minority of HIV co-infected patients will spontaneously clear HCV infection 
(see section 2.5.1).  Given the importance of HCV co-infection in causing liver-related 
morbidity and mortality in HIV co-infected individuals, ensuring successful treatment strategies 
is a priority.   
 
Since 2011, there have been significant advances in the treatment of HCV  with the 
development of a number of new drugs (154).  Data analysed as part of this thesis was 
collected in 2012-13. Therefore the large majority of patients included in had not yet 
benefitted from access to these new drugs, although small numbers were involved in clinical 
trials of the new drugs.  In this section, I will describe the effectiveness and efficacy of HCV 
treatments in the context of HIV, focussing mainly on the treatments available up until 2011.  I 
will also give a brief description of the evidence for new DAAs in HIV/HCV co-infected patients, 
which was available at the time that the data presented in this thesis was collected. A 
description of further developments which have occurred over the period of my research and 
the relevance of this thesis in the context of those further developments is provided in the 
final section of this thesis (section 10.2).  
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2.7.1 Effective treatment for HCV in the context of HIV, until 2011 
Until recently, recommended treatment for HCV infection in HCV/HIV co-infected patients has 
been, as for HCV mono-infected patients, a combination of pegylated-interferon and ribavirin.  
Earlier treatment regimens used standard interferon (without pegylation) with ribavirin (65, 
166).  A summary of SVR rates in trials among HIV/HCV co-infected individuals is shown in  
 
Table 2.5.  The proportion of individuals who achieved SVR ranged from 11% to 46% for 
individuals infected with HCV genotype 1 or 4 and from 34% to 73% in individuals infected with 
HCV genotype 2 or 3.  Therefore genotypes 1 and 4 are considered harder to treat than 
genotypes 2 and 3.  The results of these trials were included in a meta-analysis of 14 
randomised controlled trials, involving 2269 co-infected individuals, which was conducted to 
assess the benefits and harm of treatment for choric HCV and compare the various regimens 
(393).  Patients were excluded from trials if they had decompensated liver disease, significant 
co-morbidities (including chronic HBV infection) or if there was evidence of current drug or 
alcohol abuse.   
 
In the first comparison 673 patients treated with pegylated-interferon plus ribavirin, were 
compared to 667 patients treated with standard interferon plus ribavirin.  Those treated with 
pegylated-interferon plus ribavirin, were more likely to achieve SVR (RR 2.16, 95% CI 1.47-3.18 
in a random effect model) than those treated with interferon plus ribavirin.  In a subgroup 
analysis by HCV genotype, the benefit from pegylated-interferon plus ribavirin compared to 
interferon plus ribavirin was greater in patients infected with genotypes 1 or 4 than in patients 
infected with genotypes 2 or 3, but pegylated-interferon remained superior in both groups.  
There was no difference in mortality but a slightly increased risk of anaemia or flu-like 
symptoms in patients treated with pegylated-interferon plus ribavirin compared to interferon 
plus ribavirin (RR 1.57, 95% CI 1.16-2.14). A higher proportion of patients treated with 
pegylated-interferon plus ribavirin had evidence of improved liver histology compared to 
patients treated with interferon plus ribavirin.   
 
In a second comparison, a total of 359 individuals treated with pegylated-interferon plus 
ribavirin were compared to 355 patients treated with pegylated-interferon alone in the above 
meta-analysis. Pegylated-interferon was also shown to be a superior treatment regimen with 
higher proportions of patients achieving SVR (RR 2.03, 95%CI 1.57-2.63) and this was seen for 
patients infected with genotype 1 and 4 as well as patients infected with genotype 2 and 3.  No 
difference was seen between these two groups with regard to mortality or adverse events. 
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The results from this meta-analysis are comparable to that of a smaller meta-analysis 
(including only 6 trials) (394).  The authors concluded that given the clear benefit of pegylated-
interferon plus ribavirin treatment, further trials were not warranted.  
 
Table 2.5 SVR to treatment with pegylated-interferon plus ribavirin in randomised controlled 
trials 
Trial HCV 
Genotype 
Individuals with 
end of treatment 
response  
n/N (%) 
Individuals with 
SVR 
n/N (%) 
ACTG, 2004 (395) 1 or 4 15/51 (29) 7/51 (14) 
 2 or 3 12/15 (80) 11/15 (73) 
 Total 27/66 (41) 18/66 (27) 
APRICOT, 2004 (396) 1 or 4 67/176 (47) 51/176 (29) 
 2 or 3 61/95 (64) 59/95 (62) 
 Total 136/290 (47) 116/290 (40) 
Crespo, 2007 (397) 1 or 4 20/39 (51) 18/39 (46) 
 2 or 3 16/21 (76) 15/21 (71) 
 Total 36/60 (60) 33/60 (55) 
Laguno, 2004 (398) 1 or 4 13/32 (41) 12/32 (38) 
 2 or 3 13/19 (68) 10/19 (53) 
 Total 27/52 (52) 23/52 (44) 
RIBAVIC, 2004 (399) 1 or 4 32/125 (26) 21/125 (17) 
 2 or 3 40/80 (50) 35/80 (44) 
 Total 72/205 (35) 56/205 (27) 
ICOS, 2005 (400) 1 or 4 6/37 (16) 4/37 (11) 
 2 or 3 14/32 (44) 11/32 (34) 
 Total 20/69 (29) 15/69 (22) 
   
 
Treatment success rates in practice are unlikely to reach those seen in clinical trials.  Therefore 
data from observational studies is useful in assessing the rates of SVR that can be achieved in 
real-world situations.  Davies el al conducted a systematic review of treatment outcomes 
reported in observational cohort studies of HIV/HCV co-infected individuals.  Forty studies with 
a primary outcome of SVR were included and a pooled estimate for the proportion of 
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individuals achieving SVR was calculated: 38% (95 CI, 34.7%-42.3%).  When stratified by HCV 
genotype the pooled estimates for the proportions of individuals achieving SVR were 24.5% 
(95%CI 20.4-28.6%) for individuals infected with genotypes 1 or 4 and 59.8% (95% CI 47.9-
71.7%) for those infected with genotypes 2 or 3 (401).  Many of the cohorts included in this 
analysis included high proportions of IDU or those from other groups who may have poor 
adherence.  Three studies were limited to adherent populations, but removal of these studies 
from the analysis did not affect the results.  
 
Treatment for HCV in co-infected patients has a significant impact on the progression of 
fibrosis.  Patients who have an SVR to HCV treatment are less likely to progress than those who 
are either not treated or who do not respond to treatment (402, 403).  A study of 216 co-
infected individuals in Spain showed that SVR was significantly associated with regression of 
both fibrosis and cirrhosis, which occurred in 71% of those individuals with SVR (404). 
 
There is evidence from clinical trials of HCV treatment, as well as from observational studies, 
to show adverse interactions between HCV treatment and some of the older antiretroviral 
drugs.  Patients treated with ribavirin and didanosine are more likely to experience 
mitochondrial toxicity evidenced by hyperlactatemia than patients treated with ribavirin whilst 
on other HIV drugs (399, 405, 406).  Abacavir is known to compete with ribavirin and therefore 
patients who are treated with abacavir are less likely to respond to ribavirin-based HCV 
treatment (407, 408). In patients treated with zidovudine and ribavirin, higher rates of 
anaemia are observed than among patients on ribavirin with other antiretroviral drugs (409, 
410).  Finally, efavirenz has been associated with an increased risk of mood disorders in 
patients being treated for HCV (411) and atazanavir has been associated with increased risk of 
hyperbilirubinemia in patients being treated for HCV (320).  These side-effects of efavirenz and 
atazanavir are also seen in HIV mono-infected individuals (412, 413).  
 
2.7.2 HCV treatment available in the period 2011-2013 
Work has recently focussed on the development of new drugs which act directly on HCV.  In 
particular, in 2011, two PIs, boceprevir and telaprevir, were licensed for use in the USA and 
Europe (154, 414).  Here I will describe research on the efficacy of these agents, in the context 
of HIV, which was available at the time of collecting the data used for analysis within this 
thesis. 
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Phase III trials in HCV mono-infected individuals showed that for patients infected with HCV 
genotype 1, addition of boceprevir or telaprevir to the current pegylated-interferon plus 
ribavirin regimen significantly increased the proportion of individuals achieving SVR; both for 
patients who have never previously received HCV treatment (190, 193) and for those 
individuals who had previously failed treatment with pegylated-interferon and ribavirin (195, 
415).  However, these phase III trials of boceprevir and telaprevir did not include HIV co-
infected patients.   
 
Initial data from phase II b trials of telaprevir in HIV co-infected patients were first presented 
at the Conference on Retroviruses and Opportunistic Infections (CROI) in 2011.  Patients were 
randomised to receive either pegylated-interferon plus ribavirin and telaprevir, or pegylated-
interferon plus ribavirin and placebo.  The study was conducted in 13 patients not on ART but 
with high CD4 counts (> 500 cells/mm3) and among 46 patients with on ART with undetectable 
viral load and CD4 greater than 300 cells/mm3.  A higher proportion of patients in the 
telaprevir arm achieved a rapid virological response (undetectable HCV viral load at week 4) 
and an early virological response (undetectable viral load at 12 weeks) than patients in the 
placebo arm (416). Data on SVR12 (having negative HCV-RNA 12 weeks after stopping 
treatment) from the same trial was presented the following year and again showed that 
addition of telaprevir to the standard pegylated-interferon and ribavirin regimen significantly 
increased the proportion of individuals who responded to treatment: 45% of patients in the 
control arm achieved SVR12 compared to 74% of patients in the intervention arm (417).  
 
The final data from this study, including proportions of patients who achieve SVR at 6 months 
post treatment was published in 2013.  A total of 62 individuals with HIV and HCV genotype 1 
co-infection were randomised to one of two groups.  Patients in the control group received 
placebo plus pegylated-interferon and ribavirin for 12 weeks followed by 36 weeks of standard 
pegylated-interferon and ribavirin.  In the intervention arm the placebo was replaced with 
telaprevir.  In the intervention arm 74% of individuals achieved SVR compared to 45% in the 
control arm.  Although a slightly higher proportion of individuals in the intervention arm 
experienced adverse events (5%) than in the control arm (0%) the same number of individuals 
discontinued treatment in each arm (418). 
 
Data from a phase II trial of pegylated-interferon and ribavirin plus boceprevir was presented 
in 2011 at the Infectious Disease Society of America Meeting.  A total of 99 patients co-
infected HIV and HCV genotype 1 were randomised to receive either pegylated-interferon plus 
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ribavirin and boceprevir, or pegylated-interferon plus ribavirin and placebo.  At 8, 12 and 24 
weeks a significantly higher proportion of patients in the boceprevir arm achieved an 
undetectable HCV viral load than patients in the placebo arm (419) .  SVR12 data from this trial 
was also presented at CROI in 2012 and showed an increase from 26.5% of individuals 
achieving SVR12 in the control arm to 60.7% in the intervention arm (420). 
 
Final results from this study, also published in 2013, showed a significant increase in the 
proportion of individuals who achieve SVR when boceprevir is included in the treatment 
regimen.  A total of 98 individuals were randomised to receive 4 weeks of pegylated-interferon 
and ribavirin, followed by 44 weeks of either placebo or boceprevir.  In the intervention arm 
63% achieved SVR compared to 29% in the control arm.  Like the telaprevir trial, a higher 
proportion of individuals in the intervention arm experienced adverse events (421) .   
 
The results of a number of other studies investigating the use of boceprevir and telaprevir 
among HIV/HCV co-infected individuals were also presented at conferences throughout 2013, 
showing that results in HIV co-infected patients were comparable to those in HCV mono-
infected patients (422-424).  Results from studies among individuals who had previously failed 
treatment were also presented showed good levels of early response (425, 426).  The results 
of these studies led to the recommendation, in 2013, by BHIVA that individuals co-infected 
with HIV and HCV genotype 1, who are clinically in need of treatment (defined as significant 
fibrosis of F4 or cirrhosis), should be treated with pegylated-interferon and ribavirin plus either 
boceprevir or telaprevir.  However, individuals with less significant liver disease, who do not 
have a clinical need for immediate treatment, should consider deferring treatment until 
interferon free regimens are available (65). 
 
 
2.8 Treatment and management of HBV in HIV co-infected patients 
2.8.1 Efficacy of HBV mono-therapy and the development of drug resistance  
A number of antiretroviral drugs have action against HBV and therefore use of these drugs is 
recommended as part of initial antiretroviral regimen for HIV/HBV co-infected individuals 
(204).  Currently there are three licensed drugs with dual action against HIV and HBV 
(lamivudine, tenofovir and emtricitabine).  A further four drugs, which are active only against 
HBV, are also licensed for use (entecavir, interferon, adefovir and telbivudine).  In this section I 
will describe studies which show the efficacy of using single antiretroviral drugs with action 
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against HBV infection in co-infected individuals as well as development of resistance to these 
drugs. 
 
Lamivudine was shown to inhibit HBV replication in co-infected patients in an open-label trial 
of 40 patients followed for one year.  More than 96% of patients who had high levels of HBV 
replication at baseline responded to lamivudine therapy and achieved serum HBV-DNA 
concentrations of less than 5 pg/ml at 12 months; of those individuals who had low levels of 
replication at baseline, all were negative for HBsAg at 12 months (427).  The effect of 
lamivudine on HBV suppression has also been demonstrated in the CAESAR study.  This was a 
multi-centre study investigating the use of lamivudine to treat HIV but a sub-study was 
conducted investigating the effect of lamivudine on HBV replication in 122 co-infected 
individuals.  Of these 122 patients, 25 were assigned to a placebo arm and 97 were assigned to 
a lamivudine containing regimen (other drugs in the regimen were not active against HBV). At 
12 weeks the median log HBV-DNA decline was 2.0 in the patients on lamivudine compared to 
nothing in the placebo arm; at  52 weeks the median log change in HBV-DNA was 2.7 in the 
lamivudine arm compared to no change in the placebo arm (428). 
 
The effect of lamivudine treatment on HBV infection has also been shown to have significant 
clinical impact.  In the ICoNA cohort, 164 patients started HAART and 73% started with a 
lamivudine containing regimen. Patients on lamivudine experienced significantly lower levels 
of ALT over time and had a significantly reduced risk of morbidity and mortality than those 
patients whose HAART regimen did not include lamivudine over 2 years of follow-up. The 
effect of lamivudine withdrawal was also investigated in this cohort. Although withdrawal was 
not shown to significantly affect ALT flares, 72% of those who discontinued did have a clinically 
important ALT flare indicating that ALT must be closely monitored if lamivudine is discontinued 
(429). 
 
A much larger study of 2041 patients from 13 cohorts of HIV/HBV co-infected patients who 
had initiated HAART also showed decreased mortality in patients whose regimens included 
lamivudine.  The end-point of the study was liver-related disease as assessed by 3 clinicians 
who were blinded to patients’ treatment.  Overall, 57 liver-related deaths occurred.  The risk of 
liver-related death was decreased for every year that patients received lamivudine therapy (RR 
0.73 per year, 95% CI 0.59-0.90); this effect was not seen with any other NRTI.   In addition, 
there was an increase in the risk of liver-related death in patients with lower CD4 counts at 
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HAART initiation and the decrease in liver-related death due to HAART was weaker when 
adjusted for most recent CD4 count and viral load, underlining the importance of maintaining 
immune capacity and suppressing viral load (430) 
 
Despite the efficacy of lamivudine in treating HBV infection in co-infected individuals, a 
number of studies have documented the development of lamivudine resistance.  Among 13 
co-infected patients in the CAESAR study who were treated with lamivudine containing 
regimens and had high levels of HBV-DNA at 52 weeks, 5 developed resistance mutations.  The 
authors concluded that these levels of resistance were similar to those in HBV mono-infected 
individuals (431).  Another small study of 19 patients showed that over 2 years of follow-up 5 
patients developed resistance mutations (432).  In a cohort of co-infected patients in the 
Netherlands all patients were treated with lamivudine for at least 6 months and the 
percentage of patients carrying resistance mutations was 25% at 1 year and 52% at 2 years 
(433).  In a cross-sectional study of 84 co-infected individuals in Thailand the prevalence of 
drug resistance was 22.6% (434). 
 
Estimates of the proportions of patients who develop resistance are difficult to compare across 
studies since studies are often small and there may be other factors which influence the 
development of resistance in co-infected individuals and cannot be considered in such small 
groups of individuals.  Factors which have been associated with the development of 
lamivudine resistance in small studies of HIV/HBV co-infected individuals are baseline CD4 
count, body mass index (BMI), older age and being HBeAg-positive (433-435).  In addition 
studies have used varying periods of follow-up which makes the development of resistance 
difficult to compare.  One study specifically investigated the response to lamivudine 
monotherapy according to CD4 count.  Twenty-nine patients were followed-up for 33 months.  
Individuals who had a baseline CD4 count of greater than >200 cells/mm3 had significantly 
greater decreases in HBV-DNA than patients with baseline CD4 of <200 cells/mm3 and a higher 
proportion of patients with higher CD4 counts achieved undetectable HBV-DNA levels at 6 
months compared to individuals with lower CD4 counts (436). 
 
One study compared the development of resistance in 29 HIV co-infected individuals to that in 
60 HBV mono-infected individuals.  Resistance mutations were more likely to be present in the 
co-infected group (93% versus 40%, P<0.0001) and co-infected individuals were more likely to 
have multiple resistance mutations after at least 3 months of treatment (437).  A range of 
 109 
 
mutations have been shown in the DNA-polymerase gene which conveys lamivudine resistance 
(438, 439). 
 
Tenofovir monotherapy has also been shown to be effective treatment for HBV in HIV co-
infected individuals and appears to also be effective in those patients who have previously 
been treated with lamivudine.  Among 308 patients in France, use of tenofovir lowered fibrosis 
score in patients over a median of 30 months follow-up (387). More than 80% of patients 
treated with tenofovir in an HIV-positive cohort in Manchester, UK, achieved levels of HBV-
DNA <100 copies/ml over a median of 34.2 months follow-up.  Previous exposure to 
lamivudine did not affect the ability of tenofovir to control HBV replication in this cohort (440).  
In a cross-sectional study of patients who had received tenofovir in the last three months but 
who had also previously received lamivudine, lamivudine resistance was shown to persist but 
no tenofovir resistance developed (441). 
 
2.8.2 Combination therapy for HBV infection 
Combination therapy may be a more effective strategy for controlling HBV infection, both by 
suppressing HBV replication more effectively and also by limiting the development of 
resistance.  In this section, I will describe studies which investigate the efficacy of combination 
therapy for HBV infection compared to monotherapy in controlling HBV infection and studies 
which compare use of combination therapy (using more than one HBV active agent at the 
same time) to use of sequential monotherapy (using one HBV active agent followed by another 
after the resistance develops).   
 
Data from a phase 3 randomised controlled trial of tenofovir was used in a sub-study to 
compare control of HBV viral replication in patients who received tenofovir monotherapy and 
those who received lamivudine and tenofovir combination therapy.  The authors observed that 
among antiretroviral naive patients randomised to receive lamivudine plus tenofovir there was 
a greater decline in HBV-DNA than was seen among patients who were randomised to receive 
tenofovir alone over 48 weeks of follow-up.  However, this study included only small numbers 
of individuals (5 lamivudine alone and 6 lamivudine and tenofovir).  They also observed a trend 
towards reduced lamivudine resistance among patients who received combination therapy 
compared to lamivudine alone (442). 
 
In a study comparing 25 patients who commenced therapy with a combination of lamivudine 
and tenofovir with 50 patients who took lamivudine followed by tenofovir when lamivudine 
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treatment failed, there was no difference observed between the two groups with regard to 
either HBV suppression (as measured by HBV-DNA levels) or to seroconversion from HBeAg 
positivity to anti-HBe positivity over a 2 year period (443). 
 
Jain et al compared the efficacy of 3 different treatment regimens among 45 patients: group 1 
received lamivudine only for 1 year, group 2 received lamivudine and tenofovir for 1 year and 
group 3 received lamivudine alone for 6 months followed by lamivudine and tenofovir for 1 
year.  A higher proportion of patients who were treated simultaneously with lamivudine and 
tenofovir suppressed HBV-DNA and seroconverted from HBeAg positivity to anti-HBe than 
patients treated with either lamivudine monotherapy or lamivudine followed by tenofovir.  
However, this difference did not reach statistical significance (444).   
 
The use of emtricitabine as part of a combination regimen has also been investigated using 
data from 3 studies (the Multicentre AIDS cohort study, the Melbourne Australia cohort and 
the Sydney Australia cohort). Of 121 co-infected patients 31, were not on HAART, 31 were on 
either lamivudine or emtricitabine monotherapy, 11 were on tenofovir monotherapy and 49 
were on a combination of tenofovir and either or lamivudine or emtricitabine.  Significantly 
higher proportions of patients on combination therapy achieved undetectable HBV-DNA 
compared to any of the monotherapy groups and monotherapy was associated with higher 
levels of HBV-DNA in a multivariate model (445). 
 
In a study in Thailand, co-infected patients were randomised to receive either emtricitabine 
monotherapy (6 patients) or emtricitabine and tenofovir combination therapy (10 patients).  
There was a significantly greater decrease in HBV-DNA in those treated with combination 
therapy than those treated with monotherapy.  At 48 weeks of follow-up a significantly higher 
proportion of patients on combination therapy had undetectable HBV-DNA compared to 
patients on monotherapy (90% versus 33%) (446). 
 
Studies to date support the use of combination therapy, however studies are small and further 
research is necessary to compare different combinations of HBV active drugs since there is 
currently no data available which can be used to directly compare the combination of 
emtricitabine and tenofovir with lamivudine and tenofovir. 
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2.9 The outcomes of liver transplant in HIV-positive individuals 
Liver transplant is the only clinical option for patients with end-stage liver disease.  The 
outcome of liver transplant can be assessed using various measures:  patient’s survival post-
transplant, graft survival and recurrence of the hepatitis infection.  In this section, I will 
describe studies which report on these transplant outcomes in HIV-positive patients and 
studies comparing the outcomes in HIV-positive and HIV-negative patients.  Research into the 
outcomes of liver transplant in patients co-infected with HIV and hepatitis viruses is limited as 
few patients undergo the procedure.  Therefore much of the available data comes from case 
reports or case series.   
 
A meta-analysis, published in 2011, assessed the outcomes of liver transplant in HIV-positive 
patients by pooling data from published cohort studies and forming a synthetic cohort of cases 
using published reports of individual cases.  Patient survival post-transplant was similar in the 
pooled cohort data and the grouped case data: 84.5% & 83.3% at 12 months; 73.5% & 73.8% 
at 24 months; 66.2% & 68.7% at 36 months; 66.7% & 62.7% at 48 months; 63.8% & 55.9% at 
60 months, respectively.  Case data was used to identify factors associated with survival post 
transplantation.  Among these 216 patients, HBV co-infection was associated with better 
survival compared to those individuals who were HBV-negative as was having an undetectable 
HIV viral load when the transplant was carried out.  HCV co-infection was a negative predictor 
of survival in the unadjusted model but this did not remain associated in the adjusted model.   
 
In the pooled cohort, graft survival during follow up was 82.6% at 12 months; 73.7% at 24 
months; 62.0% at 36 months; 66.6% at 48 months; and 47.9% at 60 months.  Graft survival 
appeared to be higher in the grouped case data.  However, due to small sample sizes, 
particularly in later years of follow-up, this data is susceptible to bias.  As with patient survival, 
analysis of the case data indicated that HBV infection was significantly associated with 
increased graft survival, compared to those individuals who were HBV-negative, and there was 
a trend toward HCV infection being associated with decreased survival.  HIV viral suppression 
post-transplant was reported from 99 individuals in 23 case reports.  High proportions of 
patients had undetectable viral loads at 12, 24 and 60 months post-transplant (although 
numbers are small particularly for the later years of follow up). These occurred in the context 
of patients taking immunosuppressant therapy post-transplant.  Finally, the authors of this 
meta-analysis were able to assess the recurrence of HCV infection in co-infected patients who 
underwent liver transplant.  Forty five case reports, including data from 184 individuals, 
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included data on HCV co-infection.  Of these patients the large majority (94%) had HCV viremia 
after transplant and 51.6% were identified as having recurrence of active disease. SVR  to 
treatment was observed in 17/49 of patients who underwent HCV treatment post-transplant 
(447).   
 
The finding that HBV-positivity is associated with increased patient and graft survival is 
surprising.  However, this is likely due to the underlying conditions present in comparison 
group.  The HBV-negative group includes those individuals who are positive for HCV as well as 
those undergoing liver transplant for other reasons.  The optimal survival of HBV-positive 
individuals compared to HBV-negative individuals who are undergoing transplant for other 
reasons, including HCV infection, is likely due to the effectiveness of HBV treatment.  As more 
effective HCV treatments become more widely available this difference in survival may 
decrease. 
 
A limitation of this meta-analysis is that it did not compare outcomes of liver transplants in 
patients with HIV infection with those without HIV infection.  However, the authors compared 
their results  to those of studies in HIV-negative individuals and concluded that one to five year 
survival rates were similar to those reported in HIV-negative populations in Europe but slightly 
lower than those reported in North America.  Indeed of the cohort and case-control studies 
which did have HIV-negative comparison groups similar rates of patient survival, graft survival 
(448-454) and recurrence of HCV infection (454) post-transplant were observed in HIV-positive 
and HIV-negative individuals. 
 
Another limitation of many of the cohort studies investigating outcomes of liver transplant is 
that the analyses are not stratified by the aetiology of liver disease (HBV or HCV).  The few 
studies which do specifically consider HCV or HBV provide similar information to those where 
HCV and HBV liver disease is considered together in combination with liver disease of any 
other aetiology.   Coffin et al showed that there was no difference in patient or graft survival 
rates in HBV mono-infected and HIV/HBV co-infected (451), while the studies from Castells et 
al and Testillano et al and Baccarani et al  showed that patients and graft survival rates were 
also similar in HCV mono-infected and HIV/HCV co-infected individuals (449, 450, 454).  
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2.10 Summary of findings from the literature 
In HIV-positive populations HCV and HBV infection are not only prevalent but also have 
significant clinical implications.  Liver disease, in particular related to viral hepatitis infection, 
has become an important cause of morbidity among HIV-positive populations and HIV and 
hepatitis co-infected individuals have higher rates of mortality compared to HIV mono-infected 
individuals. There is some evidence to suggest that co-infected individuals may have impaired 
responses to HIV treatment compared to HIV mono-infected individuals.  Individuals who are 
co-infected with HIV and hepatitis viruses are more likely to progress to chronic hepatitis 
infection than those who are infected with a hepatitis virus alone and HIV/HBV co-infected 
individuals are more likely to have active hepatitis infection than individuals with HBV mono-
infection.  Liver disease in co-infected individuals progresses more rapidly than in hepatitis 
mono-infected individuals.  However, treatment for HIV, HBV and HCV is available and can 
limit the pathological effects of the viruses.  In addition, results of liver transplants in co-
infected individuals are similar to results in individuals without HIV.  Therefore ensuring that 
the most appropriate treatment is available for co-infected individuals is vital.   
 
Data from cohort studies is invaluable in assessing the impact of infection and the 
effectiveness of treatment outside of clinical trials.  However, the variability in results of cohort 
studies investigating the outcomes of co-infected individuals highlight the importance of 
having locally applicable studies on which to base treatment and management decisions. 
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Chapter 3 Methods 1: The UK CHIC study and statistical methods 
 
3.1 Introduction 
All the data presented in this thesis have been collected as part of UK CHIC study.  The 
standard dataset, collected annually as part of the UK CHIC study, was supplemented with 
additional data for those individuals in the cohort who are co-infected with HBV and/or HCV.  
This chapter describes the standard data collection and processing for the UK CHIC study and 
the key characteristics of the dataset.  The collection and processing of the additional data for 
hepatitis co-infected individuals is described Chapter 4.  A summary of statistical methods used 
throughout the thesis is also provided.  
 
 
3.2 The UK Collaborative HIV Cohort 
The UK CHIC study was initiated in 2001. The aim of the study is to collect data on a large 
cohort of individuals, diagnosed with HIV infection and attending for HIV care in the UK.  These 
data can be used to assess changes over time in the frequency of AIDS-defining events, 
changes in virological and immunological responses to HAART and factors associated with 
response to HAART (455).   At inception 6 centres contributed data to the study: Chelsea and 
Westminster Hospital, London; Kings College Hospital, London; Mortimer Market Centre, 
University College Hospital, London; St Mary’s Hospital, London; the Royal Free Hospital, 
London; and Brighton and Sussex University Hospital, Brighton.  These six centres provided 
data for 13833 HIV-positive individuals attending for HIV-related care.  Additional centres have 
since been recruited into the study. By the end of 2012, there were 16 UK HIV centres 
contributing data to the study: the original six centres plus St Bartholomew’s and The Royal 
London Hospitals, London; Western General Hospital, Edinburgh; North Middlesex University 
Hospital, London; Homerton University Hospital, London; Southmead Hospital, Bristol; 
Leicester Royal Infirmary, Leicester; James Cook University Hospital, Middlesbrough; Queen 
Elizabeth Hospital, Woolwich, London; St George’s Hospital, London; and York teaching 
Hospital, York. 
 
The analyses presented in this thesis utilise data from the UK CHIC dataset which was finalised 
at the end of 2012.  This dataset contains information on 47,201 patients from the 16 centres:  
The study is conducted by a team at University College London: Teresa Hill (TH) – study 
manager; Sophie Jose (SJ) – statistician; Caroline Sabin (CS) – Principal investigator; Susie 
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Huntington (SH) – PhD student; and me (AT).  The study is overseen by a steering committee 
consisting of clinical representatives from all contributing sites, the HIV community and 
epidemiologists and statisticians from the Medical Research Council’s (MRC) Clinical Trials Unit 
and Public Health England (PHE) (Appendix II).  Five separate working groups advise on specific 
research themes and include members of the steering group as well as experts in the specific 
research area.  The five current research themes are: on-going monitoring of outcomes 
(including the development of resistance) among those infected with HIV; the impact of 
antiretroviral therapy received during pregnancy on the health of HIV-positive women; the 
impact of co-infection with HCV and/or HBV; the implications of an aging HIV population; and 
understanding the transmission and persistence of drug resistant HIV.  The study has been 
approved by a Multi-centre Research Ethics Committee and by local ethics committees and is 
funded by the MRC (Grant numbers G000019, G0600337and G0900274). 
 
3.2.1 Data Collection 
Data collection is coordinated by the study manager (TH).  Individuals are included in the study 
if they are HIV-positive, aged over 16 years and have attended any one of the centres in 1996 
or thereafter.  Although data are only collected on individuals seen for care since 1996, where 
individuals had attended prior to 1996 the date of their first attendance and all available 
historic data is also collected to give a complete clinical history at that centre.  Data are 
requested from participating centres on an annual basis (Appendix III) and the database is held 
securely at the MRC Clinical Trials Unit.   
 
At any point centres may decide to clean their own database or conduct work on a particular 
set of data items thus improving the quality of the data which can be extracted.  Therefore, 
each year, the complete dataset (from 1996 onwards) is requested and re-entered into the 
database, overwriting the previous year’s data.  Data from the previous year’s data collection 
are archived.  This means that where centres have added or cleaned data retrospectively, the 
new data will be included in the next UK CHIC dataset.  Each centre submits data in electronic 
format via a secure server.  The data are provided in nine specified datasets: demographic 
information; AIDS events; antiretroviral treatment; laboratory data (CD4 and CD8 counts and 
viral loads); hepatitis data; adherence; drug toxicities; HLA-B57 tests; and attendance data 
(Table 3.1).  Each dataset contains the individual’s clinic number and date of birth so that the 
datasets can be linked.  
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Table 3.1 Datasets collected as part of standard UK CHIC data collection 
Specified dataset Information collected 
Demographics Soundex code 
 Patient initial/s 
 Sex 
 Date of first known positive HIV antibody test 
 Date of last negative HIV antibody test 
 Date of first HIV attendance at centre 
 Date when last seen by a clinician at the centre 
 HIV exposure category  
 Ethnicity  
 Country of birth  
 Whether patient is known to have died 
 Date and cause of death (where known) 
 Centre patient transferred from and date of transfer 
 Centre patient transferred to and date of transfer 
  
AIDS events Date and description of all AIDS events 
  
Antiretroviral treatment Drugs 
 Dates of starting and stopping each drug 
 Reasons for stopping each drug (up to 3 per drug) 
  
CD4 and CD8 Date of measurement 
 Absolute CD4 and CD8 counts and CD4 and CD8 percentages 
  
Viral loads Date of measurement 
 HIV viral load in copies per ml 
 Whether or not HIV-RNA is detectable 
 Specific assay used 
  
Hepatitis Date of each hepatitis test 
 Hepatitis test conducted,  
 Hepatitis test result and value if applicable 1 
  
Adherence Date of clinic visit 
 Details of pills taken and pills missed 
  
Toxicities Date of each toxicity test 
 Toxicity test conducted and test result 
  
HLA-B57 Date and result of test 
  
Attendance data Date of attendance 
 Type of attendance (for example scheduled, walk-in, virtual, 
inpatient) 
 Who the patient is seen by (for example doctor, nurse, dietician) 
 Details of pills taken and pills missed 
  
1 Quantitative test results may be available for HBsAg, anti-HBs, HBV-DNA, HCV-RNA tests 
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3.2.2 Data cleaning 
A range of cross-tabulations are conducted and queries are applied to the data by TH to 
identify inconsistencies.  For example, checks are performed for missing or invalid 
demographic items and for illogical or conflicting dates such as an HIV-negative test occurring 
after an HIV-positive test or treatment occurring after death.  The results of these checks are 
returned to the centre providing the data and are verified against clinical records.  Where 
more accurate data are obtained, both the UK CHIC dataset and the original clinic database are 
updated accordingly.  Locally assigned clinic identification numbers along with Soundex and 
patient initials are maintained in the MRC database but are removed and replaced by a unique 
identifier prior to data being made available for analysis.  Therefore the final dataset which is 
used for analysis contains pseudonymised data. 
 
3.2.3 De-duplication 
Some individuals may attend more than one clinic and be reported by all the clinics which they 
attend.  This results in multiple records for these individuals within the study dataset.  These 
records must be combined into a single record.  Initially, potential matches are identified, by 
the data manager, on the basis of Soundex, patient’s first initial and date of birth.  A 
computerised algorithm, which utilises other demographic variables and HIV-positive dates, is 
then used to categorise potential matches as definite matches, definite non-matches and 
indeterminate.  The complete clinical data for indeterminate matches are then reviewed by 
two members of the study team who make a final decision about whether the records should 
be combined or remain separate.  The reviewers assess all the available data within the 
records including anti-retroviral therapy (ART).  Where the two reviewers come to different 
conclusions a third member of the team is consulted.  Where the third reviewer is unable to 
reach a decision the records remain as two distinct records. 
 
After this review process, where records are considered to be from the same individual, the 
records are merged.  During the merge any missing data in one record is updated with 
available data from the matched record.  The merged record will contain the earliest HIV-
positive date, the earliest first seen dates and the latest HIV-negative and last seen dates.  
Inconsistent treatment information in a merged record is resolved manually.     
 
3.2.4 Death data 
Prior to 2011, the Office for National Statistics (ONS) in England and the General Register 
Office (GRO) for Scotland provided additional data on deaths.  UK CHIC records which matched 
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to a record in either ONS or GRO on the basis of initial, Soundex, date of birth and sex were 
identified.  Where this process identified matches who are recorded as having died in the UK 
CHIC dataset but with a missing date of death, the ONS/GRO date of death was used to update 
the UK CHIC dataset.  Where this process identified matches who are not recorded as having 
died in UK CHIC, this was reported to the appropriate centre for verification before the UK 
CHIC dataset was updated.  
 
From 2011 onwards, the CHIC dataset has been linked to data from the Health Protection 
Agency’s (HPA) (now PHE) Survey of Prevalent HIV Infections Diagnosed (SOPHID) using initial, 
Soundex, date of birth, gender and ethnicity.  All records in UK CHIC are linked to one or more 
record in SOPHID and a score is generated indicating the strength of the match.  Where 
patients were recorded are having died in SOPHID but not in UK CHIC the UK CHIC dataset is 
updated as long as there is no conflicting information, such as later CD4 counts or clinic visits, 
and the matching score was high (>0.8).  Where patients are recorded as having died in UK 
CHIC but not having died in SOPHID the record is maintained as the patient having died.  
Where patients are reported as having died in both datasets but there are different dates of 
death an algorithm is used to assign the most likely date of death.  This algorithm utilises 
information including dates of clinic attendances and CD4 counts, matching scores and 
commonly used estimated dates. These processes do not include any updating of cause of 
death. 
 
3.2.5 Creation of final dataset 
Once de-duplication of the dataset is complete and all death data from SOPHID has been 
incorporated, TH exports the data into text files and passes them to the study statistician (SJ) 
who prepares the individual datasets to be merged to form the final dataset.  This process is 
currently done using SAS version 9.3 (SAS Institute Inc., North Carolina, USA).  Further checks 
are conducted in the individual specified datasets and the data amended where necessary:  
duplicate laboratory tests (CD4, viral load and HLA B*5701), attendance dates and AIDS events 
are removed; viral loads are classified as undetectable according to the lower limit of the 
assay;  and excessively large CD4 and CD8 counts (CD4>3500 cells/mm3, CD4 
percentage>100%, CD8>10000 cells/mm3, CD8 percentage>100) and CD4 and CD8 counts and 
percentages of zero are removed.   
 
For data on antiretroviral therapy, dates that individuals stop and start drugs are checked.  If a 
drug start date is after a drug stop date, the dates are reversed; multiple drug regimens are 
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split into their component parts (for example, Atripla becomes efavirenz, tenofovir and 
emtricitabine).  Where one treatment episode for a drug lies completely within another 
treatment episode for the same drug or two treatment episodes of the same drug overlap, the 
record is amended taking the earliest start date and the latest stop date of that drug.  Where 
there appears to be a gap of less than one month between stopping a drug and restarting it, it 
is assumed that this has resulted in an error in prescription datasets.  Therefore this gap is 
closed by removing the stop and start dates in the middle of the total time period that the 
individual is on a drug.   
 
Finally, the individual specified datasets are merged into one and the additional death data is 
also merged into this final complete dataset.  Any ineligible patients (those under the age of 16 
in the year of data collection) and illogical dates (for example where the first seen date is 
before the date of birth or where the date of birth is very early) are removed.  Where a drug 
stop date is after a death date, it is changed to the death date since the drug stop date is likely 
to be the end of the prescription.  Dates of any laboratory measures which occurred up to 2 
days after the death date are amended to the death date as these tests are likely to have been 
entered into the database with the date of the test report rather than the date on which the 
sample was taken.  Missing last seen dates are updated with the latest laboratory test date.    
 
3.2.6 Description of UK CHIC dataset  
The current UK CHIC dataset contains data on 47201 individuals, of whom 4475 individuals are 
known to have died, leaving 42726 who are assumed to be alive.  Data from SOPHID show that 
in 2011, 73627 were seen for HIV-related care in the UK.  Therefore it is estimated that the 
2012 UK CHIC  dataset contains data on approximately  58% (42726/73627) of all individuals in 
the UK living with diagnosed HIV infection (21).  The characteristics of the current cohort are 
shown in Table 3.2.
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Table 3.2 Characteristics of individuals on the UK CHIC 2011 dataset 
 Number of individuals 
N=47201 
% 
Median age at entry into cohort (IQR) 34 (29, 40)  
Sex   
Male 34202 72.5 
Female 12995 27.5 
Unknown 4 0.01 
Ethnicity   
White 24641 52.2 
Black African 12796 27.1 
Black other 2498 5.3 
Other/ Unknown 7266 15.4 
HIV exposure category   
MSM 23341 49.5 
IDU 1694 3.6 
Male heterosexual 6343 13.4 
Female heterosexual 10847 23.0 
Other/unknown 4976 10.5 
Median Nadir CD4 count (cells/mm3) 
(IQR) 
200 (90, 328)  
HIV viral load ever undetectable 32012  67.8 
Ever on HAART 33609 71.2 
Centres attended for care   
Brighton 3297 7.0 
St Mary’s 5823 12.3 
Chelsea and Westminster 11335 24.0 
Mortimer Market Centre 7227 15.3 
Kings 4266 9.0 
Royal Free 4931 10.5 
Bart’s and the London 5172 11.0 
Edinburgh 1153 2.4 
North Middlesex 1830 3.9 
Homerton 1590 3.4 
Bristol 1330 2.8 
Leicester 1504 3.2 
Middlesbrough 526 1.1 
Woolwich 1781 3.8 
St George’s 2587 5.5 
York 304 0.6 
Individuals known to have died 4475 9.5 
 
1 Clinics attended at any time during the study period.  Individuals may have attended more 
than one of the centres. 
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As further centres have joined the study, an increased proportion of individuals included in the 
cohort are seen at centres outside of London and therefore the characteristics of the cohort 
have changed.  To describe how the cohort has changed over time individuals were classified 
by whether or not they had been followed-up in each year from 1996 to 2010.  Some patients 
may have gaps in their follow-up (for example where they transfer from a CHIC centre to 
receive their HIV care in a centre which does not participate in CHIC and then return to a CHIC 
centre at a later date).  Therefore, to assess whether a patient is followed-up in a particular 
year, the first and last dates from each centre were used.  Due to missing or inconsistent dates, 
of the total dataset, 309 individuals could not be classified as having any follow-up year.  The 
reasons for this included, missing first or last seen dates and illogical first or last seen dates 
which could not be amended using any other data items.  These individuals were therefore 
excluded from descriptions and analyses where the data are split by year. 
 
In earlier years of follow-up the cohort has higher proportions of men: 80.4% of the cohort 
under follow-up in 2000 was men compared to 73.4% in 2011.  MSM remain the predominant 
risk group in the cohort from 2000 to 2011. However, the proportion of MSM in the cohort has 
decreased from 63.5% in 2000 to 54.5% in 2011.  The proportion of individuals under follow-up 
who are of black African ethnicity has also increased since 2000 with a corresponding decrease 
in the proportion of individuals who are of white ethnicity.  Details of the characteristics of 
individuals under follow-up in each year are provided in Appendix IV. 
 
Since clinical outcomes of patients are impacted by effective treatment, it is important to 
assess how treatment patterns may have changed over time.  HAART was defined as any 
regimen which consisted of three or more antiretroviral drugs of any class.  Patients who were 
HAART experienced (had ever received a treatment regimen of 3 or more drugs) were further 
classified according to their first HAART regimen.  The proportion of patients under follow up 
who started HAART with a PI based regimen has decreased from 34.0% in 2000 to 26.8% in 
2011 while the proportion of those who started with a NNRTI based regimen has increased 
from 44.0% in 2000 to 52.6% 2010 (Appendix IV).  On-going improvements in treatment 
strategies are evidenced by the changes in immunological and virological status of patients 
under follow-up in each year.  Over time an increasing proportion of patients under follow-up 
are virologically suppressed (38.4% in the year 2000 compared to 76.5% in 2011) and a 
decreasing proportion of patients have a CD4 count less than 200 cells/mm3 within a given 
year (21.3% in the year 2000 compared to7.3% in 2011). 
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3.3 Standard hepatitis data in UK CHIC dataset 
The standard UK CHIC data specifications sent to clinics include laboratory data on hepatitis 
tests which can be used to ascertain whether or not an individual is currently infected with or 
has previously been infected with a number of hepatitis viruses.  For each test performed the 
centres are asked to provide the date of the test, the result of the test (positive, negative or 
indeterminate/equivocal) and, where a quantitative test is performed (a HBsAg or anti-HBs 
titre, a quantitative HBV-DNA test or a quantitative HCV-RNA test), a numeric value.  The data 
cleaning procedures conducted during the preparation of the final dataset (described earlier, 
see section 3.2.5) do not include any checks on data submitted in the hepatitis dataset.  Since 
the aims of this thesis are to examine hepatitis co-infection within the UK CHIC study, I 
conducted some further checks before further analysis commenced.  
 
3.3.1 De-duplication of tests 
Individuals may be tested for markers of hepatitis infection more than once.  For every 
hepatitis test I counted the number of times an individual had been tested.  This revealed a 
very high number of tests for some individuals.  For example, 25 individuals were recorded in 
the dataset as having had more than 50 HBsAg tests.  Manual checks of the records of some of 
these individuals revealed that there were duplicate tests within the dataset.  Therefore I de-
duplicated the hepatitis test data:  where the date of test, the test code and the results of the 
test were all the same, additional tests were deleted leaving one record of that test in the 
dataset. 
 
3.3.2 Checking for missing data 
For each of the HBV tests and HCV tests I examined the dataset to identify where there were 
missing data items.  There were no instances of a test date or result with a missing test code.  
Four individuals had a test code with no corresponding test date.  These tests were removed 
from the dataset.  There were higher numbers of individuals who had missing test results.  
Where the result was missing, but a numeric value was present, the result was updated 
accordingly (Table 3.3).  There are a number of different assays in use for performing 
quantitative tests.  Information on which assay was in use for each test was not available.  
Therefore the data was examined to identify those quantitative measurement which appeared 
repeatedly within the datasets and therefore may represent cut-offs for the assays in use.   The 
thresholds for positive and negative tests were determined by examining these repeatedly 
reported measurements and consulting with clinical colleagues.  Where a number of potential 
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cut-offs were identified (for example in the case of HCV-RNA and HBV-DNA) a higher threshold 
was chosen to ensure that all individuals who were negative were included as such.  It is 
recognised that this may result in an overestimation of those who are HBV-DNA or HCV-RNA 
negative.  
Table 3.3 Defining positive and negative test results from quantitative assays 
Test Value Updated result Number with 
missing result 
before 
updating with 
quantitative 
results 
Number with 
missing result 
after updating 
with 
quantitative 
results 
 
Anti-HBs >10 IU/ml 
<10 IU/ml 
Positive 
Negative 
4911 3 
HBsAg titre >0 IU/ml 
<0 IU/ml 
Positive 
Negative 
7 7 
HBV-DNA >500 IU/ml 
<500 IU/ml 
Positive 
Negative 
1148 2 
HCV-RNA >615 copies/ml 
<615 copies/ml 
Positive 
Negative 
2361 0 
 
3.3.3 Follow-up dates and hepatitis test dates 
As previously described, patients were classified by whether or not they had been followed-up 
in a particular year.  Since hepatitis tests are reported from laboratories it is possible that the 
date provided in fact relates to the date that the sample was received in the laboratory or the 
date that the result was reported.  In addition, the first and last seen dates may not be 
accurately reported since clinics may complete these items retrospectively.  Therefore, I 
examined how many hepatitis tests occurred after the last seen date and how long after the 
last seen date the subsequent hepatitis test occurred (Table 3.4).  To maximise the number of 
patients who would be included in the analyses, I included patients as under follow-up in a 
particular year if they had a hepatitis test in that year and if the test was within 6 months of 
being last seen. After doing this 323 individuals could not be assigned to any follow-up year.
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Table 3.4 Comparison of last seen dates with dates of last hepatitis tests 
Dates of last hepatitis tests and last seen dates Number of individuals 
Last hepatitis test > Last seen date 2444 
Last hepatitis test > Last seen date +1 day 2328 
Last hepatitis test > Last seen date +3 days 2293 
Last hepatitis test > Last seen date +5 days 2266 
Last hepatitis test > Last seen date +30 days 2150 
Last hepatitis test > Last seen date +180 days 1588 
Last hepatitis test > Last seen date +365 days 886 
 
3.3.4 Description of available hepatitis data 
A full analysis of patterns of testing and epidemiology of co-infection is presented later in this 
thesis, after further data collection had taken place.  However, at this stage, the number of 
HBV and HCV tests conducted and the results of those tests were examined for each calendar 
year and in each centre.  This informed the priorities for further data collection.  For those 
tests which are used for diagnosis of infection (HBsAg for HBV infection and anti-HCV for HCV 
infection), the proportion of individuals tested increases over time.  However, a particular 
increase is seen in the early 2000s (Table 3.5and Table 3.8) There is a corresponding fall in 
overall positivity as a higher proportion of lower risk individuals are tested who receive 
negative test results (Table 3.6 and Table 3.8).  Analysis by first attended centre shows that 
there is great variation between centres in the proportion of hepatitis tests which are recorded 
in the UK CHIC dataset.  For example, only 20.3% of individuals had a recorded test for HBsAg 
at centre 114 compared to 84.4% of individuals at centre 110 (Table 3.7) and only 43.8% of 
individuals had a recorded test for anti-HCV at centre 109 compared to 86.5% at centre 110 
(Table 3.9) 
 
  
 
1
25
 
Table 3.5 Individuals tested for HBV markers 1996-2011 
Year Total 
number of 
individuals 
under 
follow-up 
Tested in that year 
HBsAg % Anti-
HBs 
% Anti-
HBc 
% HBeAg % Anti-
HBe 
% Anti-
HBc 
(IgM) 
% HBV-
DNA 
% HBsAg 
titre 
% 
Total 46878 31440 67.1 21491 45.8 29631 63.2 1356 2.9 2434 5.2 680 1.5 2342 5.0 480 1.0 
1996 10463 869 8.3 610 5.8 477 4.6 79 0.8 35 0.3 4 0.04 0 0.0 0 0.0 
1997 11213 1065 9.5 640 5.7 639 5.7 94 0.8 62 0.6 2 0.02 7 0.06 0 0.0 
1998 12231 1036 8.5 589 4.8 565 4.6 95 0.8 72 0.6 2 0.02 20 0.2 20 0.2 
1999 13294 688 5.2 425 3.2 552 4.2 115 0.9 112 0.8 39 0.3 25 0.2 30 0.2 
2000 14475 1218 8.4 658 4.5 753 5.2 171 1.2 117 0.8 26 0.2 31 0.2 23 0.2 
2001 15989 2685 16.8 931 5.8 1475 9.2 255 1.6 181 1.1 15 0.1 128 0.8 37 0.2 
2002 11713 2885 24.6 897 7.7 1765 15.1 265 2.3 152 1.3 14 0.1 158 1.3 41 0.4 
2003 19377 3480 18.0 1020 5.3 1915 9.9 319 1.6 194 1.0 14 0.1 219 1.1 24 0.1 
2004 21575 4227 19.6 1297 6.0 2466 11.4 366 1.7 256 1.2 22 0.1 228 1.1 0 0 
2005 23447 5264 22.5 2335 10.0 2637 11.2 427 1.8 369 1.6 38 0.2 315 1.3 91 0.4 
2006 24953 6339 25.4 2967 11.9 3745 15.0 408 1.6 378 1.5 54 0.2 334 1.3 116 0.5 
2007 26270 7640 29.1 4697 17.9 6397 24.4 479 1.8 521 2.0 95 0.4 521 2.0 116 0.4 
2008 27352 9976 36.4 6779 24.8 8255 30.2 493 1.8 596 2.2 110 0.4 619 2.3 153 0.6 
2009 28271 10906 38.6 7117 25.2 8286 29.3 503 1.8 607 2.1 151 0.5 704 2.5 123 0.4 
2010 29326 9105 31.0 6354 21.7 7071 24.1 487 1.7 600 2.0 165 0.6 662 2.3 112 0.4 
2011 27670 8092 29.2 6934 25.1 7727 27.9 483 1.7 860 3.1 189 0.7 1104 4.0 127 0.5 
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Table 3.6 Individuals with positive HBV tests, 1996-2011 
Year Tested positive in that year 
HBsAg % of 
those 
tested 
Anti-
HBs 
% of 
those 
tested 
Anti-
HBc 
% of 
those 
tested 
HBeAg % of 
those 
tested 
Anti-
HBe 
% of 
those 
tested 
Anti-
HBc 
(IgM) 
% of 
those 
tested 
HBV-
DNA 
% of 
those 
tested 
HBsAg 
titre 
% of 
those 
tested 
Total 1828 5.8 13781 64.1 11633 39.3 879 64.8 1165 47.9 104 15.3 868 37.1 414 86.3 
1996 84 9.7 330 54.1 274 57.4 51 64.6 21 60.0 3 75.0 0 0.0 0 0.0 
1997 103 9.7 287 44.8 311 48.7 65 69.1 33 53.2 0 0.0 3 42.9 0 0.0 
1998 110 10.6 270 45.8 285 50.4 72 75.8 38 52.8 1 50.0 9 45.0 20 100.0 
1999 108 15.7 243 57.2 263 47.6 76 66.1 46 41.1 10 25.6 16 64.0 30 100.0 
2000 164 13.5 381 57.9 383 50.9 111 64.9 48 41.0 5 19.2 24 77.4 23 100.0 
2001 289 10.8 526 56.5 705 47.8 181 71.0 54 29.8 8 53.3 100 78.1 37 100.0 
2002 326 11.3 519 57.9 842 47.7 172 64.9 63 41.4 6 42.9 126 79.7 41 100.0 
2003 404 11.6 606 59.4 870 45.4 194 60.8 88 45.4 10 71.4 134 61.2 24 100.0 
2004 429 10.1 814 62.8 1115 45.2 220 60.1 117 45.7 2 9.1 130 57.0 0 0.0 
2005 478 9.1 1498 64.2 1097 41.6 230 53.9 180 48.8 10 26.3 145 46.0 76 83.5 
2006 477 7.5 1948 65.7 1482 39.6 193 47.3 154 40.7 8 14.8 120 35.9 96 82.8 
2007 526 6.9 3043 64.8 2380 37.2 196 40.9 264 50.7 7 7.4 206 39.5 96 82.8 
2008 537 5.4 4005 59.1 2808 34.0 188 38.1 261 43.8 4 3.6 235 38.0 133 86.9 
2009 553 5.1 4381 61.6 2734 33.0 191 38.0 267 44.0 9 6.0 240 34.1 107 87.0 
2010 539 5.9 4084 64.3 2243 31.7 191 39.2 223 37.2 13 7.9 240 36.3 99 88.4 
2011 503 6.2 4686 67.6 2388 30.9 181 37.5 319 37.1 22 11.6 197 17.8 115 90.6 
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Table 3.7 HBV tests conducted at each centre 
First 
centre 
code 
Total 
number of 
individuals 
Ever had an HBV test 
HBsAg % Anti-
HBs 
% Anti-
HBc 
% HBeAg % Anti-
HBe 
% Anti-
HBc 
(IgM) 
% HBV-
DNA 
% HBsAg 
titre 
% 
Total 47201 32130 68.1 21859 46.3 30307 64.2 2022 4.3 2466 5.2 703 1.5 2396 5.1 498 1.1 
101 2728 2250 82.5 2233 81.9 1136 41.6 119 4.4 199 7.3 91 3.3 252 9.2 2 0.1 
102 5225 3671 70.3 3429 65.6 3402 65.1 180 3.4 753 14.4 12 0.2 251 4.8 345 6.6 
103 9792 7945 81.1 2462 25.1 6389 65.2 504 5.1 545 5.6 107 1.1 501 5.1 15 0.2 
104 6266 5153 82.2 4245 67.7 4429 70.7 347 5.5 319 5.1 138 2.2 352 5.6 16 0.3 
105 3677 2755 74.9 1813 49.3 2913 79.2 263 7.2 303 8.2 103 2.8 164 4.5 91 2.5 
106 3713 2654 71.5 2322 62.5 2823 76.0 14 0.4 17 0.5 7 0.2 199 5.4 4 0.1 
107 4370 2475 56.6 1381 31.6 2455 56.2 252 5.8 28 0.6 9 0.2 25 0.6 4 0.1 
108 1084 495 45.7 400 36.9 520 48.0 40 3.7 33 3.0 0 0.0 31 2.9 0 0.0 
109 1598 736 46.1 137 8.6 654 40.9 76 4.8 87 5.4 59 3.7 56 3.5 3 0.2 
110 1381 1165 84.4 863 62.5 1141 82.6 90 6.5 5 0.4 1 0.1 6 0.4 4 0.3 
111 1221 806 66.0 25 2.0 757 62.0 4 0.3 37 3.0 26 2.1 484 39.6 0 0.0 
112 1444 572 39.6 613 42.5 520 36.0 22 1.5 23 1.6 10 0.7 24 1.7 3 0.2 
113 475 216 45.5 173 36.4 122 25.7 14 2.9 13 2.7 84 17.7 15 3.2 5 1.1 
114 1620 329 20.3 681 42.0 427 26.4 37 2.3 33 2.0 2 0.1 24 1.5 3 0.2 
115 2306 754 32.7 934 40.5 1066 46.2 59 2.6 67 2.9 54 2.3 10 0.4 2 0.1 
116 301 154 51.2 148 49.2 153 50.8 1 0.3 4 1.3 0 0.0 2 0.7 1 0.3 
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Table 3.8 Individuals tested  and positive for HCV, 1996-2011 
Year Number 
under 
follow-up 
Anti-HCV 
tested 
% of those in 
follow-up 
HCV-RNA 
tested 
% of those in 
follow-up 
Anti-HCV 
positive 
% of those 
tested 
HCV-RNA 
positive 
% of those 
tested 
Total 46878 34239 73.0 6541 14.0 3039 8.9 2454 37.5 
1996 10463 818 7.8 13 0.1 136 16.6 5 38.5 
1997 11213 1052 9.4 94 0.8 155 14.7 41 43.6 
1998 12231 960 7.8 70 0.6 120 12.5 38 54.3 
1999 13294 1008 7.6 123 0.9 92 9.1 71 57.7 
2000 14475 1467 10.1 133 0.9 160 10.9 91 68.4 
2001 15989 2536 15.9 208 1.3 189 7.5 147 70.7 
2002 11713 2999 25.6 460 3.9 258 8.6 234 50.9 
2003 19377 3855 19.9 633 3.3 273 7.1 250 39.5 
2004 21575 4734 21.9 619 2.9 339 7.2 268 43.3 
2005 23447 6309 26.9 795 3.4 409 6.5 376 47.3 
2006 24953 6912 27.7 675 2.7 439 6.4 293 43.4 
2007 26270 8846 33.7 1251 4.8 513 5.8 513 41.0 
2008 27352 10900 39.9 1778 6.5 640 5.9 739 41.6 
2009 28271 12298 43.5 2044 7.2 656 5.3 808 39.5 
2010 29326 13023 44.4 2079 7.1 578 4.4 811 39.0 
2011 27670 14153 51.1 1895 6.8 558 3.9 714 37.7 
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Table 3.9 HCV tests conducted at each UK CHIC centre  
 
First 
centre 
code 
Total number 
of individuals 
Anti-HCV tested % HCV-RNA 
tested 
% 
Total 47201 35007 74.2 6605 14.0 
101 2728 2286 83.8 515 18.9 
102 5225 3832 73.3 1479 28.3 
103 9792 8270 84.5 1172 12.0 
104 6266 5254 83.8 1175 18.8 
105 3677 3005 81.7 264 7.2 
106 3713 2917 78.6 633 17.0 
107 4370 2622 60.0 129 3.0 
108 1084 600 55.3 257 23.7 
109 1598 748 46.8 57 3.6 
110 1381 1195 86.5 86 6.26 
111 1221 795 65.1 668 54.76 
112 1444 696 48.2 56 3.9 
113 475 215 45.3 19 4.0 
114 1620 1090 67.3 57 3.5 
115 2306 1325 57.5 32 1.4 
116 301 157 52.2 6 2.0 
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3.4 Statistical methods 
Full details of analytical methods used in this thesis are provided in the relevant chapters.  
However, there are some standard methods used throughout.  For all analyses, the cohort 
included in the analysis was first described with regard to demographic and clinical 
characteristics.  Differences between groups were assessed using chi-squared tests for 
categorical or binary variables and Student’s t-tests for continuous variables which were 
Normally distributed and Wilcoxon rank sum tests for continuous variables which were non-
Normally distributed.  Various regression techniques were then used to identify independent 
predictors of outcomes after controlling for confounding – the presence of factors which are 
associated with both the exposure and the outcome.  This section describes the regression 
methods used.  All analyses were conducted in SAS version 9.3 (SAS Institute Inc., North 
Carolina, USA). 
 
3.4.1 Logistic regression 
Where the outcome of interest is a binary variable (or categorical in the case of multi-nominal 
logistic regression), logistic regression analysis was used to model the likelihood of a particular 
outcome given a number of explanatory variable (or exposures) which are assessed at one 
time point. 
 
The odds ratio (OR) for an outcome is defined as the odds in the exposed group divided by the 
odds in the unexposed group.  Using the notation shown in Table 3.10, an OR can be calculated 
as: 
Odds ratio=   (
𝒂
𝒃
)/(
𝒄
𝒅
) 
 
Table 3.10 Values used to calculate an odds ratio 
 Individuals with outcome Individuals without outcome 
Exposed group a b 
Not exposed group c d 
 
Therefore the likelihood that the outcome occurs (the odds of that outcome), given exposure 
to a factor of interest can be expressed as: 
 
𝑂𝑑𝑑𝑠 𝑜𝑓 𝑜𝑢𝑡𝑐𝑜𝑚𝑒 = 𝑂𝑑𝑑𝑠 𝑖𝑛 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑔𝑟𝑜𝑢𝑝 ∗ 𝑂𝑑𝑑𝑠 𝑟𝑎𝑡𝑖𝑜 𝑓𝑜𝑟 𝑒𝑥𝑝𝑜𝑠𝑒𝑑 𝑔𝑟𝑜𝑢𝑝 
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Logistic regression models are fitted on a log scale and subsequently anti-logged to give ORs 
with 95% CIs.  Therefore the above equation is transformed to: 
 
𝑙𝑜𝑔(𝑜𝑑𝑑𝑠) = log(𝑜𝑑𝑑𝑠 𝑖𝑛 𝑟𝑒𝑓𝑒𝑟𝑒𝑛𝑐𝑒 𝑔𝑟𝑜𝑢𝑝) + log (𝑜𝑑𝑑𝑠 𝑟𝑎𝑡𝑖𝑜 𝑓𝑜𝑟 𝑒𝑥𝑝𝑜𝑠𝑢𝑟𝑒 𝑔𝑟𝑜𝑢𝑝) 
 
The log(odds in the reference group) and log(odds ratio for exposure) are the regression 
coefficients: generally referred to as β.   Where more than one exposure (x1-xn) is included in 
the model the logistic regression model can be expressed as: 
 
𝑙𝑜𝑔  (𝑜𝑑𝑑𝑠 𝑜𝑓 𝑜𝑢𝑡𝑐𝑜𝑚𝑒) = 𝛽o + 𝛽1𝑥1 +  𝛽2𝑥2 +  𝛽n𝑥n 
 
The result is anti-logged to give adjusted odds ratios (AOR).  Multinomial logistic regression 
was used where the outcome was categorical (more than 2 categories).  In this case one of the 
outcome categories is chosen as the reference group and the log(odds) of each outcome 
occurring compared to this reference group are estimated with regard to the exposure 
variables entered into the model. 
 
3.4.2 Poisson regression 
Poisson regression was also used where the outcome of interest is binary.  However, this type 
of analysis allows for individuals within the cohort to be followed-up for different amounts of 
time and therefore it was used to model the rate at which the outcome occurs. This is useful in 
cohort studies where individuals may enter and leave the cohort at various different time 
points as it allows maximal use of available data, even when individuals are followed-up for 
short periods of time or at different calendar time points.  Within the model, exposure 
variables which are measured more than once may be time updated. Like logistic regression, 
Poisson models are also fitted on a log scale.  Therefore the above equation also applies but to 
give the log(rate of outcome). The model assumes that the rate at which an event occurs is 
uniform throughout the period of follow up.  There are some analyses where there is reason to 
believe that this is not the case.  In these situations some indicator of time can be included in 
the model (for example, time in study) to account for changes in the rate over time.  Rate 
ratios (RRs) and adjusted rate ratios (ARR) are produced to compare the rate of outcome in 
one group with that in another. 
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3.4.3 Survival analysis and Cox proportional Hazards Models 
Survival analysis was used where the outcome of interest was binary and a clear and logical 
time point to begin follow-up was available (for example first positive test result or start of 
treatment).  This type of analysis allows for the rate of the event to vary over time. Cumulative 
survival (the probability of not having experienced the outcome up to time, t) and the hazard 
(the instantaneous rate of the outcome at time, t) at any given time are predicted using the 
Cox proportional hazards model.  For individuals whose survival is not known beyond a 
particular time point, follow-up is censored.  The model assumes that the probability of being 
censored is unrelated to the probability of the event occurring. 
 
Kapan Meier methods were used to visually display the survival function prior to any 
regression analysis. The times at which an event occurs are t1, t2, t3, up to tj.  At all times where 
the outcome of interest does not occur the probability of survival is equal to 1.  Therefore the 
probability of survival at t1 is: 
S(t1)=1* S(t1) 
At time point 2 the probability of survival is: 
S(t2)= S(t1)* st2 
This is repeated for all time points where the outcome occurs so that the probability of survival 
up to and including event j is: 
S(tj)= S(tj-1)* stj=  st1 * st2 * stj 
The survival curve is plotted as horizontal at all time-points where an event does not occur 
with a step drop corresponding to the change in probability of survival each time an event 
occurs so that the curve represents the true population at risk which only falls when an event 
occurs. 
 
The Cox proportional hazards model considers the values of each exposure variable for an 
individual who experiences the outcome, at the time at which the event occurs.  It assumes 
that the hazard ratio between different exposure groups remains constant over time.  This is 
the proportional hazards assumption.  Like Poisson and logistic regression Cox models are 
formed on the log scale and therefore can be represented as: 
 
𝐿𝑜𝑔  (ℎ(𝑡)) = log(ℎ0(𝑡)) + 𝛽1𝑥1 +  𝛽2𝑥2 +  𝛽p𝑥n 
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The hazard ratio (HR) compares the hazards between exposure groups and gives an estimate 
of the increased hazard given the exposure of interest. In a multivariable model adjusted 
hazard ratios (AHR) estimate the hazards in each exposure group after accounting for 
confounding factors. 
 
3.4.4 General approach used in all regression analyses 
For all regression modelling the decision as to which variables should be included in the model 
was based on results of univariable analysis and a priori decisions informed by the literature.  
Only those factors which were found to be associated with the outcome in univariable analysis 
(p<0.05), or those where previous research has shown a strong association between the 
outcome and any other exposure variables, were included in multivariable modelling.  The aim 
of all analyses was to achieve a parsimonious model. Therefore variables were added to the 
model in a stepwise manner and were only retained in the model if they showed a significant 
result or altered the results for any other variables included.  A 5% significance level was used 
throughout this thesis and 95% confidence intervals (95% CI) are presented where 
appropriate. 
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Chapter 4 Methods 2: Forming an HIV and hepatitis co-infection 
dataset 
 
4.1 Introduction 
As previously described, the standard UK CHIC dataset includes dates and results of hepatitis 
tests.  However, the dataset does not include details of hepatitis specific treatment or the 
stages of liver disease in co-infected patients.  Previously published analyses of hepatitis in the 
UK CHIC study have been limited to the presence of infection and the impact of hepatitis co-
infection on HIV-related outcomes (immunological status and HIV treatment response) (244, 
259).  These analyses, as well as the description of available hepatitis data described in Chapter 
3, section 0, have indicated that not all hepatitis tests conducted may be reported to UK CHIC. 
Therefore, using only these test results to define hepatitis co-infection may result in 
underestimation of the size of the co-infected population.  
 
This chapter describes the process of identifying a cohort of individuals who are co-infected 
with HIV and HBV and/or HCV through examination of the existing UK CHIC dataset and 
subsequent validation with data obtained from clinics.  In addition, I describe the process of 
expanded data collection which was conducted in order to obtain clinical hepatitis data (liver 
outcomes and treatment information) for these individuals.   
 
In order to reduce the volume of data to be collected, a limited time period was chosen.  Only 
those individuals who had been seen for care at any point since 2004 were included in this 
process.  This time period was selected because of the changes in the proportion of individuals 
tested for hepatitis markers over time (0) and the publication of specific clinical guidelines for 
treating HIV/HCV and HIV/HBV co-infection which may have had an impact on the numbers of 
individuals tested within HIV clinics (456-459).  However, in line with standard UK CHIC data 
collection, all available information was gathered for these individuals, including historical data 
prior to 2004. 
 
 
4.2 Identification of potentially co-infected individuals 
Given the concerns that not all hepatitis tests may be reported to UK CHIC we aimed to 
supplement the existing data within UK CHIC with clinical knowledge of hepatitis co-infection 
within the centres.  For the purposes of identifying individuals who may be infected with HBV 
 135 
 
or HCV, HBV co-infection was defined as ever receiving a positive result for an HBsAg test and 
HCV co-infection was defined as ever having a positive test for anti-HCV test or a positive 
result for a HCV-RNA test.  These definitions were used to create a list of potentially co-
infected patients at each centre from the final UK CHIC 2011 dataset (from here on referred to 
as the CHIC co-infected list). 
 
The UK CHIC dataset is pseudonymised and does not contain specific patient identifiers.  
Individuals are assigned a unique identifier once data has been received from the centre 
(known as PATNUM).   Clinic identifiers (IDs) are removed from the final dataset but are kept in 
the main UK CHIC database at the MRC.  Using the MRC database, the PATNUMs of individuals 
in the CHIC lists of co-infected individuals were matched to clinic IDs to give a list of potentially 
co-infected patients who could be identified within clinic information systems.  PATNUMs and 
clinic IDs were kept separate at all times except during the matching process at the MRC to 
preserve the pseudonymised nature of the dataset used in analysis.  
 
A request was sent to each centre for a list of clinic identifiers for those individuals, seen at any 
point from 2004, who they believed to be co-infected with HBV or HCV.  These lists formed a 
secondary list of potentially co-infected individuals (from here on referred to as the centre co-
infected lists).  The CHIC co-infected lists were cross-matched with the centre co-infected lists 
to create a final list of potentially co-infected individuals (Table 4.1). Of the 16 HIV centres 
contributing to UK CHIC in 2011, only 11 were able to provide a clinical list of co-infected 
individuals.  Therefore all further data collection was conducted only at these 11 centres. 
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Table 4.1 Number of potentially co-infected patients on CHIC lists and centre lists 
Centre HBV HCV 
UK CHIC 
list1 
Centre 
list1 
Total 
potentially 
co-infected2 
UK CHIC 
list 1 
Centre 
list1 
Total 
potentially 
co-infected2 
Brighton 86 80 91 480 193 504 
St Mary’s 176 146 184 329 462 514 
Chelsea & Westminster 439 404 492 1025 991 1154 
Mortimer Market Centre  239 220 290 504 431 529 
Kings 163 198 223 97 236 288 
Royal Free 217 189 244 157 416 440 
Edinburgh 48 25 49 238 251 298 
North Middlesex 75 72 116 29 79 83 
Bristol 29 26 32 69 51 72 
Middlesbrough 13 9 13 8 11 11 
Woolwich 41 25 48 48 17 55 
Total3 1526 1394 1782 2984 3138 3948 
1 CHIC lists and centre lists are not mutually exclusive.   
2 HBV and HCV lists are not mutually exclusive.    
3 Co-infected individuals may be seen at more than one centre. 
 
 
4.3 Expanded data collection 
The hepatitis subgroup of the UK CHIC steering committee agreed a list of variables for which 
we would collect data on all co-infected patients.  Where data items could be derived from the 
existing data, newly collected data would be used for validation (Table 4.2). Only data which 
were routinely collected within the HIV clinic were collected as agreed in UK CHIC ethical 
agreements. 
 
Centres were asked, for each data item, whether the data would be available in the form of an 
electronic download or would require a review of patient notes (either in paper format or 
available as part of an electronic patient record system) (Table 4.2).  
 
Data collection was conducted from September 2012 to September 2013 in collaboration with 
research assistants based at the research unit of St Stephen’s AIDS Trust:  Ashley Moyes (AM), 
Laura Phillips (LP) and Elisha Seah (ES).  NHS research passports and letters of access were 
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obtained for each Trust to allow access to patients’ records.  Each centre was visited by me 
and at least one of AM, LP and ES to gather data which was not available in the form of an 
electronic download.  During centre visits the true status of all potentially co-infected 
individuals was ascertained.  Data were collected on standardised Excel spread sheets as free 
text and were recorded exactly as it appeared in the notes.  Collected data was uploaded to 
the File Transfer Protocol (FTP) server, a secure server run by the MRC.   
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Table 4.2 Data items to be collected and sources of data for those patients who are co-infected with HBV and/or HCV 
Type of data item Data collected 
 
Sources of data 
Behavioural Sexual orientation at time of hepatitis acquisition, injected drug 
use, alcohol consumption 
Clinical notes; HIV clinic databases; clinicians’ letters 
For HCV co-infected individuals Date of last negative and first positive anti-HCV test 
Date first positive HCV-RNA test 
Date and result of most recent anti-HCV and HCV-RNA test 
Date and result of all HCV genotype tests 
Clinical notes; HIV clinic databases; clinicians’ letters; 
laboratory downloads 
For HBV co-infected individuals Date of first and most recent anti-HBc, HBsAg, anti-HBs, HBeAg, 
anti-HBe, HBV-DNA, HBV genotype 
Clinical notes; HIV clinic databases; clinicians’ letters; 
laboratory downloads 
Other hepatitis serology Date and result of first and most recent hepatitis D antibody 
and hepatitis A antibody 
Clinical notes; HIV clinic databases; clinicians’ letters; 
laboratory downloads 
Other laboratory tests Prothrombin time, AFP Clinical notes; clinicians’ letters; laboratory downloads 
Assessments for liver disease Dates and results of liver scans, biopsies and FibroScans® Clinical notes; clinicians’ letters; radiology downloads; 
pathology records; Fibroscan® machine downloads 
Hepatitis treatment Date of starting and stopping all drugs to treat HBV or HCV. 
Dose and frequency of drug regimen, reason for stopping drug  
 
Clinical notes; clinicians’ letters 
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Type of data item Data collected 
 
Sources of data 
Complications of hepatitis 
infection 
Date of diagnosis for all instances of: ascites; portal 
hypertension; hematemesis; varices; encephalopathy; 
hepatoma 
Clinical notes; clinicians’ letters; scan results 
Liver transplantation Referral date for a liver transplant (where applicable)  
Date of liver transplant (where applicable) 
Clinical notes; clinicians’ letters 
Death Date and cause of death (where applicable) Clinical notes; HIV clinic databases 
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4.4 Merging data into UK CHIC 
A series of standardised tables, including relevant coding was created for the newly collected 
data (Appendix V).  For each centre the collected data were cleaned and formatted to populate 
these tables.  Clinic IDs of all patients were matched to the 2012 UK CHIC PATNUM and the 
clinic IDs were deleted to anonymise the dataset.  The serological data, death data and the 
demographic data were then merged back into the main UK CHIC dataset.  Other newly 
collected data (hepatitis genotype, hepatitis treatment, scans, biopsies, FibroScans®, clinical 
events and transplant data) have been kept as separate datasets which can be merged into UK 
CHIC for analyses as necessary.  All data management and analyses were conducted in SAS 
version 9.3 (SAS Institute Inc., Cary, NC, USA). 
 
4.4.1 Demographic data 
Where new data were available from the data collection which were not present in UK CHIC 
the UK CHIC dataset was updated.  Where there were conflicts between the new demographic 
data and the existing UK CHIC data, the existing UK CHIC data was maintained.  These conflicts 
were usually due to individuals being seen at more than one clinic where data cleaning 
processes during creation of the UK CHIC dataset had already ascertained the most likely 
correct data.   
 
4.4.2 Death data 
As a result of the data collection process, an additional 39 individuals were identified as having 
died compared to the existing UK CHIC data.  The UK CHIC dataset was updated accordingly for 
these individuals.  Where the date of death ascertained from data collection did not match the 
date of death in UK CHIC, the UK CHIC date was used as this has already been validated 
through other mechanisms.  Where cause of death in existing UK CHIC data did not match the 
newly collected data, the most likely cause of death was determined on a case-by-case basis. 
 
4.4.3 Hepatitis test data 
The existing UK CHIC hepatitis test data for all potentially co-infected individuals were 
extracted, merged with the newly collected serology data and de-duplicated.  Therefore the 
resulting dataset contained the existing UK CHIC data and any additional data from the data 
collection.  The existing UK CHIC dataset was then compared to the new dataset and examined 
for conflicting information.  There were a number of scenarios where the new data conflicted 
with the old data: 
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1. Same date, same test code, same result, different quantitative value 
2. Same date, same test code, different result, same quantitative value 
3. Same date, same test code, different result, different quantitative value 
  
After review of the data, the following rules were used to resolve these discrepancies. 
 
Scenario 1 (725 individuals) and scenario 2 (738 individuals):  where the old value is null and 
the new value is not null, use the new value.  Where the new value is null and the old value is 
not null, use the old value.  Where neither the old nor the new value are null but they are 
different, accept the new value.   
 
Scenario 3 (918 individuals): Accept the new data. 
 
The updated serological data was then used to replace the original serological data for these 
individuals. 
 
4.4.4 Coding Scans  
Scans and biopsies were recorded in the dataset exactly as reported to the requesting clinician.  
A number of different types of medical imaging techniques had been used in order to visualise 
the liver including US, MRI and CT scans.  With input from a clinical member of the hepatitis 
subgroup of the UK CHIC steering committee hepatitis subgroup, scan results were coded as: 
normal; suggestive of fatty infiltration; suggestive of cirrhosis; showing ascites; suggestive of 
portal hypertension; HCC; any other abnormalities.  Each scan could receive multiple codes.  
Coding was conducted as a two stage process.  At stage one, scans were coded as any of the 
above where the full text result explicitly mentioned the relevant conditions.  However, this 
resulted in a number of scans that remained uncoded.  Therefore at stage two of coding, 
complete descriptions of the imaging were used to ascertain whether any of the codes were 
relevant.     
 
Scans were coded as normal where abnormalities were noted on the scan report but were not 
relevant to the liver (for example, enlarged spleen in the absence of any hepatic abnormality).  
A summary of common descriptions found in the imaging report which led to coding are 
shown in Table 4.3.  Where scans were suggestive of portal hypertension or there was 
 142 
 
evidence of ascites, scans were coded as suggestive of cirrhosis since these complications of 
liver disease would only be likely to occur in cirrhotic individuals. 
 
Suspicious liver lesions are usually identified first on US.  However, in order to make a 
diagnosis of HCC, further imaging such as MRI is usually conducted.  Therefore where a 
visualised lesion on an US had triggered further imaging which then confirmed the presence of 
HCC the earliest scan showing the relevant lesion was coded as HCC.  Finally, a further code 
was added to indicate benign liver lesions and a further code was added to indicate a scan 
which occurred subsequent to a liver transplant. 
 
Table 4.3 Common descriptions reported in imaging results and relevant coding 
Descriptions found in liver imaging report1 Codes applied in dataset 
Coarse echotexture 
Fibrotic change 
Nodular echotexture 
Scarring 
Shrunken liver 
Heterogeneous echotexture 
 
Suggestive of cirrhosis 
Increased echotexture 
Increased reflectivity 
Areas of focal fatty sparing 
 
Suggestive of fatty infiltration 
Oesophageal varices 
Reduced hepatopetal flow 
Reversal of flow 
Portal dampening 
Dampened hepatic venous flow 
Portal vein thrombosis 
Prominent portal vein 
 
Suggestive of portal hypertension 
 
1 This is not a complete list but does include the most commonly seen descriptions 
 
4.4.5 Coding biopsies 
The inclusion of data collected from multiple centres has resulted in biopsy data in a number 
of different formats.  Some results only include a description of the biopsy material while 
others provide information in the form of scores of inflammatory activity and fibrosis stage.  
However, where scores were reported, a range of different scoring systems had been used.  In 
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total, of 862 biopsies, 484 had one or more scores included in the report (471 Ishak activity 
scores, 475 Ishak fibrosis scores, 12 METAVIR activity scores and 8 METAVIR activity scores). 
 
Therefore a set of codes were created for the types of scores used and these were included 
within the biopsy dataset.  Where a score had been given in the pathologist’s report, this result 
was retained.  However, for those biopsies where no score was available in the pathologist’s 
report a METAVIR score was assigned according to details given in text result of the report.  In 
order to validate this scoring, a sample of 20 biopsies was also scored by an experienced 
clinician.  The two scores were then compared.  The activity scores matched for 13/20 of these 
cases and fibrosis scores matched for 15/20.  Since activity score is difficult to define from text, 
I will not make any changes but have used the knowledge gained to make recommendations 
for improvement for the next round of data collection.  Where fibrosis scores did not match, 
the reasons for this were ascertained.  One was an error by one scorer which was amended (a 
cirrhotic individual who had been assigned a score of 1), the other four were individuals who 
had a description of “developing cirrhosis”.  The two scorers had either assigned these a 3 or a 
4. Subsequent to this validation all individuals with a report including this description were 
assigned a METAVIR score of 4. 
 
 
4.5 Summary of data collected 
Data collection was completed at eleven out of sixteen UK CHIC centres.  Paper notes and/or 
hospital record systems (for example radiology or pathology databases or electronic patient 
record systems) were reviewed for 95% of potentially HBV co-infected patients and 91% of 
potentially HCV co-infected patients at these centres. Where notes were not reviewed this was 
due to paper notes being physically unavailable for reviews.  This was the case for patients 
who had not been seen in the centre for long periods of time. Clinic staff were consulted about 
the possibility of obtaining all notes which were not immediately available and therefore the 
5% that were not reviewed were considered impossible to obtain in the necessary timeframe. 
 
A total of 1637 individuals were confirmed as HBV-infected and 3299 individuals were 
confirmed as HCV-infected.   A summary of new data items collected are shown Table 4.4. 
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Table 4.4 Total number of new data items collected 
Data Item Number of 
patients 
Total number Median number 
per patient 
Inter quartile 
range 
Scans 2339 6618 2 1, 4 
Biopsies 719 870 1 1, 1 
FibroScans® 1165 1592 1 1, 2 
Prothrombin time1 2464 18563 6 3, 13 
INR1 343 3561 11 4, 27 
AFP 2452 12512 4 2, 10 
HCV treatment 1098 - - - 
HCV genotype 1818 - - - 
Clinical events2 68 - - - 
Transplants 12 - - - 
 
1 Different measures of blood clotting are reported depending on the centre.  Prothrombin 
time is measured at Edinburgh, Bristol, Mortimer Market Centre, St Mary’s, Chelsea and 
Westminster, Royal Free, Woolwich, North Middlesex and Middlesbrough.  International 
Normalised Ratio (INR) is measured at Brighton, St Mary’s, Kings, Woolwich and North 
Middlesex. 
 
2 Incomplete data.  This includes mention of clinical event in medical notes and does not 
include clinical events which are reported in the results of scan 
  
Of 3299 HCV-infected individuals 55% had a known genotype (32 individuals had more than 
one genotype):  1249 (69%) genotype 1; 49 (3%) genotype 2; 15 (0.8%) genotype 2/3; 284 
(16%) genotype 3; 251 (14%) genotype 4; and 2 (0.1%) genotype 6.   Among HCV-infected 
patients, 33% had records of having received hepatitis treatment.    
 
Information on HBV treatment with tenofovir or lamivudine is available in the existing UK CHIC 
dataset since these drugs form part of the individual’s HIV treatment as well as acting against 
HBV.  Additional data on HBV treatment with entecavir, adefovir or interferon were collected 
for 30 individuals. 
 
 
4.6 Inclusion criteria for analyses 
As described in this chapter, expanded data collection was conducted at 11/16 CHIC centres 
and was limited to those patients who were seen at any point from 2004 onwards.  For all 
further analyses presented in this thesis, unless otherwise stated, only those individuals who 
had been seen at any of the 11 included centres from 2004 onwards were included.   
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To identify the individuals to be included in the analysis, the years in which each individual was 
followed-up at each centre were identified using the first and last dates that an individual was 
reported as having been seen at each centre.  Given the high number of individuals who had 
received a hepatitis test result after their last seen date and in order to maximise the volume 
of hepatitis data which could be included in the analyses, an additional 6 months at the end of 
follow-up were added where hepatitis tests occurred after the final last seen date.   
 
In order to assess the potential for the introduction of bias due to exclusion of individuals who 
had not been seen from 2004 onwards, the characteristics of those patients who were 
included were compared to the characteristics of those who were not included.  Differences in 
the groups were assessed using Chi-squared tests for categorical variables, t-tests for 
continuous variables with Normal distributions (age) and Wilcoxon rank sum tests for 
continuous  variables with distributions that were not Normal (CD4 and viral load) (Table 4.5).  
The cohort of individuals included in analyses consisted of a higher proportion of males, a 
higher proportion of individuals of white ethnicity, a higher proportion of MSM, a higher 
proportion of individuals who had received any ART and a lower proportion of individuals who 
had died.  These differences in the included and excluded individuals are likely due to the 
changes in time in the cohort overall.  
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Table 4.5 Comparison of individuals included in the analyses with those who are excluded 
 Total 
N (%) 
Included 
N (%) 
Excluded 
N (%) 
P value 
 
Total 47201 32079 15122 - 
 
Median age 
(IQR) 
 
34 (29, 40) 34 (28, 40) 34 (29, 41) <0.0001 
Male  
 
34202 (72.5) 24215 (75.2) 10077 (66.6) <0.0001 
Ethnicity     
White  
 
24641 (52.2) 18443 (57.5) 6198(41.0) <0.0001 
Black African  
 
12796 (27.1) 7945 (24.7) 4851 (32.1) 
Other black 
ethnicity  
2498 (5.3) 1607 (5.0) 891 (5.9) 
Other  
 
4396 (9.3) 3018 (9.4) 1378 (9.1) 
Not known  2870 (6.1) 1066 (3.3) 1804 (11.9) 
Exposure 
category 
    
MSM  
 
23341 (49.5) 17582 (54.8) 5759 (38.1) <0.0001 
Heterosexual  
 
17191 (36.4) 11105 (34.6) 6086 (40.3) 
IDU  
 
1694 (3.6) 963 (3.0) 731 (4.8) 
Other  
 
1862 (3.9) 1384 (4.3) 478 (3.2) 
Unknown  3113 (6.6) 1045 (3.3) 2068 (13.7) 
ARV 
experienced  
 
34915 (74.0) 25724 (80.2) 9191 (60.8) <0.0001 
Median CD4 
count at entry 
(IQR) 
315 (145, 493) 330 (168, 510) 274 (110, 460) <0.0001 
Median log 
viral load at 
entry (IQR) 
4.3 (3.0, 5.0) 4.3 (3.1, 5.0) 4.3 (2.9, 5.1) 0.51 
Died 4475 (9.5) 1622 (5.1) 2853 (18.9) <0.0001 
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4.7 Discussion 
To my knowledge, this is the first multicentre cohort of patients who are confirmed as being 
HIV and HBV and/or HCV co-infected in the UK.    
 
I experienced a number of challenges which resulted in limitations in the data collected.  Since 
the starting point for data collection was lists of potentially co-infected patients, I was not able 
to make any improvements to the denominator data.  It is likely that missing data still exists in 
the form of patients who have tested negative for HBV and HCV.  However, I hope that the 
intense effort that has been put into the data collection and the associated discussions with 
clinicians and data managers at participating centres has improved overall recording of 
hepatitis tests in clinical databases and will therefore improve the quality of the denominator 
in future UK CHIC datasets.   
 
I was only able to access data via the HIV centres and HIV clinicians.  Patients may be referred 
to another centre for their hepatitis care.  If the referral centre is also a UK CHIC site and that 
individual has ever received any HIV care at that site I will have collected data for that 
individual at both sites.  However, if an individual is referred to a non-UK CHIC site or is 
referred to a UK CHIC site but is never seen at that site for their HIV care, I may not have been 
able to gather complete information.  However, I believe that the volume of data missing for 
this reason is minimal as correspondence between centres was reviewed during the data 
collection process.   
 
The data collected here will provide valuable baseline information for treatment and 
prevention pathways.  Prospective collection of these data items in this cohort would be of 
benefit in evaluating any new treatment strategies which are implemented among in co-
infected populations.  However, given the intense nature of the data collection and the lack of 
systematic recoding of this data within centres, this would require further funding and 
dedicated research personnel.   
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Chapter 5 Methods 3: Characterising hepatitis co-infection using 
routinely collected data from HIV clinical cohorts 
 
5.1 Introduction 
Many large ongoing HIV cohort studies, including UK CHIC, collect limited data on tests 
conducted to assess whether an individual is co-infected with, or immune to, hepatitis viruses.  
In cohort studies where active follow-up of individuals occurs, known HBV or HCV status may 
form part of the baseline assessment of participants (230, 258, 261) and stored samples can be 
retested to confirm the HBV or HCV status of participants where queries remain (258, 263).  
However, for purely observational studies, data collection systems may not have been 
designed for collecting detailed information on hepatitis infection since they were initiated 
with the primary aim of collecting HIV clinical data (231, 256, 257, 259, 264).  This means that 
inconsistencies may exist within the data collected.  In addition, clinical practice varies with 
regard to the setting in which a test for hepatitis is conducted (within HIV clinics, sexual health 
clinics or hepatology clinics) and therefore how and where it is recorded. 
 
Ascertaining an individual’s hepatitis status at any one point in time in the dataset is often 
complicated by missing data and varying clinical practices with regard to testing for each of the 
hepatitis markers.  There is no consensus among study groups as to how to deal with 
inconsistencies in the data and current methods are usually formed on an ad hoc basis as and 
when problems are encountered.  In this chapter, I present a systematic analysis of the UK 
CHIC dataset which has assessed commonly occurring inconsistencies in HBV and HCV tests.  
Three separate problems were considered within the dataset.  The first was inconsistent or 
changing anti-HCV test results; the second was inconsistent or changing HBsAg test results; 
and the third was defining the HBV infection status (infected, immune or never exposed) of an 
individual.  After assessing the magnitude of each of these problems, methods were derived to 
manage these inconsistencies so that the maximum amount of data can be used in analyses 
where hepatitis co-infection is either the outcome of interest or an important explanatory 
variable.   
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5.2 Methods 
5.2.1 Inclusion criteria 
This analysis was conducted using the UK CHIC 2012 dataset prior to the addition of data 
collected as part of the expanded data collection.  Analysis of HCV data included all individuals 
who had at least one anti-HCV test result recorded in the dataset. Analysis of HBsAg tests 
included all individuals who had at least one HBsAg test recorded in the dataset.  Analysis of 
HBV infection status included all individuals who had at least one test result recorded in the 
dataset for HBsAg, anti-HBs or anti-HBc.  
 
5.2.2 HCV antibody testing 
Once an individual has been infected with HCV, anti-HCV will appear in their blood within 3 
months. This antibody remains in the blood long term as a sign of past or present infection 
(460).  Although loss of anti-HCV has been documented among HIV-positive IDU in the past 
(461, 462), testing for anti-HCV shows a high sensitivity even when CD4 counts are low (463).  
Therefore a negative result which appears after a positive result indicates an error, either in 
initial coding of tests at the centre or in data processing once the data has been received.  The 
dataset was examined for the presence of these types of discrepant results.  Where discrepant 
results were identified the complete record of the individual was reviewed.  Based on 
subsequent results, an algorithm was used to make decisions about which result was 
erroneous and which was correct.   
 
During the data collection process described in Chapter 4, those individuals who had been 
identified as potentially co-infected but who were not found to have any other evidence of co-
infection in clinical records were noted.  The final HCV status according to the algorithm was 
then compared to clinical data, obtained through the expanded data collection, in order to 
determine whether the algorithm provided a good approximation of HCV status in the absence 
of clinical information.   
 
5.2.3 HBV surface antigen testing 
HBsAg is a marker of current HBV infection which is often used to classify individuals as co-
infected in HIV cohorts.  However, individuals can clear HBsAg either after an acute infection 
which resolves (88) or following successful treatment (464-466).  All individuals who had a 
positive HBsAg result were identified.  In order to illustrate how changing test results could 
alter the results of analyses, HBV prevalence was calculated using two methods: (i) all 
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individuals who ever have a positive test result are considered infected; or (ii) only those 
individuals whose most recent HBsAg test is positive are considered positive. 
 
Among all individuals who had a positive HBsAg test, subsequent HBsAg results were examined 
to identify where individuals went from positive to negative.  The complete record of all 
individuals with changing results was reviewed.  This process was conducted with input from 
clinicians with experience in interpreting laboratory results of hepatitis tests for HIV-positive 
individuals under their care.  Commonly recurring situations were identified and the presence 
of other markers and time periods between tests were used to determine an algorithm for 
deciding which results should be considered as errors or anomalies in the dataset and which 
were true representations of clinical progression. The cumulative prevalence of HBV infection 
was calculated before applying the algorithm and after the algorithm as the proportion of all 
individuals tested for HBsAg who have ever had a positive test result recorded in the dataset.   
 
5.2.4 HBV infection status 
An individual’s HBV infection status can be further characterised as active infection, naturally 
immune as a result of a resolved infection, immune through successful vaccination or never 
having been exposed (88).  The status of an individual at any particular time point can be 
determined using the results of tests for HBsAg, anti-HBs and anti-HBc.  All possible 
combinations of these three markers were identified and assigned the most likely infection 
status.  This included those combinations of markers that did not provide a definitive infection 
status and those combinations of markers that are clinically implausible (Table 5.1).  For those 
cases where it was not possible to assign a definitive infection status, all possible infection 
statuses were identified.   
 
Using the UK CHIC dataset, at each time point where an individual was tested for any one of 
the three markers, the dataset was examined for results for the other markers on the same 
day and the individual was assigned to one of the infection categories shown in Table 5.1.  In 
order to give an indication of the proportion of individuals who fell into each category, the 
data were then summarised as the number of individuals within each infection category at 
their first data point (the first time they were tested for any one of the three markers of 
interest) and at their final data point (the last time they were tested for any one of the three 
markers).  An assessment of whether they had ever been classified into each of the possible 
infection categories at any time point was also carried out. 
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In order to reduce the number of individuals who had an unclassifiable infection status (those 
with an unknown or not possible status), the prior statuses of these individuals were examined.  
For individuals with an unknown status, potential classifiable statuses were identified and the 
existence of previous test results examined in order to determine whether any results could be 
carried forward.  A detailed description of which results were carried forward is included in 
section 5.3.3.  Briefly, where a prior status indicated the presence of an additional marker, the 
result of that marker was carried forward.   
 
To assess the impact of using this method, the proportions of individuals in each category at 
the time of their last test were examined before any prior results were carried forward and 
after prior results were used to classify status.  Finally, baseline factors associated with being 
unclassifiable at the final test were assessed using logistic regression.
 152 
 
Table 5.1 Summary of all possible combinations of test results and associated infection 
statuses1 
HBsAg Anti-HBs Anti-HBc Status 
+ _ + Infected 
+ . + Infected 
+ + + Clinically implausible 
+ _ _ Clinically implausible 
+ . _ Clinically implausible 
+ + _ Clinically implausible 
+ _ . Infected 
+ . . Infected 
+ + . Clinically implausible 
_ + + Resolved 
_ _ + Resolved 
_ . + Resolved 
_ + _ Vaccinated 
_ _ _ Never exposed 
_ . _ Unknown (never exposed or vaccinated) 
_ + . Unknown (resolved or vaccinated) 
_ _ . Unknown (never exposed or resolved) 
_ . . Unknown (never exposed, resolved or vaccinated) 
. + + Resolved 
. _ + Unknown (infected or resolved) 
. . + Unknown(infected or resolved) 
. + _ Vaccinated 
. _ _ Never Exposed 
. . _ Unknown( never exposed or vaccinated) 
. + . Unknown (resolved or vaccinated) 
. _ . Unknown (infected or never exposed) 
 
1 Dot denotes unknown status of the marker 
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5.3 Results 
5.3.1 HCV antibody testing 
Of 3293 individuals in the dataset with a positive for anti-HCV test, 232 (7.05%) individuals 
have a subsequent negative result.  Further results for these individuals were examined (Figure 
5.1).  Where no further test results were available it was assumed that the individual was HCV-
positive.  Where all further test results were negative, the positive result was assumed to be 
an error and the individual was considered to be HCV-negative.  For those individuals who had 
a further positive test result, similar assumptions were made regarding subsequent test 
results. Ten individuals had results which could not be easily assumed to be positive or 
negative since the pattern of their test results fluctuated between positive and negative 
repeatedly.  The complete records of these 10 individuals were reviewed and decisions made 
about whether or not they would be assumed to be positive or negative.   
 
Using this algorithm a total of 105 individuals had a positive test result at some point which 
was considered to be an error and 127 individuals had a negative test result at some point 
after their first positive test which was considered to be an error.    
 
Among the 232 individuals who had any changing results, 222 were seen at any one of the 11 
centres where clinical data was collected.  For these 222 individuals, the algorithm-defined 
status was compared to the status ascertained through review of clinical notes.  This 
comparison revealed that using the algorithm the correct assumption had been made in 63.1% 
(140/222) of cases but an incorrect assumption had been made in 36.9% (82/222) of cases.  
Where the incorrect assumption had been made, 10 individuals were incorrectly classified 
positive by the algorithm and 72 individuals were incorrectly classified as negative by the 
algorithm (Table 5.2).  
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No further results 
N=72 
Assumed positive 
A further positive result 
N=60 
All further results are 
negative 
N=100 
Assumed negative 
All further results are 
positive 
N=28 
Assumed positive 
A further negative result 
N=10 
No further results 
N=22 
Assumed positive 
All further results are 
negative 
N=5 
Assumed negative 
A further positive result 
N=1 
Assumed positive 
No further results 
N=4 
Assumed positive 
Individuals who have a positive 
result followed by a negative 
result 
N=232 
Figure 5.1 Assumptions about anti-HCV status in individuals who have conflicting results 
 155 
 
Table 5.2 Comparing HCV algorithm assigned status to information from clinics 
Anti-HCV status 
according to 
algorithm 
Clinical  
classification 
Number of 
individuals 
Performance of algorithm 
in defining anti-HCV status 
Positive Positive 108 Correct 
Positive Negative 10 Incorrect 
Negative Positive 72 Incorrect 
Negative Negative 32 Correct 
 
 
5.3.2 HBV surface antigen testing 
Of 2247 individuals in the dataset who had a positive HBsAg test result, 580 had a subsequent 
negative result at some point.  The majority of these individuals, n=357, then had further 
negative results and no more positive results.   These individuals were considered to have 
resolved the infection.  However, 223 individuals had a subsequent positive result.  
Subsequent results for these individuals were examined to identify patterns of changing HBsAg 
test results recorded in the dataset.   
 
Among those individuals who had changing results, the complete record was reviewed 
including tests.  This included assessing time from first positive test and the presence of other 
infection markers such as HBeAg and HBV-DNA.  Reviewing the records of these individuals 
resulted in the identification of eight situations which occurred repeatedly within the dataset 
and could be used to assess whether an individual was HBsAg positive at that time point or 
not.  These eight situations were placed in a hierarchy depending on the certainty with which 
they could be used to assume an HBsAg status.  These assumptions and the associated 
hierarchy formed an algorithm which was applied to the records of all individuals where HBsAg 
test results changed over time (Table 5.3).  After running the algorithm the number of 
individuals whose results changed over time was reduced (Table 5.4).  
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Table 5.3 Algorithm for ascertaining a patient’s HBsAg status among patients who have a 
positive test followed by a negative test 
Test result pattern Rational for assumed status 
1. Negative HBsAg result occurs on the 
same day as a positive HBsAg result 
 
Negative test result is an anomaly in the dataset 
and individual should be classified as HBsAg 
positive  
 
2. Individual has positive HBV-DNA and/ 
or positive HBeAg on the same day as 
the negative HBsAg test result 
The negative test result is likely to be an 
anomaly and the individual should be 
considered as HBsAg positive  
 
3. First negative HBsAg result after a 
positive is followed by repeated 
negatives and no further positive 
Individual has cleared the infection and should 
be classified as HBsAg negative from the time of 
their first negative result  
 
4. The first negative HBsAg after a 
positive occurs less than 6 months 
after the first HBsAg positive result 
The first positive was an acute infection which 
has then cleared.  Individuals can be considered 
as HBsAg negative from the point of their 
negative test until another positive occurs 
 
5. Prior to negative HBsAg result, the 
individual has consecutive positive 
HBsAg results which are at least six 
months apart 
 
Individual is chronically infected and should be 
classified as HBsAg positive 
6. Individual has evidence of anti-HBe or 
clearance of HBeAg at the same time 
as their negative test result 
It is plausible that the patient may have cleared 
their HBsAg even if they have become chronic 
carriers of the virus.  Therefore they should be 
considered as HBsAg negative from the point of 
their negative test until a further positive occurs 
indicating a reactivation 
 
7. Prior to the first ever positive HBsAg 
test in the dataset  the individual has 
had negative HBV tests at the same 
time as positive anti-HBc  
The individual was already chronically infected 
and the first HBsAg positive is a reactivation.  
Therefore it is plausible that the negative result 
is real as the reactivation has subsided and the 
individual should be classified as negative from 
the point of their negative test until they have 
another positive test 
 
8. The negative result is followed by at 
least one more negative result a month 
or more later 
The individual may or may not be chronically 
infected and the stage of infection is not 
determinable but given repeated negative 
results the individual should be classified as 
HBsAg negative from the point of their first 
negative until they have  a further positive 
result 
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Table 5.4 Summary of changing HBsAg results 
HBsAg results pattern Number of individuals in 
dataset 
 
Number of individuals 
after applying algorithm 
 
At least one positive 
(+) 
2247 2247 
At least one negative after a positive 
(+ -) 
580 401 
Revert to positive 
(+ - +) 
223 88 
Re-revert to negative 
(+ - + -) 
92 38 
Further inconsistent results 
(+-+-+) 
58 23 
 
 
Among those ever having tested for HBsAg the prevalence ranged from 6.6% (2026/30749) 
where cumulative prevalence was calculated, to 5.7% (1727/30744) where prevalence was 
calculated using the most recent HBsAg result, and 5.9% (1766/30742) where prevalence was 
calculated using the algorithm-defined HBsAg test results.  
 
Predictors of HBV are investigated in depth in Chapter 6.   However, in order to assess whether 
the different methods of classifying an individual’s HBsAg status has any effect on the 
predictors of HBsAg positivity I constructed 3 separate multivariable logistic regression models 
to identify factors that were associated with HBsAg positivity. Factors considered in the 
multivariable models were age, HIV exposure group, ethnicity, year of entry into study, nadir 
CD4 count, HCV co-infection and being on HBV active antiretroviral treatment.  The outcome 
was HBsAg positivity as defined by each of the 3 methods of classification.  Independent 
predictors of HBsAg positivity did not vary according to the method used to classify status 
(Appendix VI).   
   
5.3.3 HBV infection status 
 A total of 36244 individuals had been tested for at least one of HBsAg, anti-HBs or anti-HBc 
(32785 for HBsAg, 22238 for anti-HBs and 30648 for anti-HBc).  Using results for tests 
conducted on the same date, individuals were classified at each time point where there was 
evidence of a test for one of the three markers.  The number of individuals who were ever 
classified into each category, those classified as each status on their first hepatitis data point 
and those classified into each category on their final hepatitis data point are shown in Table 
5.5.  Using this method, high proportion of individuals have unclassifiable (either clinically 
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implausible or unknown due to missing data) HBV infection statuses: 24149 (66.6%) on the 
first data point and 20698 (57.1%) on final data point. 
 
Table 5.5 Combinations of test results reported with the same date and used to assign HBV 
infection status 
HBV infection status Number of individuals classified as status (%) 
Ever On first data point On final data point 
Infected 2006 (5.5) 1546 (4.3) 1561 (4.3) 
Resolved 9556 (26.4) 5724 (15.8) 6798 (18.8) 
Vaccinated 5842 (16.1) 1980 (5.5) 3991 (11.0) 
Never exposed 5369 (14.8) 2845 (7.8) 3196 (8.8) 
Clinically implausible 448 (1.2) 236 (0.7) 238 (0.7) 
Unknown 28094 (77.5) 23913 (66.0) 20460 (56.5) 
Total 36244 36244 36244 
 
 
In order to reduce the number of unclassifiable statuses (those either clinically implausible or 
unknown), prior evidence of classifiable infection statuses were used and, where possible, 
relevant results were carried forward.  This process was carried out in a series of stages. These 
stages are summarised in Table 5.6 and explained in further detail below.  
 
Stage 1:  Individuals with unclassified status but with a prior infected status 
Where individuals were defined as unknown at any time point but where one of the potential 
classifiable statuses was resolved infection, prior statuses were examined for evidence of 
infection.  Where an individual was previously known to be infected, it was assumed that they 
had developed anti-HBc which would persist.   Therefore at the time of the unclassifiable 
status they could be assumed to be anti-HBc positive. 
 
Stage 2: Individuals with unclassified infection status but prior resolved status 
Where individuals had an unclassifiable status but where one of the potential classifiable 
statuses was resolved, prior statuses were examined for evidence of resolved infection.  
Where an individual was previously known to have a resolved infection, it is assumed that this 
status has persisted and that they are now HBsAg negative and anti-HBc positive. 
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Stage 3:  Individuals with a clinically implausible status 
These were all individuals who had positive HBsAg test results in combination either with 
positive anti-HBs test results or with negative anti-HBc results.  Those individuals who had 
negative anti-HBc negative and positive HBsAg may be at a very early stage of infection and are 
therefore assumed to be infected.  Those individuals who are HBsAg positive and anti-HBs 
positive may have false positive results.  In addition, the dual presence of anti-HBs and HBsAg 
has been reported clinically in infected individuals (467).  Given the data cleaning which had 
already been conducted to identify errors in HBsAg results, the HBsAg results were considered 
more reliable and therefore these individuals were also considered to be infected.  Results for 
these individuals were not amended within the dataset, but an additional code was created to 
indicate that these combinations of test results were considered infected. 
 
Stage 4: Individuals with unclassifiable status but with prior vaccinated status 
Where individuals have a prior vaccinated status it was assumed that the vaccine induced 
immunity persists and therefore individuals are assumed to be anti-HBs positive.  In addition, 
those individuals who had prior evidence of a positive anti-HBs status (but unknown anti-HBc) 
were considered to be anti-HBs positive as long as there was no intervening evidence of 
clearing the anti-HBs or evidence of positive anti-HBc results.  
 
Stage 5: Individuals with unclassifiable status but with prior never exposed status 
Those individuals who had an unclassifiable status but where one of the potential classifiable 
statuses was never exposed were examined for any prior evidence of negative anti-HBc or 
anti-HBs results.  Where these results were available the individual was then assumed to be 
never exposed to the virus and susceptible to infection. 
 
Carrying forward prior results reduced the proportion of individuals who had an unclassifiable 
infection status on the final data point from 57.1% to 38.7%.  The number of individuals with 
an unclassifiable status one final data point after each stage of assumptions is shown in Table 
5.7. Age, HIV exposure group, ethnicity, HCV status, year of entry into the study and prior 
infection status were all strongly associated with being unclassifiable on the final data point  
(Table 5.8).  The centre where the test took place was also significantly associated with being 
unclassifiable at the final data point.
  
 
1
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Table 5.6 Summary of imputed results used to determine an individual’s HBV status at any one time point 
Test result combination in dataset at time point x1 Assumed test result combination at time point x 
HBsAg Anti-HBs Anti-HBc HBsAg Anti-HBs Anti-HBc 
Stage 1:  Individuals with prior infected status    
– + . – + + 
– – . – – + 
– . . – . + 
. + . . + + 
. – . . – + 
Stage 2: Individuals with a prior resolved status    
– + . – + + 
– – . – – + 
– . . – . + 
. + . . + + 
. – . – – + 
. – + – – + 
. . + – . + 
Stage 3:  Individuals with clinically implausible combinations    
+ + + + – + 
+ – – + – – 
+ . – + . + 
+ + – + – – 
+ + . + – + 
  
 
1
61
 
Test result combination in dataset at time point x1 Assumed test result combination at time point x 
HBsAg Anti-HBs Anti-HBc HBsAg Anti-HBs Anti-HBc 
Stage 4a:  Individuals with a prior vaccinated status     
– + . – + – 
. + . . + – 
– . – – + – 
– . . – + – 
. . – – + – 
Stage 4b:  Individuals with a prior unknown status which includes positive anti–HBs 
result and no intervening negative anti–HBs results 
   
– . – – + – 
. . – – + – 
Stage 4c:  Individuals with a prior unknown status which includes positive anti-HBs 
result and no intervening positive anti-HBc test results 
   
– . . – + – 
      
Stage 5a : Individuals with a prior never exposed status or unknown status which 
includes negative anti-HBs result 
   
– . – – – – 
. . – – – – 
Stage 5b: Never exposed or unknown status which includes negative anti-HBc result    
– – . – – – 
. – . – – – 
1 Dot denotes unknown status of the marker 
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Table 5.7 Individuals with unclassifiable infection status on their final data point, before and 
after carrying forward prior results 
Stage of 
assumptions 
Number of individuals with infection status at final data point (%) 
Infected 
 
Resolved Vaccinated Never 
exposed 
Unclassifiable 
(including 
clinically 
implausible 
statuses) 
Baseline 1561 (4.3) 6798 (18.8) 3991 (11.0) 3196 (8.8) 20698 (57.1) 
Stage 1 1561 (4.3) 6950 (19.2) 3991 (11.0) 3196 (8.8) 20546 (56.7) 
Stage 2 1561 (4.3) 9368 (25.9) 3991 (11.0) 3196 (8.8) 18128 (50.0) 
Stage 3 1799 (5.0) 9368 (25.9) 3991 (11.0) 3196 (8.8) 17890 (49.4) 
Stage 4 1799 (5.0) 9368 (25.9) 6437 (17.8) 3196 (8.8) 15444 (42.6) 
Stage 5 1799 (5.0) 9368 (25.9) 6437 (17.8) 4613 (12.7) 14027 (38.7) 
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Table 5.8 Multivariable logistic regression of factors associated with remaining unclassifiable 
on final data point1 
Predictors of remaining unclassifiable AOR 95% CI P value 
Baseline age Per 10 years 0.88 0.85-0.91 <0.0001 
HIV exposure 
group 
MSM 1 - - 
Male heterosexual 1.10 1.00-2.23 0.06 
Female heterosexual 1.23 1.12-1.36 <0.0001 
Male IDU 0.95 0.77-1.17 0.61 
Female IDU 0.93 0.70-1.23 0.59 
Other 1.46 1.26-1.69 <0.0001 
Unknown 1.31 1.09-1.57 0.0004 
Ethnicity White 1 - - 
Black African 0.64 0.59-0.71 <0.0001 
Other 0.82 0.75-0.90 <0.0001 
Unknown 0.96 0.82-1.12 0.60 
Year of study 
entry  
1996–1998 1 - - 
1999–2001 1.18 1.06-1.31 0.0002 
2002–2004 1.08 0.98-1.18 0.13 
2005–2007 0.86 0.78-0.94 0.002 
2008–2011 0.58 0.53-0.64 <0.0001 
Baseline HCV 
infection status 
Negative 1 - - 
Positive 0.69 0.61-0.77 <0.0001 
Untested 1.44 1.27-1.63 <0.0001 
Yes 0.88 0.82-0.94 0.0001 
Nadir CD4 count Per 100 cells/mm3 1.01 0.99-1.03 0.22 
Prior infection 
status2 
Infected 0.04 0.03-0.05 <0.0001 
Resolved 0.01 0.01-0.01 <0.0001 
Vaccinated 0.02 0.02-0.03 <0.0001 
Susceptible 0.1 0.09-0.11 <0.0001 
Unknown 1.65 1.55-1.76 <0.0001 
1 Model was also adjusted for centre where the test took place 
2 Prior evidence of each infection status was compared to no prior evidence of that infection 
status 
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5.4 Discussion 
5.4.1 HCV antibody testing 
A minority of individuals in the dataset have discrepant anti-HCV results.  Using subsequent 
results to classify individuals’ statuses can improve accuracy of the results in the dataset.  
However, comparing the final status assigned with the data obtained from clinical record 
review indicates that using test results alone will still result in some errors.  The importance of 
these errors in an analysis will depend on the research question being investigated, the size of 
the overall dataset and the impact of co-infection on the outcome being investigated.   Where 
clinical review of notes is not feasible, this is an effective means of ascertaining the true status 
of individuals with discrepant results.  
 
5.4.2 HBV surface antigen testing 
More than one quarter of individuals who ever have a positive HBsAg test, subsequently have 
a negative test result.  However, given that individuals may lose HBsAg either after clearing an 
acute infection (88) or following treatment (464-466), further information is required to assess 
whether the changing results reflect the true status of the individual or whether they 
represent errors in reporting of test results.  Close examination of other HBV test results in the 
dataset provides additional context which can be used to determine the individuals’ true 
HBsAg status where inconsistencies occur.  An algorithm has been developed in order to 
conduct this in a systematic way.  This algorithm was determined with strong input from 
clinicians experienced in interpreting laboratory test results for HBV.  The algorithm was 
determined by reviewing all of the test results for those individuals who had changing results.  
Processing the data through the algorithm, the assumptions were checked again with a 
clinician who confirmed that the algorithm had resulted in the most accurate assessment of 
the individual’s HBsAg status at each time point.  
 
It was not possible to use clinical data to confirm the HBsAg status of the individual as was 
done in the case of HCV, since clearance of HBsAg is clinically possible.  Therefore a further 
stage of data processing was conducted using the algorithm defined HBsAg status combined 
with anti-HBc and anti-HBs test results to define an individual’s HBV infection status.   
 
5.4.3 HBV Infection status 
Using a combination of HBsAg, anti-HBs and anti-HBc tests results that were reported with the 
same date resulted in a high proportion of individuals with an unclassifiable HBV infection 
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status at their final data point.  The proportion of individuals who can be definitively classified 
into a HBV infection category can be increased using the methods described.  However, a high 
proportion of individuals remain unclassifiable at the time of their final HBV test.  In particular, 
given that vaccination is recommended for all susceptible individuals (65), the proportion of 
individuals defined as vaccinated seems low.  We were not able to ascertain vaccination status 
of individuals during the data collection process.  Therefore we are unable to validate these 
methods using the clinical data.  Although this system of classifying individuals is useful, it may 
underestimate the proportion of individuals in each category.   
 
It is important to consider the potential for more complex statistical methods for dealing with 
missing data.  Missing data can be classified as either missing completely at random (MCAR) 
where there is no systematic difference between the recorded and the missing data items, 
missing at random (MAR) where there are systematic differences between the observed and 
the missing data but these differences are measurable as other recorded factors and the 
missing data is not dependent on any other missing data, and missing  not at random (MNAR) 
where the missing data is dependent either on unmeasured factors or on the variable itself 
(468). 
 
There are three options for dealing with the remaining missing data in analyses.  The first is to 
conduct analysis which includes only those individuals for whom the information is known.  
However, this may induce bias if data are not MCAR.  The second option is to create a separate 
category for those individuals with missing data so that they can be adjusted for in the 
analysis. Although this allows all individuals to be included in the analysis, it remains 
impossible to completely remove the effects of confounding if the true category for an 
individual is unknown.   
 
The third option for dealing with missing data is multiple imputation.  In this method, the 
missing data item is imputed using other available data and linear or logistic regression 
methods.  The data item is imputed multiple times (usually between 5 and 20) to create 
several copies of the separate dataset.  The analysis to answer a specific research question is 
then conducted on each of these imputed datasets and the results pooled to give a single 
estimate, 95% confidence intervals and P values.  However, use of multiple imputations relies 
on data being either MCAR or MAR (469).   
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The results of the multivariable model of factors associated with being unclassifiable on final 
data point indicate that data may be MAR.  That is, although there are systematic differences 
in the observed and the missing data those differences could be predicted by other measured 
variables.   It is not possible to test whether data is MNAR (469).  However, the finding that the 
proportion of individuals with a vaccinated status is low despite universal vaccination offer for 
susceptible individuals indicates that the data may be MNAR.  That is, the missing data is 
dependent on itself and those individuals who have been vaccinated are more likely to have 
missing data. Therefore use of multiple imputation is not considered to be appropriate for this 
dataset. 
 
5.4.4  Implications of findings 
To my knowledge no other observational clinical HIV cohorts have investigated methods to 
deal with inconsistent or missing hepatitis test results in such detail.  The analysis of HBsAg 
tests and HBV infection status was presented at the International Workshop on HIV 
Observational Databases, Cavtat, Croatia (2013) (Appendix VII).  A subsequent meeting was 
convened which included leaders from the European cohorts.  There was great interest in the 
methods described here and the next stage in validating these methods will be to test their 
use in other cohorts.  
 
All further analyses in this thesis utilise data that have been subject to the cleaning processes 
described in this and the previous chapter.  Final definitions of co-infection are shown in Box 
5.1. The final definition of HBV infection includes only those changes made in the cleaning of 
changing HBsAg test results.  Changes made to the infection status according to other markers 
are not included since HBsAg was considered the most reliable marker of infection.  Since it 
was not possible to use clinical notes to verify the HBsAg status of each individual is is possible 
that some errors may remain.  However, the finding that predictors of HBsAg positivity are 
unaltered when HBsAg is defined in different ways (as shown in Appendix VI) implies that this 
will not impact the results of analyses which compare HBV infected and HIV uninfected 
individuals.  The final definition of HCV infection included those changes made to changing 
anti-HCV test results.  However, where clinical data indicated that the decision changes had 
resulted in an incorrect assignment of anti-HCV status, the information from clinical data was 
used to over-ride the results of the algorithm. 
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Box 5.1 Final definitions of HBV and HCV infection 
 
 
 
 
 
 
Since this thesis is focussed on individuals who are co-infected with HBV and/or HCV it is 
considered that the methods described in this chapter are sufficient to allow determination of 
whether an individual is infected with either HBV or HCV.  If further analyses using the UK CHIC 
dataset were to be conducted which focussed on resolution of HBV or HBV vaccination, 
additional efforts would be required to obtain missing data from the centres where the 
patients attended for care.   Furthermore, determining the true HCV co-infection status of all 
potentially infected individuals within UK CHIC (i.e. those with any positive anti-HCV test result 
recorded in the dataset), should remain an important component of any future rounds of data 
collection. However, in cohorts where this is not possible the method presented in this chapter 
for cleaning anti-HCV test results represents an acceptable method for determining HCV status 
in the context of inconsistent results. 
HBV infection – Any individual who, subsequent to data cleaning, has at least 
one positive HBsAg test result reported in the dataset, irrespective of other 
serological markers 
 
HCV infection – Any individual who, subsequent to data cleaning and review of 
clinical notes, has at least one positive anti-HCV or positive HCV-RNA test result 
reported in the dataset 
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Chapter 6 Results 1: Patterns of hepatitis testing and infection in 
UK CHIC 
 
6.1 Background 
Clinical guidelines state that newly diagnosed HIV-positive individuals should be screened for 
HBV infection and immunity using tests for HBsAg and anti-HBc and anti-HBs.  Subsequently, 
those individuals who are not shown to be infected with, or immune to, HBV should be 
screened annually.  Similarly, it is recommended that newly diagnosed HIV-positive individuals 
are screened for HCV infection using an anti-HCV test and individuals who are negative should 
be screened annually thereafter (65).   
 
Infection with HBV may be followed by resolution of the infection or persistence of the virus, 
resulting in chronic HBV infection.  In HIV-negative populations 5-10% of individuals are 
expected to develop chronic infection (90).  However, HIV/HBV co-infection is associated with 
a higher likelihood of developing chronic infection (362, 363).  Individuals who resolve 
infection are immune to further infection.  Patients with chronic infection require monitoring 
for the development of liver disease and may require treatment.  In the UK, individuals at high 
risk of acquiring HBV are offered routine vaccination.  However, HIV-positive individuals may 
have a lower rate of response to vaccine than HIV-negative individuals, depending on the dose 
used (470-472).  The different courses of chronic HBV infection and the resulting varying 
serological profiles may affect both management strategies and outcomes.   
 
Infection with HCV may be followed by clearance of the infection, either spontaneously or as a 
result of treatment.  However, the large majority of infected individuals go on to develop 
chronic HCV infection (147, 326).  Neither current infection nor previous clearance of HCV 
infection prevents re-infection at a later date.  Transmission of HCV has traditionally been 
considered to be parenteral and therefore its prevalence is associated with injecting drug use.  
However, since 2003, in the UK and Europe there have been increasing numbers of diagnoses 
of acute HCV among HIV-positive MSM (234, 235).  Ongoing sexual transmission of HCV among 
networks of HIV-positive MSM means that there is risk of re-infection even if an individual 
clears the virus (473).   
 
Seven HCV genotypes have been identified (141).  The genotype with which an individual is 
infected may impact decisions about treatment since some genotypes (2 and 3) are considered 
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easier to treat than others (1 and 4).  The genotype an individual is infected with may, in part, 
be dependent on how they acquired their infection as different genotypes circulate more 
commonly among different populations. 
 
Understanding the epidemiology of hepatitis co-infection among HIV-positive individuals 
allows effective planning of prevention, detection and treatment services.  While a number of 
studies have estimated prevalence of and factors associated with co-infection among HIV-
positive cohorts in developed countries (Chapter 2 Table 2.1 and Table 2.2), the differing HIV 
epidemics in these countries means that results are not generalisable to the UK.  Previous 
analyses of UK CHIC, examining testing and infection rates, have shown lower than desirable 
levels of HBsAg and anti-HCV testing (244, 259).  However, it was noted that these low 
reported levels of testing may be due to missing data rather than a lack of testing in clinical 
practice.  Therefore the resulting estimates of prevalence and incidence are limited. 
 
In the following analyses I describe patterns of testing and estimate the prevalence and 
incidence of HBV and/or HCV co-infection in the largest clinical cohort of HIV-positive 
individuals in the UK.  The analyses are focused on the patients who have been seen for care at 
any one of the contributing centres from 2004 onwards.  Prior to this period, testing for 
hepatitis among HIV-positive individuals was not routine practice.  In addition, the process of 
expanded hepatitis data collection was limited to co-infected patients who had been seen 
since 2004 onwards.  This process has improved data quality for that period and included the 
first collection of HCV genotype data among this cohort.  
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6.2 Methods 
6.2.1 Patterns of hepatitis testing 
6.2.1.1 Proportion of individuals tested for HBsAg and anti-HCV 
The following analyses were conducted separately for HBsAg and anti-HCV.  The cumulative 
proportion of individuals tested for each marker was calculated as a proportion of all 
individuals under follow-up who had ever tested.  To investigate trends over time in 
cumulative testing, the dataset was split by year.  Individuals were considered to have been 
followed-up in a given year if their first seen date was at any time before the end of that year 
and their last seen date was not before the start of that year.  All individuals followed-up in a 
given year were included in the analysis for that year.  The proportion of all individuals under 
follow-up in each year who had received a test by the end of that year was calculated.   
 
Annual testing was investigated among individuals who were considered eligible for testing 
within a given year.  The number of individuals eligible for HBsAg testing within a particular 
year was defined as all those individuals under follow-up in that year, who had not previously 
had a positive HBsAg or anti-HBs test by the start of that year (that is, they were not already 
known to be infected or immune).  The number of individuals eligible for anti-HCV testing was 
defined as all those individuals under follow-up within a year, who had not had a positive anti-
HCV or HCV-RNA test by the start of that year (that is, they were not already known to be 
infected). Of all individuals who were eligible for testing within each year, the proportion who 
received a test result in that year was calculated. 
 
To describe both cumulative and annual testing in more detail, within each year data was 
stratified by age group at start of year, ethnicity, HIV exposure group, CD4 count at start of 
year and HIV viral load at start of year and the proportion tested in each subgroup per year 
calculated. 
 
6.2.1.2 Factors associated with first test and repeat testing 
Separate logistic regression models were constructed for each year to identify predictors of 
having a first test in each year and to examine whether predictors of first test had changed 
over time.  Individuals were included in the analysis for a given year if they were under follow-
up in that year and had not previously received a test.  Age at start of year, ethnicity and HIV 
exposure group were included in each model.  To maximise the number of individuals who 
could be included in the analysis and to ensure that those who had missing CD4 counts or 
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missing HIV viral load information would be included in the analysis, CD4 count and viral load 
were combined into one variable, HIV infection category, as shown in Table 6.1.  This was also 
included in each model.  Those individuals who had a CD4 count of <200 cells/mm3 were 
considered to have advanced HIV infection irrespective of HIV viral load.  Those individuals 
who had HIV viral loads of >50 copies/ml were considered to have uncontrolled HIV infection, 
where as those whose viral load was <50copies/ ml were considered to have controlled HIV 
infection.   
 
Table 6.1 Categorising HIV infection 
HIV viral load 
(copies/ml) 
CD4 count (cell/mm3) 
<200 >200 Missing 
< 50 Advanced Controlled Controlled 
51-10000 Advanced Uncontrolled Uncontrolled 
>10000 Advanced Uncontrolled Advanced 
Missing Advanced Uncontrolled Unknown 
  
 
Yearly datasets were then appended to give a complete dataset for the period 2004-2011. 
Logistic regression was used to identify independent demographic and clinical predictors of 
testing.  Independent variables included in the analysis were age, ethnicity, exposure, year of 
follow-up and HIV infection category.  Age and HIV infection category were time-updated at 
the start of each calendar year.  As descriptive analysis revealed that increases in testing over 
time differed by demographic factors, a series of further models were constructed in order to 
test for the presence of interactions between year and demographic variables (age, HIV 
exposure group and ethnicity).  This was done by including an interaction term between year 
and the demographic variable of interest in the model.  Where significant interactions were 
identified the dataset was stratified by the relevant demographic factor of interest and the 
predicted probability of having a test for an individual within each group was calculated for 
each year. 
 
The above analyses were repeated to investigate factors associated with repeat testing.  
Individuals were included in the analysis for a given year if they had previously had a test 
before the start of that year but had not previously been shown to be infected or immune to 
infection.  As above separate multivariable models were constructed for each year of follow-
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up, followed by a model including data for all years from 2004-2011.  Since individuals may be 
eligible for repeat testing in more than one year and may also be tested in more than one year, 
generalised estimating equations were used to account for the repeated tests per individual.  
The presence of interactions between year and demographic factors was also examined in this 
analysis, as described above.  
 
6.2.2 Epidemiology of HBV 
All of the following analyses were conducted using data which had been examined for 
inconsistencies and cleaned as previously described.  Infection statuses, which had previously 
been defined using the results of HBsAg, anti-HBc and anti-HBs tests were also used in these 
analyses (Chapter 5).    
 
6.2.2.1 Cumulative prevalence of HBV infection 
All individuals who had ever been tested for HBsAg were included in this analysis.  The 
prevalence of HBV co-infection was calculated as the proportion of all tested individuals who 
had received a positive HBsAg test result.  A sensitivity analysis was conducted where all 
individuals in the cohort were included in the denominator, irrespective of whether they had 
been tested for HBsAg. 
 
To examine trends over time, the annual cumulative prevalence was calculated for each year 
from 2004 to 2011.  Annual cumulative prevalence was calculated as the proportion of all 
individuals under follow-up in a given year and tested by the end of that year, who had 
received a positive test result by the end of that year.  The dataset was stratified by 
demographic and HIV clinical variables to investigate whether changes over time in the 
cumulative prevalence differed among subgroups. 
 
Baseline characteristics of individuals who had ever received a positive HBsAg test result and 
those who had not were compared. Logistic regression was conducted to identify those 
demographic and HIV-infection factors associated with HBV-infection.  Independent variables 
included in the analysis were age, ethnicity, exposure, HIV infection category (defined as 
previously described in patterns of testing section) and year.  Age and HIV infection category 
were updated at the start of each year.  Calendar year was also included in the model as a 
continuous variable.   
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6.2.2.2 Resolution of HBV infection versus chronicity   
Among those individuals who had a positive HBsAg test result, subsequent infection statuses 
were examined to assess the proportion of individuals who resolve an infection and those who 
are chronically infected.  Individuals were classified as being chronically infected if they had a 
subsequent infected status 6 months or more after their first positive HBsAg test and they 
were defined as having resolved infection if they had a subsequent resolved status at any point 
after their first positive HBsAg test.  The time to resolution was calculated as the time from 
first positive to first resolved status.  More than half of individuals who went on to resolve 
infection had a time to resolution of greater than 6 months.  Since resolution of infection 
occurs within the first 6 months of infection, these times to resolution of greater than 6 
months are likely due to non-availability of test results within the dataset.  Given this 
assumption of missing information it was not possible to conduct a time-updated analysis of 
factors associated with resolution.  Therefore logistic regression was used to identify baseline 
factors associated with resolution.  For this analysis, baseline was defined as the date of first 
positive HBsAg test. 
 
6.2.2.3 Infection status over time 
HBV infection status was assessed using results of HBsAg tests, anti-HBc tests and anti-HBs 
tests as previously described (Chapter 5, section 5.3.3).  Briefly, an HBV infection status was 
assigned to individuals each time they were tested for one of the three markers of interest.  
For individuals with an unknown status, potential clinically plausible classifiable statuses were 
identified.  Where there was prior evidence of one of these potential infection statuses, that 
status was carried forward. Results were not carried forward where more than one potential 
status was clinically plausible.  Among all individuals who had ever had a classifiable status, 
infection status of individuals at the end of each year was used to examine changes in infection 
status from 2004 to 2011.  Chi-squared tests for trend were used to assess the significance of 
observed trends. 
 
6.2.2.4 Incidence of HBV infection 
Among individuals who had had a test for at least one of HBsAg, anti-HBc or anti-HBs from 
2004 onwards, all tests up until the end of the first year of follow-up were examined in order 
to determine whether or not the individual was susceptible to infection.  Susceptibility was 
defined as a negative anti-HBs result and a negative or missing HBsAg and anti-HBc result.  For 
those individuals who had changing results for one of the markers during the first year of 
follow-up, only the first result for each marker was used to define susceptibility.  Susceptible 
 174 
 
individuals who had at least one further test were included in the analysis.  Individuals were 
followed-up from the date of their first test after 2004 until they had an incident infection or 
until their last seen date.  Follow-up was censored when an individual had a positive anti-HBs 
result. 
 
HBV incident infection was defined as a new positive HBsAg or anti-HBc result.  The incidence 
rate was calculated by dividing the number of incident infections by the total number of 
person-years of follow-up.  Factors associated with HBV incidence were examined using 
univariable and multivariable Poisson regression.  The following characteristics were 
examined:  age at first test; ethnicity; HIV exposure category; current CD4 count; current HIV 
viral load; whether an individual was on tenofovir as part of their HIV antiretroviral regimen; 
and year of follow-up.  CD4 count and viral load were included as time-updated variables 
which were updated at the start of each year of follow-up.   
 
There were 16 individuals who had a first positive test after a positive anti-HBs test result.  
Data for these individuals had been censored at the time of anti-HBs as they were thought to 
have become immune and therefore were not considered as incident infections.  There are 
two possible reasons for an individual to have a positive HBsAg or anti-HBc result after a 
positive anti-HBs result.  The first is that their positive anti-HBs result is, in fact, a marker of 
infection rather than vaccination; the second is that the positive anti-HBs result is a marker of 
vaccination but the individual then loses the vaccine-induced immunity over time and 
becomes susceptible (474-476).  Therefore two sensitivity analyses were conducted which 
varied the definition of incident infection.  Sensitivity analysis 1 allowed individuals who had a 
positive HBsAg or a positive anti-HBc after a positive anti-HBs test to be considered as incident 
infections with the date of the positive anti-HBs used as the date of the incident infection, 
therefore making the assumption that the anti-HBs was actually a marker of infection.  In 
sensitivity analysis 2, individuals who had a positive HBsAg or positive anti-HBc after a positive 
anti-HBs were also considered to have incident infections but the date of incident infection 
was taken as the date of positive HBsAg or anti-HBc therefore making the assumption that 
these individuals had been vaccinated but had lost their vaccine induced immunity and then 
become infected.  
 
One final sensitivity analysis (sensitivity analysis 3) was conducted which varied the way that 
susceptible individuals were defined.  In this analysis, individuals had to have had a negative 
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HBsAg or negative anti-HBc test as well as a negative anti-HBs test to be defined as 
susceptible.  The incidence of HBV infection from the initial calculation was compared to the 
incidence calculated in the sensitivity analyses.   
 
6.2.3 Epidemiology of HCV 
All of the following analyses were conducted using data on anti-HCV tests which had been 
examined for inconsistencies and cleaned as previously described (Chapter 5, section 5.2.2) 
 
6.2.3.1 Cumulative prevalence of HCV 
All individuals who had ever been tested for anti-HCV or HCV-RNA were included in this 
analysis.  The prevalence of HCV co-infection was calculated as the proportion of all individuals 
ever tested for anti-HCV or HCV-RNA who had received a positive result.  A sensitivity analysis 
was conducted which included all individuals under follow-up in the denominator irrespective 
of whether they had ever been tested. 
 
To examine trends over time the annual cumulative prevalence was calculated for each year 
from 2004 to 2011.  This was calculated as the proportion of all individuals under follow-up 
and tested by the end of a given year, who had received a positive test result by the end of 
that year.  Annual cumulative prevalence was calculated for the complete dataset as well as 
after stratification by age at start of year, ethnicity, HIV exposure group, CD4 count at start of 
year and viral load at start of year. 
 
Differences in baseline characteristics of those with and without a positive HCV test result 
were examined.  Logistic regression was performed to identify those demographic and HIV 
infection factors associated with HCV infection.  Independent variables included in the analysis 
were age and HIV infection category, which were updated at the start of each year, calendar 
year, ethnicity and HIV exposure category.   
 
6.2.3.2 Active HCV infection 
Active HCV infection was defined as a positive HCV-RNA test result.  The proportion of all 
individuals with any evidence of HCV infection (positive anti-HCV or HCV-RNA tests), who could 
be defined as having active infection at any time during follow-up was calculated.  The annual 
prevalence of active infection was calculated for each year from 2004 to 2011 as the 
proportion of individuals with any evidence of infection, tested for HCV-RNA within the year of 
interest who had a positive HCV-RNA result in that year.  In a sensitivity analysis, a more 
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relaxed definition of having active HCV infection within a year was used whereby individuals 
were considered to have active infection from the point at which they first had a positive HCV-
RNA test result until there was evidence of a negative test result. 
 
Factors associated with having active infection were examined using univariable and 
multivariable logistic regression.  Independent variables included in the analysis were age, 
ethnicity, HIV exposure group, calendar year and HIV infection category.  Age and HIV infection 
category were updated at the start of each year. 
 
6.2.3.3 Acute HCV infection 
To investigate the proportion of individuals who were diagnosed with acute HCV infection, the 
dataset was restricted to those individuals who had ever had a positive HCV test (either anti-
HCV or HCV-RNA) after the start of 2004 and who had also been tested for HCV-RNA at any 
point from 2004 onwards.  The date of their first positive HCV-RNA test was identified.  
Individuals who had a negative anti-HCV test within the 6 months preceding their first positive 
HCV-RNA test were defined as having acute infection.  In addition, clinical data obtained from 
the expanded hepatitis data collection was examined.  The number of individuals who had 
been stated as having acute infection in their clinical notes was added to those who were 
defined as being acutely infected according to their serology results to give a total population 
of individuals who were identified as having had acute HCV infection. 
 
To investigate the proportion of individuals who spontaneously cleared acute infection, all 
individuals with any evidence of HCV treatment were excluded.  Spontaneous clearance was 
defined as a subsequent negative result after being defined as acutely infected without 
evidence of subsequent positive HCV-RNA tests in the first 6 months after acute infection.  
Among those diagnosed with acute infection who cleared infection, time to clearance was 
estimated as the time between the first positive RNA test and the first negative after diagnosis 
of acute infection. 
 
6.2.3.4 Incidence of HCV infection 
Individuals were included in the analysis of HCV incidence if they had been tested for either 
anti-HCV or HCV-RNA at any point from 2004 onwards.  All HCV tests up until the end of one 
year after the start of follow-up were used to define an individual’s HCV status at the start of 
follow-up.  For those individuals who had changing results in the first year of follow-up, only 
the first results were used to define their status.  Individuals who had a negative anti-HCV test 
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and either negative or missing HCV-RNA test at the beginning of follow-up and who had at 
least one further test for either anti-HCV or HCV-RNA were included in the analysis.  Incident 
infection was defined as any positive anti-HCV or HCV-RNA test after the start of follow-up. 
Individuals were followed from their first test after the start of 2004 until they had a positive 
anti-HCV or positive HCV-RNA test result or until they were last seen. 
 
The incidence rate was calculated by dividing the number of incident infections by the total 
number of person-years of follow-up.  Factors associated with HCV incidence were examined 
using univariable and multivariable Poisson regression.  Associations between HCV incidence 
and the following characteristics were examined:  age at first test; ethnicity; HIV exposure 
category; current CD4 count; current HIV viral load and year.  CD4 count and viral load were 
included as time updated variables which were updated at the start of each year of follow-up.  
 
6.2.3.5 HCV genotypes 
Individuals with any evidence of active infection (HCV-RNA positive at any point) were included 
in the analysis.  For each individual, the number of recorded genotypes was calculated.  First 
reported genotype and subtype was assessed among all individuals with active infection who 
had at least one reported genotype.  The number of individuals that had more than one 
different reported genotype, or more than one subtype for the same genotype, was 
calculated.  These individuals were considered to have been re-infected.  
 
It is possible for individuals to have the same genotype and subtype reported more than once.  
This may be due to reinfection with the same genotype or due to repeated laboratory 
assessment of the same infection.  Data on dates when genotype was reported are limited 
(61% of all reported genotypes have no associated date).  Consequently, where an individual 
had had more than one infection, it was not possible to assess temporality of the genotypes.  
Therefore, to further assess the distribution of genotypes, individuals who were defined as 
having been re-infected with HCV were excluded from the analysis.  Reinfection was defined as 
either changing genotype or having a positive HCV-RNA result after 6 months or more of 
negative RNA tests.  For all further analyses of genotype only the first reported genotype was 
considered. 
 
To assess changes over time in genotype the proportion of all infections with each genotype 
was calculated by year of first positive HCV test both for the total population and stratified by 
HIV exposure category.   Multinomial logistic regression was used to assess the likelihood of an 
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individual being infected with genotypes 2, 3, 4, or other/unknown genotypes with genotype 1 
being used as the reference group. 
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6.3 Results 
6.3.1 Patterns of hepatitis testing 
6.3.1.1 Proportion of individuals tested for HBV and HCV  
Among the 32079 individuals included in the analysis, the cumulative proportion of individuals 
who have been tested for HBsAg was 82.2% (26377/32079), 95% CI 81.8-82.6%, and the 
cumulative proportion of individuals who have been tested for anti-HCV was 87.6% 
(28111/32079), 95% CI 87.3-88.0%.  The median number of HBsAg and anti-HCV tests per 
individuals was 2 for each test (interquartile ranges (IQRs) 1, 4 and 1, 5 respectively).   
 
6.3.1.2 Changes in proportion tested over time 
The cumulative proportion of individuals under follow-up in each year who had ever had a test 
for HBsAg increased significantly from 54.2% in 2004 to 87.7% in 2011 (Chi-squared test for 
trend p<0.0001) (Table 6.2).  Among individuals eligible for annual testing, the proportion who 
received an HBsAg test within a given year increased from 20.5% in 2004 to 42.6% in 2009 but 
then declined to 29.4% over the next two years (Table 6.2).  The cumulative proportion of 
individuals under follow-up in each year who had ever had a test for anti-HCV increased from 
57.2% in 2004 to 93.4% in 2011 (Chi-squared test for trend p<0.0001) (Table 6.3).  The 
proportion of individuals eligible for annual anti-HCV testing who received a test within a given 
year increased consistently year on year from 25.5% in 2004 to 55.0% in 2011 (Chi-squared 
test for trend p<0.0001) (Table 6.3).   
 
Table 6.2 HBsAg testing over time 
Year Total 
number of 
individuals 
under 
follow-up 
Cumulative 
number 
tested by 
the end of 
that year 
% (95% CI) 
 
Eligible 
for testing 
in that 
year 
Number 
tested 
within 
that 
year 
% (95% CI) 
2004 18177 9846 54.2 (53.4-54.9) 14898 3054 20.5 (19.9-21.2) 
2005 19583 11849 60.5 (59.8-61.2) 15855 4032 25.4 (24.8-26.1) 
2006 20780 13720 66.0 (65.4-66.7) 16046 4585 28.6 (27.9-29.3) 
2007 21817 15538 71.2 (70.6-71.8) 16216 5164 31.8 (31.1-32.6) 
2008 22770 17627 77.4 (76.9-78.0) 15816 6431 40.7 (39.9-41.4) 
2009 23525 19447 82.7 (82.2-23.1) 14960 6369 42.6 (41.8-43.4) 
2010 24251 20521 84.6 (84.2-85.1) 14732 4944 33.6 (32.8-34.3) 
2011 22460 19694 87.7 (87.2-88.1) 13635 4010 29.4 (28.7-30.2) 
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Table 6.3 Anti-HCV testing over time 
Year Total 
number of 
individuals 
under 
follow-up 
Cumulative 
number 
tested by 
the end of 
that year 
% (95% CI) 
 
Eligible 
for 
testing 
in that 
year 
Number 
tested 
within 
that 
year 
% (95% CI) 
 
2004 18177 10395 57.0 (56.3-57.7) 17285 4412 25.5 (24.9-26.2) 
2005 19583 12931 66.0 (65.4-66.7) 18525 5941 32.1 (31.4-32.7) 
2006 20780 14943 71.9 (71.3-72.5) 19463 6434 33.6 (32.9-34.2) 
2007 21817 17059 78.2 (77.6-78.7) 20343 8196 40.3 (39.6-41.0) 
2008 22770 19062 83.7 (83.2-84.4) 21101 10005 47.4 (46.7-48.1) 
2009 23525 20616 87.6 (87.2-88.0) 21624 11100 51.3 (50.7-52.0) 
2010 24251 21855 90.1 (89.7-90.5) 22191 11099 50.0 (49.4-50.7) 
2011 22460 20982 93.4 (93.1-93.7) 20488 11259 55.0 (54.3-55.6) 
 
 
When stratified by demographic and HIV-related variables, the proportion of individuals ever 
tested for HBsAg increased among all subgroups between 2004 and 2011 (Figure 6.1).  
However, the magnitude of the increase differed by subgroup.  For example, when stratified 
by HIV exposure category, the exposure group with the highest proportion of individuals who 
have ever been tested for HBsAg was MSM in every year of follow-up.  However, the greatest 
increase in proportion ever tested was seen among individuals from other or unknown HIV 
exposure groups and the smallest increase was seen amongst IDU.  The differences in 
proportions of individuals who had ever tested in 2004 compared to in 2011 were: 32.5% for 
MSM; 28.2% for IDU; 35.9% for male heterosexuals; 35.3% for female heterosexuals; and 
45.1% for individuals belonging to other HIV exposure categories (Figure 6.1c).  A similar 
pattern was seen when the dataset was stratified by ethnicity.  The group with the highest 
proportion of individuals tested in each year was individuals of white ethnicity.  However, this 
group also had the smallest increase in the proportion tested over time, the greatest increase 
being seen among individuals of other or unknown ethnicities.  The differences in proportion 
ever tested between 2004 and 2011 were: 31.1% for white individuals; 31.9% for black African 
individuals; 39.1% for individuals of black other ethnicities and 48.8% for individuals of other 
or unknown ethnicities (Figure 6.1b).  When stratified by age, there was a greater increase 
among <35 year olds (a difference of 22.1% between 2004 and 2011) but the increase among 
35-45 year olds and among >45 year olds was similar (13.8 and 13.3 respectively) (Figure 6.1a).  
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When stratified by HIV clinical factors, those individuals with missing CD4 counts and viral 
loads had greater increases than those with known CD4 counts and viral loads. 
 
The proportion of eligible individuals who had an HBsAg test within a given year followed the 
same patterns over time for all subgroups with the exception of the groups of individuals with 
unknown CD4 count and unknown HIV viral load (Figure 6.2).  For all but these two subgroups 
the proportion tested in the year increased between 2004 and 2009 and then fell between 
2009 and 2012.  Although the proportion of eligible individuals who tested within a given year 
fell between 2009 and 2011, it still remained higher than the 2004 levels in all subgroups.  The 
increases between 2004 and 2009 were greater among some subgroups than among others.  
When stratified by HIV exposure group, the proportion of eligible individuals who were tested 
within a given year increased in every group in the period 2004 to 2009, but the increase was 
greatest among individuals of other/unknown exposure and the lowest increase was among 
IDU.  The differences in proportions between 2004 and 2009 were: 26.4% for MSM; 9.0% for 
IDU; 17.9% for male heterosexuals; 17.2% for female heterosexuals and 33.7% for individuals 
of other or unknown HIV exposure group (Figure 6.2c).   When stratified by ethnicity, between 
2004 and 2009, white individuals had the highest proportion of eligible individuals tested for 
HBsAg within every year.  The lowest increase in testing of eligible individuals within the year 
was among black African individuals (15% difference between 2004 and 2009) and the greatest 
increase was seen among individuals of other or unknown ethnicity (37.3% difference between 
2004 and 2009) (Figure 6.2b).  Smaller differences in the magnitude of increase from 2004 to 
2009 were seen when data was stratified by age group: 19.4% difference among those <35 
years; 2.2% difference among those aged 35-45 years; 22.3% difference among those older 
than 45 years) (Figure 6.2a).   
 
The proportion of individuals ever tested for anti-HCV increased among all subgroups between 
2004 and 2012 (Figure 6.3).  When stratified by HIV exposure group, in 2004, the exposure 
group with the highest proportion of individuals who had ever been tested for anti-HCV was 
IDU.  However, the increase in the proportion of IDU tested was less than that among MSM 
and thus, from 2006 onwards, the exposure category with the highest proportion of individuals 
who had ever tested for anti-HCV was MSM (Figure 6.3c).  The differences in proportions ever 
tested in 2004 compared to 2011 were:  36.1% for MSM; 21.4% for IDU; 37.6% for male 
heterosexuals; 36.5% for female heterosexuals; and 50.4% for individuals belonging to other 
risk groups.  When stratified by ethnicity, although white individuals remained the group with 
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the highest proportion ever tested in each year the increase in testing was lowest in this group 
and greatest among individuals of other/unknown ethnicity: 33.3% difference for white 
individuals; 36.2% difference for black African individuals; 36.8% difference for other black 
individuals and 52.7% difference for individuals of other or unknown ethnicity (Figure 6.3b).  
When stratified by age group the increase between 2004 and 2011 was greatest among 
individuals aged under 35 years (40.6% difference) while the increase among those aged 35-45 
years and those over 45 years was similar (34.1% and 33.2% respectively).  
 
The proportion of eligible individuals who had an anti-HCV test within a given year also 
increased in each subgroup between 2004 and 2012 (Figure 6.4).  Like the patterns of 
cumulative testing, differences between the subgroups existed in the magnitude of the 
increase.  For example, the differences in proportion of eligible individuals tested within a 
given year between 2004 and 2011 were: 34.2% for MSM; 21.9% for IDU; 21.8% for male 
heterosexuals; 17.5% for female heterosexuals; and 46.0% for individuals of other/unknown 
exposure group (Figure 6.4c).  Differences in the increase in testing over time were also seen 
when the dataset was stratified by ethnicity (Figure 6.4b).  While white individuals had the 
highest proportion of eligible individuals tested within each year, the greatest increase was 
seen among individuals of other or known ethnicity and the lowest increase was seen among 
individuals of black African ethnicity.  Differences in the proportion of eligible individuals who 
tested within a given year between 2004 and 2011 were: 32.5% for white individuals; 16.9% 
for black African individuals; 31.5% for individuals of other black ethnicity and 42.3% for 
individuals of other/unknown ethnicity.  Similar increases in the proportion of eligible 
individuals who tested within a year were seen among all age groups: differences of 35.2% for 
those aged <35 years; 29.1% for those aged 35-45 years; 34.0% for those aged over 45 years.  
When stratified by HIV clinical variables, individuals with missing CD4 or missing HIV viral loads 
had the greatest increases.
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Figure 6.1 Change in proportion of individuals ever tested for HBsAg, by calendar year, overall and stratified by demographic and HIV clinical factors 
  
 
1
8
4
 
 
Figure 6.2 Change in proportion of eligible individuals tested for HBsAg within a year, by calendar year, overall and stratified by demographic and HIV clinical factors 
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Figure 6.3 Change in proportion of individuals ever tested for anti-HCV, by calendar year, overall and stratified by demographic and HIV clinical factors 
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Figure 6.4 Change over time in proportion of eligible individuals tested for anti-HCV within a year overall and stratified by demographic and HIV clinical factors 
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6.3.1.3 Factors associated with having a first test 
A separate multivariable model was conducted for each year of follow-up to examine how the 
factors associated with first HBsAg test by the end of that year changed over time (Table 6.4).  
From 2004 to 2007 there were no significant differences in the likelihood of having a first test 
between IDU and MSM.  However, from 2008 onwards IDU were significantly less likely than 
MSM to have a first test.  Compared to MSM, male and female heterosexuals were 
significantly less likely to have a first test for HBsAg each year.  Comparing IDU to MSM over 
time, the odds ratio decreased from 1.29 (95% CI 0.97-1.72) in 2004 to 0.39 (95% CI 0.24-0.63) 
in 2011.  Similarly, comparing individuals of black African ethnicity to individuals of white 
ethnicity over time the odd ratio decreased from 1.18 (95% CI 0.98-1.43) in 2004 to 0.75 (95% 
CI 0.61-0.93) in 2011.   
 
Considering the complete dataset from 2004-2011, univariable and multivariable logistic 
regression was conducted to identify factors associated with first HBsAg test (Table 6.5).  Year 
of follow-up was included as a covariate and age and HIV infection category were updated at 
the start of each year.  Ethnicity and exposure were also included in the models.  In univariable 
analysis age, ethnicity, HIV exposure group, year and HIV infection status were all associated 
with the likelihood of a first HBsAg test.  However, in a multivariable model adjusting for all 
these factors, only HIV exposure group, HIV infection category and year remained associated 
with having a first HBsAg test.  Compared to MSM, IDU were significantly less likely to test as 
were male and female heterosexuals and individuals of other/unknown HIV exposure groups.  
Calendar year was significantly associated with a first test with individuals being more likely to 
have a first test in later years.  Compared to individuals with controlled HIV those with 
advanced HIV, uncontrolled or unknown HIV infection category were all more likely to have a 
first test. 
 
A series of models was then run to test for interactions between time (calendar year) and 
demographic factors.  All models were adjusted for age group, HIV exposure group, ethnicity, 
HIV infection category and year (Table 6.6).  Model 1 included an interaction between year and 
age group. A significant interaction was found between all age groups and year (p<0.0001 for 
all age groups).  Model 2 included an interaction between year and ethnicity.  Only black 
ethnicity was found to have a significant interaction with year (p<0.0001) and therefore the 
other interactions were removed from this model.  Model 3 included an interaction between 
year and HIV exposure group.  A significant interaction was found between year and all HIV 
exposure categories (p<0.0001 for all interactions).  The probabilities of testing per year were 
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calculated using parameter estimates from each of the models.  Figure 6.5 shows how the 
probability of first test changes over time among those groups where a significant interaction 
was detected, compared to the probability in the reference group.  The reference group are 
MSM of white ethnicity, aged <35 years, with controlled HIV infection (denoted by the dark 
blue line in all graphs). 
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Table 6.4 Adjusted odds ratios for likelihood of first testing for HBsAg according to characteristics at baseline, by year of follow-up 
  AOR  (95% CI) from multivariable models of factors associated with having a first HBsAg test 
 
Year  2004 2005 2006 2007 2008 2009 2010 2011 
 
Age (years) <35 1 1 1 1 1 1 1 1 
 35-45 0.99 
(0.87-1.12) 
1.03 
(0.93-1.15) 
0.93 
(0.83-1.04) 
1.18 
(1.05-1.32) 
0.95 
(0.85-1.06) 
0.94 
(0.84-1.06) 
0.88 
(0.76-1.01) 
0.77 
(0.65-0.91) 
 >45 1.12 
(0.95-1.32) 
1.02 
(0.88-1.17) 
1.02 
(0.89-1.18) 
1.22 
(1.06-1.40) 
0.97 
(0.85-1.12) 
0.95 
(0.82-1.09) 
0.77 
(0.65-0.91 
0.64 
(0.53-0.77) 
Ethnicity White 1 1 1 1 1 1 1 1 
 Black 1.18 
(0.98-1.43) 
1.39 
(1.18-1.63) 
1.24 
(1.06-1.46) 
1.16 
(0.98-1.37) 
0.93 
(0.80-1.08) 
0.71 
(0.60-0.84) 
0.75 
(0.62-0.91) 
0.75 
(0.61-0.93) 
 Other black ethnicity 0.64 
(0.48-0.87) 
0.99 
(0.78-1.25) 
0.96 
(0.76-1.22) 
0.84 
(0.66-1.06) 
1.13 
(0.92-1.40) 
1.31 
(1.04-1.64) 
1.01 
(0.76-1.33) 
1.07 
(0.77-1.48) 
 Other 0.64 
(0.53-0.77) 
1.17 
(1.02-1.35) 
1.06 
(0.92-1.23) 
1.08 
(0.94-1.26) 
0.93 
(0.80-1.08) 
0.87 
(0.74-1.03) 
0.92 
(0.77-1.10) 
0.99 
(0.80-1.23) 
Exposure MSM 1 1 1 1 1 1 1 1 
 IDU 1.29 
(0.97-1.72) 
0.82 
(0.62-1.09) 
0.93 
(0.70-1.22) 
0.87 
(0.65-1.16) 
0.64 
(0.46-0.87) 
0.68 
(0.49-0.94) 
0.36 
(0.23-0.57) 
0.39 
(0.24-0.63) 
 Male heterosexual 0.84 
(0.69-1.03) 
0.72 
(0.61-0.86) 
0.98 
(0.83-1.16) 
0.80 
(0.67-0.95) 
0.83 
(0.70-0.98) 
0.79 
(0.66-0.95) 
0.63 
(0.51-0.77) 
0.58 
(0.45-0.73) 
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  AOR  (95% CI) from multivariable models of factors associated with having a first HBsAg test 
 
Year  2004 2005 2006 2007 2008 2009 2010 2011 
 
 Female heterosexual 0.73 
(0.60-0.89) 
0.66 
(0.56-0.77) 
0.78 
(0.66-0.91) 
0.78 
(0.66-0.91) 
0.74 
(0.63-0.87) 
0.69 
(0.59-0.82) 
0.47 
(0.39-0.58) 
0.52 
(0.42-0.66) 
 Other 0.38 
(0.28-0.52) 
0.26 
(0.20-0.35) 
0.37 
(0.30-0.47) 
0.40 
(0.32-0.49) 
0.98 
(0.83-1.15) 
1.09 
(0.92-1.30) 
0.67 
(0.55-0.83) 
0.38 
(0.30-0.48) 
HIV infection 
category 
Advanced 1.24 
(0.99-1.56) 
1.09 
(0.90-1.32) 
1.14 
(0.93-1.39) 
1.22 
(0.99-1.50) 
0.96 
(0.77-1.21) 
1.30 
(1.03-1.65) 
1.21 
(0.87-1.68) 
2.18 
(1.58-3.01) 
 Uncontrolled 1.11 
(0.94-1.33) 
1.10 
(0.96-1.27) 
1.00 
(0.86-1.15) 
1.08 
(0.93-1.24) 
1.12 
(0.97-1.28) 
1.24 
(1.06-1.44) 
1.36 
(1.12-1.65) 
1.36 
(1.11-1.67) 
 Controlled 1 1 1 1 1 1 1 1 
 Unknown 3.00 
(2.59-3.47) 
2.44 
(2.17-2.76) 
2.34 
(2.07-2.64) 
2.44 
(2.16-2.77) 
2.22 
(1.97-2.50) 
2.44 
(2.15-2.76) 
4.26 
(3.67-4.94) 
11.4 
(9.57-13.49) 
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Table 6.5 Univariable and multivariable logistic regression of factors associated with first HBsAg test 
  Univariable analysis Multivariable analysis 
   OR 95% CI P value AOR 95% CI P value 
Age (years) <35 1 - - 1 - - 
 35-45 0.79 (0.76-0.82) <0.0001 0.97 (0.93-1.01) 0.13 
 >45 
 
0.78 (0.75-0.82) <0.0001 0.95 (0.90-1.01) 0.08 
Ethnicity White 1 - - 1 - - 
 Black African 0.73 (0.71-0.79) <0.0001 0.98 (0.93-1.05)  
 Other Black ethnicity 0.88 (0.82-0.95) 0.002 0.98 (0.90-1.07) 0.62 
 Other/unknown 
 
0.93 (0.89-0.99) 0.02 0.75 (0.91-1.02) 0.72 
Exposure group MSM 1 - - 1 - - 
 IDU 0.64 (0.57-0.71) <0.0001 0.75 (0.67-0.84) <0.0001 
 Male heterosexual 0.74 (0.71-0.79) <0.0001 0.79 (0.74-0.85) <0.0001 
 Female heterosexual 0.63 (0.60-0.66) <0.0001 0.69 (0.64-0.73) <0.0001 
 Other/unknown 
 
0.89 (0.84-0.96) 0.001 0.61 (0.56-0.65) <0.0001 
HIV infection category Advanced 1.07 (0.99-1.16) 0.09 1.25 (1.16-1.36) <0.0001 
 Uncontrolled 1.12 (1.06-1.18) <0.0001 1.18 (1.11-1.24) <0.0001 
 Controlled 1 - - 1 - - 
 Unknown 
 
2.87 (2.75-2.99) <0.0001 2.92 (2.79-0.06) <0.0001 
Year (per year) 
 
1.17 (1.17-1.19) <0.0001 1.19 (1.18-1.20) <0.0001 
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Table 6.6 Adjusted odds ratios for models predicting likelihood of first HBsAg test including interactions between year and demographic variables1 
Factor AOR  95% CI P value 
Model 12    
Age <35 years 1 - - 
Age 35-45 years  1.15 1.07-1.24 0.0002 
Age >45 years  1.32 1.21-1.45 <.0001 
Year (per later year) 1.25 1.23-1.26 <.0001 
Year*Age 35-45 years 0.94 0.93-0.96 <.0001 
Year*Age >45 years  0.91 0.89-0.93 <.0001 
Model 23    
White 1 - - 
Black African 1.57 1.45-1.72 <.0001 
Other black 0.99 0.91-1.07 0.7489 
Other/unknown ethnicity 0.97 0.91-1.02 0.2259 
Year (per later year) 1.24 1.23-1.25 <.0001 
Year*Black African 0.87 0.85-0.89 <.0001 
Model 34    
MSM    
IDU 1.24 1.03-1.49 0.0242 
Male heterosexual 1.11 1.00-1.23 0.0454 
Female heterosexual 1.02 0.94-1.12 0.6102 
Other 0.38 0.33-0.44 <.0001 
  
 
1
93
 
Factor AOR  95% CI P value 
Year (per later year) 1.24 1.23-1.26 <.0001 
Year*IDU 0.85 0.80-0.89 <.0001 
Year*Male heterosexual 0.90 0.88-0.92 <.0001 
Year*Female heterosexual 0.88 0.87-0.90 <.0001 
Year*Other/unknown exposure 1.12 1.08-1.15 <.0001 
 
1 All models adjusted for age, ethnicity, HIV exposure group, calendar year and HIV infection category 
2Model 1 includes an interaction between year and age group 
3Model 2 includes an interaction between year and black African ethnicity 
4Mode 3 includes an interaction between year and HIV exposure group 
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Figure 6.5 Modelled probability of having a first HBsAg test stratified by those demographic 
factors with significant interactions with calendar year 
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The same process was conducted for anti-HCV testing and separate logistic regression models 
were constructed for each year (Table 6.7).  In 2004, there was no significant difference 
between MSM and IDU with regard to testing for anti-HCV.  However, from 2005 onwards, IDU 
were significantly less likely than MSM to have a first test for HCV with the ORs decreasing 
year on year from 0.66 (95% CI 0.48-0.90) in 2005 to 0.27 (95% CI 0.16-0.47) in 2011.  
Comparing individuals of black African ethnicity to those of white ethnicity there was no 
significance difference from 2004 to 2008.  However, from 2009 onwards, black African 
individuals were significantly less likely to have a first test, with the ORs decreasing from 0.99 
(95 % CI 0.83-1.18) in 2004 to 0.75 (95% CI 0.60-0.93) in 2011.   
 
Univariable and multivariable logistic regression was then conducted to identify factors 
associated with first anti-HCV for the complete dataset 2004-2011.  Year of follow-up was 
included as a covariate, age and HIV infection category were updated at the start of each year 
and HIV exposure group and ethnicity were also included in the model.  In univariable analysis 
age, ethnicity, HIV exposure group, HIV infection category and year were all associated with 
first anti-HCV test.  These factors remained significant in the multivariable model (Table 6.8).  
Compared to individuals <35 years old, older individuals were less likely to have a first test for 
anti-HCV (AOR, 95% CI: 0.91 0.87-0.94 and 0.80, 0.76-0.85 for individuals aged 35-45 and those 
over the age of 45 respectively).  Compared to white individuals, there was no significant 
difference between black African individuals and those with other/unknown ethnicity in the 
likelihood of having a first test.  However, individuals of other black ethnicities were 
significantly more likely to have had a first test (AOR, 95% CI: 1.16, 1.06-1.26).  Compared to 
MSM, individuals of all other exposure categories were less likely to have a first test.  
Compared to individuals with controlled HIV infection, those with advanced or uncontrolled 
and those with known HIV infection category were more likely to have a first test for HCV-Ab.  
Year of follow-up was significantly associated with likelihood of first test (AOR, 95% CI: 1.24, 
1.23-1.25 per year).  
 
Separate models were constructed to test for interactions between year and demographic 
factors (Table 6.9).  All models included age group, ethnicity, HIV exposure group, HIV infection 
stage and year.  Model 1 included an interaction between year and age category.  A significant 
interaction was detected between year and the age group 35-45 years and between year and 
the age group over 45 years (P<0.0001 for both age categories).  Model 2 included an 
interaction between ethnicity and year.  A significant interaction was detected between black 
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African ethnicity and year, but not between year and other black ethnicity or year and 
other/unknown ethnicity.  Therefore model 2 was rerun including only the interaction 
between year and black African ethnicity.  Model 3 included an interaction between year and 
HIV exposure group.  A significant interaction between year and all exposure groups (P<0.0001 
for all HIV exposure groups) was detected.  Using the parameter estimates from these models, 
the modelled probability of a first test among each group, per year, was calculated.  Figure 6.6 
shows how the probability of a first anti-HCV test changes over time in each group where a 
significant interaction was detected compared to the reference group.  The reference group is 
white, MSM, aged <35 who have controlled HIV infection (denoted by the dark blue line in all 
graphs).   
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Table 6.7 Adjusted odds ratios for likelihood of first testing for anti-HCV according to characteristics at baseline, by year of follow-up 
  AOR (95% CI) from multivariable models of factors associated with having a first anti-HCV test 
 
Year  2004 
 
2005 2006 2007 2008 2009 2010 2011 
Age <35 1 1 1 1 1 1 1 1 
 35-45 0.94 
(0.83-1.05) 
0.95 
(0.86-1.05) 
0.93 
(0.84-1.04) 
1.00 
(0.89-1.11) 
0.86 
(0.77-0.97) 
0.89 
(0.78-1.02) 
0.86 
(0.74-0.99) 
0.73 
(0.60-0.88) 
 >45 0.89 
(0.76-1.05) 
0.86 
(0.75-0.99) 
0.98 
(0.85-1.13) 
0.89 
(0.77-1.02) 
0.76 
(0.66-0.88) 
0.80 
(0.68-0.93) 
0.72 
(0.61-0.85) 
0.49 
(0.40-0.61) 
Ethnicity White 1 1 1 1 1 1 1 1 
 Black African 0.99 
(0.83-1.18) 
1.28 
(1.10-1.49) 
1.36 
(1.16-1.60) 
1.20 
(1.03-1.41) 
1.00 
(0.85-1.17) 
0.78 
(0.65-0.93) 
0.83 
(0.68-1.00) 
0.75 
(0.60-0.93) 
 Other black ethnicity 0.80 
(0.62-1.03) 
1.18 
(0.95-1.46) 
1.31 
(1.04-1.64) 
1.13 
(0.90-1.42) 
1.31 
(1.04-1.66) 
1.28 
(0.99-1.67) 
1.10 
(0.81-1.50) 
1.43 
(0.97-2.11) 
 Other 0.64 
(0.54-0.76) 
1.41 
(1.25-1.61) 
1.22 
(1.06-1.41) 
1.03 
(0.89-1.20) 
0.94 
(0.80-1.10) 
0.79 
(0.67-0.95) 
1.00 
(0.83-1.20) 
0.93 
(0.73-1.19) 
Exposure MSM 1 1 1 1 1 1 1 1 
 IDU 0.96 
(0.69-1.35) 
0.66 
(0.48-0.90) 
0.70 
(0.51-0.95) 
0.71 
(0.52-0.98) 
0.77 
(0.55-1.08) 
0.45 
(0.30-0.68) 
0.40 
(0.25-0.63) 
0.27 
(0.16-0.47) 
 Male heterosexual 0.97 
(0.81-1.17) 
0.63 
(0.54-0.74) 
0.79 
(0.67-0.93) 
0.76 
(0.64-0.90) 
0.79 
(0.66-0.94) 
0.82 
(0.67-1.00) 
0.54 
(0.44-0.67) 
0.41 
(0.32-0.54) 
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  AOR (95% CI) from multivariable models of factors associated with having a first anti-HCV test 
 
Year  2004 
 
2005 2006 2007 2008 2009 2010 2011 
 Female heterosexual 0.90 
(0.75-1.07) 
0.66 
(0.57-0.76) 
0.71 
(0.61-0.84) 
0.70 
(0.60-0.82) 
0.75 
(0.64-0.89) 
0.73 
(0.60-0.87) 
0.47 
(0.39-0.58) 
0.34 
(0.27-0.43) 
 Other 0.38 
(0.28-0.51) 
0.31 
(0.24-0.39) 
0.30 
(0.23-0.38) 
0.32 
(0.26-0.39) 
0.84 
(0.71-0.98) 
0.90 
(0.75-1.08) 
0.61 
(0.49-0.75) 
0.29 
(0.23-0.37) 
HIV infection 
category 
Advanced 1.06 
(0.86-1.32) 
0.98 
(0.82-1.18) 
0.98 
(0.80-1.20) 
1.19 
(0.96-1.46) 
1.05 
(0.83-1.33) 
1.70 
(1.31-2.21) 
0.93 
(0.66-1.31) 
1.28 
(0.88-1.87) 
 Uncontrolled 1.19 
(1.01-1.40) 
1.14 
(1.00-1.30) 
1.20 
(1.05-1.39) 
1.55 
(1.34-1.79) 
1.47 
(1.26-1.72) 
1.60 
(1.34-1.92) 
1.51 
(1.22-1.87) 
1.62 
(1.27-2.07) 
 Controlled 1 1 1 1 1 1 1 1 
 Unknown 2.32 
(2.02-2.65) 
1.59 
(1.42-1.78) 
1.57 
(1.39-1.78) 
1.94 
(1.71-2.20) 
1.87 
(1.64-2.13) 
2.47 
(2.15-2.85) 
2.91 
(2.49-3.40) 
5.99 
(4.95-7.26) 
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Table 6.8 Univariable and multivariable logistic regressions analysis of factors associated with first anti-HCV test 
  Univariable analysis Multivariable model  
  OR 95% CI P value AOR 95% CI P value 
Age <35 1 - - 1 - - 
 35-45 0.78 0.74-0.81 <0.0001 0.91 0.87-0.94 <0.0001 
 >45 
 
0.71 0.67-0.75 <0.0001 0.80 0.76-0.85 <0.0001 
Ethnicity White 1 - - 1 - - 
 Black African 0.78 0.74-0.81 <0.0001 1.03 0.97-1.09 0.36 
 Other black ethnicity 1.03 0.95-1.12 0.47 1.16 1.06-1.26 0.001 
 Other/unknown 
 
0.95 0.90-1.00 0.07 1.01 0.96-1.07 0.69 
Exposure group MSM 1 - - 1 - - 
 IDU 0.59 0.52-0.67 <0.0001 0.63 0.55-0.72 <0.0001 
 Male heterosexual 0.71 0.67-0.75 <0.0001 0.73 0.58-0.78 <0.0001 
 Female heterosexual 0.67 0.65-0.70 <0.0001 0.67 0.63-0.72 <0.0001 
 Other/unknown 
 
0.74 0.70-0.79 <0.0001 0.52 0.48-0.56 <0.0001 
HIV infection category Advanced 1.00 0.92-1.08 1.00 1.15 1.05-1.25 0.001 
 Uncontrolled 1.34 1.27-1.42 <0.0001 1.39 1.32-1.48 <0.0001 
 Controlled 1 - - 1 - - 
 Unknown 
 
2.30 2.20-22.40 <0.0001 2.13 2.04-2.24 <0.0001 
Year (per year) 1.23 1.22-1.24 <0.0001 1.24 1.23-1.25 <0.0001 
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Table 6.9 Adjusted odds ratios for models predicting likelihood first anti-HCV test including interactions between year and demographic variables1 
Factor AOR 95% CI  P value 
Model 12    
Age <35 years 1 - - 
Age 35-45 years  1.05 0.98-1.13 0.1353 
Age >45 years  1.09 0.99-1.19 0.0703 
Year (per later year) 1.29 1.27-1.31 <.0001 
Year*Age 35-45 years 0.95 0.93-0.97 <.0001 
Year*Age >45 years  0.91 0.89-0.93 <.0001 
Model 23    
White 1 - - 
Black African 1.56 1.70-5.44 <.0001 
Other black 1.17 1.28-3.58 0.0006 
Other/unknown ethnicity 1.01 1.07-2.93 0.618 
Year (per later year) 1.29 1.30-3.68 <.0001 
Year*Black African 0.88 0.89-2.45 <.0001 
Model 34    
MSM 1 - - 
IDU 0.94 0.76-1.17 0.5899 
Male heterosexual 1.02 0.92-1.13 0.72 
Female heterosexual 1.02 0.93-1.11 0.6944 
Other 0.34 0.29-0.39 <.0001 
Year (per later year) 1.30 1.29-1.32 <.0001 
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Factor AOR 95% CI  P value 
Year*IDU 0.87 0.82-0.92 <.0001 
Year*Male heterosexual 0.89 0.87-0.92 <.0001 
Year*Female heterosexual 0.87 0.85-0.89 <.0001 
Year*Other/unknown exposure 1.10 1.06-1.14 <.0001 
 
1 All models adjusted for age, ethnicity, HIV exposure group, calendar year and HIV infection category 
2 Mode 1 includes an interaction between year and age group 
3 Model 2 includes and interaction between year and black African ethnicity 
4 Mode 3 includes an interaction between year and HIV exposure categories
 202 
 
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.6 Modelled probability of having a first anti-HCV test stratified by those 
demographic factors with significant interactions with calendar year 
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6.3.1.4  Factors associated with repeat testing 
The proportion of individuals in each year who had a repeat HBsAg test within that year 
increased significantly from 20.4% to 44.4% over the period 2004-2008 (p<0.0001) but 
subsequently declined significantly from 44.7% to 23.4% over the period 2009-2011 (p<0.0001) 
(Table 6.10).  The proportion of individuals in each year who had a repeat anti-HCV test within 
that year increased significantly from 33.1% in 2004 to 54.4% in 2011 (p<0.0001) (Table 6.11). 
 
Table 6.10 Proportion of individuals repeat testing for HBsAg, by year 
Year Numbers previously 
tested but who have 
never received a 
positive result 
Number tested within 
year 
% 
2004 5382 1530 28.4% 
2005 6159 1722 28.00% 
2006 7229 2342 32.4% 
2007 8250 3003 36.4% 
2008 8540 3788 44.4% 
2009 8806 3937 44.7% 
2010 9522 3142 33.0% 
2011 9330 2184 23.4% 
 
Table 6.11 Proportion of individuals repeat testing for anti-HCV, by year 
Year Numbers previously 
tested but who have 
never received a 
positive result 
Number tested within 
year 
% 
2004 7643 2531 33.1% 
2005 9013 3042 33.8% 
2006 11166 3930 35.2% 
2007 12966 5534 42.7% 
2008 14769 7325 49.6% 
2009 16448 8760 53.3% 
2010 17799 9036 50.8% 
2011 17114 9314 54.4% 
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A separate multivariable model was constructed for each year.  Each model included age 
group, ethnicity, HIV exposure category and HIV infection category.  The AORs for repeat 
testing in a given year are shown in (Table 6.12).  In most years, there was no difference in the 
likelihood of repeat testing between individuals aged <35 years and those aged 35-45 years. 
However, there was some evidence that in 2007 and 2011 individuals aged 35-45 years were 
significantly less likely to have a repeat test than individuals aged <35 years old.  However, it 
appears that those aged over 45 are less likely to have a repeat HBsAg test when compared to 
those aged <35 in every year.  Compared to MSM, IDU were significantly less likely to have a 
repeat test for HBsAg from 2005 to 2010.  Similarly, male and female heterosexuals were less 
likely to have a repeat test than MSM from 2004 to 2010.  With the exception of 2007 and 
2009, compared to white individuals, there were no significant differences in the likelihood of 
individuals of black African ethnicity having a repeat test for HBsAg.  In general there were few 
significant differences in repeat testing according to HIV infection category.  However, in 2006 
and 2009 individuals with advanced or uncontrolled HIV infection were significantly less likely 
to have a repeat HBsAg test than individuals with controlled HIV infection.  In addition, in later 
years (2010 and 2011), individuals with missing CD4 and HIV viral load data were more likely to 
have a repeat test for HBsAg than those with controlled HIV infection. 
 
In a multivariable model including the complete dataset (2004-2011), year of follow-up was 
included as a categorical variable as the observed changes in repeat testing over time were not 
linear.  Table 6.13 shows the results of a model of factors associated with repeat HBsAg 
testing.  In multivariable analysis, compared to younger individuals, those aged 34-45 years 
and those aged >45 years were less likely to have a repeat test, although for individuals aged 
35-45 the effect size was small (AOR, 95% CI: 0.94, 0.90-0.99).  Compared to white individuals, 
individuals of black African ethnicity were less likely to have a repeat HBsAg test (AOR, 95% CI:  
0.88, 0.82-0.94).  Compared to MSM, individuals of all other HIV exposure groups were less 
likely to have a repeat test.  HIV infection category was also significantly associated with having 
a repeat test, with those who had advanced infection being less likely to repeat test than those 
with controlled HIV infection (AOR, 95% CI: 0.88, 0.82-0.94) while those with unknown HIV 
infection category were more likely to have a repeat HBsAg test (AOR, 95% CI: 1.12, 1.01-1.25).  
Taking 2004 as the reference year, there was a significant association between each year and 
HBsAg testing.  There was no difference in the likelihood of testing in 2005 compared to 2004, 
but individuals under follow-up in all years until 2010 were more likely to have a repeat test 
than those under follow-up in 2004.    
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Three separate models were then constructed to test for interactions between year and 
demographic variables.  As before, year was included as a categorical variable for each of these 
models.  Model 1 included an interaction between age group and year; this model did not 
reveal any significant interactions (data not shown).  Model 2 included an interaction between 
year and ethnicity.  Significant interactions were only identified between year and black 
African ethnicity therefore the interaction terms between year and black other ethnicity and 
year and other ethnicity were removed from the model leaving only the interaction between 
year and black African ethnicity.  Model 3 included an interaction between exposure group and 
year.  No significant interactions were identified between male heterosexual and other 
exposure, and therefore these two interactions were removed from the models.  In contrast, 
significant interactions were identified between IDU and year and female heterosexual 
exposure and year.  Significant interactions were identified between year and black African 
ethnicity, year and IDU and year and female heterosexual exposure. Table 6.14 shows the 
significant interactions identified in these models.  Where significant interactions were 
identified the modelled probability over time in the groups where a significant interaction was 
present was then plotted compared to the reference group.  A stepwise graph was used since 
year was categorical and not continuous (Figure 6.7).  The reference group was white, MSM, 
aged <35 with controlled HIV infection (denoted by a blue line). 
 
This process was repeated for HCV testing and separate multivariable models were 
constructed to identify factors associated with repeat anti-HCV testing in each year of follow-
up.  Table 6.15 shows the AORs for repeat anti-HCV testing in each year.  There were no 
significant differences in the likelihood of repeat anti-HCV testing between individuals aged 
<35 years and those aged 35-45 years in any year.  However, in later years, those aged over 45 
were less likely to have a repeat anti-HCV test than those aged <35.  From 2005 onwards black 
African individuals were less likely to have a repeat test than white individuals and from 2004 
to 2010 individuals of other black ethnicities were less likely to have a repeat anti-HCV test 
than white individuals.  Compared to MSM, IDU were significantly less likely to have a repeat 
anti-HCV test in most years (2005, 2006, 2008, 2009 and 2011).  Male and female 
heterosexuals were less likely to have a repeat anti-HCV test in every year of follow-up.  
Compared to individuals with controlled HIV infection those with advanced or uncontrolled 
HIV infection were less likely to have a repeat anti-HCV test and those whose HIV infection 
category was unknown due to missing CD4 and viral load measurements were more likely to 
have a repeat anti-HCV test from 2005 onwards. 
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In a multivariable model including data for all years, year of follow-up was included as a 
continuous variable.  Table 6.16 shows the results of univariable and multivariable logistic 
regression of factors associated with repeat anti-HCV testing.  Age group, ethnicity, HIV 
exposure group, HIV infection category and year were all significantly associated with having a 
repeat anti-HCV test in univariable analysis and these associations remained when the 
variables were entered into a multivariable model.  Older individuals (>45 years) were less 
likely to have a repeat anti-HCV test than individuals aged under 35 years (AOR, 95% CI: 0.85, 
0.82-0.89).  Compared to white individuals, those of black African ethnicity were less likely to 
have a repeat anti-HCV test (AOR, 95% CI: 0.67, 0.63-0.71) as were those of other black 
ethnicities (AOR: 95% CI: 0.73, 0.68-0.79).  Individuals of all other exposure groups were 
significantly less likely to have a repeat anti-HCV test than MSM, as were individuals with 
advanced or uncontrolled HIV infection when compared to those with controlled HIV infection.  
Year was significantly associated with testing, with testing being more likely in later years (AOR 
1.17 per later year, 95% CI 1.16-1.18).   
 
Three separate models were then constructed to examine potential interactions between year 
and demographic characteristics.  Model 1 included an interaction between year and age 
group.  There was no significant interaction between age group 35-45 and year but there was a 
significant interaction between year and age group >45.  Therefore the interaction term for 
year and age 35-45 was removed from the model.  Model 2 included an interaction between 
ethnicity and year.  No significant interaction was identified between black African ethnicity 
and year and so this was removed from the model but significant interactions were identified 
between year and black other ethnicity and year and other/unknown ethnicity.  Model 3 
included an interaction between year and HIV exposure group.  The only significant interaction 
identified was between year and other/unknown exposure, therefore interactions between 
year and all other exposure categories were removed from the model.  ORs for these models 
are shown in Table 6.17.  Where significant interactions were identified, the probability of 
testing in the group where an interaction was present compared to the reference group was 
plotted (Figure 6.8).  The reference group was white MSM, aged <35 years with controlled HIV 
infection (denoted by the dark blue line in all graphs). 
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Table 6.12 Adjusted odds ratios for the likelihood of having a repeat HBsAg testing according to characteristics at baseline, by year of follow-up 
  AOR  (95% CI) 
 
Year  2004 2005 2006 2007 2008 2009 2010 2011 
Age <35 
 
1 1 1 1 1 1 1 1 
 35-45 0.94  
(0.82-1.08) 
0.90  
(0.79-1.03) 
0.97  
(0.86-1.10) 
0.86 
(0.76-0.96) 
0.94 
(0.84-1.05) 
1.04  
(0.93-1.16) 
0.93  
(0.83-1.04) 
0.84  
(0.74-0.96) 
 >45 0.70  
(0.58-0.85) 
0.68  
(0.57-0.81) 
0.76 
(0.65-0.88) 
0.82 
(0.71-0.93) 
0.83  
(0.73-0.95) 
0.87  
(0.77-0.99) 
0.87  
(0.77-0.99) 
0.76  
(0.66-0.87) 
Ethnicity White 
 
1 1 1 1 1 1 1 1 
 Black African 0.87  
(0.68-1.11) 
0.91  
(0.73-1.13) 
0.88  
(0.72-1.06) 
0.73  
(0.62-0.86) 
0.97 
(0.84-1.13) 
0.79  
(0.68-0.91) 
0.89  
(0.77-1.03) 
1.11  
(0.95-1.30) 
 Other black ethnicity 0.75 
(0.54-1.03) 
0.90  
(0.67-1.19) 
0.65  
(0.50-0.86) 
0.79  
(0.63-0.99) 
1.06  
(0.86-1.30) 
0.77  
(0.63-0.94) 
0.87  
(0.71-1.06) 
1.44  
(1.17-1.76) 
 Other 1.11  
(0.89-1.39) 
0.91  
(0.74-1.12) 
0.98 
(0.82-1.17) 
0.86  
(0.74-1.01) 
0.79  
(0.68-0.92) 
0.96  
(0.83-1.12) 
0.99  
(0.86-1.15) 
0.87  
(0.74-1.04) 
Exposure MSM 
 
1 1 1 1 1 1 1 1 
 IDU 0.82  
(0.60-1.11) 
0.51  
(0.37-0.71) 
0.43  
(0.32-0.58) 
0.50  
(0.38-0.64) 
0.52  
(0.41-0.66) 
0.42  
(0.32-0.53) 
0.66  
(0.51-0.85) 
1.09  
(0.82-1.46) 
 Male heterosexual 0.57  
(0.44-0.73) 
0.61  
(0.49-0.77) 
0.52  
(0.43-0.63) 
0.67  
(0.57-0.79) 
0.50  
(0.43-0.59) 
0.58  
(0.50-0.67) 
0.66  
(0.56-0.76) 
1.22  
(1.03-1.44) 
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  AOR  (95% CI) 
 
Year  2004 2005 2006 2007 2008 2009 2010 2011 
 Female heterosexual 0.38  
(0.30-0.48) 
0.57  
(0.46-0.70) 
0.45  
(0.38-0.55) 
0.64  
(0.55-0.75) 
0.50  
(0.43-0.58) 
0.52  
(0.45-0.59) 
0.59  
(0.51-0.68) 
1.12  
(0.95-1.31) 
 Other 0.52  
(0.34-0.82) 
0.55  
(0.36-0.83) 
0.35  
(0.24-0.53) 
0.70  
(0.52-0.94) 
0.59 
 (0.45-0.77) 
0.70  
(0.57-0.84) 
0.94  
(0.79-1.11) 
0.57  
(0.46-0.70) 
HIV infection 
category  
Advanced 0.90  
(0.73-1.10) 
1.02 
(0.83-1.24) 
0.72  
(0.59-0.87) 
0.90  
(0.76-1.06) 
0.90  
(0.77-1.05) 
0.69  
(0.58-0.82) 
0.98  
(0.82-1.17) 
1.11  
(0.90-1.38) 
 Uncontrolled 1.02 
(0.89-1.17) 
1.02  
(0.90-1.16) 
0.85  
(0.79-0.95) 
0.99  
(0.89-1.10) 
0.90  
(0.82-1.05) 
0.83  
(0.75-0.92) 
1.03 
 (0.92-1.14) 
1.03 
 (0.92-1.16) 
 Controlled 1 1 1 1 1 1 1 1 
 Unknown 0.86  
(0.66-1.11) 
0.84 
(0.64-1.09) 
0.69  
(0.54-0.90) 
0.95 
(0.74-1.22) 
1.24  
(0.92-1.66) 
1.32  
(0.91-1.91) 
2.93  
(1.87-4.61) 
7.03  
(3.81-12.99) 
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Table 6.13 Univariable and multivariable logistic regression of factors associated with repeat testing for HBsAg 
  Univariable analysis Multivariable analysis 
  OR 95% CI P value AOR 95% CI P value 
Age group (years) <35 1 - - 1 - - 
 35-45 1.00 0.96-1.05 0.98 0.94 0.90-0.99 0.0131 
 >45 0.89 0.85-0.94 <0.0001 0.82 0.78-0.87 <0.0001 
Ethnicity White 1 - - 1 - - 
 Black African 0.63 0.61-0.66 <0.0001 0.88 0.82-0.94 0.0002 
 Other black 0.78 0.71-0.85 <0.0001 0.91 0.83-1.00 0.0393 
 Other/unknown 0.85 0.80-0.91 <0.0001 0.92 0.86-0.98 0.0101 
 HIV exposure group       
HIV exposure group MSM 1 - - 1 - - 
 IDU 0.58 0.52-0.65 <0.0001 0.57 0.51-0.65 <0.0001 
 Male heterosexual 0.61 0.57-0.64 <0.0001 0.64 0.60-0.69 <0.0001 
 Female heterosexual 0.57 0.54-0.60 <0.0001 0.58 0.55-0.62 <0.0001 
 Other/unknown 0.63 0.58-0.69 <0.0001 0.65 0.60-0.72 <0.0001 
HIV infection category Advanced 0.82 0.77-0.87 <0.0001 0.88 0.82-0.94 0.0002 
 Uncontrolled 0.97 0.93-1.01 0.16 0.95 0.91-0.99 0.0236 
 Controlled 1 - - 1 - - 
 Unknown 1.28 1.16-1.42 <0.0001 1.12 1.01-1.25  
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  Univariable analysis Multivariable analysis 
  OR 95% CI P value AOR 95% CI P value 
Year 2004 1 - - 1 - - 
 2005 0.98 0.91-1.06 0.59 0.99 0.91-1.07 0.7552 
 2006 1.21 1.12-1.30 <0.0001 1.24 1.15-1.34 <0.0001 
 2007 1.44 1.34-1.55 <0.0001 1.51 1.41-1.62 <0.0001 
 2008 2.13 1.99-2.28 <0.0001 2.28 2.12-2.44 <0.0001 
 2009 2.09 1.95-2.24 <0.0001 2.28 2.12-2.44 <0.0001 
 2010 1.26 1.17-1.35 <0.0001 1.37 1.27-1.47 <0.0001 
 2011 0.78 0.72-0.84 <0.0001 0.83 0.77-0.90 <0.0001 
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Table 6.14 Adjusted ORs for models predicting the likelihood of repeat HBsAg testing including interactions between year and demographic variables1 
Factor AOR 95% CI  P value 
Model 22    
White 1 - - 
Black African 0.67 0.56-0.80 0.56-0.80 
Other black 0.91 0.83-0.99 0.83-0.99 
Other/unknown ethnicity 0.92 0.86-0.98 0.86-0.98 
2004 1 - - 
2005 0.94 0.86-1.02 <0.0001 
2006 1.23 1.13-1.33 <0.0001 
2007 1.47 1.36-1.60 <0.0001 
2008 2.20 2.03-2.38 <0.0001 
2009 2.29 2.11-2.48 <0.0001 
2010 1.31 1.21-1.42 <0.0001 
2011 0.68 0.63-0.75 <0.0001 
2005*Black African 1.37 1.11-1.70 0.004 
2006*Black African 1.11 0.91-1.35 0.32 
2007*Black African 1.19 0.98-1.45 0.07 
2008*Black African 1.26 1.05-1.52 0.01 
2009*Black African 1.08 0.89-1.30 0.42 
2010*Black African 1.29 1.07-1.57 0.01 
2011*Black African 2.49 2.04-3.05 <0.0001 
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Factor AOR 95% CI  P value 
Model 3 3    
MSM 1 - - 
IDU 0.86 0.63-1.17 0.35 
Male heterosexual 0.64 0.60-0.69 <0.0001 
Female heterosexual 0.40 0.33-0.48 <0.0001 
Other 0.66 00.360-0.73 <0.0001 
2004 1 - - 
2005 0.95 0.87-1.03 0.21 
2006 1.24 1.15-1.35 <0.0001 
2007 1.46 1.35-1.58 <0.0001 
2008 2.23 2.06-2.41 <0.0001 
2009 2.31 2.13-2.50 <0.0001 
2010 1.32 1.22-1.44 <0.0001 
2011 0.68 0.62-0.74 <0.0001 
2005*IDU 0.61 0.40-0.94 0.03 
2006*IDU 0.52 0.35-0.80 0.003 
2007*IDU 0.58 0.39-0.86 0.006 
2008*IDU 0.62 0.43-0.88 0.008 
2009*IDU 0.49 0.33-0.71 0.0002 
2010*IDU 0.74 0.50-1.08 0.12 
2011*IDU 1.09 0.71-1.67 0.67 
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Factor AOR 95% CI  P value 
2005*Female heterosexual 1.53 1.22-1.92 0.0002 
2006*Female heterosexual 1.21 0.98-1.50 0.08 
2007*Female heterosexual 1.46 1.18-1.80 0.0004 
2008*Female heterosexual 1.37 1.12-1.68 0.002 
2009*Female heterosexual 1.22 1.00-1.50 0.05 
2010*Female heterosexual 1.40 1.13-1.72 0.0002 
2011*Female heterosexual 2.91 2.35-3.62 <0.0001 
 
1 All models adjusted for age, ethnicity, HIV exposure group, calendar year and HIV infection category 
2 Model 2 includes an interaction between year and black African ethnicity 
3 Model 3 includes and interaction between year and IDU and year and female heterosexual HIV exposure
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Figure 6.7 Modelled probability of having a repeat HBsAg test stratified by those 
demographic factors with significant interactions with calendar year 
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Table 6.15 Adjusted odds ratios for likelihood having repeat test testing for anti-HCV, by year of follow-up 
  AOR  (95% CI) 
 
Year  2004 
 
2005 2006 2007 2008 2009 2010 2011 
Age  <35 
 
1 1 1 1 1 1 1 1 
 35-45 0.96  
(0.85-1.09) 
N/A 0.97  
(0.87-1.07) 
N/A 0.99  
(0.91-1.08) 
1.08  
(1.00-1.18) 
N/A 0.96  
(0.88-1.04) 
 >45 0.92 
(0.80-1.07) 
N/A 0.88  
(0.78-1.00) 
N/A 0.84  
(0.77-0.93) 
0.90  
(0.82-0.99) 
N/A 0.79  
(0.73-0.87) 
Ethnicity White 1 1 1 1 1 1 1 1 
 Black 0.91  
(0.73-1.13) 
0.78  
(0.64-0.95) 
0.60  
(0.50-0.71) 
0.62  
(0.54-0.71) 
0.77  
(0.68-0.87) 
0.67  
(0.60-0.76) 
0.67  
(0.60-0.75) 
0.64  
(0.57-0.71) 
 Other black ethnicity 0.68  
(0.52-0.88) 
0.67  
(0.53-0.85) 
0.54  
(0.44-0.68) 
0.65  
(0.54-0.78) 
0.84  
(0.71-0.99) 
0.78  
(0.67-0.90) 
0.69  
(0.60-0.80) 
0.90  
(0.78-1.04) 
 Other 0.96  
(0.79-1.16) 
0.87  
(0.73-1.03) 
0.93  
(0.81-1.06) 
0.94  
(0.84-1.06) 
0.95  
(0.85-1.06) 
0.99  
(0.89-1.10) 
1.07  
(0.96-1.18) 
1.10 
(0.99-1.22) 
Exposure MSM 1 1 1 1 1 1 1 1 
 IDU 0.68  
(0.39-1.20) 
0.47  
(0.26-0.84) 
0.41  
(0.23-0.70) 
0.69  
(0.43-1.10) 
0.52  
(0.33-0.81) 
0.61  
(0.40-0.95) 
0.75 
 (0.49-1.16) 
0.50  
(0.32-0.78) 
 Male heterosexual 0.36  
(0.29-0.45) 
0.44  
(0.36-0.53) 
0.47  
(0.39-0.55) 
0.51  
(0.45-0.59) 
0.42  
(0.37-0.48) 
0.47  
(0.42-0.53) 
0.39  
(0.34-0.43) 
0.50  
(0.45-0.56) 
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  AOR  (95% CI) 
 
Year  2004 
 
2005 2006 2007 2008 2009 2010 2011 
 Female heterosexual 0.24  
(0.19-0.30) 
0.33  
(0.27-0.40) 
0.31  
(0.27-0.37) 
0.43  
(0.38-0.49) 
0.37  
(0.33-0.42) 
0.43  
(0.38-0.48) 
0.33 
 (0.30-0.37) 
0.37  
(0.33-0.41) 
 Other 0.45  
(0.31-0.66) 
0.51  
(0.36-0.74) 
0.46  
(0.33-0.64) 
0.54 
 (0.42-0.71) 
0.58  
(0.46-0.72) 
0.73  
(0.62-0.86) 
0.90  
(0.78-1.04) 
1.05  
(0.91-1.21) 
HIV infection 
category  
Advanced 0.82 
 (0.68-0.97) 
0.80  
(0.68-0.94) 
0.70 
 (059-0.82) 
0.76  
(0.66-0.88) 
0.83  
(0.72-0.95) 
0.67  
(0.58-0.77) 
0.76  
(0.66-0.88) 
0.76  
(0.64-0.89) 
 Uncontrolled 0.87  
(0.78-0.97) 
0.91  
(0.82-1.00) 
0.88  
(0.80-0.96) 
0.89  
(0.82-0.96) 
0.83  
(0.77-0.90) 
0.88  
(0.81-0.95) 
0.92 
 (0.86-1.00) 
0.96  
(0.89-1.04) 
 Controlled 1 1 1 1 1 1 1 1 
 Unknown 0.88  
(0.60-1.28) 
1.47  
(1.05-2.05) 
1.13  
(0.83-1.55) 
1.61 
 (1.17-2.22) 
1.13  
(0.86-1.50) 
1.37  
(1.00-1.86) 
2.00 
 (1.38-2.92) 
2.22  
(1.29-3.83) 
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Table 6.16 Univariable and multivariable logistic regression of factors associated with repeat anti-HCV testing 
  Univariable analysis Multivariable analysis 
  OR 95% CI P value AOR 95% CI P value 
Age group (years) <35 1 - - 1 - - 
 35-45 1.09 1.04-1.13 <0.0001 0.99 0.95-1.03 0.52 
 >45 
 
1.13 1.08-1.78 <0.0001 0.85 0.82-0.89 <0.0001 
Ethnicity White 1 - - 1 - - 
 Black African 0.33 0.32-0.34 <0.0001 0.67 0.63-0.71 <0.0001 
 Other black 0.54 0.50-0.58 <0.0001 0.73 0.68-0.79 <0.0001 
 Other/unknown 
 
0.87 0.82-0.91 <0.0001 0.98 0.93-1.03 0.50 
HIV exposure group MSM 1 - - 1 - - 
 IDU 0.54 0.44-0.67 <0.0001 0.58 0.47-0.71 <0.0001 
 Male heterosexual 0.37 0.35-0.39 <0.0001 0.45 0.43-0.48 <0.0001 
 Female heterosexual 0.30 0.28-0.31 <0.0001 0.37 0.35-0.38 <0.0001 
 Other/unknown 
 
0.80 0.74-0.87 <0.0001 0.76 0.70-0.83 <0.0001 
HIV infection category Advanced 0.59 0.56-0.63 <0.0001 0.76 0.72-0.81 <0.0001 
 Uncontrolled 0.86 0.84-0.89 <0.0001 0.89 0.86-0.92 <0.0001 
 Controlled 1 - - 1 - - 
 Unknown 
 
1.66 1.45-1.89 <0.0001 1.45 1.27-1.66 <0.0001 
Year  (per year) 1.15 1.14-1.16 <0.0001 1.17 1.16-1.18 <0.0001 
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Table 6.17 Adjusted odd ratios for models predicting likelihood repeat anti-HCV test including interactions between year and demographic variables1 
Factor AOR 95% CI  P value 
Model 1    
Age <35 1 - - 
Age 35-45 years  0.99 0.95-1.03 0.52 
Age >45 years  0.95 0.88-1.02 0.14 
Year 1.18 1.17-1.19 <0.0001 
Year*Age >45 years  0.98 0.96-0.99 0.0003 
Model 2    
White 1 - - 
Black African 0.67 0.64-0.71 <0.0001 
Other black 0.58 0.50-0.67 <0.0001 
Other/unknown ethnicity 0.84 0.75-0.93 0.001 
Year 1.16 1.16-1.17 <0.0001 
Year*Other black 1.05 1.02-1.08 0.0003 
Year* Other/unknown ethnicity 1.04 1.02-1.06 0.0006 
Model 3    
MSM 1 - - 
IDU 0.58 0.47-0.71 <0.0001 
Male heterosexual 0.45 0.43-0.48 <0.0001 
Female heterosexual 0.36 0.34-0.39 <0.0001 
Other 0.40 0.32-0.50 <0.0001 
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Factor AOR 95% CI  P value 
Year 1.17 1.16-1.17 <0.0001 
Year*Other/unknown exposure 1.14 1.09-1.18 <0.0001 
 
1 All models adjusted for age, ethnicity, HIV exposure group, calendar year and HIV infection category 
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Figure 6.8 Changing probability of having a repeat anti-HCV test over time according to 
varying demographic factors 
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6.3.2 Epidemiology of HBV  
6.3.2.1 Cumulative prevalence of HBV 
Of 26377 individuals who had ever had an HBsAg test, 1778 had received at least one positive 
result, a prevalence of 6.7% (95% CI: 6.4-7.0%).  In a sensitivity analysis, when all individuals 
were included in the denominator irrespective of whether they had ever been tested, the 
cumulative prevalence of HBsAg was 5.5% (1778/32079), 95% CI 5.3%-5.8%.  Among 
individuals who were under follow-up in each year and had been tested for HBsAg the 
cumulative prevalence decreased from 8.0% in 2004 to 6.4% in 2011 (Figure 6.9).  Given the 
differences in patterns of testing over time, the cumulative prevalence over time was also 
examined stratified by exposure category, ethnicity, age, CD4 count and HIV viral load.  
Cumulative prevalence decreased for all subgroups of age, and among all ethnicities.  
However, when stratified by HIV exposure category, although the prevalence of HBsAg 
decreased among MSM and male and female heterosexuals, it remained more stable among 
IDU and individuals of other or unknown HIV exposure group, with a slight rise in the period 
2004 to 2006.  From 2004 to 2011 there was a decrease in prevalence among all subgroups 
defined by CD4 count and viral load.  
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Figure 6.9 Cumulative prevalence of HBV infection, by calendar year, stratified by demographic and HIV clinical factors and for the total cohort 
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The baseline characteristics of individuals who ever had a positive HBsAg test result, compared 
with those who never receive a positive result are shown in Table 6.18. 
 
Table 6.18 Baseline characteristics of individuals who have ever had a positive HBsAg test 
compared with those whose test results remain HBsAg-negative throughout their follow-up 
 HBsAg-
positive 
N=1778 
% HBsAg-negative 
N=24589 
% P value 
Median age at first HBsAg  
test (years) (IQR) 
 
36 (31, 42) - 36 (30, 43) - 0.42 
Ethnicity      
White 960 54.0 15181 61.7 <0.0001 
Black African 472 26.5 5320 21.6 
Other black 94 5.3 1230 5.0 
Other/unknown 
 
252 14.2 2868 11.7 
HIV exposure group      
MSM 1031 58.0 14745 60.0 <0.0001 
IDU 79 4.4 661 2.7 
Male heterosexual 309 17.4 2808 11.4 
Female heterosexual 263 14.8 4811 19.6 
Other/unknown 
 
96 5.4 1574 6.4 
Year of first HBsAg test      
<1996 155 8.7 1359 5.5 <0.0001 
1996-1999 143 8.0 1310 5.3 
2000-2004 574 32.3 6519 26.5 
2005-2009 730 41.1 11765 47.9 
2010-2012 
 
176 9.9 3646 14.8 
Median CD4 at first 
HBsAg test (cells/mm3) 
(IQR) 
 
340 (180, 512) - 404 (253, 577) - <0.0001 
Median log HIV viral load 
at first HBsAg test(log10 
copies/ml) (IQR) 
3.6 (1.7, 4.7) - 3.5 (1.7, 4.7) - 0.01 
 
In univariable and multivariable analysis, older individuals were more likely to be HBsAg-
positive (AOR, 95% CI: 1.05, 1.03-1.07 per 10 years).  Compared to MSM, IDU were more likely 
to be HBsAg-positive (AOR, 95% CI: 1.33, 1.19-1.49) as were heterosexual males (AOR, 95% CI: 
1.49, 1.40-1.58).  Female heterosexuals and individuals of other or unknown exposure group 
were less likely than MSM to be HBsAg-positive.  Compared to individuals of white ethnicity 
those of black African, black other and other/unknown ethnicities were all more likely to be 
HBsAg-positive.  Overall, black African ethnicity was the strongest predictor of HBsAg 
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positivity:  AOR 2.33 (95% CI, 2.15-2.52).  Individuals whose HIV infection was classified as 
advanced were more likely than those who had controlled HIV infection to be HBsAg-positive.  
However, those who had unknown or uncontrolled (but not advanced) HIV infection were less 
likely to be HBsAg-positive than those with controlled HIV.  Conversely, those with advanced 
HIV were significantly more likely than those with controlled HIV to be HBsAg-positive (AOR 
1.40, 95% CI: 1.31-1.51) (Table 6.19).  There was a significant interaction detected between 
IDU and year (AOR 1.05, p<0.0001).  This corresponds with the more stable trends in 
prevalence in this group compared to those in other exposure categories, as seen in Figure 6.9.  
However, adjusting for this interaction did not alter the direction or significance of any of the 
other effects.  No other significant interactions between year and demographic factors were 
identified.  
 
6.3.2.2 Resolution of infection versus chronicity 
Of 1778 individuals who had a positive HBsAg result, 384 (21.6%) could not be further 
classified as having chronic infection or resolving infection. Of 1394 individuals who could be 
further classified, 1169 (83.0%) had chronic infection and 225 (16.1%) resolved their infection 
in the 6 months after their first positive result.  In multivariable analysis, individuals of black 
African ethnicity were less likely to resolve infection compared to those of white ethnicity 
(AOR, 95% CI: 0.50, 0.28-0.91).  Although male and female heterosexuals and individuals in 
other or unknown HIV exposure groups were less likely to resolve infection, compared to MSM 
in univariable analysis, these associations were not significant in the multivariable model.   
Being on tenofovir either at time of first positive HBsAg test, or starting tenofovir within 6 
months of first positive HBsAg test, did not appear to be associated with resolving infection in 
univariable analysis and therefore these variables were not entered into the multivariable 
model (Table 6.20).  While HIV infection category at time of first positive HBsAg test was 
associated with resolving infection in univariable analysis, the only association which remained 
in the multivariable model was that between resolving infection and unknown HIV infection 
category. 
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Table 6.19 Univariable and multivariable logistic regressions analysis of time-updated factors associated with HBsAg positivity 
  Univariable analysis Multivariable analysis 
  OR 
 
95%CI P value AOR 
 
95%CI P value 
Age  
 
(per 10 years) 1.08 1.05-1.10 <0.0001 1.05 1.03-1.07 <0.0001 
Exposure MSM 1 - - 1 - - 
 IDU 1.39 1.24-1.55 <0.0001 1.33 1.19-1.49 <0.0001 
 Heterosexual male 1.49 1.40-1.58 <0.0001 0.85 0.79-0.92 <0.0001 
 Heterosexual female 0.71 0.67-0.76 <0.0001 0.39 0.36-0.43 <0.0001 
 Other 
 0.86 0.76-0.96 0.01 0.7 0.62-0.79 <0.0001 
Ethnicity White 1 - - 1 - - 
 Black African 1.37 1.30-1.44 <0.0001 2.33 2.15-2.52 <0.0001 
 Black other 1.3 1.18-1.43 <0.0001 1.65 1.49-1.82 <0.0001 
 Other 
 1.45 1.35-1.55 <0.0001 1.67 1.49-1.82 <0.0001 
Year  
 
(per year) 
0.96 0.95-0.97 <0.0001 0.96 0.95-0.96 <0.0001 
HIV  infection category Advanced 1.55 1.45-1.67 <0.0001 1.4 1.31-1.51 <0.0001 
 Uncontrolled 0.78 0.74-0.82 <0.0001 0.78 0.74-0.82 <0.0001 
 Controlled 1 - - 1 - - 
 Unknown 0.72 0.67-0.78 <0.0001 0.72 0.66-0.78 <0.0001 
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Table 6.20 Univariable and multivariable logistic regression of baseline factors associated with resolving HBV infection 
 HBV infection Univariable analysis Multivariable analysis 
 Resolve 
infection 
% Chronic 
infection 
%  OR 95%CI P value AOR 95%CI P value 
Total 225 16.1 1169 83.9       
Median age (IQR) 37 (30, 43) 36 (31,42) 1.06 0.90-1.26 0.45    
Ethnicity           
White  144 18.0 656 82.0 1 - - 1 - - 
Black African 33 9.9 302 90.2 0.50 0.33-0.74 0.001 0.50 0.28-0.91 0.02 
Other black 12 17.1 58 82.9 0.94 0.49-1.80 0.86 1.01 0.51-1.98 0.99 
Other/unknown 36 19.1 153 81.0 1.07 0.72-1.61 0.73 1.15 0.75-1.75 0.53 
HIV Exposure           
MSM 162 18.2 730 81.8 1 - - 1 - - 
IDU 9 18.0 41 82.0 0.99 0.47-2.08 0.98 1.00 0.47-2.12 0.99 
Heterosexual male 27 12.0 198 88.0 0.61 0.40-0.95 0.03 0.85 0.48-1.50 0.57 
Heterosexual female 20 11.7 151 88.3 0.60 0.36-0.98 0.04 0.92 0.48-1.80 0.80 
Other/unknown 7 12.5 49 87.5 0.64 0.29-1.45 0.29 0.69 0.30-1.61 0.39 
Year of first positive HBsAg            
<1996 24 21.1 90 79.0 1.39 0.84-2.29 0.20 1.25 0.74-2.14 0.41 
1996-1999 32 24.8 97 75.2 1.71 1.09-2.71 0.02 1.64 1.02-2.64 0.04 
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 HBV infection Univariable analysis Multivariable analysis 
 Resolve 
infection 
% Chronic 
infection 
%  OR 95%CI P value AOR 95%CI P value 
2000-2004 62 12.3 442 87.7 0.73 0.52-1.03 0.07 0.71 0.49-1.01 0.05 
2005-2009 93 16.2 483 83.9 1 - - 1 - - 
2010-2012 14 19.7 57 80.3 1.28 0.68-2.38 0.45 1.46 0.77-2.76 0.25 
HIV infection category           
Advanced 54 16.1 282 83.9 1.22 0.81-1.84 0.35 1.54 1.00-2.37 0.05 
Uncontrolled 77 16.5 391 93.6 1.25 0.86-1.83 0.24 1.38 0.93-2.04 0.11 
Controlled 53 13.6 337 86.4 1 - - 1 - - 
Unknown 41 18.6 159 72.3 1.64 1.05-2.57 0.03 1.84 1.16-2.94 0.01 
On tenofovir at first positive 
HBsAg 
          
No 195 16.5 990 83.5 1 - -    
Yes 30 14.4 179 85.7 0.85 0.56-1.29 0.45    
On tenofovir in 6 months 
after first positive HBsAg 
          
No 178 13.2 1169 86.8 1 - -    
Yes 47 19.3 197 80.7 1.30 0.91-1.86 0.15    
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6.3.2.3 Changes over time in HBV infection status 
A total of 28338 individuals who had ever had a test for one of the three HBV markers of 
interest were included in the analysis of trends over time.   Among these individuals the 
prevalence of HBV-infected status increased significantly over time from 3.9% in 2004 to 4.7% 
in 2008 (Chi-squared test for trend p= 0.01).  Similarly, between 2004 and 2011 the proportion 
of individuals with an HBV resolved status increased from 14.3% to 27.4% (p<0.0001), the 
proportion of vaccinated individuals increased from 5.9% to 20.7% (p<0.0001) and the 
proportion of individuals never exposed to HBV increased from 4.6% to 13.2% (p<0.0001).  
Conversely, the proportion of individuals with an unknown HBV status decreased over time 
from 71.3% in 2004 to 34.0% in 2004 (Chi-squared test for trend p<0.0001) (Figure 6.10).   
 
 
 
 
 
 
 
 
 
 
6.3.2.4 Incidence of HBV infection 
Details of individuals selected for inclusion in the analysis are shown in Figure 6.11.  The 2445 
included individuals contributed a total of 8962 person-years of follow-up.  There were a total 
of 104 incident infections among these individuals giving an incidence rate of 1.16 infections 
per 100 person-years of follow-up (95% CI 0.94-1.38).   
Figure 6.10 HBV infection status of individuals in the cohort, 2004-2011 
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In sensitivity analysis 1, where individuals who had a positive anti-HBc or HBsAg after a positive 
anti-HBs were considered to have an incident infection at the point when they became anti-
HBs positive, and in sensitivity analysis 2, where individuals who had a positive HBsAg or anti-
HBc after a positive anti-HBs were considered to be individuals who had been vaccinated but 
had lost immunity the incidence rate increased to 1.35 per 100 person-years.  In sensitivity 
analysis 3 where individuals had to have had a negative anti-HBs or HBsAg to be considered 
susceptible, a total of 3673 individuals were susceptible, of whom 2267 had a further test and 
Figure 6.11 Selection of individuals included in analysis of HBV incidence 
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so were included in the analysis; 98 of these had an incident infection.  Thus, the incident rate 
was increased to 1.18 per 100 person-years of follow-up (Table 6.21). 
 
Table 6.21 Incidence rates of HBV infection calculated with varying methods 
Method of 
calculation 
Events/total person-
years of follow-up 
Incidence rate  
(per 100 person-
years) 
95% CI 
Basic 104/8962 1.16 0.94-1.38 
Sensitivity analysis 1 121/8964 1.35 1.11-1.59 
Sensitivity analysis 2 121/8995 1.35 1.11-1.60 
Sensitivity analysis 3 98/8310 1.18 0.95-1.41 
 
Factors associated with HBV incidence are shown in Table 6.22.  HIV exposure group and HIV 
viral load were the only variables where significant associations were observed.  In 
multivariable analysis, individuals with higher HIV viral loads (>50 copies/ml) were more likely 
to have an incident infection than those with undetectable viral loads (<50 copies/ml) (ARR, 
95% CI: 1.27, 1.09-1.47) and compared to MSM, female heterosexuals were less likely to have 
an incident HBV infection (ARR, 95% CI: 0.33, 0.16-0.65).  There was no effect of age at first 
test, ethnicity, current CD4 count, being on a tenofovir containing HIV antiretroviral regimen, 
or year on the rate of incident infection. 
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Table 6.22 Univariable and multivariable Poisson regression of factors associated with HBV incidence 
  Events / 
person-years 
Incidence 
rate 
Univariable analysis Multivariable analysis 
  RR (95% CI) P value ARR (95% CI) P value 
Age at first test (years) <35 36 / 2913 1.24 1 - - - 
 35-45 35 / 3926 0.89 0.72 (0.45-1.15) 0.17 - - 
 >45 33 / 2124 1.56 1.26 (0.78-2.01) 0.34 - - 
Ethnicity White 64 / 5784 1.11 1 - - - 
 Black African 18 / 1740 1.03 0.93 (0.55-1.58) 0.80 - - 
 Black other 5 / 500 1.00 0.90 (0.36-2.25) 0.83 - - 
 Other/unknown 17 / 938 1.81 1.64 (0.96-2.80) 0.07 - - 
Exposure MSM 75 / 5154 1.46 1 - - - 
 IDU 1 / 198 0.51 0.35 (0.05-2.50) 0.29 0.35 (0.05-2.51) 0.29 
 Male heterosexual 13 / 1267 1.03 0.70 (0.39-1.27) 0.24 0.7 (0.42-1.40) 0.36 
 Female heterosexual 12 / 2010 0.60 0.41 (0.22-0.75) 0.004 0.33 (0.16-0.65) 0.002 
 
Other 3 / 334 0.90 0.62 (0.19-1.96) 0.41 0.44 (0.11-1.79) 0.25 
Current CD4 (cells/mm3) ≤200 9 / 706 1.27 1 - - - 
 201-350 12 / 1747 0.69 0.99 (0.99-1.00) 0.21 - - 
 351-500 27 / 2279 1.18 1.00 (0.99-1.01) 0.83 - - 
 >500 50 / 3659 1.37 1.00 (0.99-1.01) 0.88 - - 
Current viral load  ≤50 53 / 5716 0.93 1 - 1 - 
(copies/ml) >50 44 / 2650 1.66 1.79 (1.20-2.67) 0.004 1.27 (1.09-1.47) 0.002 
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  Events / 
person-years 
Incidence 
rate 
Univariable analysis Multivariable analysis 
  RR (95% CI) P value ARR (95% CI) P value 
On tenofovir Yes 40 / 3839 1.04 0.83 (0.56-1.24) 0.37 - - 
 
No 64 / 5123 1.25 1 - - - 
Year 2004-2005 7 / 921 0.76 1 - - - 
 2006-2007 20 / 2413 0.83 1.09 (0.46-2.58) 0.84 - - 
 2008-2009 44 / 3143 1.40 1.84 (0.83-4.09) 0.13 - - 
 2010-2011 33 / 2485 1.33 1.75 (0.77-3.95) 0.18 - - 
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6.3.3 Epidemiology of HCV 
6.3.3.1 Cumulative prevalence of HCV infection 
Of the 28251 individuals who had ever been tested for anti-HCV or HCV-RNA, 2946 had ever 
had a positive result, a prevalence of 10.4% (95% CI 10.1-10.8%).  In a sensitivity analysis 
where all individuals were included in the denominator, irrespective of whether or not they 
had ever been tested, HCV prevalence was 9.2% (95% CI 8.9-9.5%). 
 
Cumulative prevalence of HCV among individuals under follow-up in each year remained 
relatively stable between 2004 (10.4%, 95% CI 9.7-10.9%) and 2011 (10.0%, 95% CI 9.6-10.4%).  
However, there were some differences in trends when the dataset was stratified by 
demographic and HIV clinical variables (Figure 6.12).  When stratified by age, the cumulative 
prevalence appears to remain stable among those aged <35 years: 7.46% (95% CI: 6.6%-8.4%) 
in 2004 and 6.91% (95% CI: 6.9%-7.6%) in 2011.  Among 35-45 year olds, however, the 
prevalence appears to have decreased over the same time period from 12.6% (95% CI: 11.7%-
13.5%) in 2004 to 10.5% (9.8%-11.1%) in 2011 and among those over the age of 45 the 
prevalence increased from 8.8% in 2004 (95% CI: 7.6%-10.0%) in 2004 to 11.2% (95% CI: 
10.5%-11.9%) in 2011.  When stratified by exposure category the cumulative prevalence of 
HCV was highest among IDU and prevalence in this group remained stable over time: 85.7% 
(95% CI: 82.5%-88.8%) in 2004; and 83.3% (95% CI: 80.1%-86.5%) in 2011.  In contrast, the 
prevalence was much lower in other exposure categories and among MSM the prevalence 
increases among from 7.3% (95% CI: 6.7%-7.9%) in 2004 to 9.9% (95% CI 9.4%-10.4%) in 2011.   
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Figure 6.12 Cumulative prevalence of HCV infection, by calendar year, stratified by demographic and HIV clinical factors and for the total cohort 
  
235 
The baseline characteristics of individuals who had ever had a positive test compared to those 
who have never received a positive test result are shown in Table 6.23.  
 
Table 6.23 Baseline characteristics of individuals who have ever had a positive HCV test and 
those whose test results remain negative throughout their follow-up 
 HCV-positive 
N=2946 
% HCV-negative 
N=25305 
% P value 
Median age at first 
HCV test (years) 
(IQR) 
 
36 
 
(31, 41) 36 (30, 43) <0.0001 
Ethnicity      
White 2398 81.4 14630 57.8 <0.0001 
Black African 159 5.4 6232 24.6 
Other black 69 2.3 1369 5.4 
Other/unknown 
 
320 10.8 3074 12.1 
HIV exposure group      
MSM 1673 56.8 14860 58.7 <0.0001 
IDU 695 23.6 140 0.5 
Male heterosexual 198 6.7 3191 12.6 
Female 
heterosexual 
190 6.4 5516 21.8 
Other/unknown 
 
190 6.4 1598 6.3 
Year of first HCV 
test 
     
<1996 205 7.0 404 1.6 <0.0001 
1996-1999 392 13.3 1842 7.3 
2000-2004 978 33.2 6895 27.2 
2005-2009 1160 39.4 12304 4.9 
2010-2012 
 
211 7.2 3660 14.5 
Median CD4 at first 
HCV test (cell/mm3) 
(IQR) 
 
400 (247, 580) 390 (240, 564) 0.03 
Median log10 viral 
load at first HCV 
test (copies/ml) 
(IQR) 
3.8 (1.7-4.8) 3.7 (1.7, 4.7) 0.0004 
 
Factors associated with ever having had a positive HCV test were investigated using a 
multivariable logistic regression model including calendar year and age, year and HIV infection 
category as time updated covariates (Table 6.24).  Older individuals were more likely to have 
ever had a positive HCV test compared to younger individuals.  Compared to white individuals, 
those of black African ethnicity were significantly less likely to have a positive HCV test (AOR, 
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95% CI: 0.22, 0.20-0.24) as were individuals of other black ethnicities (AOR, 95% CI: 0.34, 0.29-
0.38) and individuals of other or unknown ethnicity (AOR, 95% CI: 0.62, 0.67-0.77).  Injecting 
drug use was the strongest predictor of HCV positivity with an AOR of 55.16, 95% CI 50.63-
60.10, compared to MSM, while male heterosexuals were also more likely than MSM to have a 
positive test (AOR, 95% CI: 1.27, 1.18-1.38).  Calendar year was not significantly associated 
with HCV positivity in univariable analysis and therefore was not entered into the multivariable 
model.  Compared to individuals defined as having controlled HIV infection there was no 
difference in the likelihood of those with uncontrolled HIV infection being HCV-positive.  
However, those with advanced HIV infection were more likely to be HCV-positive (AOR, 95% CI: 
1.25, 1.26-1.35) and those with unknown HIV infection category were less likely to be HCV-
positive (AOR, 95% CI: 0.65, 0.59-0.71). 
 
Given the high prevalence of HCV among IDU (83% were HCV-positive), the model was rerun, 
excluding IDU in order to check that the strong association between injecting drug use and HIV 
infection was not masking any other associations.   The associations between all other 
variables and HCV positivity remained unchanged. However, excluding IDU from the analysis 
introduced a small but statistically significant association between year and HCV positivity 
(AOR 1.03 per later year, 95% CI 1.02-1.04) (Table 6.25). 
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Table 6.24 Univariable and multivariable logistic regression of time updated factors associated with HCV positivity 
  Univariable analysis Multivariable analysis 
  OR 95% CI P value OR 95% CI P value 
Age group <35 1 - - 1 - - 
 35-45 1.64 1.57-1.73 <0.0001 1.45 1.37-1.53 <0.0001 
 >45 
 
1.49 1.41-1.57 <0.0001 1.17 1.10-1.24 <0.0001 
Ethnicity White 1 - - 1 - - 
 Black African 0.17 0.16-0.19 <0.0001 0.22 0.20-0.24 <0.0001 
 Black other 0.3 0.27-0.34 <0.0001 0.34 0.29-0.38 <0.0001 
 Other 
 
0.65 0.61-0.69 <0.0001 0.72 0.67-0.77 <0.0001 
HIV exposure  MSM 1 - - 1 - - 
group IDU 53.89 49.54-58.62 <0.0001 55.16 50.63-60.10 <0.0001 
 Heterosexual male 0.65 0.60-0.70 <0.0001 1.27 1.18-1.38 <0.0001 
 Heterosexual female 0.37 0.35-0.40 <0.0001 0.93 0.86-1.01 0.09 
 Other 
 
1.31 1.20-1.43 <0.0001 1.93 1.76-2.11 <0.0001 
Year (per later year) 
 
1 0.99-1.01 0.91    
HIV infection  Advanced 1.42 1.33-1.51 <0.0001 1.25 1.16-1.35 <0.0001 
category Uncontrolled 0.99 0.95-1.04 0.73 0.99 0.65-1.04 0.80 
 Controlled 1 - - 1 - - 
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Table 6.25 Univariable and multivariable logistic regression of time updated factors associated with HCV positivity, excluding IDU 
  Univariable analysis Multivariable analysis 
  OR 95% CI P value OR 95% CI P value 
Age group  <35 1 - - 1 - - 
(years) 35-45 1.57 1.48-1.65 <0.0001 1.44 1.36-1.52 <0.0001 
 >45 
 
1.42 1.34-1.51 <0.0001 1.14 1.07-1.21 <0.0001 
Ethnicity White 1 - - 1 - - 
 Black African 0.23 0.21-0.25 <0.0001 0.22 0.20-0.24 <0.0001 
 Black other 0.34 0.30-0.39 <0.0001 0.33 0.29-0.38 <0.0001 
 Other 
 
0.71 0.66-0.76 <0.0001 0.7 0.65-0.75 <0.0001 
HIV exposure  MSM 1 - - 1 - - 
group IDU N/A N/A N/A N/A N/A N/A 
 Heterosexual 
male 
0.65 0.60-0.70 <0.0001 1.27 1.17-1.37 <0.0001 
 Heterosexual 
female 
0.37 0.35-0.40 <0.0001 0.92 0.85-1.00 0.06 
 Other 
 
1.31 1.20-1.43 <0.0001 1.87 1.71-2.05 <0.0001 
Year (per year) 
 
1.03 1.02-1.04 <0.0001 1.03 1.02-1.04 <0.0001 
HIV infection  Advanced 1.07 0.99-1.16 0.11 1.28 1.18-1.39 <0.0001 
category Uncontrolled 0.96 0.91-1.00 0.07 1 0.65-1.05 0.9 
 Controlled 1 - - 1 - - 
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6.3.3.2 Active infection 
Of the 2946 individuals who had evidence of HCV infection, 2608 (88.5%) had ever been tested 
for HCV-RNA and 2272 (87.1%) had ever received a positive result indicating active infection.  
The proportion of individuals with active infection in each year is shown in Table 6.26.  The 
prevalence of active infection increased significantly over time between 2004 and 2011 (Chi-
squared test for trend p=0.001).   As a sensitivity analysis the proportion of individuals with 
active infection in each year was recalculated using a less strict definition of active infection.  
In this calculation, prior results were carried forward where no test was conducted within a 
given year. 
 
Table 6.26 Proportion of anti-HCV positive individuals with active infection in each year 
Year Any 
evidence 
of HCV 
infection 
Strict definition of active 
infection 
Relaxed definition of active 
infection 
Tested 
for HCV-
RNA in 
year 
Positive 
HCV-
RNA 
test in 
year 
% Tested for 
HCV-RNA in 
year 
Positive 
HCV-
RNA 
test in 
year 
% 
2004 1072 372 234 62.9 372 234 62.9 
2005 1285 453 292 64.5 614 402 65.5 
2006 1449 436 278 63.8 785 509 64.8 
2007 1659 708 467 66.0 1135 757 66.7 
2008 1892 988 671 67.9 1499 1014 67.7 
2009 2073 1065 730 68.5 1765 1192 67.5 
2010 2182 1058 711 67.2 1919 1271 66.2 
2011 2094 947 671 70.9 1860 1255 67.5 
 
Factors associated with having active HCV infection (using the more strict definition) were 
investigated using logistic regression including calendar year.  Age and HIV infection category 
were time updated at the start of each year.  Generalised estimating equations were used to 
account for the inclusion of repeated tests for each individual.  Results of this analysis are 
shown in Table 6.27.  In univariable analysis, both age and HIV infection category were 
associated with having active infection.  Exposure group, ethnicity and year were not found to 
be associated with having active HCV infection.  When age and HIV infection category were 
entered into a multivariable model, only the association between HIV infection category and 
active HCV infection remained.  Those individuals who had uncontrolled HIV infection were 
significantly more likely to have active infection than those with controlled HIV infection (AOR, 
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95% CI: 1.34, 1.16-1.53) as were those whose HIV infection category was unknown due to 
missing CD4 and viral load measurements (AOR, 95% CI: 2.27, 1.77-2.92). 
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Table 6.27 Univariable and multivariable logistic regressions analysis of factors associated with having active HCV infection 
 Univariable analysis Multivariable analysis 
OR 
 
95% CI P value AOR 
 
95% CI P value 
Age group  <35 1 - - 1 - - 
(years) 35-45 0.76 0.63-0.91 0.003 0.86 0.71-1.03 0. 01 
 >45 
 
0.73 0.59-0.89 0.002 0.86 0.69-1.06 0.16 
Ethnicity White 1 - - 1 - - 
 Black African 0.94 0.62-1.42 0.78    
 Black other 0.96 0.56-1.67 0.90    
 Other 
 
1.16 0.90-1.50 0.26    
Exposure MSM 1 - - 1 - - 
 Heterosexual 
male 
1.14 0.94-1.39 0.19    
 Heterosexual 
female 
1.30 0.90-1.88 0.16    
 Other 
 
1.16 0.90-1.50 0.26    
Year (per year) 
 
0.98 0.95-1.00 0.08    
HIV infection  Advanced 0.96 0.78-1.17 0.68 0.95 0.78-1.17 0.65 
category Uncontrolled 1.36 1.19-1.56 <0.0001 1.34 1.16-1.53 <0.0001 
 Controlled 1 - - 1 - - 
 Unknown 2.34 1.84-2.99 <0.0001 2.27 1.77-2.92 <0.0001 
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6.3.3.3 Acute HCV infection 
Of all individuals who had ever had evidence of HCV infection, 2138 received their first positive 
result at some time after the start of 2004.  1653 individuals had a positive RNA result from 
2004 onwards and 267 had a negative anti-HCV test within the preceding 6 months and could 
therefore be classified as having acute infection.  408 individuals had a diagnosis of acute 
infection mentioned in their clinical notes. Of these 110 had also been defined as acute using 
their serological data.  Combining all this information gave a total of 565 individuals with acute 
HCV infection.  The characteristics of individuals defined as having acute infection are shown in 
Table 6.28. 
 
Table 6.28 Characteristics of individuals defined as having acute HCV infection 
 Total  number 
with active 
infection 
 
Defined as 
acute 
 
 
% 
 
 
 
P value 
Total 1653 565 34%  
Median age at first positive HCV 
test (IQR) 
39 
(34, 44) 
39 
(34, 44) 
- 0.23 
Ethnicity     
White 1355 490 47% 0.0004 
Black African 65 9 1% 
Other black 38 12 9% 
Other/unknown 195 54 3% 
HIV exposure group     
MSM 1140 518 47% <0.0001 
IDU 250 3 1% 
Male heterosexual 105 9 9% 
Female heterosexual 73 2 3% 
Other/unknown 121 33 27% 
Median CD4 at first positive HCV 
test (IQR) 
457 
(320, 626) 
520 
(380, 670) 
- <0.0001 
HIV viral load at first positive HCV 
test 
    
Undetectable  840 306 37% 0.05 
Detectable 813 259 32% 
 
Among the individuals with acute infection, 355 individuals had a single HCV-RNA test while 
210 had a further HCV-RNA test, therefore the course of their infection could be examined.  
145 individuals had a negative HCV-RNA result after their positive.  Of these 63 had a 
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subsequent positive within the six months after the first positive test and therefore their 
negative test result was considered to be a temporary drop in viral load.  Therefore 128 
individuals with an acute infection were considered to have cleared the infection.  Excluding 
those who had any evidence of HCV treatment (97 individuals), there were 31 individuals who 
could be classified as having acute infection which spontaneously resolved (14.8% ,31/210).  
Among those individuals who cleared infection without evidence of treatment the median 
time from first positive RNA test to first subsequent negative test was 5.2 months (IQR 2.6, 
14.2 months).  For 15 individuals the time from first positive HCV-RNA to evidence of cleared 
infection was greater than 6 months.  The majority of individuals who cleared infection were 
white (83.3%), MSM (97%) and had undetectable HIV viral load <50 copies/ml), CD4 count was 
490 cells/mm3 (IQR 340, 665). 
 
6.3.3.4 Incidence of HCV 
A total of 16386 individuals fulfilled the inclusion criteria for analysis of HCV incidence, that is 
they were known to be anti-HCV negative at the start of follow-up, and contributed a total of 
76628 person-years to the analysis.  Of these, 700 individuals had an incident infection during 
follow-up; an incidence of 0.91 per 100 person-years of follow-up.  Overall, incidence appeared 
to remain stable over time: 0.82 per 100 person-years in 2004 (95% CI 0.46-1.36) and 0.88 
(0.71-1.06) in 2011 as shown in Table 6.29.  
 
 244 
 
 
Table 6.29 HCV incidence over time 
Year HCV incidence per 100 person-years (95% CI) 
Total MSM IDU Male 
heterosexual 
Female 
heterosexual 
Other 
exposure 
category 
2004 0.82 
(0.46-1.37) 
1.03  
(0.58-1.70) 
0.00 
(0.00-32.17) 
0.00  
(0.00-2.90) 
0.00 
(0.00-1.87) 
0.00 
(0.00-
17.44) 
2005 1.01 
(0.74-1.28) 
1.22  
(0.89-1.56) 
0.00 
(0.00-11.36) 
0.48 
(0.06-1.74) 
0.15 
(0.00-0.85) 
0.00 
(0.00-4.68) 
2006 0.84  
(0.64-1.04) 
1.02  
(0.77-1.27) 
6.97  
(1.44-20.37) 
0.42 
(0.09-1.23) 
0.00 
(0.00-0.33) 
0.00 
(0.00-2.75) 
2007 1.07 
(0.87-1.28) 
1.38  
(1.11-1.64) 
2.11  
(0.00-11.74) 
0.31 
(0.06-0.91) 
0.13 
(0.02-0.47) 
0.51 
(0.00-2.83) 
2008 0.96  
(0.79-1.13) 
1.21  
(0.98-1.44) 
3.21 
(0.39-11.59) 
0.17 
(0.02-0.61) 
0.10 
(0.01-37) 
1.74 
(0.64-3.79) 
2009 0.88 
(0.72-1.04) 
1.18  
(0.96-1.40) 
0.00 
(0.00-5.84) 
0.15 
(0.02-0.54) 
0.10 
(0.01-0.33) 
0.83 
(0.27-1.93) 
2010 0.83 
(0.68-0.98) 
1.03  
(0.83-1.23) 
0.00 
(0.00-8.20) 
0.22 
(0.04-0.63) 
0.09 
(0.01-0.31) 
1.64  
(0.85-2.87) 
2011 0.89 
(0.71-1.06) 
1.07  
(0.83-1.30) 
0.00 
(0.00-2.90) 
0.57 
(0.21-1.24) 
0.17 
(0.03-0.49) 
1.38 
(0.60-2.73) 
 
 
In multivariable Poisson regression, individuals over 45 years of age were significantly less 
likely than individuals under 35 to have an incident infection (ARR, 95% CI: 0.53, 0.42-0.68).  
Individuals of black African ethnicity were less likely than individuals of white ethnicity to have 
an incident HCV infection (ARR, 95% CI: 0.43, 0.25-0.72) as were individuals of other black 
ethnicities (ARR, 95% CI: 0.62, 0.39-0.98).  Compared to MSM, male and female heterosexuals 
were less likely to have an incident HCV infection: ARR and 95% CIs 0.40, 0.25-0.65 and 0.15, 
0.08-0.28, respectively.  There was no difference in the likelihood of incident infection 
between MSM and IDU (ARR, 95% CI: 0.98, 0.37-2.62) or individuals with other or unknown 
HIV exposure category. Individuals with detectable HIV viral loads were more likely to have an 
incident infection than those with undetectable viral loads (ARR, 95% CI: 1.15, 1.08-1.22).  
There was no effect of year on HCV incidence (Table 6.30). 
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Table 6.30 Univariable and multivariable Poisson regression of factors associated with HCV incidence 
 Events / 
person-years 
Incidence 
rate 
Univariable model Multivariable model   
RR 
(95% CI) 
P value ARR (95% CI) P value 
Age at first test <35 251/23759 1.06 1 - 1 - 
(years) 35-45 335/33566 1.00 0.98 (0.83-1.15) 0.77 0.96 (0.81-1.13) 0.62 
 >45 99/17034 0.58 0.57 (0.45-0.72) <0.0001 0.53 (0.42-0.68) <0.0001 
Ethnicity White 586/51323 1.14 1 - 1 - 
 Black African 22/13137 0.17 0.15 (0.10-0.22) <0.0001 0.43 (0.25-0.72) 0.001 
 Black other 19/3655 0.52 0.46 (0.29-0.71) 0.001 0.62 (0.39-0.98) 0.04 
 Other/unknown 73/8514 0.86 0.75 (0.59-0.96) 0.02 0.82 (0.64-1.06) 0.13 
Exposure MSM 629/54619 1.15 1 - 1 - 
 IDU 6/371 1.62 1.41 (0.63-3.14) 0.46 0.98 (0.37-2.62) 0.97 
 Male heterosexual 21/7185 0.29 0.25 (0.16-0.39) <0.0001 0.40 (0.25-0.65) 0.0002 
 Female heterosexual 12/11764 0.10 0.09 (0.05-0.16) <0.0001 0.15 (0.08-0.28) <0.0001 
 Other 32/2689 1.19 1.03 (0.72-1.47) 0.86 1.07 (0.72-1.58) 0.75 
Current CD4 <200 30/4441 0.68 1 - - - 
(cells/mm3) 201-350 108/13792 0.78 1.00 (1.00-1.00) 0.49 - - 
 351-500 192/20301 0.95 1.00 (1.00-1.00) 0.07 - - 
 >500 340/34791 0.98 1.00 (1-00-1.01) 0.04 - - 
Current HIV viral  <50 406/51065 0.79 1 - 1 - 
load (copies/ml) >50 263/22022 1.19 1.50 (1.29-1.75) <0.0001 1.15 (1.08-1.22) <0.0001 
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 Events / 
person-years 
Incidence 
rate 
Univariable model Multivariable model   
RR 
(95% CI) 
P value ARR (95% CI) P value 
Year 2004-2005 69/7170 0.96 1 - 1 - 
 2006-2007 178/18329 0.97 1.01 (0.76-1.33) 0.95 1.04 (0.78-1.38) 0.81 
 2008-2009 238/25905 0.92 0.95 (0.73-1.25) 0.73 1.05 (0.76-1.34) 0.73 
 2010-2011 215/25224 0.85 0.89 (0.68-1.16) 0.38 1.01 (1.08-1.22) 0.95 
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6.3.3.5 HCV genotypes 
Among 2272 individuals with any evidence of active infection, 1570 (69.1%) had at least one 
genotype reported and 989 had at least one subtype reported.  The most commonly reported 
genotype in this cohort was genotype 1 with subtype “a” predominating (Table 6.31).  A total 
of 197 individuals had more than one genotype reported.  However, only 35 individuals had a 
subsequent genotype which was different to their first reported.  Among individuals where the 
same genotype was reported more than once, 7 individuals had different subtypes reported. 
 
Table 6.31 First reported HCV genotype and subtype among individuals with active HCV 
infection 
Genotype Subtype Number of 
individuals 
% of total 
1 a 525 33.44% 
 b 125 7.96% 
 c 1 0.06% 
 Unknown 423 29.94% 
 Total 1074 68.41% 
2 a 3 0.19% 
 b 17 1.08% 
 c 2 0.13% 
 Unknown 21 1.34% 
 Total 43 2.74% 
3 a 191 12.17% 
 b 1 0.06% 
 Unknown 49 3.12% 
 Total 241 15.35% 
4 a 4 0.25% 
 b 1 0.06% 
 c 1 0.06% 
 d 38 2.42% 
 e 2 0.13% 
 h 2 0.13% 
 Unknown 153 9.75% 
 Total 201 12.80% 
6 Unknown 2 0.13% 
 Total 2 0.13% 
2/3 Unknown 9 0.57% 
 Total 9 0.57% 
 
Subsequent analysis excluded those individuals who were defined as having had reinfection.   
A total of 169 individuals were excluded (128 excluded on the basis of a serological definition, 
24 excluded on the basis of changing genotypes or subtypes, and 17 excluded on the basis of 
serological data combined with genotype data).    
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Genotype 1 was the most common genotype irrespective of year of first positive test.  
However, from 1996 to 2010, the proportion of individuals with genotype 1 increased from 
36.6% to 50.6% while the proportion of individuals with genotype 3 infections decreased from 
17.1% to 9.3% and the proportion of individuals with unknown or other genotypes decreased 
from 39.0% to 32.6%.  When stratified by risk group, the proportion of individuals infected 
with genotype 1 increased among MSM, male and female heterosexuals and individuals of 
other ethnicity while the proportion of IDU infected with genotype 1 remained stable.  
Similarly, while remaining stable among IDU, the proportion of individuals who were infected 
with an unknown or other genotype decreased among MSM, male and female heterosexuals 
and individuals of other/unknown exposure category (Figure 6.13). 
 
The baseline characteristics of individuals with each genotype are shown in Table 6.32.  In 
multinomial regression using genotype 1 as the reference category, exposure category had the 
strongest association with genotype.  IDU and female heterosexuals were more likely than 
MSM to be infected with genotype 2 than genotype 1: AOR and 95% CI: 2.64, 1.14-6.14; and 
4.07, 1.13-14.6, respectively.  IDU and male and female heterosexuals were all more likely than 
MSM to be genotype 3:  AORs and 95% CI 4.1, 2.7-6.1; 9.5, 4.8-18.8; and 5.2, 2.7-10.1 
respectively.  Male heterosexuals were also more likely than MSM to be infected with 
genotype 4 HCV (AOR, 95% CI: 2.71, 1.31-5.60) or have other/unknown genotypes (AOR, 95% 
CI: 1.84, 1.08-1.43).  Year of first positive HCV test was also associated with the likelihood of 
being infected with different genotypes; compared to individuals with a first positive HCV test 
in 2006-2010, individuals whose first positive test was in the period 1996-2000 were more 
likely to be infected with genotype 3 than genotype 1 (AOR, 95% CI: 1.93, 1.04-3.58), as were 
individuals with a first positive HCV test in the period 2001-2005 (AOR, 95% CI: 1.58, 1.02-
2.47).  Individuals in these two groups were also more likely than individuals with a first 
positive test in 2006-2010 to have other or unknown genotypes than genotype 1 (Table 6.33). 
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Figure 6.13 Proportion of individuals infected with each HCV genotype according to year of 
first positive HCV test, stratified by HIV exposure category 
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Table 6.32 Baseline characteristics of individuals infected with different HCV genotypes 
 Genotype 
1 
n (%) 
Genotype 
2 
n (%) 
Genotype 
3 
n (%) 
Genotype 
4 
n (%) 
Other/ 
unknown 
genotype 
n (%) 
P value 
Median age (years) 
 (IQR) 
38 
(33, 43) 
38 
(35, 45) 
36 
(31, 42) 
39 
(35, 44) 
38 
(32, 43) 
0.02 
Median CD4 count 
(cells/mm3) (IQR) 
450 
(310, 610) 
415 
(320, 620) 
390 
(223, 545) 
459 
(302, 627) 
415 
(265, 598) 
0.004 
Log10 HIV viral load 
(copies/ml) (IQR) 
2.1 
(1.7, 4.5) 
2.2 
(1.7, 3.8) 
3.2 
(1.7, 4.5) 
1.7 
(1.7, 4.5) 
3.1 
(1.7, 4.6) 
0.01 
Year of entry into UK 
CHIC 
      
1996-1999 404 (44.4) 20 (2.2) 114 (12.5) 73 (8.3) 296 (35.6) 0.0003 
2000-2004 248 (46.7) 6 (1.1) 37 (7.0) 55 (10.4) 185 (34.8)  
2005-2009 281 (51.4) 12 (2.2) 51 (9.3) 45 (8.2) 158 (28.9)  
2010-2011 44 (37.9) 2 (1.7) 21 (18.1) 9 (7.8) 40 (34.5)  
Ethnicity       
White 834 (47.7) 34 (1.9) 197 (11.3) 142 (8.1) 543 (31.0) <0.0001 
Black African 21 (27.6) 2 (2.6) 1 (1.3) 16 (21.1) 36 (47.4)  
Black other 24 (54.6) 1 (2.3) 3 (6.8) 4 (9.1) 12 (27.3)  
Other/unknown 98 (42.1) 3 (1.3) 22 (9.4) 22 (9.4) 88 (37.8)  
HIV exposure 
category 
      
MSM 659 (52.3) 17 (1.4) 73 (5.8) 114 (9.1) 397 (31.5) <0.0001 
IDU 170 (36.2) 13 (2.8) 96 (20.4) 24 (5.1) 167 (35.5)  
Male heterosexual 39 (30.2) 3 (2.3) 22 (17.1) 18 (14.0) 47 (36.4)  
Female heterosexual 39 (37.5) 4 (3.9) 18 (17.3) 15 (14.4) 28 (26.9)  
Other 70 (50.0) 3 (2.1) 14 (10.0) 13 (9.3) 40 (28.6)  
Year of first positive 
HCV test 
      
<1996 35 (33.0) 4 (3.8) 17 (16.0) 6 (6.6) 43 (40.6) <0.0001 
1996-2000 70 (32.7) 5 (2.3) 39 (18.2) 13 (6.1) 87 (40.7)  
2001-2005 246 (41.5) 10 (1.7) 63 (10.6) 62 (10.5) 212 (35.8)  
2006-2010 520 (53.6) 19 (2.0) 80 (8.2) 86 (8.9) 266 (27.4)  
>2010 106 (48.4) 2 (0.9) 24 (11.0) 16 (7.3) 71 (32.4)  
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Table 6.33 Multinomial logistic regression of factors associated with infection with different 
HCV genotype 
 AOR (95% CI) 
 Genotype 
1 
 
Genotype 2 
 
Genotype 3 
 
Genotype 4 
 
Other/ 
unknown 
genotype 
Age (per 10 years 
older) 
1 1.37 
(0.89-2.10) 
0.90  
(0.72-1.12) 
1.18 
(0.96-1.47) 
1.00 
(0.86-1.14) 
CD4 count (per 100 
cells/mm3 higher) 
1 1.06  
(0.93-1.21) 
0.97 
(0.91-1.04) 
1.06  
(0.99-1.13) 
0.98 
(0.94-1.03) 
Year of entry into UK 
CHIC 
     
1996-1999 1 1 1 1 1 
2000-2004 1 0.67  
(0.24-1.85) 
0.58 
(0.36-0.94) 
1.04  
(0.68-1.60) 
0.92 
(0.70-1.19) 
2005-2009 1 1.03  
(0.39-2.72) 
0.66  
(0.40-1.09) 
0.98 
(0.60-1.61) 
0.99 
(0.73-1.33) 
2010-2011 1 2.10 
(0.38-11.6) 
2.15 
(0.99-4.67) 
1.72  
(0.69-4.28) 
1.82 
(1.06-3.13) 
Ethnicity      
White 1 1 1 1 1 
Black African 1 1.19  
(0.22-6.51) 
- 2.55  
(1.10-5.91) 
2.48 
(1.31-4.69) 
Black other 1 1.11 
(0.14-8.81) 
0.48  
(0.14-1.74) 
0.54  
(0.12-2.37) 
0.96 
(0.48-1.92) 
Other/unknown 1 0.79 
(0.23-2.69) 
0.93  
(0.54-1.59) 
1.41  
(0.84-2.35) 
1.33 
(0.97-1.84) 
HIV exposure 
category 
     
MSM 1 1 1 1 1 
IDU 1 2.64 
(1.14-6.14) 
4.10 
(2.74-6.14) 
0.65 
(0.37-1.15) 
1.08 
(0.81-1.43) 
Male heterosexual 1 4.43 
(1.11-17.60) 
9.53  
(4.84-18.77) 
2.71  
(1.31-5.60) 
1.84 
(1.08-1.43) 
Female heterosexual 1 4.07 
(1.13-14.60) 
5.19  
(2.66-10.14) 
1.40  
(0.65-3.02) 
0.66 
(0.37-1.17) 
Other 1 1.28 
(0.28-5.91) 
1.51  
(0.73-3.16) 
0.86  
(0.41-1.82) 
0.77 
(0.49-1.20) 
Year of first positive 
HCV test 
     
<1996 1 2.43  
(0.51-11.50) 
1.04  
(0.43-2.49) 
1.81 
(0.61-5.39) 
2.13 
(1.16-3.92) 
1996-2000 1 2.14  
(0.62-7.39) 
1.93 
(1.04-3.58) 
1.46 
(0.66-3.21) 
2.57 
(1.68-3.93) 
2001-2005 1 1.05  
(0.41-2.68) 
1.58  
(1.02-2.47) 
1.63  
(1.07-2.49) 
2.27 
(1.75-2.94) 
2006-2010 1 1 1 1 1 
>2010 1 0.43 
(0.09-2.09) 
1.26 
(0.67-2.36) 
0.73 
(0.39-1.39) 
1.13 
(0.79-1.63) 
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6.4 Discussion 
6.4.1 Summary  
In this chapter I have presented the patterns of testing for HBV and HCV, and estimated 
prevalence and incidence of the two infections.  These data show that while a high proportion 
of individuals in the cohort have tested for HBsAg and/or anti-HCV (82.2% and 87.6% 
respectively), the level of annual testing, as recommended in clinical guidelines, remains low.  
While the proportion of individuals ever tested for either infection has increased over time 
among all HIV exposure categories, it appears that the overall change is being driven by an 
increase in testing among MSM.  I also report a decrease over time in the proportion of 
individuals whose HBV status cannot be classified, indicating that either testing or the 
reporting of these tests has increased. 
 
The estimated prevalence of HBV and HCV among individuals who have been tested is 6.7% 
and 10.4% respectively and there is on-going incidence of both infections (estimated at 1.2 per 
100 person-years for HBV and 0.91 per 100 person-years for HCV).  IDU have the highest 
prevalence of both HBV and HCV.  However, this is much more pronounced in HCV where the 
prevalence among IDU is 82.9% compared to 3.3%-10.1% in other risk groups.  By contrast, the 
prevalence of HBV in IDU was 10.7% compared to 5.2%-9.9% in other risk groups.  While the 
cumulative prevalence of HBV has decreased year on year from 2004 to 2011, the cumulative 
prevalence of HCV appears to have remained stable in the cohort over the same time period.  
However, this stable prevalence of HCV in the cohort overall is masking a steady increase in 
prevalence among MSM.  I report a low level of clearance of HBsAg (16.1% with a resolved 
infection status after an infected status) and HCV (16.3% of acute HCV spontaneously 
resolving), indicating a high burden of chronic infections.  A high proportion of individuals 
infected with HCV are shown to have active infection in each year.  This pool of active infection 
is likely contributing to on-going incidence of the infection.  Among individuals with active HCV 
infection genotype 1 is the most common followed by genotype 3.  Genotype 3 was seen more 
commonly among IDU and heterosexuals than among MSM.  
 
6.4.2 Interpretation of results 
6.4.2.1 Patterns of testing 
The significant interactions between time and demographic factors (in particular ethnicity and 
HIV exposure group) in the models of first HBsAg and first anti-HCV test reveal how patterns of 
testing have changed over time.  In earlier years the probability of having a first HBsAg test and 
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that of having a first anti-HCV test was greatest among black African individuals than among 
white individuals. However, the probability of having a first test increased more among white 
individuals so that in later years white individuals had a higher probability of first test.   
Similarly, the probability of having a first HBsAg test and that of having a first anti-HCV test 
increased more among MSM over time than among any other group.   
 
The overall increase in testing, combined with the changes in probability of testing among 
subgroup, may be an indication of less selective testing in more recent years.  While sex 
between men is a known risk factor for HBV infection the majority of reported infections are 
the result of sex between men and women and HBV prevalence is highest among individuals of 
black and minority ethnic groups (83).  The changes in patterns of first HBsAg test among 
subgroups may indicate that clinicians are moving away from targeted testing of black African 
individuals and are beginning to consider sex between men as an increasingly important risk 
factor for infection.  While injecting drug use remains the greatest risk factor for HCV infection 
in the UK, there have been recent outbreaks of HCV infection reported among MSM.  The 
changes in the patterns of a first anti-HCV test may represent a response to these outbreaks of 
HCV infection among MSM.  In models of both first HBsAg and first anti-HCV test, being of 
unknown HIV infection category (i.e. having no data on CD4 count and no data on HIV viral 
load) was a strong predictor of first test.  This may indicate that individuals are being screened 
for hepatitis infection at their first attendance (as recommended by guidelines), prior to the 
results of initial HIV viral load and CD4 tests. 
 
Repeat testing for HBsAg increased over time until 2009 but then declined from 2009 onwards.  
This same pattern was not seen for anti-HCV testing and the reasons for it are unclear.  One 
possibility is that individuals have been defined as eligible for repeat testing when in fact they 
are not.  This may be the case where data on anti-HBs data is missing where individuals may 
have received HBV vaccination and/or are immune.  For these immune individuals, testing for 
HBsAg would be unnecessary.  Stratification by exposure group showed that the increase in 
repeat HBsAg testing (prior to 2009) was greater among MSM than among IDU and greater 
among white individuals than among black Africans.  The patterns were similar to those seen 
for first testing.  However, for repeat anti-HCV testing  fewer interactions between time and 
demographic variables were present, indicating that repeat testing for anti-HCV had increased 
more consistently across subgroups.    
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6.4.2.2 Epidemiology of HBV 
The prevalence of HBV is greatest among those subgroups known to be at highest risk of 
infection in the general population:  IDU and black African individuals.  The associations seen 
between HBV-positivity and HIV infection category are difficult to interpret as temporality 
cannot be assessed.  For example, individuals with uncontrolled HIV infection were 
significantly more likely to be HBsAg-positive than individuals with controlled HIV infection.  
This could be interpreted as HBV infection leading to increased progression of HIV infection, or 
it could be interpreted as uncontrolled HIV infection leading to higher likelihood of acquiring 
HBV.  However, the data within UK CHIC only provides information on the dates that an 
individual was tested and not the true date of infection.  Therefore the causality in either 
direction cannot be ascertained.  Conversely, having advanced HIV infection was associated 
with decreased likelihood of HBsAg positivity.   However, it should be noted that higher HIV 
viral load was also associated with incident HBV infection.  Previous studies have found no 
evidence of the impact of HBV on progression of HIV (258, 302, 303).  
 
The decrease in prevalence over time among all subgroups, with the exception of IDU, may 
represent the success of vaccination for HBV, which is targeted at high risk individuals, 
particularly in sexual health clinics.  Indeed, the proportion of individuals defined as having a 
vaccinated status has increased over time in this cohort.  However, ongoing incidence of HBV 
infection indicates that there remains a need to ensure that all susceptible individuals are 
vaccinated for HBV.  This decrease in prevalence also needs to be interpreted in the context of 
increases in testing.  If the overall increase in testing has led to an increase in the number of 
lower risk individuals being tested, this will, in turn, lead to an increase in the denominator.  If 
the numerator has not increased to the same degree and this would be observed as a decrease 
in prevalence.  Similarly, the incidence of HBV remained steady over the period studied.  
However, if the denominator has increased due to higher rates of testing, but the numerator 
has not increased to the same extent, as a higher proportion of low risk individuals are tested, 
increases in incidence may be masked.   
 
6.4.2.3 Epidemiology of HCV 
While the prevalence of HCV infection is greatest among IDU, the importance of MSM as a risk 
group for HCV was confirmed by the increases in prevalence in this group over time as well as 
the ongoing incidence which is higher in MSM than in any other risk group.  The incidence of 
HCV infection is low among IDU due to the small numbers classified as susceptible to infection.  
Among this group, HCV is usually acquired soon after they start injecting.  In addition, among 
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individuals with active infection, the prevalence of acute infection was highest among MSM.  
This may, in part, be a reflection of the higher levels of testing among MSM in recent years.  
However, it is clear that, in this cohort MSM are at increased risk of HCV infection.  The 
proportion of male heterosexuals who are positive for anti-HCV is lower than the proportion of 
MSM who are positive for anti-HCV and in univariable analysis, male heterosexuals were less 
likely to be HCV-positive than MSM.  However, in multivariable analysis, this association was 
reversed and heterosexual males were more likely to be anti-HCV positive than MSM.  In order 
to investigate the reasons for this, other variables were removed from the model in turn.  This 
process identified that the reversal in the direction of association between anti-HCV positivity 
and heterosexual HIV exposure was due to adjusting for ethnicity.  A possible explanation for 
this is that some males are misclassified as heterosexual where in fact they are MSM or IDU.  If 
this misclassification occurred differentially in particular ethnic groups and those individuals 
who were misclassified were at increased risk of infection, this could result in the association 
of male heterosexual risk with anti-HCV prevalence after ethnicity is added to the model.  For 
example, before adjusting for ethnicity, the effect of heterosexual male group on HCV 
prevalence is predominantly capturing the effect of black African males (who are low risk for 
HCV infection).  However, after adjusting for ethnicity the effect of black African ethnicity on 
risk of HCV is removed and it is possible that the remaining association is now capturing the 
effect of men who are IDU but who are misclassified as heterosexual males.  
 
The process of expanded data collection resulted in ascertainment of HCV genotype for the 
majority of individuals known to have active infection.  In the UK CHIC cohort, there was an 
association between HCV genotype 3 infection and injecting drug use and heterosexual HIV 
exposure groups.  A systematic review of HCV epidemiology across Europe, Canada and Israel 
found that genotype 3 HCV infection was more common in countries where IDU was the main 
reason for HCV infection (123).  In addition several studies have found an association between 
IDU and HCV genotype 3 infection both in the UK (477, 478) and elsewhere in Europe (479, 
480).  Therefore the association of genotype 3 infection with male heterosexual exposure and 
IDU categories supports the theory that some IDU may have been misclassified as male 
heterosexuals.    
 
6.4.3 Comparisons with published literature 
The proportions of individuals tested in these analyses are higher than those previously 
reported for the same cohort (244, 259).  There are a number of possible reasons for this.  
Firstly, the present analyses were limited to patients who have been followed since 2004 
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onwards.  Patients who died or who were lost to follow-up in earlier years may have been less 
likely to have had a hepatitis test and therefore excluding these individuals from our analysis 
would lead to an increase in the estimated proportion tested.  Secondly, the expanded 
hepatitis data collection included supplementing the existing serology data where additional 
information was contained within the clinical notes, therefore further tests may have been 
added.  Finally, it is possible that individuals who attended centres not included in this analysis, 
which were included in the previous analyses, are less likely to have tested.   A 2009-2010 
BHIVA audit of 140 sites providing HIV care reported that only 71% of centres tested annually 
for HBsAg or anti-HBc and only 66% of centres tested annually for anti-HCV (481). 
 
In these analyses the prevalence of HBsAg is consistent with that reported by Price et al (259).  
The prevalence of HCV is greater than that reported by Turner et al (244).  There are a number 
of possible reasons for this.  Firstly there may be difference in the clinic populations included in 
each analysis.  Turner et al included all data in UK CHIC from 1996-2007, by contrast I have 
presented data from 11 selected centres from 2004 onwards.  As previously shown (Chapter 3, 
section 3.2.6), the cohort of individuals included in the analyses presented in this chapter has a 
higher proportion of males, a higher proportion of MSM and a higher proportion of white 
individuals.  Secondly, the difference in the prevalence of HCV presented in this chapter and 
that presented by Turner et al may be due to improved data quality, in particular in the 
reporting of HCV-RNA testing.  In order to assess prevalence of HCV infection in the analyses 
presented in this chapter, both anti-HVC and HCV-RNA tests were used.  Therefore those 
individuals who had been diagnosed with acute HCV infection (HCV-RNA positive and anti-HCV 
negative or missing) were included.  This had not been possible in the previous analysis since 
the numbers tested for HCV-RNA were small.  Finally, the higher prevalence of HCV seen in the 
present analysis compared to the analysis by Turner et al (244), may also be due to the impact 
of increased transmission of HCV among MSM which has been reported elsewhere (234, 235, 
238).  My estimates of prevalence are lower than those seen in many cohorts in other 
countries (Chapter 2 Table 2.1).  This is likely due to the lower number of individuals in UK CHIC 
who acquired their HIV infection through injecting drug use.  
 
The analysis presented in this chapter resulted in a lower incidence of HBV than previously 
reported by Price et al (259).  The improvement in data as a result of the data collection 
process may have increased the proportion of individuals who could be classified as 
susceptible but who did not become infected, which may have resulted in a lower incidence.  
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Alternatively, it may be that there has been a decrease in incidence since the earlier years 
which were included in the analysis by Price et al but were excluded from my own analysis.  
This is the first estimate of HCV incidence in a large cohort of HIV-positive individuals in the UK.  
However, the finding that HCV incidence is significantly lower among heterosexuals compared 
to MSM is in agreement with other published work reporting incidence (235, 482-484) and 
outbreaks of HCV among HIV-positive MSM (232-234). 
 
6.4.4 Strengths and weaknesses 
These analyses are based on a large cohort of HIV-positive individuals attending a variety of 
centres across England and Scotland.  The process of expanded data collection for hepatitis co-
infected individuals has resulted in an increase in the volume of serological data for those 
individuals who have co-infection.  However, I report that more than 20% of individuals are 
without any reported HBsAg tests and 12% do not have any tests for anti-HCV reported.  It was 
not within the scope of the data collection process to review the testing history of all HIV-
positive individuals at each centre and therefore it is possible that there are still missing data 
for some individuals who are not thought to be co-infected based on currently available data.  
This missing data may affect estimates of prevalence and incidence of HBV and HCV co-
infection.  However, the sensitivity analyses described in this chapter indicate that even with 
missing data included the estimates would not change substantially.  Since these data are 
based on laboratory testing and individuals may be seen at more than one centre (including 
centres which do not contribute to UK CHIC) it is possible that individuals may have additional 
tests performed elsewhere and if the centre where the test was conducted is not part of UK 
CHIC we would be unaware of the test or the results. 
 
As discussed previously (Chapter 5, section 5.4.3), the data on anti-HBs tests are lacking and 
therefore ascertainment of an individual’s vaccine induced immunity is limited.  This missing 
data may affect the number of individuals who can be defined as susceptible and are therefore 
included in the analysis of HBV incidence.  Further work is required to improve the quality of 
data for those individuals who are not co-infected, in particular to gather data on anti-HBs 
tests so that vaccination status can be assessed. 
 
Individual’s testing patterns, in part, depend on their attendance patterns at a centre and, in 
part, on the practices within a centre.  If an individual attends infrequently, there is less 
opportunity for them to be tested regularly for hepatitis infection. The UK CHIC data set does 
currently not include a variable which measures frequency of attendance.  Therefore it was not 
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possible to include this in the analysis.  Work in ongoing as part of another UK CHIC project, 
the REACH study, to develop methods for assessing frequency of attendance.   Once this work 
is complete it would be useful to include a measure of attendance in the analyses of repeat 
testing since frequency of attendance impacts the number of opportunities which an individual 
has to test. 
 
Independently of an individual’s attendance pattern, some clinicians may choose to offer tests 
less or more regularly depending how “at-risk” they perceive an individual to be.  These 
differences in testing, in combination with movement between clinics that do not contribute 
to UK CHIC, mean that it is not possible to ascertain the date on which an individual became 
infected with HBV or HCV.  While it was possible to define acute HCV infection where an 
individual had a negative test in the preceding 6 months before their first positive, this 
resulted in small numbers of individuals being identified as having acute infection.  In addition I 
have shown that a high proportion of individuals with HBV have chronic infection.  However 
this should not be an estimate of the proportion of individuals who progress from acute to 
chronic infection since it is possible that these individuals were already chronically infected 
before the first positive result appears in the UK CHIC dataset. 
 
Individuals in UK CHIC are assigned to only one HIV exposure category.  The expanded data 
collection aimed to collect information on whether an individual had ever injected drugs as 
well as their sexual orientation at the time of hepatitis acquisition or diagnosis for those 
individuals who were co-infected.  However, as these data were only collected for those 
individuals who were co-infected it is not possible to include it in analyses of prevalence or 
incidence.  It is therefore possible that some individuals who are recorded in UK CHIC as having 
acquired their HIV infection through sex between men or through heterosexual sex do, in fact, 
have a history of injecting drug use which may or may put them at additional risk of acquiring 
hepatitis.   
 
In UK CHIC an individual’s ethnicity is recorded rather than their country of birth.  This is due to 
the recognition that black African ethnicity is a risk factor for HIV infection.  However, in the 
case of HBV infection, ethnicity may be less important than country of birth since country of 
birth is a major risk factor for acquiring HBV through vertical transmission and therefore is also 
a major risk factor for developing chronic HBV infection.  Therefore in the epidemiology of HBV 
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infection country of birth information could lead to a more in depth understanding of the 
patterns of infection.  However, we were unable to examine this using the UK CHIC dataset. 
 
In the analysis of genotypes individuals were excluded where they were defined as having had 
a possible reinfection since it was not possible to assign the genotype to the correct infection.  
However, the definition used to define reinfection was broad since information on treatment 
was not included in this analysis.  The definition of 6 months of negative results followed by a 
positive result may include some individuals who have 6 months of negative results while on 
treatment but who rebound when treatment ceases.  Therefore the number of individuals 
here does not represent an accurate description of the proportion of individuals who are re-
infected.  In order to examine reinfection in detail, further analysis, including outcomes of 
treatment, would be necessary.  However, this definition was chosen to be inclusive and 
therefore exclude all possible situations where a reinfection may be the case.  The possible 
over-estimation of the number of individuals with a reinfection may reduce the number of 
individuals included further than is necessary and therefore, reduce the power of the analysis.  
However, this over estimation should not introduce any bias into the analysis as there is no 
reason to believe that the any genotype would be more likely to be excluded on this basis than 
any other. 
 
6.4.5 Conclusions 
While the prevalence of HBV and HCV is lower among this UK cohort than seen in other 
countries, there are still more than 3000 individuals with some evidence of hepatitis co-
infection.  Within clinics, in the context of high levels of HIV viral load suppression, the care of 
individuals with hepatitis co-infection represents a substantial proportion of the workload.  
The ongoing incidence, particularly of HCV among MSM, emphasises the importance of 
prevention.  While the majority of individuals in this cohort have been tested for HBV or HCV 
at least once the rates of annual testing are low.  Testing for HBV and HCV not only provides 
access to appropriate treatment for those who are diagnosed, but can also be the gateway to 
vaccination for those who are not immune to HBV and facilitates discussion about practices to 
reduce the risk of acquiring HCV.   
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Chapter 7 Results 2:  HCV treatment strategies and outcomes 
 
7.1 Background 
In the absence of HCV treatment ~85% of individuals infected with HCV will go on to develop 
chronic infection (326).  Compared to HCV mono-infected individuals, HIV/HCV co-infected 
individuals have accelerated progression of liver disease (332) and increased risk of HCC (335) 
and mortality (252, 291).  Therefore the provision of successful treatment for HCV is important 
in improving clinical outcomes for co-infected individuals.  
 
Until recently, standard treatment for HCV has been a combination of pegylated-interferon 
and ribavirin (204).  Treatment for HCV with this combination of drugs is long (usually 48 
weeks), requires weekly injections and can induce side effects which make it difficult to 
continue with treatment such as anaemia, neutropenia and severe depression (485, 486). 
Therefore, while there is substantial evidence for the efficacy of pegylated-interferon and 
ribavirin treatment in HIV co-infected individuals from clinical trials, the long duration of 
treatment and the potential for side effects and adverse events while on treatment means 
that, in practice, individuals may not complete courses of treatment, may have treatment 
breaks or may be considered ineligible for treatment due to co-existing physical or mental 
health conditions (186, 487-489).   
 
The aim of HCV treatment is an SVR, defined as a negative HCV-RNA test 6 months after 
treatment has ceased.  Among HIV/HCV co-infected individuals, achievement of an SVR is 
associated with a reduction in the risk of liver-related events such as death, HCC, 
decompensation and transplant (490) and it may reverse the fibrosis and cirrhosis caused by 
HCV infection (404).  The overall proportion of HIV/HCV co-infected individuals who achieve 
SVR to pegylated-interferon with ribavirin treatment has been estimated as 37% in clinical 
trials (393) and 38% in cohort studies (401).  However, it has not been estimated within an 
HIV-positive cohort in the UK.   
 
In clinical trials of pegylated-interferon and ribavirin treatment among HIV/HCV co-infected 
individuals independent predictors of SVR which have been identified are HCV genotype 
(genotypes 1 and 4 are significantly less likely to achieve SVR than individuals infected with 
genotype 2 or 3), lower baseline HCV viral load male gender and younger age (<40 years old)  
(395-399). The effects of HCV genotype and baseline HCV viral load on the likelihood of 
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achieving SVR have also been observed in cohort studies (401, 491-494).  In addition, some 
smaller cohort studies have also suggested that CD4 count and the degree of liver fibrosis at 
the start of treatment may predict SVR among HIV-positive individuals (177, 492, 495-498).  
However, these findings have not been confirmed in larger studies.   
 
In 2011, the first anti-HCV DAAs were approved for use in the USA and Europe.  Since then 
numerous other DAAs have entered into trials including both HCV mono-infected and HIV/HCV 
co-infected individuals (154).  In the UK, since 2013, recommended therapy for HCV genotype 
1 infection in HIV co-infected patients has been triple therapy with pegylated-interferon, 
ribavirin and either telaprevir or boceprevir (65).  For infection with HCV genotype 2 or 3, the 
standard treatment regimen remained dual therapy pegylated-interferon and ribavirin for 48 
weeks.  In individuals without cirrhosis who have a rapid virological response, treatment could 
be shortened to 24 weeks.  Similarly, pegylated-interferon and ribavirin remained standard of 
care for those with genotype 4 infection.  Treatment of genotype 4 HCV infection should be for 
a total of 48 weeks but can be stopped at 12 weeks if HCV-RNA remains detectable as SVR is, 
therefore, unlikely (65).  
 
The landscape of HCV treatment is changing fast. In 2014, three additional DAAs were licensed 
for use in Europe.  The most recent guidelines from the European Association for the study of 
the liver include recommendations for treatment combinations which are interferon-free.  
However, access to these newer drugs is still not universal (499).  Therefore, among individuals 
with minimal liver damage as a result of HCV infection, deferral of treatment may be 
considered (500).  In the context of the development of new treatments, there is a need to 
understand current HCV treatment patterns and responses among HIV co-infected individuals 
in the UK.  This will assist in planning within services who will deliver treatment by helping to 
identify those individuals who are most at need of new treatment strategies.
 262 
 
7.2 Methods 
7.2.1 Inclusion criteria 
Anti-HCV and HCV-RNA test results were cleaned as previously described (Chapter 5).  All 
analyses presented here included only those individuals who had ever received a positive RNA 
test result before the end of follow-up. 
 
7.2.2 Hepatitis treatment data cleaning 
The treatment data for individuals who were known to be co-infected with HCV were 
examined for missing information.  There were 48 individuals who had documented treatment 
but had no start or stop dates for this treatment.  The complete treatment record for these 
individuals was examined and the start and stop dates were updated for one individual 
according to information available in the treatment notes.  No information was available for 
the other 47 individuals preventing the dates from being updated.   
 
There were 54 individuals who had a date of stopping treatment but for whom date of starting 
treatment was missing.   The complete records of these individuals were examined.  Where 
there was information in the free text treatment notes or in the reason for stopping which 
indicated that the individual had not received a complete course of treatment the start date 
was not updated and remained blank (7 individuals).  Where there was information available 
within the treatment notes which indicated a treatment start date, the start dates were 
updated accordingly (4 individuals).  Where there was no evidence of early termination of 
treatment the treatment period was assumed to be 48 weeks and therefore the treatment 
start date was imputed as 48 weeks prior to the treatment stop date (43 individuals). 
 
There were 158 individuals who had a date of starting treatment available but who had 
missing dates for stopping treatment.  The complete records of these individuals were 
examined.  Of all individuals with missing treatment stop dates, 64 individuals started their 
treatment after 1st January 2012.  For these individuals the treatment stop date was left blank 
as they may still have been completing treatment at the time of data collection.  Six individuals 
had information in their treatment records which indicated that they had stopped but no date 
for stopping was available, therefore the stop date was left blank.  Three individuals did not 
have their stop dates updated as there was further information within the treatment notes 
which implied that they did not complete treatment.  For 92 individuals, where there was no 
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indication that they had stopped treatment early, the treatment stop date was imputed as 48 
weeks after the start date.  
 
The data were then examined to identify situations where there seemed to be multiple 
records of treatment which, in fact, formed part of the same treatment episode.  Where an 
episode of treatment fell entirely within another episode of treatment with the same drug, 
that episode was removed.  Where there were multiple entries for the same drug within an 
individual record, with different start dates but the same stop dates, the latest start date was 
removed.  Where there were multiple entries for the same drug within an individual’s record, 
with the same start dates but different stop dates, the earliest stop date was removed.  Where 
there were multiple episodes of the same drug which were overlapping, these episodes were 
combined to form one episode of treatment including the earliest start date and the latest 
stop date.  Examples of these situations are shown in Table 7.1. 
 
Table 7.1 Examples of amendments made to hepatitis drug start and stop dates 
Description of data 
 
Record 1 Record 2 Final record 
One episode of treatment falls 
entirely within another episode of 
treatment with the same drug 
Drug start date: 
01/03/2007 
 
Drug Stop date: 
31/01/2008 
Drug start date: 
01/05/2007 
 
Drug Stop date: 
31/07/2007 
 
Drug start date: 
01/03/2007 
 
Drug Stop date: 
31/01/2008 
Multiple entries for same drug with 
different start date and same stop 
dates 
Drug start date: 
01/03/2007 
 
Drug Stop date: 
31/01/2008 
Drug start date: 
09/02/2007 
 
Drug Stop date: 
31/01/2008 
Drug start date: 
01/03/2007 
 
Drug Stop date: 
31/01/2008 
Multiple entries for same drug with 
same start date and different stop 
dates 
Drug start date: 
01/03/2007 
 
Drug Stop date: 
28/11/2007 
Drug start date: 
01/03/2007 
 
Drug Stop date: 
31/01/2008 
Drug start date: 
01/03/2007 
 
Drug Stop date: 
31/01/2008 
Multiple entries for same drug 
dates which overlap 
Drug start date: 
01/03/2007 
 
Drug Stop date: 
31/01/2008 
Drug start date: 
04/05/2007 
 
Drug Stop date: 
03/04/2008 
Drug start date: 
01/03/2007 
 
Drug Stop date: 
03/04/2008 
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Dates of starting and stopping each drug were used to define a course of treatment.  Where 
start dates and stop dates were the same or overlapping for more than one drug this was 
considered as a single course of treatment.  Where the date of starting a drug was after the 
date of stopping any other drugs, this was considered a subsequent course of treatment.  
Drugs used within each episode of treatment were summarised.  A total of 14 different drug 
regimens were recorded in the dataset.   Where a combination of drugs was recorded which 
was not clinically plausible, this combination was amended to the combination most similar 
which would be likely to be used in clinical practice.  After making these amendments only 9 
different regimens were identified (Table 7.2). 
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Table 7.2 Amending HCV drug combinations recorded in dataset 
Treatment Regimen recorded in dataset 
 
Amendment made Justification 
No treatment No amendment Individuals not treated 
Pegylated-interferon alone No amendment May be used to treat acute infection 
Interferon alone If start date >2001 amend to pegylated-interferon  
 
 
 
 
If start date <2001 do not amend 
Monotherapy may be used to treat acute infection.   
 
From 2001 onwards most interferon treatment would 
utilise pegylated-interferon  
 
Prior to 2001 some non-pegylated-interferon may have 
been in use 
Pegylated-interferon + Ribavirin No amendment Standard of care for all HCV until 2013   
 
Remains standard of care for acute HCV of all genotypes 
and chronic HCV infection with all genotypes other than 
genotype 1 
  
 
2
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Treatment Regimen recorded in dataset 
 
Amendment made Justification 
Interferon + Ribavirin If start date >2001 amend to Pegylated-interferon + 
Ribavirin 
 
If start date <2001 do not amend 
From 2001 onwards most interferon treatment would 
utilise pegylated-interferon 
 
Prior to 2001 some non-pegylated-interferon may have 
been in use 
Ribavirin alone If start date >2001 amend to Pegylated-interferon + 
Ribavirin 
 
 
If start date <2001 amend to  Interferon + Ribavirin 
Ribavirin alone has never been used as treatment for 
HCV and from 2001 onward all interferon used was 
pegylated 
 
Ribavirin has never been used as a sole treatment prior 
to 2001 interferon used was non-pegylated  
Pegylated-interferon + Ribavirin + interferon If start date >2001 amend to Pegylated-interferon + 
Ribavirin 
 
If start date <2001 amend to  interferon + Ribavirin 
From 2001 onwards most interferon treatment would 
utilise pegylated-interferon 
 
Prior to 2001 some non-pegylated-interferon may have 
been in use 
Pegylated-interferon + Ribavirin + Telaprevir No amendment Individuals in trials or on newer recommended 
treatments 
Pegylated-interferon + Ribavirin + 
Boceprevir 
No amendment Individuals in trials or on newer recommended 
treatments 
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Treatment Regimen recorded in dataset 
 
Amendment made Justification 
Pegylated-interferon + Ribavirin + 
unknown/other  DAA 
No amendment Individuals treated with new regimens 
Ribavirin + Telaprevir Add Pegylated-interferon  Telaprevir only licensed for use in triple therapy 
Ribavirin + Sofosbuvir No amendment Possible trial use 
Ribavirin + Boceprevir Add Pegylated-interferon + Ribavirin Boceprevir only licensed for use in triple therapy 
Telaprevir alone Add Pegylated-interferon + Ribavirin Telaprevir only licensed for use in triple therapy 
Sofosbuvir alone No amendment Possible trial use 
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7.2.3 Factors associated with starting HCV treatment 
Individuals were excluded from the analysis if the date of starting treatment was unknown, if 
the date of starting treatment was before the date of the first positive HCV-RNA test result, or 
if the date of starting treatment was before the date of entry into UK CHIC.  Baseline 
characteristics of individuals who started treatment and those who did not were compared. 
 
Individuals were followed-up from either their entry into UK CHIC or their first positive HCV 
test (anti-HCV or HCV-RNA), whichever occurred later, until their last date of follow-up or until 
they started treatment.  Individuals’ follow-up was censored if they showed evidence of 
clearing the infection without evidence of treatment.  A further group of individuals whose 
date of starting follow-up and date of stopping follow-up were the same (i.e. they had a total 
follow-up time of 0 days) were excluded from the analysis. 
 
Time from first positive HCV test to starting treatment was described using the Kaplan Meier 
method.  Cox regression was used to identify demographic and HIV-related clinical factors 
which may be associated with starting HCV treatment.  CD4 and HIV viral load were time 
updated in the model and other variables were fixed at the time of first positive test result.  
The final model was adjusted for age, HIV exposure group, year of first positive HCV test, 
current CD4, current viral load and whether an individual was diagnosed with acute HCV 
infection.  
 
7.2.4 Characteristics of treatment episodes 
For further analyses, each individual episode of treatment was included separately.  Four 
episodes of treatment were recorded as having a duration of zero days.  These episodes of 
treatment were excluded from further analyses.  Median time on each treatment for each 
episode was calculated and the differences tested for significance using a Wilcoxon rank sum 
test.    
 
Time spent on treatment was rounded to the nearest week.  A standard course of treatment 
was considered to be 48 weeks.  However, some recorded dates of starting and stopping 
treatment may have been estimated from data which was available in clinical notes.  Therefore 
the definition of a standard course of treatment was extended to include individuals who were 
recorded as having received between 44 and 52 weeks of treatment.  Recorded reasons for 
stopping treatment were investigated among episodes of treatment which were defined as 
having stopped prematurely (stopped at less than 44 weeks). 
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7.2.5 Defining serological response to HCV treatment 
Analysis of response to treatment excluded those episodes of treatment which included new 
DAAs.  The response of individuals to these newer hepatitis treatment regimens is beyond the 
scope of this thesis as there has not been sufficient follow-up time of individuals on these 
drugs as part of normal clinical practice and most individuals recorded as being on regimens 
including DAAs will have been participants in clinical trials.  Treatment episodes were included 
in the analysis if they had start and stop dates available and if there was at least one HCV-RNA 
test result available after stopping treatment. 
 
To examine the potential for investigating end of treatment (EOT) response using the 
serological data in this cohort, the time from stopping treatment to first RNA test result was 
examined.  Since exact stop dates were may have been estimated during the data collection 
process the first HCV-RNA tests results in the period one month before stopping treatment, 
and before starting any subsequent episodes of treatment, were used (Table 7.3).  Similarly, to 
investigate the potential for examining SVR using the serological data in this in this cohort the 
first test result at 6 months or more after stopping treatment was identified and the time from 
stopping treatment to this test was calculated (Table 7.4). 
 
Table 7.3 First HCV-RNA test results after stopping treatment and before starting any 
subsequent episodes of treatment 
Time to first test 
result after 
stopping 
treatment 
Total Number 
positive 
% Number 
negative 
% 
≤1 week 223 19 15.5 104 84.6 
1 week- 1 month 85 12 14.1 73 85.9 
1-3 months 106 37 34.9 69 65.1 
3-6 months 57 23 40.4 34 59.7 
>6 months 124 73 58.9 51 41.1 
Total 495 164 33.1 331 66.9 
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Table 7.4 First HCV-RNA test results 6 months or more after stopping treatment and before 
starting any subsequent episodes of treatment 
Time from 6 months 
post stopping 
treatment to next 
HCV-RNA test result  
Total Number 
positive 
% Number 
negative 
% 
0 days 1 0 0.0 1 100.0 
1 week-1 month 20 3 15.0 17 85.0 
1-3 months 161 44 27.3 117 72.7 
3-6 months 46 14 30.4 32 69.6 
>6 months 171 92 50.8 79 46.2 
Total 399 153 38.4 246 61.7 
 
Given that there are variable times between stopping treatment and follow-up tests in this 
cohort and that the dates for some episodes of treatment were estimated, EOT response and 
SVR could not be accurately determined using the generally adopted definitions.  Therefore, an 
initial treatment response period was defined as the period from one month before stopping 
treatment to 6 months after stopping treatment.  Individuals whose first test result in this time 
period was negative were defined as having a successful initial treatment response.  Those 
individuals whose first result in the initial response period was positive were considered to 
have failed treatment in the initial treatment response period. 
 
Where an individual with a negative result in the initial response period had a further negative 
test result beyond the 6 month cut off, with no intervening positive test results, it was 
assumed that this individual had in fact had a long term response to treatment and therefore 
the outcome of treatment was successful.  Where an individual with a negative result in the 
initial response period had no further test results after the initial treatment response, it was 
not possible to determine the long term treatment response.  Where an individual had a 
negative result in the initial treatment response period and their subsequent result was 
outside of the 6 month cut-off but was positive, it was not possible to ascertain whether this 
positive result was due to reinfection or treatment failure. 
 
Among those individuals who had a successful initial treatment response, long term treatment 
response (LTR) was defined in a variety of ways: 
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Method 1:  LTR was defined using the first follow-up test result at least 6 months after 
stopping treatment as long as this was no more than 6 months after the date of the test used 
to define initial treatment response.   
 
Method2:  LTR was defined as a negative follow-up test which was at least 6 months after 
stopping treatment but no more than 1 year after the initial treatment response.   
 
Method 3:  LTR was defined on the basis of the first follow-up test which occurred at least 6 
months after stopping treatment and no time limit was included (i.e. all positive results are 
treated as treatment failures), irrespective of time. 
 
Method 4:  Individuals were defined as having a negative LTR if the follow-up test result was 
negative, irrespective of time.  For those individuals where the follow-up test was positive, 
those who had changing genotypes were considered to have been re-infected and those who 
did not have changing genotypes were considered to have failed treatment. 
 
Characteristics of individuals with successful LTR as defined using each of the methods were 
described.   
 
7.2.6 Factors associated with treatment failure 
In order to assess factors associated with treatment failure only those individuals who had an 
HCV-RNA test result in the first year after stopping treatment were included in the analysis.  
Individuals were followed from the date of stopping treatment for one year or until their last 
seen date (whichever was first).  Any positive HCV-RNA test result in the follow-up period was 
considered as treatment failure.  Follow-up was censored if there was evidence of a 
subsequent episode of treatment within a year of stopping treatment, even if there was no 
evidence of a positive result and these individuals were considered to have failed treatment.   
 
Cox regression was used to identify individual-level, HIV-related and HCV-related factors which 
may be associated with treatment failure.  CD4 count, HIV viral load were included as time 
updated covariates.  A high proportion of individuals had missing HCV viral loads at baseline, 
and therefore when HCV viral load was included in the final model many associations were 
non-significant due to the small numbers.  A sensitivity analysis was conducted where baseline 
viral load included any HCV viral load test which was conducted in the 6 months prior to 
starting HCV treatment or the month after starting treatment.  If more than one result was 
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available in this time period, the result closest in time to the date of starting treatment was 
used. 
 
7.2.7 Characteristics of individuals in need of treatment 
To describe the characteristics of individuals who needed treatment, a cohort of individuals 
who had either never received treatment, or who had failed their first episode of treatment 
was identified.  Although some individuals who have failed their first episode of treatment may 
have had a successful subsequent episode of treatment, this was not considered as they would 
have benefited from newer, more effective treatment options.   The liver disease in these 
individuals was assessed using three methods:  biopsy results, APRI score and FibroScan® 
results.  APRI score was calculated using the formula:  100*(AST/upper limit of 
normal)/Platelets (211).  For the purpose of this analysis the upper limit of normal for AST was 
taken as 30IU/L.
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7.3 Results 
7.3.1 HCV treatment regimens 
Of 2272 individuals who ever had a positive HCV-RNA test, a total of 929 (40.9%) had evidence 
of receiving treatment for HCV.  The majority of treated individuals (n=815) received only one 
course of treatment, but 100 individuals received 2 courses of treatment and 14 individuals 
received three courses of treatment.  Treatment regimens used are shown in Table 7.5.  
 
Table 7.5 Episode of treatment and drugs included as part of treatment regimen 
 
7.3.2 Factors associated with starting HCV treatment 
Excluding 49 individuals whose date of starting first episode of treatment was unknown, 58 
individuals who started HCV treatment before their first positive test recorded in the dataset 
and 2 individuals whose first treatment was before entry into the cohort,  2163 individuals 
were included in the analysis, of whom 37.9% (820/2163) received any HCV treatment.  The 
baseline characteristics of these individuals are shown in Table 7.6.  Among the individuals 
who started treatment, the median time between first positive test and starting first HCV 
treatment was 11.2 months (IQR 3.7, 46.6 months). 
 
In order to assess time to starting treatment, a further 22 individuals were excluded from the 
analysis because they had the same follow-up start date and follow-up stop date (i.e. had zero 
follow-up time).  Therefore there were 819/2141 individuals ever treated who were included 
Drugs included in regimen Number of individuals on regimen (%) 
First 
treatment 
episode 
Second 
treatment 
episode 
Third 
treatment 
episode 
Pegylated-interferon alone 40 (4.3) 3 (2.6) 0 (0.0) 
Interferon alone 3 (0.3) 0 (0.0) 0 (0.0) 
Pegylated-interferon + Ribavirin 833 (89.7) 91 (79.8) 12 (85.7) 
Interferon + Ribavirin 3 (0.3) 0 (0.0) 0 (0.0) 
Pegylated-interferon + Ribavirin + Telaprevir 24 (2.63) 13 (11.4) 0 (0.0) 
Pegylated-interferon + Ribavirin + Boceprevir 3 (0.3) 1 (0.9) 0 (0.0) 
Pegylated-interferon + Ribavirin + unknown DDA 20 (2.2) 5 (4.4) 0 (0.0) 
Ribavirin + Sofosbuvir 3 (0.3) 0 (0.0) 0 (0.0) 
Sofosbuvir alone 0 (0.0) 1 (0.9) 2 (14.3) 
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in the analysis.  The median length of follow-up among those included in the analysis was 3.0 
years (IQR 0.6, 6.8 years).  Median follow up was 4.3 years (IQR 1.5, 8.2) for untreated 
individuals and 0.9 years (IQR 0.3-3.7) for treated individuals.  The probability of starting 
treatment over time is shown in Figure 7.1.   
 
Table 7.6 Baseline characteristics of individuals who start treatment for HCV and those who 
do not 
 Treated 
N=820 
% Never 
treated 
N=1343 
% P value 
Median age (years) 
(IQR) 
38  (33, 43) 37  (32, 43) 0.72 
Ethnicity      
White 697 85.0 1109 82.6 0.19 
Black African 21 2.6 57 4.2 
Other black 18 2.2 28 2.1 
Other/unknown 84 10.2 149 11.1 
HIV exposure group      
MSM 602 73.7 720 53.6 <0.0001 
IDU 109 13.3 361 26.9 
Male heterosexual 29 3.5 102 7.6 
Female heterosexual 28 3.4 76 5.7 
Other/unknown 52 6.3 84 6.3 
Year of first positive HCV test     
<1996 36 4.4 72 5.4 0.01 
1996-1999 49 6.0 117 8.7 
2000-2004 175 21.3 332 24.7 
2005-2009 395 48.2 603 44.9 
>2010 165 20.1 219 16.3 
Median CD4 
(cells/mm3) 
(IQR) 1 
475  
 
(342, 640) 400  
 
(255, 
574) 
<0.0001 
HIV Viral load 
(copies/ml) 
     
<50 351 42.8 448  33.4 <0.0001 
>50 375 45.7 685 51.0 
Unknown 94 11.5 210 15.6 
Diagnosed in acute 
infection 
     
Yes 357 43.5 244 16.7 <0.0001 
No 463 56.5 1099 81.8 
Median HCV viral load 
(IU/ml)(IQR)2 
1000594  
 
(108000, 
5574112) 
737059 
 
(11405, 
3375276) 
0.001 
1 Baseline CD4 count is unknown for 56 treated and 133 untreated individuals 
2 Baseline HCV viral load is unknown for 336 treated and 699 untreated individuals 
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Figure 7.1 Kaplan Meier curve of probability of starting HCV treatment 
 
 
 
HRs from the Cox model for factors associated with starting treatment are shown in Table 7.7.  
In the univariable analysis, age at start of follow-up, HIV exposure group, year of first positive 
HCV test, CD4 count, HIV viral load and being diagnosed with acute HCV infection were all 
significantly associated with starting treatment.  The association between age and starting 
treatment was not maintained in the multivariable model.  In multivariable analysis, MSM 
were the group most likely to start HCV treatment, IDU were significantly less likely than MSM 
to start HCV treatment (AHR, 95% CI: 0.60, 0.47-0.76) as were male heterosexuals (AHR, 95% 
CI: 0.57, 0.39-0.83) and female heterosexuals (ARH, 95% CI: 0.64, 0.43-0.95).  Year of first 
positive HCV test remained significantly associated with likelihood of starting treatment in the 
multivariable model.  Individuals who had their first recorded positive HCV test in earlier years 
were significantly less likely to start treatment than those with a first positive test in the 2005-
2009 period, while individuals in the who had a first positive test from 2010 onwards were 
most likely to start treatment (AHR, 95% CI: 1.91, 1.57-2.32).  Individuals with higher CD4 
counts were more likely to start treatment (AHR, 95% CI: 1.06, 1.03-1.09 per 100 cells/mm3 
increase) and individuals with higher HIV viral loads were less likely to start treatment (AHR, 
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95% CI: 0.88, 0.83-0.94 per log10 copies/ml).  Being diagnosed with acute HCV infection was the 
strongest predictor of starting treatment.   
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Table 7.7 Univariable and multivariable Cox regression analyses of factors associated with starting first HCV treatment 
 Univariable Multivariable 
HR 95% CI P value AHR 95% CI P value 
Baseline age (per 10 years older) 1.18 1.09-1.29 <0.0001 0.93 0.85-1.02 0.10 
Ethnicity       
White 1 - - - - - 
Black African 0.73 0.47-1.12 0.15 - - - 
Other black  1.05 0.66-1.67 0.84 - - - 
Other/unknown 1.05 0.84-1.32 0.66 - - - 
Exposure       
MSM 1 - - 1 - - 
IDU 0.30 0.24-0.36 <0.0001 0.60 0.47-0.76 <0.0001 
Male heterosexual 0.39 0.27-0.56 <0.0001 0.57 0.39-0.83 0.004 
Female heterosexual 0.40 0.27-0.59 <0.0001 0.64 0.43-0.95 0.03 
Other/unknown 1.02 0.77-1.35 0.91 1.25 0.93-1.67 0.14 
Year of first positive HCV test       
<1996 0.10 0.06-1.15 <0.0001 0.21 0.13-0.34 <0.0001 
1996-1999 0.13 0.09-0.19 <0.0001 0.24 0.16-0.35 <0.0001 
2000-2004 0.40 0.33-0.49 <0.0001 0.48 0.40-0.60 <0.0001 
2005-2009 1 - - 1 - - 
>2010 2.40 1.98-2.91 <0.0001 1.91 1.57-2.32 <0.0001 
CD4 count (per 100 cells/mm3 
increase)1 
1.13 1.11-1.16 <0.0001 1.06 1.03-1.09 0.0002 
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 Univariable Multivariable 
HR 95% CI P value AHR 95% CI P value 
HIV viral load (per log10 copies/ml 
increase)1 
0.77 0.72-0.82 <0.0001 0.88 0.83-0.94 0.0003 
Acute HCV at first positive test       
No 1 - - 1 - - 
Yes 4.66 4.03-5.40 <0.0001 2.69 2.29-3.17 <0.0001 
1 CD4 count and HIV viral load were included in the analysis as time updated variables
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7.3.3 Characteristics of treatment episodes 
There were a total of 903 separate episodes of treatment.  Median time on treatment was 
46.6 weeks (IQR 24, 48).  However this differed significantly by episode of treatment (p=0.01) 
(Table 7.8). Among 427 treatment episodes with a duration of less than 44 weeks, a reason for 
stopping was recorded for 137 episodes.  These reasons for stopping are shown in Table 7.9.   
 
Table 7.8 Time on treatment by treatment episode 
Treatment Episode Median time on treatment (IQR) 
1 47.7 (24, 48) 
2 26.3 (22, 48) 
3 25.1 (24.1, 31.5) 
Total 47.6 (24, 48) 
 
Table 7.9 Recorded reasons for stopping HCV treatment before 44 weeks of treatment 
Reason for stopping treatment early Number of individuals 
N=137 
% 
Completed planned course 17 12.4 
Virological breakthrough 9 6.6 
Non-response 38 27.7 
Side effects 43 31.4 
Patient lost to follow-up 2 1.5 
Patient choice 13 9.5 
Early response 8 5.8 
Other illness 5 3.7 
Patient died 1 1.0 
Treatment break 1 1.0 
 
 
7.3.4 Defining serological response to treatment 
Among all episodes of treatment (n=903), 64 were excluded as they included new DAAs as part 
of the regimen, 25 were excluded as there was no treatment stop date available and 319 were 
excluded as there were no RNA test results available after stopping treatment.  Therefore a 
total of 495 episodes of treatment were included in the analysis of serological response to 
treatment.  Baseline characteristics (at time of starting treatment) of included and excluded 
episodes of treatment are shown in Table 7.10.   
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Table 7.10 Baseline characteristics of those treatment episodes included in the analysis of 
treatment response compared to excluded episodes 
 Included 
treatment 
episodes  
N=495 
% Excluded 
treatment 
episodes 
N=408 
% P value 
Median age (years) (IQR) 40 (35, 45) - 41 (36, 47) - 0.04 
Ethnicity      
White 433 87.5 338 82.8 0.21 
Black African 9 1.8 14 3.4 
Other black 10 2.0 10 2.5 
Other/unknown 43 6.7 46 11.3 
HIV exposure group      
MSM 367 74.1 298 73.0 <0.0001 
IDU 75 15.2 44 10.8 
Male heterosexual 22 4.4 8 2.0 
Female heterosexual 18 3.8 12 2.9 
Other/unknown 13 2.6 46 12.0 
Year of starting 
treatment 
     
1996-1999 1 0.2 3 0.7 <0.0001 
2000-2004 71 14.3 10 2.5 
2005-2009 315 63.6 103 25.2 
>2010 108 21.8 292 71.6 
Median CD4 (cells/mm3) 
(IQR) 1 
500 (386, 600) - 508 (385, 
660) 
- 0.04 
Nadir CD4 (cells/mm3)  
(IQR) 2 
219 (122, 349) - 229 (143, 
320) 
- 0.66 
Median HIV viral load 
(copies/ml) (IQR) 3 
50 (50, 151) - 40 (40, 50) - 0.01 
Diagnosed with acute 
HCV infection 
     
Yes 218 44.0 187 45.8 0.59 
No 277 56.0 221 54.2 
Median HCV viral (IQR)4 737500 
(97965, 
2541476) 
- 850000 
(86006, 
3383309) 
- 0.64 
Treatment episode      
First  492 99.4 323 79.2 <0.0001 
Second 3 0.6 78 19.1 
Third 
 
 
0 0.0 7 1.7 
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 Included 
treatment 
episodes  
N=495 
% Excluded 
treatment 
episodes 
N=408 
% P value 
HAART regimen      
PI based 146 29.4 128 31.4 0.51 
NNRTI based 125 25.3 104 25.4 
Other 107 21.6 96 23.5 
Not on anti- HIV drugs 117 23.6 80 19.6 
HBV co-infected      
No 375 75.8 314 77.0 0.54 
Yes 67 13.5 59 14.5 
Unknown 53 10.7 35 8.6 
 
1 Baseline CD4 count was unknown for 22 included and 109 excluded episodes of treatment.  
2 Nadir CD4 count was unknown for 1 included and 2 excluded episodes of treatment. 
3 Baseline HIV viral load was unknown for 25 included and 109 excluded episodes of treatment. 
4 Baseline HCV viral load was unknown 295 included 225 excluded episodes of treatment.  
 
A result within the initial treatment response period (as defined in methods section) was 
available for 395 individuals, of whom 300 (75.9%, 95% CI 71.7%-80.2%) were negative in this 
time period and 95 (24.1%, 95% CI 19.8-28.3%) were positive.  The median time from 
treatment stop date to initial treatment response result was 4 days (IQR -1, 32). The 95 
individuals who were positive in the initial treatment response period were considered to have 
failed treatment.  Baseline characteristics (at the time of starting HCV treatment) of individuals 
with positive and negative results in the initial treatment response period are shown in Table 
7.11.  Those treatment episodes which were initially successful had lower HCV viral loads at 
baseline than those which failed. There were no other significant differences between these 
groups.
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Table 7.11 Characteristics of individuals with HCV-RNA test results in the initial treatment 
response period 
 Initial 
treatment 
success 
N=300 
% Initial 
treatment 
failure 
N=95 
% P value 
Median age (years) (IQR) 40.5 (35, 
45.5) 
- 40 (35, 45) - 0.13 
Ethnicity      
White 266 88.7 80 84.2 0.47 
Black African 5 1.7 1 1.1 
Other black 4 1.3 3 3.2 
Other/unknown 25 8.3 11 11.6 
HIV exposure group      
MSM 226 75.3 69 72.6 0.59 
IDU 42 14.0 16 16.8 
Male heterosexual 13 4.3 4 4.2 
Female heterosexual 13 4.3 2 2.1 
Other/unknown 6 2.0 4 4.2 
Year of starting 
treatment 
     
1996-1999 1 0.3 0 0.0 0.87 
2000-2004 40 13.3 15 15.8 
2005-2009 187 62.3 57 60.0 
>2010 72 24.0 23 24.2 
Median CD4 count 
(cells/mm3) (IQR) 1 
510 (386, 
679) 
- 490 (385, 
683) 
- 0.27 
Nadir CD4 (cells/mm3)  
(IQR) 2 
361 (212, 
537) 
- 221 (74, 380) - 0.35 
Median HIV viral load 
(copies/ml) (IQR) 3 
50 (50, 63) - 50 (50, 209) - 0.46 
Diagnosed in acute HCV infection     
Yes 159 53.0 60 63.2 0.08 
No 141 47.0 35 36.8 
Median HCV viral load 
(IQR)4 
635596 
(38900, 
2040539) 
- 1000000 
(388618, 
7397260) 
- 0.03 
Treatment episode      
First  298 99.3 94 98.9 0.71 
Second 2 0.6 1 1.1 
HAART regimen       
PI based 82 27.3 33 34.7 0.33 
NNRTI based 83 27.7 21 22.1 
Other 69 23.0 17 17.9 
Not on anti- HIV drugs 66 22.0 24 25.3 
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 Initial 
treatment 
success 
N=300 
% Initial 
treatment 
failure 
N=95 
% P value 
HBV co-infected      
No  235 78.3 71 74.7 0.11 
Yes 39 13.0 9 9.5 
Unknown 26 8.7 15 15.8 
1 Unknown for 13 initially successful treatment episodes and 7 failed treatment episodes. 
2 Unknown for 1 initially successful treatment episode. 
3 Unknown for 12 initially successful treatment episodes and 7 failed treatment episodes.  
4 Unknown for 153 initially successful treatment episodes and 62 individuals with failed 
treatment episodes. 
 
Among the 300 individuals who had a negative test result in the initial treatment response 
period, the median time to negative result was 3.5 days (IQR -1, 27).  Among these individuals 
237/300 had a further test result which was at least 6 months after the stopping treatment.  
LTR was examined among those who had a successful initial treatment response using each of 
the methods described in the methods section.  The proportion of individuals with a successful 
LTR ranged from 78.4% to 85.7% (Table 7.12) depending on the method used to define LTR.  
Characteristics of individuals with successful LTR are shown in Table 7.13. 
 
Table 7.12 LTR to HCV treatment among those with a negative result in the initial treatment 
response period, defined using 6 different methods 
Method1 Total HCV-RNA 
Positive 
HCV-
RNA 
Negative 
% with 
successful 
treatment 
(95% CI) 
Median time to 
LTR definition 
(IQR) 
LTR method 1 37 8 29 78.4 
(65.1 -91.6) 
200 
(190, 231) 
LTR method 2 168 24 144 85.7 
(80.4-91.0) 
233 
(199, 267) 
LTR method 3 237 40 197 83.1 
(78.4-87.9) 
258 
(210, 399) 
LTR method 4 237 38 199 84.0  
(79.3-88.6) 
253  
(209, 385) 
 
1 LTR method 1 utilised the first follow-up test result at least 6 months after stopping and no 
more than 6 months after the date of the test used to define initial treatment response; LTR 
method 2 utilised any negative follow-up test 6-12 months after stopping; LTR method 3 
utilised the first follow-up test which occurred at least 6 months after stopping treatment; and 
LTR method 4 utilised used all negative results at least 6 months after stopping treatment but 
used additional information from genotypes to assess the positive test results see section 7.2.5 
for details.
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Table 7.13 Baseline characteristics of individuals with successful and LTR defined using a variety of methods 
 Individuals with successful LTR response 
LTR1 
N=29 
% LTR2 
N=144 
% LTR3 
N=197 
% LTR4 
N=199 
% 
Median age (IQR) 41 
(37, 48) 
 41 
(37, 46) 
 41 
(37, 52) 
 41 
(37, 45) 
 
Ethnicity         
White 28 77.8 130 85.5 180 82.6 183 83.9 
Black African 0 0 2 66.7 2 66.7 2 66.7 
Black other 0 0 1 100 2 100 2 100 
Other/unknown 1 100 11 91.7 13 92.9 13 92.9 
HIV exposure group         
MSM 22 78.6 112 86.8 155 84.7 158 86.3 
IDU 4 66.7 21 87.5 27 81.8 27 81.8 
Male heterosexual 2 100 6 100 9 90 9 90 
Female heterosexual 1 100 3 50 4 50 4 50 
Other 0 0 2 66.7 2 66.7 2 66.7 
Year of starting treatment         
1996-1999 0 0 0 0 0 0 0 0 
2000-2004 4 80 24 82.8 33 13.9 33 84.6 
2005-2009 20 80 91 86.7 131 82.9 134 84.8 
>2010 5 83.3 29 87.9 33 94.6 33 84.6 
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 Individuals with successful LTR response 
LTR1 
N=29 
% LTR2 
N=144 
% LTR3 
N=197 
% LTR4 
N=199 
% 
Latest CD4 (cells/mm3) 
(Median( IQR)) 1 
473 
 
(391, 603) 500 
 
(385, 650) 502 
 
(384, 655) 501 
 
(358, 658) 
Nadir CD4 (cells/mm3)  
(Median( IQR)) 2 
193 
 
(98, 380) 201 
 
(114, 340) 209 
 
(112, 350) 204 
 
(111, 349) 
HIV viral load (copies/ml)         
<50 24 80 103 88 140 83.8 143 85.6 
>50 5 71.4 37 78.7 53 80.3 53 80.3 
Unknown 0 0.0 4 100.0 4 100.0 4 100.0 
Diagnosed in acute infection         
Yes 14 87.5 73 85.9 101 83.5 101 83.5 
No 15 71.4 71 85.4 96 82.8 99 85.3 
Median HCV viral load (IU/ml) 
(IQR)4 
631642 
 
(103207, 
29850000) 
574642 
 
(18206, 
1797360) 
520839  (13998, 
1800000) 
520839 
 
(13998, 
1800000) 
HAART regimen         
PI based 12 80 44 88 55 84.6 55 84.6 
NNRTI based 6 75 37 88.1 55 85.9 56 87.5 
Other 0 0 34 87.2 43 79.6 45 83.3 
No anti-HIV drugs 4 57.1 29 78.4 44 81.5 44 81.5 
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 Individuals with successful LTR response 
LTR1 
N=29 
% LTR2 
N=144 
% LTR3 
N=197 
% LTR4 
N=199 
% 
HCV genotype         
1 17 73.9 73 84.8 99 80.5 100 80.7 
2 1 100 6 100 8 100 9 100 
3 7 100 21 91.3 32 88.9 32 88.9 
4 1 100 16 88.9 25 92.6 25 92.6 
Other/unknown 3 60 28 80 33 76.7 34 82.9 
HBV co-infected         
No 22 75.9 119 87.5 165 85.1 167 86.1 
Yes 5 100 15 83.3 19 76 20 80 
Unknown 2 66.7 10 71.4 13 72.2 13 72.2 
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7.3.5 Factors associated with treatment failure 
A total of 417 individuals had at least one HCV-RNA test in the year after stopping treatment 
and were included in the analysis, of whom 150 failed treatment in the year after stopping 
treatment.  The probability of treatment failure over time after stopping treatment is shown 
Figure 7.2. In univariable analysis, not being diagnosed with acute HCV infection, higher 
baseline HCV viral load, HCV genotype 1 or 4 infection, HBV co-infection and shorter time on 
treatment were all associated with failing treatment in the first year (Table 7.14). 
 
Figure 7.2 Kaplan Meier curve and corresponding life table for the probability of treatment 
failure in the first year after stopping treatment 
Weeks 
from 
stopping 
treatment 
4 8 12 16 20 24 28 32 36 40 44 48 52 
Number at 
risk 
375 347 324 308 302 290 261 249 245 233 227 221 215 
 
 
In multivariable model 1, including all those factors associated with treatment failure in the 
univariable analysis, only baseline HCV viral load (AHR, 95% CI: 1.26, 1.04-1.54) and time on 
treatment (AHR, 95% CI: 0.64, 0.51-0.80 per additional month on treatment) remained 
associated with treatment failure (Table 7.15).  However, a high number of individuals had 
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missing baseline HCV viral load measurements (234 individuals).  Therefore two additional 
models were constructed.   Model 2 was not adjusted for HCV viral load and model 3 in 
included HCV viral load with an expanded definition:  the viral load measurement which was 
closest to the time of starting treatment in the 6 months before starting and the one month 
after stating was taken as baseline.  Use of the expanded definition of baseline viral load 
resulted in the number of individuals with unknown baseline HCV viral load being reduced 
from 234 to 91.   
 
In model 2, individuals diagnosed with acute infection were significantly less likely to fail 
treatment than those who were not diagnosed in the acute stage (AHR, 95% CI: 0.59, 0.41-
0.84).  Individuals with genotype 2 or 3 infection were significantly less likely to fail treatment 
than those with genotype 1 or genotype 4 infection (AHR, 95%: CI 0.34, 0.18-0.64).  Longer 
time spent on treatment was also associated with being less likely to fail treatment (AHR, 95% 
CI: 0.70, 0.60-0.80 per additional month on treatment) (Table 7.15).  These associations 
remained, with little change to the effect size, when the expanded definition HCV viral load 
was included (model 3).  In addition, in model 3, higher baseline HCV viral load was also found 
to be associated with failing treatment (AHR, 95% CI: 1.26, 1.12-1.42) (Table 7.15).
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Table 7.14 Characteristics of included treatment episodes and univariable Cox regression of 
factors associated with treatment failure in the first year after stopping treatment 
 Treatment outcome Univariable analysis1 
Failure 
N (%)  
Did not fail  
N (%) 
HR 95% CI P value 
Total 150 267    
Median age (IQR) 2 40 (35, 45) 41 (35, 46) 0.87 0.70-1.08 0.21 
Ethnicity      
White 129 (86.0) 235 (88.0) 1 - - 
Black African 4 (2.7) 3 (1.1) 1.73 0.64-4.68 0.28 
Black other 4 (2.7) 5 (1.9) 1.59 0.59-4.31 0.36 
Other/unknown 13 (9.0) 24 (9.0) 1.09 0.62-1.93 0.76 
HIV |Exposure group      
MSM 105 (70.0) 206 (77.2) 1 - - 
IDU 25 (16.7) 35 (13.1) 1.38 0.89-2.13 0.15 
Male heterosexual 7 (4.7) 12 (4.5) 1.02 0.47-2.19 0.96 
Female heterosexual 8 (5.3) 8 (3.0) 1.98 0.97-4.07 0.06 
Other/unknown 5 (3.3) 6 (2.3) 1.93 0.79-4.74 0.15 
Year of starting 
treatment 
     
1996-1999 1 (0.7) 0 (0.0) 2.78 0.39-19.97 0.31 
2000-2004 23 (15.3) 32 (12.0) 1.34 0.85-1.13 0.21 
2005-2009 86 (57.3) 173 (64.8) 1 - - 
>2010 40 (26.7) 62 (23.2) 1.67 1.14-2.43 0.01 
Median CD4 count 
(IQR)  (cells mm3)3 
509  
(386, 700) 
503 
(390,660) 
0.99 0.92-1.07 0.88 
Median HIV viral load 
(IQR) (log copies/ml)4 
1.7  
(1.7, 2.0) 
1.7  
(1.7, 2.6) 
0.93 0.79-1.09 0.36 
Acute HCV infection      
Yes 58 (38.7) 130 (48.7) 0.70 0.50-0.97 0.03 
No 92 (61.3) 137 (51.3) 1 - - 
Median HCV viral 
load (IQR) (log10 
IU/ml)5 
6.0  
(5.5, 6.8) 
5.8  
(4.5, 6.3) 
1.26 1.04-1.53 0.02 
Treatment episode      
First 149 (99.3) 265 (99.3) 1 - - 
Second 1 (0.7) 2 (0.7) 1.01 0.14-7.20 0.99 
HAART regimen      
PI based 52 (34.7) 72 (27.0) 1 - - 
NNRTI based 32 (21.3) 75 (28.1) 0.70 0.45-1.08 0.11 
Other 32 (21.3) 58 (21.7) 0.82 0.53-1.28 0.39 
Not on HARRT 34 (22.7) 62 (23.2) 0.86 0.56-1.33 0.50 
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 Treatment outcome Univariable analysis1 
Failure 
N (%)  
Did not fail  
N (%) 
HR 95% CI P value 
HCV genotype      
1 or 4 104 (69.3) 174 (65.2) 1 - - 
2 or 3 11 (7.3) 52 (19.5) 0.42 0.23-0.78 0.01 
Other/unknown 35 (23.3) 41 (15.4) 1.32 0.90-1.94 0.15 
HBV co-infected      
No 109 (72.7) 211 (79.0) 1 - - 
Yes 19 (12.7) 35 (13.1) 1.06 0.65-1.73 0.82 
Unknown 22 (14.7) 21 (7.9) 1.74 1.10-2.75 0.02 
Median time on 
treatment (months) 6 
45 (24, 48) 48 (30, 48) 0.75 0.66-0.86 <0.0001 
 
1 CD4 count and HIV viral load were analysed in univariable analyses as time updated variables 
2 HR per additional 10 years of age 
3 HR per additional 100 cells/mm3 
4 HR per additional log10 copies/ml 
5 HR per additional log IU/ml 
6 HR per additional month on treatment
  
2
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Table 7.15 Multivariable Cox regression of factors associated with treatment failure in the first year after stopping treatment 
 Multivariable model 1 – all factors 
associated with treatment failure in 
univariable analysis 
Multivariable model 2 – excluding 
baseline HCV viral load 
Multivariable model 3 – including 
baseline viral load (expanded definition) 
 AHR 95% CI P value AHR 95% CI P value AHR 95% CI P value 
Acute HCV infection          
Yes 0.62 0.36-1.07 0.09 0.59 0.41-0.84 0.003 0.61 0.41-0.92 0.01 
No 1 - - 1 - - 1 - - 
HCV viral load 
(per log copies/ml) 
1.26 1.04-1.54 0.02 N/A N/A N/A 1.26 1.12-1.42 0.0001 
HCV genotype          
1 or 4 1 - - 1 - - 1 - - 
2 or 3 0.45 0.17-1.22 0.11 0.34 0.18-0.64 0.001 0.34 0.15-0.81 0.01 
Other/unknown 1.80 0.99-3.27 0.05 1.37 0.92-2.03 0.11 1.67 1.04-2.69 0.04 
HBV co-infected          
No 1 - - 1 - - 1 - - 
Yes 1.68 0.75-3.76 0.21 1.23 0.75-2.02 0.42 1.31 0.74-2.31 0.36 
Unknown 2.36 1.01-5.53 0.05 1.60 0.99-2.60 0.06 1.65 0.85-3.30 0.16 
Time on treatment 
(per month) 
0.64 0.51-0.80 0.0001 0.70 0.60-0.80 <0.0001 0.58 0.50-0.69 <0.0001 
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7.3.6 Individuals in need of HCV treatment 
A total of 1322 individuals who were co-infected with HCV had never received treatment for 
their HCV infection.  138 individuals who had started treatment were defined as having failed 
treatment within the one year after stopping treatment.  HCV infection characteristics and 
stage of liver disease in these individuals are described in Table 7.16. 
 
Table 7.16 Most recent HCV infection status and liver disease in individuals requiring HCV 
treatment 
  Never 
treated 
Failed 
treatment 
Total requiring 
treatment (%) 
HCV viral load 
(IU/ml) 
≤615 181 22 203 (13.9) 
 615-800000 386 49 435 (29.8) 
 >800000 578 66 644 (44.1) 
 Unknown 177 1 178 (12.2) 
HCV genotype 1 or 4 624 98 722 (49.5) 
 2 or 3 153 11 164 (11.2) 
 Other/unknown 545 29 574 (39.3) 
APRI score ≤0.5 108 13 121 (8.3) 
 0.6-1.5 183 45 228 (15.6) 
 1.5-2.0 17 2 19 (1.3) 
 >2.0 73 10 83 (5.6) 
 Unknown 941 68 1009 (69.1) 
FibroScan® result <7 KPa 242 49 291 (20.0) 
 7-9 KPa 55 9 64 (4.4) 
 10-13 KPa 40 10 50 (3.4) 
 >14 KPa 36 11 47 (3.2) 
 Unknown 949 59 1008 (69.0) 
Biopsy result1 No significant fibrosis 85 14 99 (6.8) 
 Fibrosis, but no 
cirrhosis 
68 18 86 (5.9) 
 Cirrhosis 34 4 38 (2.6) 
 Unknown 1135 102 1237 (84.7) 
Any evidence of 
cirrhosis2 
No cirrhosis 561 90 951 (65.1) 
Cirrhosis 85 13 98 (6.7) 
 Unknown 676 35 711 (48.7) 
 
1 No fibrosis includes those with Ishak or METAVIR score of 0-1; Fibrosis without cirrhosis 
includes those with Ishak score 1-5 or METAVIR score 2-3;  Cirrhosis includes those with Ishak 
score 6 or METAVIR score 4 
2 Any cirrhosis defined as an APRI score of 2 of more a FibroScan® of 14 or more, an Ishak score 
of 6 or a METAVIR score of 4 
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7.4 Discussion 
7.4.1 Summary of findings 
Overall 37.9% ofHIV/HCV co-infected individuals had started treatment for HCV while under 
follow-up in UK CHIC although only just over of half of all episodes of treatment continued to 
at least 44 weeks.  It was not possible to define EOT response or SVR, using the established 
definitions, from the serological data in this cohort.  However, 33% of individuals in this cohort 
are known to have failed treatment within the first year of stopping treatment, with time on 
treatment being the strongest predictor of failure.  Of those individuals who remain in need of 
HCV treatment a small but important group are known to have cirrhosis. 
 
7.4.2 Interpretation of results 
A high proportion of individuals started treatment within a year of their first positive test 
result.  In addition, being diagnosed with acute HCV infection was an independent predictor 
for starting HCV treatment. These findings may be due to an increase in awareness of acute 
HCV as the result of ongoing outbreaks among MSM across Europe.  Interestingly, in this 
cohort, individuals who had their first positive test in later years were more likely to start 
treatment.  This would be consistent with the hypothesis that clinicians have become more 
aware of acute HCV in recent years.  However, this finding is contrary to the suggestion in 
clinical guidelines that individuals may choose to defer treatment until newer, interferon-free, 
regimens are available (65).   
 
MSM were the group most likely to commence HCV treatment.  IDU were significantly less 
likely than MSM to start HCV treatment.  This may reflect concerns by clinicians and the 
individuals themselves about lack of adherence to treatment.  Indeed, it has been shown that 
IDU are significantly less likely to start HIV treatment, or do so at later stages of disease, 
compared to MSM and this is often due to concerns about adherence or irregular attendance 
for care (501-503).  In addition, IDU may have a higher rate of co-existing mental health 
conditions which are a contraindication to treatment with interferon-containing regimens.  
Higher CD4 counts and lower HIV viral loads were also independent predictors of starting 
treatment which reflects clinical guidelines that an individual’s HIV infection should be stable 
before starting HCV treatment (65, 154, 166). 
 
Response to treatment was assessed in a number of ways:  treatment success in the initial 
treatment response period; long term treatment response; and treatment failure within a year 
of stopping treatment.  In this cohort, where HCV-RNA test results after treatment were 
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available, three quarters of individuals had an initially successful treatment.  Between 78% and 
86% of these individuals maintained their treatment success over the long term, giving an 
overall treatment success rate of 58%-67% (and, conversely, a treatment failure rate of 33%- 
42%).  This is consistent with the calculated treatment failure rate within one year of stopping 
treatment (36%).  In addition, factors associated with treatment failure, as identified through a 
Cox proportional hazards model, were consistent with known risk factors for treatment failure:  
not being diagnosed with acute infection, having genotype 1 or genotype 4 infection, having a 
high baseline HCV viral load and longer time on treatment.  In observational cohort studies 
where only routinely recorded clinical data are available there may be insufficient HCV-RNA 
test results reported to allow determination of EOT response or SVR.  Taken together, the 
agreement in treatment failure rates as defined using two methods, and the identification of 
known risk factors for treatment failure, indicates that in the absence of sufficient serological 
data to define SVR, use of relaxed definitions of initial treatment response, LTR and treatment 
failure within a year may be an effective alternative method to assess the outcomes of HCV 
treatment.    
 
7.4.3 Comparisons with the literature 
The proportion of individuals in UK CHIC who have received treatment for HCV during follow-
up is greater than that reported among HIV/HCV co-infected populations in Canada (504, 505), 
Ireland (506) and from the EuroSIDA cohort (507) where treatment rates between 6% (in one 
centre in Canada) and 28% (in Ireland) of individuals have been reported.  However, the 
estimate presented in this chapter, for the UK CHIC study, is comparable to that reported from 
centres across Germany and Austria (508).  This may be due to the differences in the co-
infected populations between the cohorts.  A number of previous studies have reported that 
there are particularly low rates of treatment among IDU (508, 509).  The co-infected 
population in UK CHIC contains a higher proportion of MSM and a lower proportion of IDU 
which may explain the higher proportions of individuals in this cohort who receive treatment 
compared to other cohorts.  Prescribing patterns across the various settings where these 
cohort studies have taken place may also vary.  For example treatment may be more 
accessible in some countries than on others.   
 
The proportion of individuals who fail treatment within the first year after stopping and the 
proportion of individuals who have successful treatment (as defined as an initial successful 
treatment and successful long term treatment response) are higher than the SVR rates 
reported in trials and cohort studies (393, 401).  However, since response to treatment was 
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estimated using a non-standard method, it is difficult to compare these results.  In the analyses 
presented in this chapter HCV viral load at the start of treatment, HCV genotype, being 
diagnosed with acute infection and longer duration of treatment were all associated with 
being less likely to fail treatment.  This is in agreement with previously published research. 
 
HCV genotype and baseline HCV viral load are established predictors of SVR both in clinical trial 
settings and among cohorts of HIV/HCV co-infected individuals.  For example, in a large 
prospective cohort study in Spain and Germany, individuals with genotype 2 or 3 infection 
were nearly 5 times more likely to achieve SVR than individuals with genotype 1 infection.  In 
the same study individuals with baseline HCV viral load of <600000 IU/ml were more than 
twice as likely to achieve SVR than individuals with baseline HCV viral load ≥600000 IU/ml 
(491).  Similarly, among a cohort of 1701 HIV/HCV co-infected patients in Spain, 38% achieved 
an SVR and SVR was more than 5 times more likely among individuals with genotype 2 or 3 
infection than among individuals with genotype 1 infection.  The Spanish study used a different 
cut-off to investigate the effect of HCV viral load.  However, the effect of higher HCV viral load 
at baseline was also evident in this study where individuals with HCV viral load <500000 IU/ml 
at baseline were significantly more likely to achieve SVR than individuals with HCV viral load 
>500000 IU/ml at baseline (AOR, 95% CI 1.75, 1.34-2.23) (494). 
 
In the present analysis, not being diagnosed with acute HCV infection was a predictor of failing 
treatment in the first year.  This finding is in agreement with previous studies which have 
assessed the SVR rate among individuals who are treated in the acute phase of infection.  In 
general SVR rates among individuals who are treated during acute infection are more than 
double those among individuals treated in the chronic phase of infection.  For example, within 
a small clinic cohort in the UK 62.5% of HIV/HCV co-infected patients achieved SVR when they 
were treated during acute infection (510).  Similarly among 141 HIV/HCV co-infected 
individuals treated with pegylated-interferon monotherapy, 64.8% achieved SVR (511).  
 
I found no associations between failing HCV treatment and any HIV-related covariates 
investigated (CD4 count, HIV viral load or HAART regimen at time of starting HCV treatment).  
Previous studies have reported mixed results with regard to these factors as predictors of 
successful HCV treatment.  Clinical trials of pegylated-interferon and ribavirin among HIV/HCV 
co-infected individuals have not found any associations between SVR and either CD4 count or 
HIV viral load (395-399).  However, in these clinical trials the majority of included individuals 
had CD4 counts >500cells/mm3 and therefore the trials may not have had sufficient power to 
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detect the impact of  lower CD4 on the likelihood of SVR.  One small cohort study has found 
that CD4 may be associated with SVR.  In this study, of 32 HIV/HCV co-infected individuals 
those individuals who had a CD4 count >450 at the time of starting HCV treatment were 
significantly more likely to achieve SVR than those whose CD4 count was <450 cells/mm3 and 
that this was related to the early decrease in HCV viral load at the start of treatment (495).  A 
larger study of 141 HIV/HCV co-infected individuals assessing predictors of SVR found that 
individuals with baseline CD4 >300 cells/mm3 were significantly more likely to achieve SVR 
than those with CD4 counts <300cells/mm3 (512).  In addition, a further small cohort study of 
43 HIV/HCV co-infected individuals found that SVR was significantly lower among individuals 
who had previous nadir CD4 count of <350 cells/mm3 (492).  Similarly, there is evidence from 
cohort studies that having had a previous AIDS event may be associated with failing treatment 
(177, 494).  The analyses presented in this chapter may confirm the hypothesis that HIV-
related factors are not associated with failing treatment.  However, it should be noted that the 
median CD4 count at starting treatment was >500 cells/mm3, both for those individuals who 
fail treatment and for those who do not fail treatment.  Therefore in this cohort CD4 counts 
may not have been low enough to detect differences in treatment outcomes for those 
individuals with CD4 counts <450 or <350 as has been shown in previous research.   
 
Among those HIV/HCV co-infected individuals in UK CHIC who are in need of treatment, a small 
percentage were known to have cirrhosis.  The proportion of untreated individuals who have 
significant fibrosis or cirrhosis in UK CHIC is lower than that reported elsewhere (507).  The 
proportion of individuals who have failed treatment and have significant fibrosis or cirrhosis is 
also less in UK CHIC than has been reported elsewhere (513).  Again, this may be due to the 
smaller proportion of co-infected individuals who are IDU in UK CHIC compared to other 
cohorts.  IDU are likely to have acquired their infection very early in their injecting history and 
therefore many of them have been infected for long periods of time, whereas MSM have, in 
general, more recently acquired infection.  I have previously shown that HCV incidence is 
higher among MSM in this cohort than among other risk groups (Chapter 6, section 6.3.3.4).  
Therefore liver disease has not progressed to such an extent in these individuals with more 
recent infections. 
 
7.4.4 Strengths and weaknesses 
Information on whether individuals are treated or not was obtained both from clinical lists 
compiled by the treating clinicians and nurses, and through review of notes.  This has resulted 
in a high proportion of individuals having been recorded as having started treatment for HCV 
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and therefore a large cohort of treated patients whose data are available for analysis.  
However, the greatest limitation in the analyses presented in this chapter is missing data for 
post treatment HCV-RNA test results.  The difference in treatment success rate reported in this 
chapter and SVRs reported in other cohorts may, in part, be due to the high number of 
individuals who do not have an HCV-RNA test result available after stopping treatment.  For 
example, individuals without HCV-RNA test results may be poor attenders and less adherent to 
a treatment regimen.  Therefore it is possible that these individuals may also be less likely to 
achieve SVR.   
 
Early virological response (EVR) to HCV treatment is defined as a decrease in HCV viral load of 
2log10 by week 12 of treatment.  EVR is strongly associated with SVR in HIV/HCV co-infected 
individuals (514).  However, the limited number of peri and post treatment HCV-RNA test 
results which were available for analysis also meant that that it was not possible to assess 
changes in HCV-RNA levels over time and therefore EVR could not be investigated in this 
cohort.  In addition, a small number of co-infected individuals who had been treated had one 
or more biopsy result or FibroScan® result available.  Therefore, it was not possible to assess 
the effect of liver disease on response to treatment or changes in liver disease among 
individuals who are treated successfully compared to those who fail treatment and those who 
are untreated.  In previous research the degree of fibrosis/cirrhosis present at the start of 
treatment has been shown to be associated with treatment success.  In particular, those with a 
METAVIR fibrosis score >F2 are significantly less likely to achieve SVR than those with METAVIR 
<2 (177, 498).  This is also seen in clinical trials (399).   
 
There are some further limitations which are important to consider in interpreting the results 
of these analyses.  Using the data available in UK CHIC it was not possible to assign a date of 
infection with HCV.  Therefore, in the analysis of time to starting treatment, the first reported 
positive HCV test was used as a baseline.  Individuals may have been infected for some time 
before this date and therefore time to treatment may be underestimated.  However, there is 
no reason to believe that this underestimation would differ in subgroups and therefore this 
should not affect the results of the Cox model.  The number of individuals who had a recorded 
reason for stopping treatment was low.  Therefore, it was not possible to undertake any 
further analysis of clinical events which occur during treatment and lead to treatment 
cessation. 
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7.4.5 Conclusions 
In this cohort of HIV/HCV co-infected individuals there are a high number of individuals who 
have never received treatment for HCV and an important group of individuals who have failed 
treatment.  Although the rates of cirrhosis in these individuals is currently low, without 
treatment success liver disease in these individuals will continue to progress.  Those individuals 
who have failed previous treatment and those who have never received treatment but who 
are at high risk of failing standard interferon-based treatments should be prioritised for newer 
DAA containing regimens.  A subsequent round of hepatitis data collection for UK CHIC is 
planned.  During this process, ensuring that post treatment HCV-RNA test results are available 
and recorded for all treated individuals should be a priority.  Further analysis of the 
subsequent round of data collected for this cohort should evaluate the whether these 
individuals have received treatment as the number of options for treatment regimens 
increases.   
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Chapter 8 Results 3:  HBV treatment strategies and response to 
treatment 
 
8.1 Background 
Controlling HBV replication is key to limiting the progression of HBV-related liver disease, since 
it has been demonstrated among HBV-mono-infected individuals that higher HBV viral load is 
associated with increased progression of liver disease (100, 102).  HIV/HBV co-infected 
individuals have higher levels of HBV-DNA, slower rates of HBeAg clearance (260, 364, 382) 
and increased progression of HBV-related liver disease (261) than HIV mono-infected 
individuals.  However, treatment of HBV and HIV infection has been shown to lead to 
regression of fibrosis among co-infected individuals (386, 387) and improvements in 
biochemical measures of liver function even among individuals with advanced liver disease 
(515). 
 
Among HIV/HBV co-infected individuals, higher HBV-DNA levels are associated with lower CD4 
count (304, 388).  In addition, higher CD4 counts are associated with lower rates of HCC (334, 
335, 367).  Therefore the aims of HBV treatment in the context of HIV infection are to reduce 
the HBV viral load and facilitate seroconversion from HBeAg positivity to anti-HBe positivity 
while achieving high CD4 counts and suppressed HIV infection.  
 
HIV and HBV both use reverse transcriptase as part of their replication cycle and therefore 
there are a number of drugs which are active against both viruses:  tenofovir; emtricitabine; 
lamivudine; and entecavir.  In addition, HBV can also be treated with adefovir, telbivudine or 
interferon.  In the UK, current guidelines for managing HIV/HBV co-infected individuals 
recommend commencing treatment for all individuals with a CD4 count less than 500 
cells/mm3.  Additionally, it is recommended that all individuals with CD4 counts of greater than 
500 cells/mm3 should have the option of commencing treatment with a specific 
recommendation to start treatment immediately where HBV-DNA levels are at least 2000 
IU/ml or where the individual has significant fibrosis (a METAVIR score of ≥2, Ishak stage ≥2 or 
a FibroScan® result ≥9KPa) (65).   
 
Individuals starting treatment with CD4 counts more than 500 cells/mm3 should receive 
tenofovir and emtricitabine as part of their combination HIV treatment while those with CD4 
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counts of less than 500 cells/mm3 should receive tenofovir and either emtricitabine or 
lamivudine as part of their combination HIV treatment.  Use of other drugs active against HBV 
should be used only where a patient does not wish to or cannot use these recommended 
regimens (65).  These recommendations are applicable to all HBV co-infected individuals 
irrespective of whether the individuals are chronically or newly infected. 
 
In this chapter I will describe the strategies for treating HBV infection in the context of HIV 
within the UK CHIC study and assess the virological outcomes of HBV treatment among 
HIV/HBV co-infected individuals.
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8.2 Methods 
8.2.1 Inclusion criteria 
Hepatitis test data was cleaned as previously described and individuals were assigned to 
infection categories according to results of HBsAg, anti-HBc and anti-HBs tests (Chapter 5, 
section 5.3.3).  Only those who had ever had an infected status were included in this analysis.     
 
While interferon can be used to treat HBV infection, it is the primary treatment option for HCV 
infection.  Therefore, where individuals are triple-infected, and there is evidence of interferon 
treatment, this treatment is likely in use for HCV infection.  Therefore these analyses were 
restricted to those individuals who were HIV/HBV co-infected without evidence of HCV 
infection.  There were 444 individuals in the dataset who had evidence of HIV/HBV/HCV triple 
infection.  Of these, 233 individuals had their first positive HCV test before or at the same time 
as their first positive HBV test.  These 223 individuals were excluded from all analysis.  A 
further 211 individuals had their first HCV-positive test after their first positive HBV test.  These 
individuals were included in the analysis of HBV treatment but their follow-up was censored 
when they became HCV-positive.  Differences between those individuals who were included in 
the analysis, those who were excluded and those who were included but whose follow-up was 
censored are shown in Table 8.1. 
 
Among the HBV co-infected cohort, there were 16 individuals who had evidence of treatment 
for HBV infection but for whom the dates of treatment were missing.  These individuals were 
excluded from the analyses.
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Table 8.1 Characteristics of individuals included in the analysis compared to those who are 
excluded on the basis of HCV positivity 
 Included  
N=1318 
Excluded from 
start N=233 
Included but 
censored 
 N=211 
P-value 
N % N % N %  
Median age 
(years)(IQR) 
37 (31, 43) 39 (34, 45) 37 (31, 41) 0.002 
Ethnicity        
White  640 48.6 160 68.7 149 70.6 <0.0001 
Black African  441 33.5 15 6.4 15 7.1  
Other black 79 6.0 3 1.3 11 5.2  
Other/unknown 158 12.0 55 23.6 36 17.1  
HIV exposure 
group 
       
MSM 734 55.7 114 48.9 170 80.6 <0.0001 
IDU 14 1.1 55 23.6 9 4.3  
Male heterosexual 258 19.6 34 14.6 16 7.6  
Female 
heterosexual 236 17.9 21 9.0 5 2.4  
Other/unknown 76 5.8 9 3.9 11 5.2  
Year of first 
positive HIV test 
       
<1996 102 7.7 2 1.0 11 5.2 <0.0001 
1996-1999 109 8.3 5 2.2 21 10.0  
2000-2004 473 35.9 29 12.5 48 22.8  
2005-2009 477 36.2 146 62.7 125 59.2  
>2010 157 11.9 51 21.9 6 2.8  
Median CD4 count 
(cells/mm3) (IQR)1 
308 (150, 479) 401 (226, 605) 448 (290, 630) <0.0001 
HIV viral load 
(copies/ml) 
       
<50 298 22.6 104 44.6 61 28.9 <0.0001 
>50 756 57.4 115 49.4 109 51.7  
Unknown 264 20.0 14 6.0 41 19.4  
HIV treatment        
None 724 54.9 89 38.2 124 58.7 <0.0001 
<3 drugs 59 4.5 5 2.2 3 1.4  
>3 drugs 535 40.6 139 59.6 84 39.8  
HBV treatment        
None 832 63.1 95 40.8 138 65.4 <0.0001 
1 drug 235 17.8 55 23.6 46 21.8  
>1 drug 251 19.0 83 35.6 27 12.8  
1 CD4 count was unknown for 159 included individuals, 13 excluded individuals and 26 
individuals whose follow-up was censored 
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8.2.2 First recorded HBV-active treatment  
Baseline date was defined as the latest of the first HBsAg test or entry into the study cohort.  
Cohort entry was used as baseline for those individuals who had a first positive HBsAg test 
prior to this date as data is more reliable once an individual has entered the cohort and is 
under active follow-up.  HBV-active treatment was defined as any regimen which included at 
least one of lamivudine; tenofovir; emtricitabine; adefovir; entecavir; telbivudine; or interferon 
(pegylated or not).  HBV treatment regimens were defined as a recommended regimen type 
where two or more HBV-active drugs were being used; or an other regimen type where only 
one HBV-active drug was being used. HAART was defined as three or more HIV drugs (which 
may include those HIV drugs which are also active against HBV).  
 
Individuals were defined as being on HBV treatment at the start of follow-up if there was 
evidence that they were currently taking any HBV-active drugs at the time of their first positive 
HBsAg test.  Individuals who either were or were not on HBV treatment at baseline were then 
further characterised according to their HIV treatment:  HAART; non-HAART HIV treatment 
(fewer than three HIV active drugs); or no HIV treatment.  Similarly, those individuals who 
were on HBV treatment at baseline were further categorised according to the number of HBV-
active drugs they were taking.  The specific drugs included in the HBV treatment regimens 
which were in use at baseline were then described.   
 
Multivariable logistic regression was used to assess baseline characteristics associated with 
being on HBV treatment at the start of follow-up.   Baseline age and CD4 count were included 
as continuous variables.  Ethnicity, HIV exposure group, HIV viral load, HBV viral load and 
HBeAg status were included as categorical variables.  Baseline HBV-DNA value and baseline 
HBeAg status were unknown for 85% and 33% of individuals respectively.  Therefore three 
separate multivariable models were constructed.  Model 1 included baseline demographic and 
HIV-related covariates found to be associated with being on treatment in the univariable 
analysis.  Model 2 also included baseline HBV-DNA, where known, and model 3 included 
baseline HBeAg where known.  
 
Starting HBV treatment for the first time was assessed among those individuals who were not 
on HBV treatment at baseline.  Individuals were defined as starting HBV treatment if there was 
evidence of them commencing any regimen including at least one agent active against HBV.  
These individuals were further characterised according to their HIV treatment and the number 
of HBV-active drugs contained in the first regimen.  Those individuals who were not on HBV 
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treatment at baseline and who did not start HBV treatment during follow-up were 
characterised according to whether or not they started HIV treatment during follow-up.   
 
Time to starting treatment was described using Kaplan Meier plots.  Those individuals who did 
not commence treatment were followed-up until their last seen date or their date of death, 
where an individual had died.  Predictors of starting HBV treatment were identified using a 
multivariable Cox proportional hazards model.  CD4 count, HIV viral load, HBV viral load and 
HBeAg status were included in the analysis as time-updated variables.  Age, ethnicity, HIV 
exposure group and year of first positive test were fixed at baseline.    
 
Among those individuals whose first evidence of HBV treatment was with a regimen that 
included only one HBV-active agent, changes in treatment regimen were examined to identify 
those individuals who were still not on a recommended regimen type by the end of follow-up.  
The clinical characteristics of these individuals were described.  
   
8.2.3 Virological response to treatment 
Three virological outcomes of HBV treatment were assessed:  loss of HBeAg; development of 
anti-HBe; and suppression of HBV replication.   Baseline HBeAg status was assessed as the 
result of any HBeAg test up to two weeks after starting treatment.  Individuals were included 
in the analysis if they were HBeAg-positive at baseline, and had at least one further HBeAg test 
result available after starting treatment.  Loss of HBeAg was defined as any negative HBeAg 
test result after the start of treatment.  Anti-HBe seroconversion was assessed among those 
individuals who had evidence of HBeAg loss after starting treatment.  Seroconversion was 
defined as any positive anti-HBe test after loss of HBeAg.  Suppression of HBV viral replication 
was assessed among all individuals who were known to be HBV-DNA positive at baseline.  
Suppression was defined as any negative HBV-DNA test result after starting treatment.   
 
For all analyses individuals were followed from the latest of starting HBV treatment or entry 
into the cohort until the earliest of evidence of the outcome of interest, the last follow-up date 
or the date of death.  Factors associated with each treatment outcome were assessed using 
Cox proportional hazards models (a separate model was constructed for each treatment 
outcome).  CD4 count, HIV viral load and HBV regimen type were included in the analyses as 
time-updated variables.  Age, ethnicity, HIV exposure group and year of first positive HBsAg 
test were fixed at baseline.  Baseline HBeAg was also included in the analysis of factors 
associated with suppression of HBV viral replication.  HBV treatment type (recommended or 
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not) was included in all models irrespective of associations in the univariable analyses in order 
to test whether apparent differences in treatment response according to other demographic 
and clinical characteristics were, in fact, due to use of different treatment strategies.
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8.3 Results 
8.3.1 First recorded HBV-active treatment 
There were 1529 HIV/HBV co-infected individuals, included in the analysis.  Of these 559 
(36.6%) were taking any drugs which were active against HBV at baseline.  Further details 
about HIV and HBV treatment at baseline are shown in Figure 8.1.  The majority of individuals 
who were on HBV-active treatment at the start of follow-up were on a HAART regimen which 
included at least two HBV-active drugs.  Baseline characteristics of individuals who were on 
treatment at the start of follow-up compared to those who were not were compared using 
ORs from univariable logistic regression (Table 8.2). In univariable analysis, older individuals 
were significantly more likely to be on HBV-active treatment at the start of follow-up.  
Compared to those individuals whose first positive HBV test was in 2005-9, those whose first 
positive HBV test was in earlier years were less likely to be on HBV-active treatment at the 
start of follow-up.  Individuals with detectable HIV viral load and unknown HIV viral load were 
less likely to be in HBV-active treatment at the start of follow up than those with undetectable 
viral load.  Individuals with higher HBV viral load (>2000 IU/ml) were more likely than those 
with HBV viral load <2000 IU/ml to be on treatment at the start of follow-up. 
 
Three multivariable models were constructed to identify those factors which were 
independently associated with being on treatment at the start of follow-up (Table 8.3).  The 
basic model (model 1) included those demographic and HIV-related factors identified as being 
significantly associated with being on treatment at the start of follow-up in the univariable 
analysis:  age; year of first positive test; and HIV viral load.  These variables remained 
associated with being on treatment at the start of follow-up after being entered to the 
multivariable model.  Older individuals remained significantly more likely to be on treatment at 
the start of follow-up than younger individuals (AOR, 95% CI: 1.26, 1.09-1.46 per additional 10 
years of age).  Compared to those individuals whose first recorded evidence of HBV infection 
was in 2005-2009, those who were first recorded as infected before 1996 were less likely to be 
on treatment at the start of follow-up (AOR, 95% CI: 0.29, 0.12-0.71), as were those whose first 
positive HBV test was in 2000-2004 (AOR, 95% CI: 0.74, 0.56-0.98).  Compared to individuals 
with undetectable HIV viral load, those with detectable HIV viral load (>50 copies/ml) were 
significantly less likely to be on HBV-active treatment at the start of follow-up (AOR, 95% CI: 
0.10, 0.07-0.14).   
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These associations remained unchanged when either HBV-DNA status or HBeAg status were 
added to the model.  When HBV-DNA status was included in the model (model 2), those with 
unknown HBV-DNA levels were less likely to be on treatment than those with lower HBV-DNA 
levels (AOR 0.42, 95% CI: 0.26-0.68).  There was no significant difference between those with 
higher or lower HBV-DNA in the likelihood of being on treatment (AOR 0.58, 95% CI: 0.32-
1.08).  When HBeAg status was added to the basic model (model 3), there was no association 
shown between HBeAg status and being on treatment at the start of follow-up. 
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>1 HBV drug 
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1 HBV drug 
N=1 
Figure 8.1 HIV and HBV treatment among co-infected individuals at baseline 
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Table 8.2 Baseline characteristics and crude odds ratios from univariable logistic regression of factors associated with being on HBV-active treatment at 
the start of follow-up 
 Not on treatment On treatment Univariable analysis 
Number % Number % OR 95% CI P value 
Median age (years) (IQR) 36 (30, 41) 39 (34, 45) 1.61 1.42-1.83 <0.0001 
Ethnicity        
White 509 52.5 280 50.1 1 - - 
Black African 278 28.7 178 31.8 1.16 0.92-1.48 0.21 
Black other 58 6.0 32 5.7 1.00 0.64-1.58 0.99 
Other/unknown 125 12.9 69 12.3 1.00 0.72-1.39 0.98 
HIV exposure group        
MSM 599 61.8 305 54.6 1 - - 
IDU 12 1.2 11 2.0 1.80 0.79-4.13 0.16 
Male heterosexual 157 16.2 117 20.9 1.46 1.11-1.93 0.01 
Female heterosexual 146 15.1 95 17.0 1.28 0.95-1.71 0.10 
Other/unknown 56 5.8 31 5.6 1.09 0.69-1.72 0.72 
Year of first positive HBV test        
<1996 107 11.0 6 1.1 0.07 0.03-0.17 <0.0001 
1996-1999 100 10.3 30 5.4 0.39 0.25-0.61 <0.0001 
2000-2004 329 33.9 192 34.4 0.76 0.60-0.97 0.03 
2005-2009 341 35.2 261 46.7 1 - - 
>2010 93 9.6 70 12.5 0.98 0.69-1.40 0.92 
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 Not on treatment On treatment Univariable analysis 
Number % Number % OR 95% CI P value 
Median CD4 count 
(cells/mm3) (IQR) 
335 (185, 504) 310 (143, 500) 0.98 0.94-1.03 0.36 
HIV viral load (copies/ml)        
<50 70 7.2 289 51.7 1 - - 
>50 626 64.5 239 42.8 0.09 0.07-0.13 <0.0001 
Unknown 274 28.3 31 5.6 0.03 0.02-0.04 <0.0001 
HBV viral load (IU/ml)        
<2000 35 3.6 70 12.5 1 - - 
>2000 65 6.7 56 10.0 0.43 0.25-0.74 0.002 
Unknown 870 89.7 433 77.5 0.24 0.16-0.38 <0.0001 
HBeAg status        
Negative 292 30.1 141 25.2 0.95 0.73-1.24 0.71 
Positive 392 40.4 199 35.6 1 - - 
Unknown 286 29.5 219 39.2 1.51 1.18-1.93 0.001 
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Table 8.3 Adjusted odds ratios from multivariable logistic regression models of factors associated with being on HBV-active treatment at the start of 
follow-up 
 Multivariable model 11 Multivariable model 22 Multivariable model 33 
AOR 95% CI P value AOR 95% CI P value AOR 95% CI P value 
Median age (years) (IQR)4 1.26 1.09-1.46 0.001 1.24 1.07-1.44 0.004 1.27 1.10-1.47 0.001 
Year of first positive HBV 
test 
         
<1996 0.29 0.12-0.71 0.01 0.31 0.12-0.76 0.01 0.29 0.12-0.72 0.01 
1996-1999 0.79 0.48-1.30 0.36 0.87 0.53-1.43 0.57 0.84 0.50-1.38 0.49 
2000-2004 0.74 0.56-0.98 0.03 0.76 0.57-1.01 0.06 0.74 0.56-0.98 0.04 
2005-2009 1 - - 1 - - 1 - - 
>2010 0.91 0.61-1.37 0.65 0.84 0.55-1.26 0.40 0.95 0.63-1.44 0.82 
HIV viral load (copies/ml)          
<50 1 - - 1 - - 1 - - 
>50 0.10 0.07-0.14 <0.0001 0.10 0.08-0.14 <0.0001 0.10 0.08-0.14 <0.0001 
Unknown 0.04 0.03-0.07 <0.0001 0.04 0.03-0.07 <0.0001 0.04 0.03-0.07 <0.0001 
HBV viral load (IU/ml)          
<2000 - - - 1 - - - - - 
>2000 - - - 0.58 0.32-1.08 0.09 - - - 
Unknown - - - 0.42 0.26-0.68 0.001 - - - 
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 Multivariable model 11 Multivariable model 22 Multivariable model 33 
AOR 95% CI P value AOR 95% CI P value AOR 95% CI P value 
HBeAg status          
Negative - - - - - - 0.92 0.68-1.27 0.62 
Positive - - - - - - 1 - - 
Unknown - - - - - - 1.19 0.88-1.60 0.26 
 
1 Model 1 includes those demographic and HIV-related factors associated with being on treatment in univariable analysis. 
2 Model 2 includes those demographic and HIV-related factors associated with being on treatment in univariable analysis and HBV viral load 
3 Model 3 includes those demographic and HIV-related factors associated with being on treatment in univariable analysis and HBeAg status 
4 OR per 10 additional years
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Those individuals who were not on treatment at baseline were followed-up until they started 
treatment, were lost to follow-up or died.  The majority of individuals who started treatment 
during follow-up commenced HAART which included at least two HIV active drugs.  Of those 
who did not start treatment, only a small minority started any kind of HIV treatment.  Details 
of treatment commencement among these individuals are shown in Figure 8.2.  The 970 
individuals contributed a total of 1985 person-years of follow-up during which 750 started 
treatment.  Median follow-up was 0.9 years (IQR 0.2, 3.0): 0.78 (IQR 0.19, 2.71) among those 
who started HBV treatment during follow-up and 1.77 (IQR 0.42, 3.89) among those who did 
not start HBV treatment during follow-up.  Time to starting treatment is shown in Figure 8.3.   
 
 In univariable analysis, starting treatment was associated with older age, black ethnicity (black 
African and other black ethnic groups were more likely to start treatment), heterosexual HIV 
exposure group (male and female), other HIV exposure group, having first positive test after 
2005 and having a lower CD4 count (Table 8.4).  In multivariable analysis the association with 
black African ethnicity was lost (AHR, 95% CI: 0.85, 0.65-1.11) while individuals of other black 
remained more likely than white individuals to start treatment (AHR, 95% CI: 1.45, 1.05-2.00). 
The association between heterosexual HIV exposure and starting treatment was lost after 
adjusting for other factors. In addition there was no significant difference in starting treatment 
between MSM and individuals of other HIV exposure groups.  However, in the multivariable 
analysis, compared to MSM, IDU were significantly less likely to start treatment (AHR 0.45, 
95% CI: 0.22-0.96). The associations seen in univariable analysis between later years of first 
positive and starting treatment were also observed in the multivariable model.  CD4 count also 
remained significantly associated with starting treatment, with those individuals who had 
higher CD4 counts being less likely to start treatment (AHR, 95% CI: 0.61, 0.58-0.64).  
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Figure 8.2 HIV and HBV treatment among co-infected individuals who start treatment during 
follow-up 
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Table 8.4 Hazards ratios from univariable and multivariable Cox Proportional Hazards models of factors associated with starting treatment 
 Univariable analysis Multivariable analysis 
HR 95% CI P value AHR 95% CI P value 
Baseline age (per additional 10 years) 1.28 1.17-1.40 <0.0001 1.02 1.01-1.02 0.001 
Ethnicity       
White 1 - - 1 - - 
Black African 1.29 1.09-1.52 0.003 0.85 0.65-1.11 0.21 
Other black 1.57 1.15-2.13 0.004 1.45 1.05-2.00 0.02 
Other/unknown 0.94 0.74-1.19 0.59 0.79 0.61-1.02 0.06 
HIV Exposure group       
MSM 1 - - 1 - - 
IDU 0.71 0.34-1.50 0.37 0.45 0.22-0.96 0.04 
Male heterosexual 1.57 1.29-1.92 <0.0001 0.86 0.66-1.13 0.28 
Female heterosexual 1.41 1.15-1.73 0.001 1.05 0.78-1.43 0.74 
Other/unknown 1.91 1.38-2.66 0.0001 1.11 0.78-1.59 0.57 
Year of first HBV-positive test       
<1996 0.57 0.44-0.72 <0.0001 0.29 0.22-0.38 <0.0001 
1996-1999 0.68 0.53-0.87 0.002 0.42 0.32-0.55 <0.0001 
2000-2004 0.79 0.66-0.95 0.01 0.52 0.43-0.63 <0.0001 
2005-2009 1 - - 1 - - 
>2010 1.97 1.47-2.64 <0.0001 2.39 1.48-3.22 <0.0001 
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 Univariable analysis Multivariable analysis 
HR 95% CI P value AHR 95% CI P value 
Current CD4 count (per 100 cells/mm3) 0.67 0.64-0.69 <0.0001 0.61 0.58-0.64 <0.0001 
Current HIV Viral load (copies/ml)       
<50 1 - - - - - 
>50 1.22 0.98-1.52 0.08 - - - 
Current HBV-DNA (IU/ml)1       
<2000 1 - - - - - 
>2000 1.63 1.15-2.33 0.01 - - - 
Current HBeAg status2       
Positive 1.09 0.92-1.28 0.32 - - - 
Negative 1 - - - - - 
  
1 HBV-DNA was not included in the multivariable model as only 254 individuals had at least one measure during follow-up (158 treated individuals and 69 
individuals who did not start treatment). 
2 Only 656 individuals had at least one HBeAg test during follow-up (520 treated individuals and 136 individuals who were not treated)
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Figure 8.3 Kaplan Meier curve and corresponding life table showing time to starting HBV-
active treatment 
 
Time from 
first positive 
2 4 6 8 10 12     14 
Number 
eligible 
340 170 85 42 17 8     3 
 
 
Among both those who started treatment at or before the start of follow-up and those who 
commenced treatment after the start of follow-up, the most common initial treatment 
strategy was HAART which included two or more HBV-active drugs.  First HBV-active treatment 
regimens used are shown in Table 8.5.  The most commonly used first HBV-active regimen was 
lamivudine only followed by tenofovir plus emtricitabine. 
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Table 8.5 HBV-active drug combinations used in first recorded HBV-active regimen 
HBV drug combination Individuals on HBV 
treatment at baseline 
Individuals starting 
HBV treatment after 
baseline 
Total 
 Number % Number % Number  % 
Regimens of 1 HBV-active drug  
Lamivudine 245 43.8 276 36.8 521 39.8 
Tenofovir 32 5.7 49 6.5 81 6.2 
Adefovir  1 0.2 6 0.8 7 0.5 
Emtricitabine  3 0.5 4 0.5 7 0.5 
Interferon 0 0.0 1 0.1 1 0.1 
Unknown drug 0 0.0 3 0.4 3 0.2 
Regimens including >1 HBV-active drug 
Tenofovir + emtricitabine  178 31.8 315 42.0 493 37.7 
Lamivudine + tenofovir 94 16.8 94 12.5 188 14.4 
Tenofovir + emtricitabine 
+ interferon 
1 0.2 0 0.0 1 0.1 
Lamivudine + tenofovir + 
emtricitabine 
5 0.9 2 0.3 7 0.5 
 
 
Among all those individuals who have any HBV treatment (N=1309), 679 start treatment on a 
recommended regimen (one which includes at least three HIV-active drugs and 2 HBV-active 
drugs).  Of the 630 individuals whose first HBV treatment is not a recommended regimen, 445 
(70.6%) subsequently switch to a recommended regimen (median time to switching to 
recommended regimen was 3.1 years, IQR 0.9-5.7 years).  Clinical characteristics of the 185 
individuals who did not receive a recommended regimen during follow-up are shown in Table 
8.6.  The majority of these individuals had high CD4 counts (>60% had a CD4 count >350 
cells/mm3) and detectable HIV viral load (>50 copies/ml).  HBV-DNA was unknown for 70% of 
these individuals but where known the majority had HBV-DNA <2000 IU/ml.  Almost half of 
these individuals were known to be HBeAg-negative.  There was a very small group of 
individuals (N=6) who had evidence of cirrhosis.  For all these individuals cirrhosis had been 
identified by liver biopsy.
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Table 8.6 Clinical Characteristics of individuals on non-standard HBV-active regimens at the 
end of follow-up 
  Number of 
individuals 
% 
Median age (years) (IQR)  45  (38, 51) 
CD4 count (cells/mm3) ≤200 29 15.7 
 201-350 37 20.0 
 351-500 37 20.0 
 >500 80 43.2 
 Unknown 2 1.1 
HIV viral load (copies/ml) ≤50 131 70.8 
 >50 51 27.6 
 Unknown 3 1.6 
HBV viral load (IU/ml) <2000 45 24.3 
 ≥2000 10 5.4 
 Unknown 130 70.3 
HBeAg status Negative 91 49.2 
 Positive 47 25.4 
 Unknown 47 25.4 
APRI Score 0-0.5 10 5.4 
 0.6-1.5 10 5.4 
 1.5-2.0 0 0.0 
 >2.0 1 0.5 
 Unknown 164 88.6 
FibroScan® Result (KPa) <7  5 2.7 
 7-9 1 0.5 
 10-13 0 0.0 
 >14 0 0.0 
 Unknown 179 96.8 
Biopsy result No significant fibrosis 1 0.5 
 Fibrosis, but no cirrhosis 7 3.8 
 Cirrhosis 6 3.52 
 Unknown 171 92.4 
Any evidence of cirrhosis No cirrhosis 32 17.3 
 Cirrhosis 6 3.2 
 Unknown 147 79.5 
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8.3.2 Virological response to treatment 
Of all treated individuals, 769 had a baseline HBeAg status, 319 were HBeAg-negative and 450 
were HBeAg-positive.  Of the 450 who were positive at baseline 372 had at least one further 
HBeAg test result after starting treatment and so were included in the analysis.  Of the 372 
HBeAg-positive individuals with a further test result available, 147 (39.5%) had a negative test 
at some point during follow-up.  Median time follow-up time was 4.1 years (IQR 1.5, 10.9 
years):   1.6 years (IQR 0.7, 4.3 years) for individuals who lost HBeAg; and 5.9 years (IQR 3.0, 
9.4 years) for those who did not lose HBeAg.  Of the 147 individuals who lost HBeAg, an anti-
HBe test result was available for 137 individuals.  Of these, 79/137 (57.7%) could be defined as 
having seroconverted to anti-HBe positive after starting treatment.   
 
Baseline HBV-DNA status was known for 404 individuals: 296 (73.3%) were positive and 108 
(26.7%) were negative.  Of those who were positive at baseline, 252 had at least one further 
test result after starting treatment so response to treatment could be assessed.  Among these 
individuals 206 (81.7%) had a response to treatment defined as a negative test result after 
starting treatment.  Median follow-up among those who did not suppress HBV was 1.8 years 
(IQR 0.8, 3.8) and median time to suppression was 0.9 years (IQR 0.4, 1.7 years).  
 
Independent predictors of each of the three treatment outcomes were investigated using 
separate Cox proportional hazards models.  Results of the univariable analyses are shown in 
Table 8.7.  Results of the multivariable analyses are shown in Figure 8.4.  Being on a 
recommended HBV treatment regimen was significantly associated with loss of HBeAg after 
commencing treatment (AHR 1.67, 95% CI: 1.17-2.39) compared to being on other treatment 
regimens.  Compared to those who commenced HBV treatment in the years 2000-2004, those 
who commenced treatment in later years (2005-2009) were significantly more likely to have 
evidence of anti-HBe seroconversion (AHR 2.21, 95% CI: 1.16-4.22).  Higher CD4 count was 
significantly associated with HBV-DNA suppression, although the effect size was small (AHR 
1.10, 95% CI: 1.03-1.18 per 100 cells/mm3 increase).  Compared to those who were HBeAg-
negative at baseline, those who were HBeAg-positive were less likely to supress HBV-DNA 
(AHR 0.51, 95% CI: 0.35-0.75). 
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Table 8.7 Hazard ratios from univariable Cox proportional hazards models of predictors of HBV treatment response 
 HBeAg loss Anti-HBe seroconversion HBV-DNA suppression 
HR 95% CI P value HR 95% CI P value HR 95% CI P value 
Age (per 10 years) 1.16 0.95-1.42 0.16 0.90 0.67-1.20 0.47 1.08 0.91-1.29 0.36 
Ethnicity          
White 1 - - 1 - - 1 - - 
Black African 0.45 0.27-0.76 0.003 1.08 0.53-2.18 0.83 0.82 0.60-1.13 0.23 
Other black 0.47 0.21-1.08 0.08 0.53 0.07-3.80 0.52 0.64 0.33-1.28 0.21 
Other/unknown 1.21 0.72-2.02 0.047 1.21 0.62-2.37 0.58 0.78 0.51-1.21 0.27 
HIV Exposure group          
MSM 1 - - 1 - - 1 - - 
IDU 1.11 0.27-4.50 0.88 0.93 0.13-6.71 0.94 1.14 0.36-3.59 0.82 
Male heterosexual 0.43 0.24-0.78 0.01 1.25 0.57-2.75 0.57 0.77 0.53-1.13 0.18 
Female heterosexual 0.65 0.34-1.24 0.19 0.27 1.61-0.69 0.27 0.82 0.55-1.22 0.32 
Other/unknown 0.85 0.41-1.74 0.65 1.00 0.36-2.75 0.99 0.70 0.39-1.27 0.24 
Year of first HBV-
positive test 
         
<1996 1.45 0.84-2.50 0.18 1.27 0.63-2.58 0.51 1.28 0.52-0.35 0.60 
1996-1999 1.15 0.73-1.83 0.55 1.65 0.93-2.94 0.09 1.84 0.66-4.95 0.25 
2000-2004 1 -  1 -  1 - - 
2005-2009 1.17 0.76-1.79 0.47 2.41 1.30-4.47 0.01 0.98 0.74-1.32 0.92 
>2010 1.78 0.71-4.51 0.22 5.75 1.31-25.30 0.02 1.02 0.58-1.80 0.94 
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 HBeAg loss Anti-HBe seroconversion HBV-DNA suppression 
HR 95% CI P value HR 95% CI P value HR 95% CI P value 
Current CD4 count (per 
100 cells/mm3) 
1.04 0.98-1.10 0.16 0.94 0.85-1.03 0.19 1.07 1.02-1.13 0.01 
Current HIV viral load 
(copies/ml) 
         
<50 1 - - 1 - - 1 - - 
>50 0.80 0.54-1.18 0.26 1.34 0.79-2.28 0.27 0.89 0.64-1.24 0.49 
Timing of starting HBV 
treatment 
         
Before first positive 1 - - 0.66 0.41-1.07 0.09 0.83 0.62-1.11 0.20 
After first positive 0.73 0.53-1.02 0.06 1 - - 1 - - 
HBV treatment type          
Recommended regimen 1.65 1.15-2.35 0.01 1.31 0.81-2.11 0.27 1.42 0.97-2.07 0.07 
Other regimen 1 - - 1 - - 1 - - 
HBeAg status          
Negative N/A N/A N/A N/A N/A N/A 1 - - 
Positive N/A N/A N/A N/A N/A N/A 0.55 0.38-0.79 0.001 
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Figure 8.4 Adjusted hazard ratios from multivariable Cox proportional hazards models of factors associated with each of the three virological responses to HBV 
treatment (HBeAg loss, anti-HBe seroconversion and HBV-DNA suppression) 
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8.4 Discussion 
8.4.1 Summary of findings 
In this cohort of HIV/HBV co-infected individuals, the large majority commenced treatment for 
HIV and HBV either before or during follow-up.  In addition, the most common treatment 
regimens included at least 3 anti-HIV and 2 anti-HBV drugs. Tenofovir and emtricitabine was 
the most commonly used combination of anti-HBV drugs followed by tenofovir and 
lamivudine.  These results indicate that guidelines for treatment of HIV/HBV co-infection are 
largely well adhered to among this group of patients.     
 
Among those where response to treatment could be assessed, being on a recommended 
treatment regimen (compared to being on a regimen containing only one anti-HBV drug), 
having a higher CD4 count, starting treatment in later years and being HBeAg-negative at 
baseline were all predictors of favourable treatment responses.  However, more than 60% of 
individuals remained HBeAg-positive and almost 20% of individuals did not suppress HBV-DNA 
throughout follow-up despite receiving treatment. 
 
8.4.2 Interpretation of results 
Although the majority of individuals in this cohort did start treatment for HBV during follow-up 
it is important to understand who those individuals who have not been treated are.  There 
were several predictors of not starting treatment.  Firstly, in this cohort, not starting treatment 
for HBV infection was independently associated with higher CD4 count.  Since the guidelines 
for treatment recommend commencing treatment when CD4 count falls below 500 cells/mm3, 
it is likely that the association between higher CD4 counts and not starting treatment is due to 
individuals who have yet to reach the threshold for commencing treatment.  Secondly, 
individuals who had a very long standing HBV infection (a first positive result prior to 1996) 
were less likely to be on treatment at the start of follow-up and less likely to commence 
treatment during follow-up.  One explanation for this is that this group of individuals may 
include those who have cleared their HBV infection previously.  Finally, IDU were less likely to 
start HBV treatment compared to MSM.  This finding is consistent with other analyses which 
have shown that IDU are less likely to start HIV treatment than individuals who acquired their 
HIV through sex or other transmission modes (516, 517) and are more likely to be lost to 
follow-up at all stages of care (518). 
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Similarly, although most individuals either commenced treatment with 2 or more HBV drugs or 
switched to a regimen of 2 or more HBV drugs it is important to understand the possible 
reasons why a small group of individuals start treatment with a regimen containing only one 
HBV-active drug.  A high proportion of these individuals was known to be HBeAg-negative and 
had low levels of HBV-DNA and high CD4 counts. These results indicate that these individuals 
have yet to reach any of the thresholds for treatment commencement.     
 
An important finding of the analyses presented in this chapter is that those individuals who 
started treatment on a recommended regimen (at least two HBV drugs) were more likely to 
lose HBeAg than those who started on any other regimen.  Since HBeAg loss is associated with 
favourable liver outcomes (260) and low levels of HBV-DNA (519), this finding reinforces the 
importance of using at least two HBV-active drugs within an HIV/HBV treatment regimen. 
Although this analysis did not specifically investigate the impact of HAART on HBV infection, 
the finding that higher CD4 counts were associated with suppression of HBV replication also 
highlights the importance of successful HIV treatment as a key component of HBV 
management in the co-infected population.   
 
Individuals whose first positive HBsAg tests were in later years were more likely to develop 
anti-HBe.  It is possible that this is due to use of lamivudine monotherapy for HBV infection 
among those who were first positive for HBV in earlier years.  This association remained even 
after adjusting for HBV treatment regimen type.  However, given the limited number of 
individuals in earlier years who would have been treated using more than one HBV-active 
drug, it may not be possible to explain all of the calendar year effect by adjusting for treatment 
type and it is possible that the effect of calendar year is still due, in part, to the use of less 
effective single drug treatment regimens in the earlier years.   
 
8.4.3 Comparisons with literature 
In UK CHIC, 37% of co-infected individuals were already on HBV-active treatment at the time of 
their first positive HBsAg test and of those who were not 77% subsequently started treatment, 
giving a total of 86% of co-infected patients in UK CHIC who receive any treatment for HBV 
infection. This is comparable with findings from a cohort of 427 HIV/HBV co-infected 
individuals seen for care at Italian hospitals; 88% of whom had received treatment for HBV at 
some point during their infection (520). A recent study of the management of HBV in mono-
infected individuals found that only one third of individuals were on treatment and that only 
18% were on a recommended regimen (521).  Therefore the finding that the majority of co-
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infected individuals in this cohort do commence treatment and either do so with, or switch to, 
a recommended regimen is encouraging. 
 
Previous studies investigating HBeAg loss among cohorts of HIV/HBV co-infected individuals 
have shown variation from 18% to 46% in the proportions of individuals who lose HBeAg after 
starting treatment (386, 388, 391, 444, 446, 522).  All of these studies included very small 
numbers of individuals (<100 HBeAg-positive individuals in each study).  However, the 
estimates of the number of individuals who lose HBeAg are comparable with the figure of 
39.5% reported in this chapter.  In the analyses presented in this chapter, of those individuals 
who lose HBeAg, 57.7% were known to seroconvert to anti-HBe positive.  This estimate is 
comparable with that from Kosi et al (523) who observed seroconversion among 25/57 HBeAg-
positive individuals who were followed-up for 5 years.  Other studies have shown lower 
proportions of individuals who seroconvert to anti-HBe positive.  Jain et al reported that only 
16% of patients showed evidence of seroconversion (444) and Lacombe et al reported that 
17% of individuals seroconverted (524).  Again, both of these studies include small numbers of 
HBeAg-positive individuals (N=32 in Jain et al and N=24 in Lacombe et al).  In addition, shorter 
durations of follow-up were observed in these studies; all individuals were followed for 1 year 
in the study by Jain et al and median follow-up in the study by Lacombe et al was 1.4 years.   
By contrast, in the present study median follow-up among HBeAg-positive individuals was 4.1 
years.  This shorter follow-up in previous studies may, in part, explain the differences in the 
proportion of individuals who have evidence of anti-HBe seroconversion seen in previous 
studies and that reported in this chapter.    
 
Among HIV/HBV co-infected individuals in UK CHIC, being on a recommended HBV treatment 
regimen (>2 HBV-active drugs) was significantly associated with losing HBeAg.  The association 
between treatment regimen and likelihood of losing HBeAg was investigated in three of the 
previously mentioned studies (386, 388, 444).  None of these studies found significant 
associations between treatment type and HBeAg loss, but this is likely to be due to the small 
number of individuals included in the studies.  However, Jain et al did report that a higher 
proportion of individuals who received tenofovir and lamivudine in combination lost HBeAg 
compared to those who received lamivudine alone.  
 
The finding in this chapter that the large majority of treated individuals suppress HBV 
replication (measured by loss of HBV-DNA) is in agreement with other studies (386, 440, 446, 
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522, 523) as is the association of baseline HBeAg status with suppression of HBV replication 
(388, 522, 525).  A number of previous studies have found an association between HBV 
treatment regimen and HBV viral suppression.  For example Jain et al showed that 80% of 
individuals who received tenofovir and lamivudine in combination suppressed HBV replication 
compared to only 60% of individuals who received lamivudine alone.  However, small numbers 
mean that this difference was not statistically significant (444).  In addition, significantly 
greater decreases in HBV-DNA have been observed among individuals who receive a 
combination of tenofovir and emtricitabine compared to those who receive emtricitabine 
alone (446).  A recently published study, of 115 HIV/HBV co-infected individuals receiving 
lamivudine or emtricitabine monotherapy or tenofovir plus lamivudine or emtricitabine, 
followed individuals for a total of 144 weeks of treatment.  While there were not significant 
differences in viral suppression at 24 weeks, by the end of follow-up a significantly higher 
proportion of those receiving dual therapy had suppressed HBV replication than those 
receiving monotherapy (526).  In agreement with these studies, in the present analysis a 
higher proportion of individuals on a recommended regimen suppressed HBV replication than 
those on other regimens.  However, after adjusting for CD4 count and baseline HBeAg status 
the association was not significant.   
 
In this cohort higher CD4 count was significantly associated with HBV viral suppression when 
entered into the model as a time updated covariate.  This finding is in agreement with the 
study published by Nunez et al, which showed that greater CD4 gains in response to treatment 
are significantly associated with having undetectable HBV-DNA after a median of 52 weeks of 
follow-up (388).  Therefore, the finding in the present analysis that HBV treatment type is not 
significantly associated with HBV suppression may be due to a lack of power, with too small a 
sample to detect any difference in HBV suppression between the two treatment groups.  
However, it is also possible that CD4 count is acting as a confounder since it is associated both 
with treatment type and with HBV suppression and therefore adjusting for CD4 removes 
associations between treatment type and HBV suppression. 
 
8.4.4 Strengths and weaknesses 
Compared to previous analyses of HBV treatment among cohorts of co-infected individuals, 
this analysis included a large sample of individuals who have attended for care at multiple 
centres.  Therefore, I have been able to assess the association of a large number of factors and 
response to treatment.  However, the analyses are limited by a lack of availability of some 
data. The HBV-DNA status was unknown for a high proportion of individuals.  It is unclear 
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whether this is due to non-reporting of these test results to UK CHIC or whether co-infected 
individuals are not being monitored for HBV-DNA levels in clinical practice.  A previous study 
conducted in a clinical cohort in the USA indicated that monitoring HBV-DNA levels in co-
infected individuals was suboptimal among a co-infected group of patients (527).  Similarly, a 
higher proportion of individuals did have HBeAg and anti-HBe test results available but there 
were still a significant proportion of individuals who were not included in the analysis of 
treatment response as test results were not available.  Therefore, when future data collection 
is undertaken, the availability of information on HBV-DNA, HBeAg and anti-HBe test results 
should be investigated.   
 
There are several additional factors which may influence the response to treatment, which 
were not included in the analyses presented in this chapter.  Individuals may enter the UK CHIC 
cohort at any point either prior or subsequent to acquiring HBV infection.  Therefore we were 
unable to assess the effect of the duration of HBV infection on the response to treatment.  We 
are also unable to assess the effect of HBV genotype on response to treatment.  Currently, 
clinical guidelines do not recommend routinely assessing HBV genotype and therefore there is 
no routinely collected data available (65).  However, previous studies have not found any 
association between HBV treatment response and infection with different genotypes (528).  In 
addition we were not able to assess the impact of resistance to anti-HBV drugs in this cohort.  
However, given the high levels of viral suppression demonstrated this is unlikely to have been 
an important factor in this cohort. It is known that use of lamivudine monotherapy can lead to 
the development of resistance.  However, in this cohort, while some individuals did commence 
treatment on lamivudine monotherapy, most later switched to a regimen of two or more 
drugs.  Other studies have shown that prior exposure to lamivudine monotherapy does not 
affect the response to subsequent use of tenofovir containing regimens (440, 441). 
 
There are several known side effects from long term use of tenofovir.  In particular, it is 
associated with renal damage and this has been observed in co-infected individuals (529, 530).  
This may lead to discontinuation of tenofovir as treatment which may have implications for the 
ongoing suppression of the infection.   Investigating changes in treatment due to renal toxicity 
was beyond the scope of this analysis.  However, further analyses in this cohort should 
investigate this. 
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8.4.5 Conclusions 
The analyses presented in this chapter have shown high levels of treatment for HBV infection 
with appropriate treatment regimens and a high proportion of individuals supressing their 
infection in this large cohort of co-infected individuals.  Although this is encouraging, 
treatment for HBV does not clear the virus and therefore it is important that co-infected 
individuals are continually monitored for the development of liver disease.   
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Chapter 9 Results 4:  Mortality and clinical progression of liver 
disease among HIV and hepatitis co-infected individuals 
 
9.1 Background 
Among HIV-positive populations, since the introduction of HAART, an increasing proportion of 
deaths have been due to liver disease and HBV and/or HCV co-infection (269, 270, 272, 273, 
531).  HIV-positive individuals co-infected with HBV and/or HCV have higher rates of 
progression to chronic hepatitis infection (326, 363, 382) and faster progression to fibrosis, 
cirrhosis, HCC and end-stage liver disease (261, 331, 332, 366) than individuals with hepatitis 
infection alone.   
 
Meta-analyses investigating the impact of HBV and/or HCV co-infection on mortality among 
HIV-positive individuals have shown that co-infection is significantly associated with increased 
mortality (275, 303). However there is variation in results when the included studies are 
examined independently.  These differences may be due to variations in underlying mortality 
rates in the cohorts studied as well as differences in treatment and management strategies for 
both HIV and hepatitis.  Therefore, previous findings may not be generalizable to a UK setting. 
 
A number of studies which have found no significant difference in mortality rates between 
HIV/HCV co-infected and HIV mono-infected individuals have observed higher numbers of 
deaths among co-infected individuals, but the association between co-infection and mortality 
is lost after adjusting for HIV infection related parameters (such as use of HAART and CD4 cell 
count) (277, 278, 280, 281).  Similarly, for studies that found no significant association 
between HIV/HBV co-infection and mortality, higher rates of mortality were often observed 
which were found to be non-significant only after entry into a multivariable model (257, 302).  
The large majority of previous studies examining mortality among co-infected individuals have 
reported on all-cause mortality and therefore it is not possible to examine whether the 
apparent increase in mortality is due to liver disease among co-infected individuals or due to 
other causes. 
 
The aims of this chapter are to compare mortality rates in co-infected individuals and HIV 
mono-infected individuals and to identify factors which may be associated with mortality 
among co-infected individuals in a UK context.  In addition, this chapter aims to identify factors 
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associated with progression of liver disease to cirrhosis; development of complications of liver 
disease; and survival among individuals with complicated liver disease.  
9.2 Methods 
9.2.1 Inclusion criteria 
Only those individuals who had been tested for HBsAg and for HCV-Ab/HCV-RNA were 
included in the analysis.  HBV and HCV data were cleaned as previously described (Chapter 5).  
For all analyses presented, individuals were defined as being HBV-infected from the date of 
their first positive HBsAg test and being HCV-infected from the date of their first positive anti-
HCV or HCV-RNA test. 
 
9.2.2 Defining causes of death 
In UK CHIC cause of death is received from the centres as part of the standard annual data 
submission.  Additional information on cause of death was collected as part of the expanded 
hepatitis data collection and any additional information was merged into the main UK CHIC 
dataset as previously described (Chapter 4, section 4.4.2).  In addition to the information on 
cause of death that was available to me at the time of the expanded data collection, there has 
been a subsequent standard UK CHIC data submission since the completion of the hepatitis 
data collection.  This may include further causes of death.  Finally, as part of an on-going 
project examining causes of death, UK CHIC data has been linked to death data from several 
additional sources.  In creating the UK CHIC standard dataset, data are obtained from ONS and 
PHE and the date of death updated where necessary (Chapter 3, section 3.2.4).  However, ONS 
and PHE datasets also include information on causes of death which, until now, had not been 
added into the UK CHIC dataset.  In addition, UK CHIC centres submit Cause of Death (CODE) 
forms for those individuals at their centres who have died.  CODE forms are standardised case 
report forms used by a number of HIV cohort studies in Europe which provide detailed 
information on cause of death where known (532).  In order to maximise the number of 
individuals for whom there was a known cause of death in the subsequent analyses, relevant 
information from all these sources of data were combined. 
 
For this analysis, recorded causes of death were coded as liver-related or not liver-related and 
as AIDS-related or not AIDS-related.  In order to ensure that all information on causes of death 
was utilised, cause of death information was divided into three datasets:  UK CHIC data 
(including data collected from the expanded hepatitis data collection); updated UK CHIC data 
from the latest data submission; and external data from PHE, ONS and CODE forms.  Deaths in 
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each of these three datasets were coded separately.  Coding was done without knowledge of 
an individual’s hepatitis status although there may have been reference to co-infection within 
the information recorded on cause of death.   
 
Deaths were coded as liver-related where there was clear evidence that disease in the liver 
had contributed to death.  This included, for example, decompensated liver disease, HCC, liver 
failure and cancers with liver metastases.   Where a non-liver-related cause of death was 
recorded but there was additional mention of viral hepatitis, this was not coded as a liver-
related death.  Deaths were coded as AIDS-related either where AIDS was stated as a cause of 
death or where the cause of death included any condition included on the Centers for Disease 
Control (CDC) list of AIDS-defining conditions (44).  The three coded datasets were then 
combined and compared to make a final decision about whether a death should be coded as 
liver-related or not and as AIDS-related or not.  
 
There were a total of 1622 deaths among individuals included in the analyses.  When coding 
from the three datasets was compared, there were conflicting liver-related death codes for 29 
individuals and conflicting AIDS-related death codes for 81 individuals.  For these individuals all 
stated causes of death were reviewed in order to make a final decision about whether or not 
the death was liver-related, AIDS-related or neither.  Where coding from two of the datasets 
were in agreement and only one dataset was conflicting, the coding from the agreeing 
datasets was used this was used.  Where coding was available in one or more datasets but 
missing from another dataset, the available coding was used as the final code.  Where no 
decision could be made the death was left uncoded (2/29 conflicting liver-related deaths and 
8/81 conflicting AIDS-related deaths).  A cause of death, from any data source, which could be 
coded as liver-related or not liver-related, was available for 1319 individuals.  A cause of death 
which could be coded as AIDS-related or not AIDS-related was available for 1312 individuals 
(Table 9.1)  
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Table 9.1 Data sources used to code deaths as liver-related or AIDS-related 
Data source Individuals with a cause of 
death which could be 
defined as liver-related or 
non-liver-related1 
Individuals with a cause of 
death which could be 
defined as AIDS-related or 
non-AIDS-related1 
UK CHIC plus expanded 
hepatitis data collection 
302 302 
Updated UK CHIC standard data 412 412 
External data (PHE, ONS or 
CODE) 
1240 1229 
Total 1319 1312 
1 Individuals may have a cause of death recorded in more than one data source. 
 
9.2.3 Defining cirrhosis status 
In a number of the analyses presented throughout this chapter, data were included on 
whether a hepatitis co-infected individual had cirrhosis or not.  Confirmed cirrhosis status was 
defined using either APRI score, biopsy result or FibroScan® result.  APRI scores of greater than 
2, FibroScan® results of greater than 14, biopsies with Ishak scores of 5 or 6 and biopsies with 
METAVIR scores of 4 were considered to be evidence of cirrhosis.   
 
There was further evidence of cirrhosis in the results of liver imaging.  However, liver imaging 
has a much lower sensitivity for diagnosis of cirrhosis (533, 534).  In the analysis of 
complications of liver disease,  which utilised scan data in determining an outcome, those 
individuals who had a scan which had been coded as suggestive of cirrhosis were also 
considered to have been diagnosed with cirrhosis.  The number of individuals with confirmed 
cirrhosis, as diagnosed though APRI score, biopsy and FibroScan® and the number of 
individuals with scans suggestive of cirrhosis are shown in Table 9.2.
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Table 9.2 Diagnosis of cirrhosis by APRI score, Biopsy, FibroScan® and other imaging methods 
Liver disease assessment Total with 
measurement 
Number with any 
evidence of cirrhosis 
% 
APRI score 972 354 36.4 
Biopsy 583 135 23.1 
FibroScan® 1043 104 10.0 
Total confirmed 1872 522 27.9 
Scans suggestive of cirrhosis 1190 217 5.5 
Total (confirmed + 
suggestive) 
2729 611 22.4 
 
9.2.4 Comparing mortality rates among HIV mono-infected and HIV/hepatitis co-
infected individuals 
Individuals were followed from the latest of their first HBV or HCV test, entry into UK CHIC, or 
1st January 2004.  A last date of follow-up was determined as the maximum of CD4 counts, 
viral loads, hepatitis dates and recorded last seen dates.  Individuals who had not died were 
included in the analysis until their last follow-up date.  For those who had a recorded death, 
follow-up was continued until their date of death.  Seven individuals were known to have died 
but there was no death date available.  For these individuals the date of death was imputed as 
the last date of follow-up. Baseline characteristics of individuals who had died compared to 
those who had not died were described and compared. 
 
For all individuals with a date of death, 180 days was added to the last date of follow-up, if the 
date of death occurred within that 180 days the individual was included in the analysis as 
having died.  If the date of death occurred after that 180 days, the individual was included in 
the analysis but was censored at their last date of follow-up and were not considered to have 
died while under follow-up since most individuals will be seen in clinic at least once every 6 
months.  This methodology was used in order to minimise bias that may be introduced from 
the inclusion of deaths that are reported through ONS after follow-up within the cohort has 
ceased. There were 15 individuals in this dataset who had a date of death that was more than 
6 months after their last date of follow-up and whose follow-up was therefore censored prior 
to death.  A comparison between these individuals and those individuals who died during 
follow-up is shown in Table 9.3.
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Table 9.3 Baseline characteristics of those individuals whose deaths occurred during follow-
up compared to those whose deaths occurred after follow-up 
 Deaths 
occurring >6 
months after 
last date of 
follow-up 
 
N=15 
% Deaths occurring 
<6 months after 
their last date of 
follow-up 
 
N=1065 
% P value 
Median age (years) 
(IQR) 
38 (34,43) - 41 (36, 49) - 0.19 
Ethnicity      
White 13 86.67 735 69.01 0.19 
Black African 0 0.00 185 17.37  
Other/unknown 2 13.33 145 13.62  
HIV exposure group      
MSM 2 13.33 587 55.12 <0.0001 
IDU 12 80.00 120 11.27  
Male heterosexual 0 0.00 152 14.27  
Female heterosexual 1 6.67 141 13.24  
Other unknown 0 0.00 65 6.10  
Median CD4 count 
(cells/mm3) (IQR)  
386 (190, 515) - 290 (133, 497) - 0.28 
HIV viral load 
(copies/ml) 
     
<50 5 33.33 402 37.75 0.58 
>50 10 66.67 608 57.09  
Unknown 0 0.00 55 5.16  
HAART regimen      
NNRTI based 1 6.67 221 20.75 0.35 
PI based 4 26.67 149 13.99  
Other regimen 4 26.67 237 22.25  
Not on ART 6 40.00 458 43.00  
Year of entry into 
cohort 
     
1996-1999 11 73.33 552 51.83 0.005 
2000-2004 2 13.33 253 23.76  
2005-2009 0 0.00 236 22.16  
≥2010 2 13.33 24 2.25  
Hepatitis infection 
status  
     
HIV mono-infected 4 26.67 816 76.62 <0.0001 
HIV/HBV co-infected 1 6.67 87 8.17  
HIV/HCV co-infected 10 66.67 145 13.62  
HIV/HBV/HCV triple-
infected 
0 0.00 17 1.60  
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Individuals were categorised at baseline as HIV mono-infected, HIV/HBV co-infected, HIV/HCV 
co-infected or HIV/HBV/HCV triple-infected.  Individuals moved in one direction from HIV 
mono-infected to a co-infection or triple-infection category if there was evidence of a positive 
test result during follow-up.  The total number of person-years of follow up was calculated for 
each co-infection category using the date at which an individual entered that co-infected 
category and their last date of follow-up within that category.   Mortality rates were calculated 
as the total number of deaths divided by the total person-years of follow-up.   
 
In order to investigate whether the different mortality rates in each co-infection group were 
confounded by other variables, Poisson regression was used to identify predictors of all-cause 
mortality, liver-related mortality and AIDS-related mortality.  Fixed covariates were ethnicity 
and HIV exposure group.  Age, CD4 count, HIV viral load, HAART and calendar year were 
updated every three months.  Hepatitis co-infection status was updated where a change 
occurred (as described above).   
 
Final models of all-cause mortality, liver-related mortality and AIDS-related mortality were 
arrived at using the same systematic approach in order to allow comparison of the results.  
Initially all covariates were included in the multivariable model.  However, variables included in 
the final models were selected using a backwards selection process to identify those factors 
that confounded the effect of co-infection on mortality and to achieve a parsimonious model.  
This process resulted in ethnicity being removed from the final model as, although it showed 
weak association with mortality in the univariable model, its removal from the model did not 
affect the estimates for co-infection.   
 
HIV-positive IDU have higher mortality rates than HIV-positive individuals who acquired their 
HIV infection through other routes (24, 61, 535).  To test the effect of this on the model, all 
individuals who had acquired their HIV through injecting drug use were excluded and the 
results compared to the model which included IDU.   
 
All-cause, liver-related and AIDS-related mortality rates were particularly high in the most 
recent year of follow-up (2012).  This is likely to be due to a bias in the dataset resulting from 
the data collection process which was conducted from 2012-2013.  Where individuals who 
were co-infected had died in 2012, this may have been recorded during the data collection as 
the information was available in the clinical records of that individual.  However, there are far 
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fewer years of follow-up in 2012 in the dataset as a whole (including HIV mono-infected 
individuals) than in other years, due to a delay in reporting standard data to UK CHIC.  
Therefore the mortality rate in 2012 may be overestimated.  For this reason, in a final model 
data from 2012 were excluded.    
 
9.2.5 Predictors of mortality among co-infected individuals 
To further investigate mortality among co-infected individuals, including parameters that are 
specific to hepatitis co-infection, separate datasets of the HBV-positive (n=1689) and HCV-
positive (n=2657) individuals were created.  Individuals who were triple-infected were included 
in both datasets and the presence of triple-infection was adjusted for in all analyses. 
 
For each co-infection dataset, individuals were followed from the latest of their first evidence 
of infection with the hepatitis virus of interest, or 1st January 2004 until their date of death 
(for those who died) or their last date of follow-up.    
 
Independent predictors of mortality among the two co-infected groups were identified using 
univariable and multivariable Cox regression.  Baseline age, ethnicity and exposure category 
were treated as fixed covariates in all models.  CD4 count, HIV viral load and HIV/HBV/HCV 
triple-infection were treated as time-updated covariates.  CD4 count was included as a 
continuous variable while HIV viral load was included as a categorical variable.  
 
In the HIV/HBV co-infected group, HAART use and HBV treatment were initially investigated 
separately as predictors of mortality in univariable analysis.  However, the large majority of 
individuals on hepatitis treatment are on treatment as part of their HAART regimen (for 
example with lamivudine or tenofovir (Chapter 8).  Therefore in the final model HBV treatment 
was included as a time dependent covariate, but use of HAART was excluded.  All other factors 
that were associated with mortality in univariable analysis were included in the multivariable 
model.  Only 1187/1679 individuals had any HBeAg test results available and 654/1679 had 
any measure of cirrhosis (a biopsy, FibroScan® or APRI score) available.  Therefore these 
variables were added to the final model separately. 
 
In the HIV/HCV co-infected group, use of HAART was included as a time updated covariate.  
HCV treatment was defined as successful, failed or of unknown outcome using the initial 
treatment response and long-term treatment response as described in Chapter 7.  HCV 
treatment outcome was then included as a time dependent categorical variable.  Whether an 
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individual had been diagnosed with acute HCV and HCV genotype were included as fixed co-
variates.  All factors associated with mortality in univariable analysis were included in the 
multivariable model.   
 
Of all HIV/HCV co-infected individuals included in the analysis, 1415/2651 individuals had any 
measure of cirrhosis and 2382/2651 individuals had HCV-RNA test results available. Separate 
models also included HCV-RNA as a time updated covariate and cirrhosis status as a time 
updated covariate as large numbers of individuals did not have RNA test results or measures of 
cirrhosis available.  Given the very high prevalence of HCV among IDU, a sensitivity analysis 
was conducted where IDU were removed from the model.   
 
9.2.6 Predictors of cirrhosis among hepatitis co-infected individuals 
Cirrhosis may remain asymptomatic for long periods of time, therefore confirmation of 
cirrhosis by laboratory tests, biopsy or FibroScan® may occur long after damage to the liver has 
occurred and, as such, the date at which an individual is confirmed as having cirrhosis may not 
represent the point at which liver damage has occurred.  Therefore, cirrhosis was treated as a 
binary variable: ever having had cirrhosis or never having had cirrhosis.   Logistic regression of 
baseline characteristics was carried out to investigate factors associated with this outcome 
measure.   
 
For HIV/HBV co-infected individuals, baseline characteristics included in the analysis were age, 
ethnicity, HIV exposure group, CD4 count, HIV viral load, HBV treatment, HAART, HBeAg status 
and HCV infection.  A second model excluded HBeAg status as a large number of individuals 
had unknown HBeAg status at baseline.  For HIV/HCV co-infected individuals, baseline 
characteristics included in the analysis were age, ethnicity, HIV exposure group, CD4 count, HIV 
viral load, HAART, HCV-RNA status, HBV infection, HCV genotype and whether or not an 
individual was diagnosed with acute HCV infection.  HCV treatment was not included in the 
analysis since evidence of advanced fibrosis or compensated cirrhosis may be an indication for 
starting HCV treatment (204). 
 
9.2.7 Complications of liver disease 
Complicated liver disease was defined as:  decompensated cirrhosis (that is, cirrhosis with any 
of ascites, portal hypertension, gastroesophageal varices or hematemesis (vomiting of blood), 
HCC or liver transplant (536)); HCC without evidence of cirrhosis; or evidence of having 
undergone a liver transplant but without a diagnosis of cirrhosis.  For the purpose of these 
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analyses, in addition to those who had a confirmed diagnosis of cirrhosis through APRI score, 
biopsy or FibroScan®, those individuals who had other imaging that was coded as suggestive of 
cirrhosis were also considered to be cirrhotic.   Evidence of complicated liver disease was 
available from three data sources collected as part of the expanded hepatitis data collection: 
scans; biopsies; record in clinical notes (Table 9.4). 
 
Table 9.4 Data sources for information on complications of liver disease 
Evidence of complicated 
liver disease 
Possible data source 
Scan results Biopsies Clinical notes 
Ascites    
Portal hypertension    
Hematemesis    
Gastroesophageal varices    
Hepatocellular carcinoma    
Transplant    
 
Baseline characteristics of individuals who experienced any complications of liver disease and 
those who did not were compared.   Individuals were followed from the date of a first positive 
hepatitis test or 1st January 2004, whichever was the latest, until their first recorded 
complication of liver disease or their last follow-up date for those who did not experience 
complications.  Rates of developing complications were calculated among individuals who 
experienced their first complication after the start of follow-up as the total number of 
individuals who experienced a complication out of the total person-years of follow-up.  
Predictors of first complications of liver disease were assessed using Cox regression models.   
 
In models of predictors of first complications among HIV/HBV and HIV/HCV co-infected groups, 
baseline age, ethnicity and HIV exposure group were treated as fixed covariates.   CD4 count, 
HIV viral load and triple-infection were treated as time updated covariates.  Among HIV/HBV 
co-infected individuals, HAART, HBV treatment and HBeAg status were also treated as time 
updated covariates.  Among HIV/HCV co-infected individuals, HCV-RNA status was treated as a 
time updated co-variate while HCV genotype and whether an individual was diagnosed with 
acute infection or not were treated as fixed covariates. 
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Finally, among those individuals who experienced a complication of liver disease, survival after 
first complication was described using Kaplan Meier curves and overall mortality rates.  
Individuals who had undergone a liver transplant were excluded from this analysis as it was 
assumed that liver transplant would increase their survival. 
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9.3 Results 
9.3.1 Comparing mortality rates among HIV mono-infected and HIV/hepatitis co-
infected individuals 
Of the 26377 individuals who had ever been tested for HBsAg and the 28251 individuals who 
had ever been tested for HCV-Ab and/or HCV-RNA, 25753 individuals had been tested for both 
infections.  Twenty-three individuals had a date of death which was before or on the same 
date as the start of follow-up and were therefore excluded from the analysis.  244 individuals 
had a last follow-up date which was the same as their date of starting follow-up and were 
therefore removed from the analysis.  Therefore a total of 25486 individuals were included.  
Overall 4.2% (1065/25486) of individuals died during follow-up.  Baseline characteristics of 
individuals who died during follow-up and those who did not are shown in Table 9.5. 
 
The 25486 individuals contributed a total of 121814 person-years of follow-up.  Median follow 
up time was 4.6 years (IQR 2.0, 7.2 years) per person.  A total of 1065 individuals died, giving 
an overall all-cause mortality rate of 8.7 per 1000 person-years (95% CI 8.2-9.3). A total of 95 
individuals died of liver-related causes (a mortality rate of 0.8 per 1000 person-years, 95% CI 
0.6-1.0) and 198 individuals died of AIDS (a mortality rate of 1.6 per 1000 person-years, 95% CI 
1.4-1.9).  Allowing individuals to move between co-infection categories in one direction where 
new evidence of infection was available,  all-cause mortality was higher among co-infected 
individuals than among HIV mono-infected individuals; 7.4 per 1000 person-years in HIV mono-
infected individuals compared to 13.8 per 1000 person-years and 16.9 per 1000 person-years 
in HBV and HCV co-infected individuals, respectively.  Similarly liver-related mortality was also 
higher among hepatitis co-infected individuals than in HIV mono-infected individuals; 0.3 per 
1000 person-years in HIV mono-infected compared to 3.5 per 1000 person-years and 3.3 per 
1000 person-years in HIV/HBV and HIV/HCV co-infected individuals, respectively.  AIDS-related 
mortality appeared to be higher among HIV/HBV co-infected individuals (2.2 per 1000 person-
years) and among HIV/HBV/HCV triple-infected individuals (3.6 per 1000 person-years) 
compared to HIV mono-infected individuals (1.6 per 1000 person-years) but there was little 
difference in AIDS-related mortality rates between HIV-mono-infected and HIV/HCV co-
infected individuals (1.3 per 1000 person-years) (Table 9.6).
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Table 9.5 Baseline characteristics of individuals who died and those who did not die during 
follow-up 
 Remained 
alive 
N=24421 
% Died 
N=1065 
% P- value 
Median Age (years) (IQR) 37 (31, 43) 41 (36, 49) <0.0001 
Ethnicity      
White 15050 61.6 735 69.0 <0.0001 
Black African 5263 21.6 185 17.4  
Other/unknown 4108 16.8 145 13.6  
HIV exposure group      
MSM 14903 61.0 587 55.1 <0.0001 
IDU 583 2.4 120 11.3  
Male heterosexual 2803 11.5 152 14.3  
Female heterosexual 4652 19.1 141 13.2  
Other/unknown 1480 6.1 65 6.1  
Median CD4 count 
(cells/mm3) (IQR)1 
413 (273, 582) 497.5 (290, 
698) 
<0.0001 
HIV viral load (copies/ml)      
≤50 9162 37.5 402 37.8 0.001 
>50 13243 54.2 608 57.1  
Unknown 2016 8.3 55 5.2  
HAART regimen      
NNRTI based 5079 20.8 221 50.8 <0.0001 
PI based 2603 10.7 149 14.0  
Other regimen 3094 12.7 237 22.3  
Not on ART 13645 55.9 458 43.0  
Year of entry into UK CHIC      
1996-1999 7952 32.6 552 51.8 <0.0001 
2000-2004 6478 26.5 253 23.8  
2005-2009 7697 31.5 236 22.2  
≥2010 2294 9.4 24 2.3  
Hepatitis infection status 
at start of follow-up 
     
HIV mono-infected 21923 89.8 816 76.6 <0.0001 
HIV/HBV co-infected 1129 4.6 87 8.2  
HIV/HCV co-infected 1259 5.2 145 13.6  
HIV/HBV/HCV triple-
infected 
110 0.5 17 1.6  
1Baseline CD4 count was unknown for 1730 individuals who did not die and 37 individuals who 
died 
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Table 9.6 All-cause, liver-related and AIDS-related mortality by hepatitis co-infection 
category 
HIV/ 
hepatitis  
infection 
Person-
years 
follow-up 
All-cause mortality Liver-related 
mortality 
AIDS-related 
mortality 
Number 
of 
deaths 
Mortality 
rate1  
(95% CI) 
Number 
of 
deaths 
Mortality 
rate1  
(95% CI) 
Number 
of 
deaths 
Mortalit
y rate1  
(95% CI) 
HIV  
N=22739 
 
103057 761 7.4 
(6.9-7.9) 
27 0.3  
(0.2-0.4) 
164 1.6 
(1.4-1.9) 
HIV/HBV  
N=1427 
 
6933 96 13.8 
(11.2-16.9) 
24 3.5 
(2.2-5.2) 
15 2.2 
(1.2-3.6) 
 
HIV/HCV  
N=2325 
 
10180 172 16.9 
(14.5-19.6) 
34 3.3 
(2.3-4.7) 
13 1.3 
(0.7-2.2) 
 
HIV/HBV/
HCV  
N=435 
 
1644 36 21.9  
(15.3-30.3) 
10 6.1 
(2.9-11.2) 
 
6 3.6 
(1.3-7.9) 
 
Total 
N=25486 
121814 1065 8.7  
(8.2-9.3) 
95 0.8  
(0.6-1.0) 
198 1.6 
(1.4-1.9) 
1 Mortality rates per 1000 person-years of follow-up 
In order to assess whether the observed differences in mortality rates between co-infection 
groups were due to co-infection or confounding factors, Poisson regression models were used 
to adjust for potential confounders and to obtain crude and adjusted rate ratios. 
 
9.3.1.1 Association of HIV/hepatitis co-infection with all-cause mortality 
The results of analyses to test the association between hepatitis co-infection and all-cause 
mortality after adjusting for confounding factors are shown in Table 9.7.  In multivariable 
model 1, compared to HIV mono-infection, hepatitis co-infection was strongly associated with 
all-cause mortality with ARRs of 1.43 (95% CI 1.15-1.79) for HIV/HBV co-infection, 1.28 (95% CI 
1.04-1.57) for HIV/HCV co-infection and 1.80 (95% CI 1.27-2.54) for HIV/HBV/HCV triple-
infection.   
 
Some other associations were also observed in model 1.  Older individuals were more likely to 
die (ARR 1.66, 95% CI: 1.56-1.77, per 10 years).  Compared to MSM, IDU has significantly 
higher rates of mortality (ARR, 95% CI: 2.51, 1.96-3.21) as did those individuals whose HIV 
exposure group was other/unknown (ARR, 95% CI: 1.88, 1.42-2.47).  Individuals with higher 
CD4 counts were less likely to die (ARR, 95% CI: 0.72, 0.69-0.75 per additional 100 cells/mm3).  
Compared to individuals with undetectable HIV viral loads, those with HIV viral loads 50-10000 
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copies/ml and those with HIV viral loads >10000 copies/ml were significantly more likely to die 
(ARRs, 95% CIs: 1.46, 1.26-1.76 and 2.52, 2.19-2.89, respectively).  Compared to those 
individuals who were not on HIV treatment, all-cause mortality was significantly higher among 
those individuals who were on HIV treatment (ARR, 95% CI: 1.42, 1019-1.71). Taking 2009 as 
the reference group, it appeared that individuals under follow-up in 2004 had significantly 
lower mortality rates (ARR, 95% CI: 0.74, 0.58-0.96) and those under follow-up in 2011 had 
significantly higher mortality rates (ARR, 95% CI: 1.40, 1.10-1.78).  Those under follow-up in 
2012 also had significantly higher rates of all-cause mortality.  However as this is likely due to 
ascertainment bias (as discussed in 9.2.4), 2012 data was excluded in model 3.      
 
In model 2, where IDU were excluded from the analysis, HIV/HBV co-infection remained 
significantly associated with all-cause mortality.  However, the association of increased 
mortality with HCV co-infection and with HIV/HBV/HCV triple-infection was lost in this model.  
This may indicate the effect of HIV/HCV and HIV/HBV/HCV co-infection on all-cause mortality 
is higher among IDU than among individuals who did not acquire their HIV through IDU.  All 
other associations with all-cause mortality remained unchanged when IDU were excluded from 
the analysis. 
 
In model 3, IDU were included but follow-up in 2012 was excluded from the analysis.  
HIV/HBV, HIV/HCV and HBV/HCV co-infection all remained associated with increased mortality 
compared to HIV mono-infection in this model, however the associations were slightly 
stronger than they had been in model 1:  ARRs, 95% CIs: 1.60, 1.28-2.00 for HIV/HBV co-
infection; 1.43, 1.16-1.76 for HIV/HCV co-infection; and 2.29, 1.62-3.24 for HIV/HBV/HCV 
triple-infection.  All other associations with mortality remained, in the same direction and with 
similar ARR, as described for model 1. 
 
9.3.1.2 Association of HIV/hepatitis co-infection with liver-related mortality 
The results of the analyses testing the association between hepatitis co-infection and liver-
related mortality are shown in Table 9.8.  In model 1, hepatitis co-infection was strongly 
associated with liver-related mortality compared to HIV mono-infection (ARRs, 95% CIs:  8.97, 
5.07-15.88 for HIV/HBV co-infection; 5.70, 3.13-10.37 for HIV/HCV co-infection; and 12.35, 
5.70-26.77 for HIV/HBV/HCV triple-infection).  In addition to co-infection there were a number 
of other factors which were significantly associated with liver-related mortality.  Older 
individuals were more likely to have a liver-related death than younger individuals (ARR, 95% 
CI: 1.56 1.23-1.93, per 10 years).  IDU had significantly higher liver-related mortality compared 
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to MSM (ARR, 95% CI: 2.76, 1.54-4.91).  Liver-related mortality was significantly lower among 
individuals with higher CD4 counts (ARR, 95% CI: 0.63, 0.56-0.72).  Compared to those with 
undetectable HIV viral load, liver-related mortality was significantly higher among those with 
HIV viral loads >10000 copies/ml (ARR, 95% CI: 3.64, 2.06-6.45) and compared to those not on 
HIV treatment, mortality rate was significantly higher among those who were on HIV 
treatment (ARR, 95% CI: 3.10, 1.61-5.97).   
 
In model 2, where IDU were excluded from the analysis, the association between liver-related 
mortality and hepatitis co-infection remained compared to HIV mono-infection.  ARRs 
comparing HBV co-infection and HCV co-infection to HIV mono-infection were similar to those 
obtained from model 1 (8.83 and 5.14, respectively).  However, while there was still a strong 
association between liver-related mortality and HIV/HBV/HCV triple-infection compared to HIV 
mono-infection, the effect size was smaller when IDU were excluded than it had been in model 
1.  Other associations remained as described in model 1. 
 
In model 3, where follow-up from 2012 was excluded from the analysis, the association 
between liver-related mortality and hepatitis co-infection remained.  The effect of hepatitis co-
infection on liver-related mortality was increased compared to in model 1:  ARR, 95% CIs 
10.43, 5.78-18.80 for HIV/HBV co-infection; 6.19, 3.31-11.60 for HIV/HCV co-infection; and 
15.19, 6.94-33.23 for HIV/HBV/HCV triple-infection.  All other associations with liver-related 
mortality remained similar to those seen in model 1 with regard to size and direction of effect. 
 
In each of the three models, individuals on HAART were at least 4 times more likely to have a 
liver-related death than individuals who were not on HAART.  Being on HAART was significantly 
associated with liver-related death in univariable analysis and the effect size increased after 
adjusting for HIV viral load.  No other variables had a substantial impact on the effect of HAART 
on the rate of liver-related death.  This effect size was large and unexpected and was highly 
significant in each of the models.  Given that the effect size appeared to be dependent on HIV 
viral load some further investigations into the HIV viral load, HAART and liver-related death 
associations were undertaken.  
 
Firstly, the analysis was repeated stratified by hepatitis co-infection status.  Among HIV mono-
infected individuals, HAART was not found to be associated with liver-related death in 
univariable analysis (RR, 95% CI: 2.19, 0.76-6.34), but became associated with liver-related 
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death after adjusting for HIV viral load (ARR, 95% CI: 8.06, 2.43-26.81), and remained 
associated with liver-related death when other co-variates were included in the model (ARR, 
95% CI: 5.21, 1.51-18.02).  Among the HIV/HBV co-infected group, HAART was not associated 
with liver-related death in univariable analysis, after adjusting for HIV viral load, or in the 
complete multivariable model.  Finally, among HIV/HCV co-infected individuals, being on 
HAART was associated with liver-related death in univariable analysis (RR, 95% CI: 5.06, 1.21-
21.11) and the effect size was increased after adjusting for HIV viral load (ARR, 95% CI: 18.95, 
4.18-85.84).  This association between being on HAART and liver-related death, remained after 
adjusting for all other covariates (ARR, 95% CI: 6.96, 1.53-31.75). 
 
Subsequently, the dataset was stratified by HAART status in order to examine the effect of HIV 
viral load on liver-related death.  Among individuals who were on HAART, in univariable 
analysis, compared to those with undetectable HIV viral load, those with HIV viral loads of 50-
10000 copies/ml had significantly higher rates of liver-related mortality (RR, 95% CI 2.38, 1.32-
4.32).  The effect size was greater among those with very high HIV viral loads (>10000 
copies/ml) (RR, 95% CI 9.05, 5.33-15.34).  After adjusting for other covariates, in multivariable 
analysis, the association between liver-related mortality and mid-level HIV viral load was 
attenuated (ARR, 95% CI 1.57, 0.86-2.89), while the association between liver-related mortality 
and very high HIV viral load remained (ARR, 95% CI 3.42, 1.88-6.24).  Among individuals who 
were not on HAART there were no events among individuals with undetectable HIV viral loads. 
 
Individuals on HAART with high viral loads are likely to be very different to those with high viral 
loads who are not on HAART.  For example, those who are off HAART with high viral loads may 
be more newly infected, have good immune function and not yet be in need of HAART.  
However, those who are on HAART and have high viral loads are likely to be failing treatment 
and therefore may have more advanced disease.  Given, these likely differences, and the 
results described above which show a close association between HAART, HIV viral load, and 
liver-related mortality, HAART and HIV viral load were combined into one covariate with the 
following categories:  On HAART with undetectable HIV viral load; on HAART with viral load 50-
10000 copies/ml; on HAART with high viral load (>10000 copies/ml); not on HAART with HIV 
viral load <10000 copies/ml; and not on HAART with high HIV viral load (>10000 copies/ml).    
 
In univariable analysis, there was no significant difference in liver-related mortality between 
those who were off HAART with high viral loads and those who were off HAART with 
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undetectable viral loads.  There was also no significant difference between those who were off 
HAART with high viral loads and those who were on HAART with undetectable viral loads.  
However, those who were on HAART and had HIV viral loads of 50-10000 copies/ml or >10000 
copies/ml had higher rates of liver-related mortality than those who were not on HAART with 
high HIV viral loads. 
 
In multivariable analysis, compared to those individuals who were off  HAART with high HIV 
viral loads, there were no significant differences in liver-related mortality for individuals who 
were not on HAART with high viral loads and those who were not on HAART with mid/low HIV 
viral loads.  However, individuals who were on HAART and had high HIV viral loads had 
significantly higher rates of liver-related mortality than those who were not on HAART with 
high HIV viral loads (ARR, 95% CI: 3.91, 1.75-8.78).  These associations are shown in Table 9.10.  
Including HIV viral load and HAART as a combined co-variate did not alter any of the other 
association with liver-related mortality, in particular, the associations between liver-related 
mortality and hepatitis co-infection remained as shown in Table 9.8 
 
9.3.1.3 Association of hepatitis co-infection with AIDS-related mortality 
In contrast to all-cause and liver-related mortality, HIV/HBV co-infection and HIV/HBV/HCV 
triple-infection were not associated with AIDS-related mortality after adjusting for 
confounding (Table 9.9).  However, HIV/HCV co-infection was associated with a decreased risk 
of AIDS-related mortality (ARR, 95% CI: 0.34, 95% CI 0.17-0.70 in model 1).  The results of these 
analyses are shown in Table 9.9.  Like the all-cause and liver-related mortality, AIDS-related 
mortality was significantly higher among older individuals (ARR, 95% CI: 1.27, 1.09-1.49).  
Compared to MSM, AIDS-related mortality was significantly higher among IDU (ARR, 95% CI: 
3.16, 1.64-6.12) and individuals from other/unknown HIV exposure groups (ARR, 95% CI: 2.02, 
1.11-3.69).  AIDS-related mortality was also significantly higher among individuals with lower 
CD4 counts (ARR, 95% CI: 0.42, 0.37-0.47 per additional 100 cells/mm3) and compared to 
individuals with undetectable HIV viral loads, mortality was significantly higher among 
individuals with HIV viral loads of 50-10000 copies/ml (ARR, 95% CI: 1.67, 1.10-2.53) and 
among individuals with HIV viral loads >10000 copies/ml (ARR, 95% CI: 2.30, 1.51-3.50). 
 
When IDU were excluded from the analysis (model 2), the association between reduced AIDS-
related mortality and HIV/HCV co-infection was weakened (ARR, 95% CI: 0.38, 0.16-0.95).  
Other associations remained similar in size and direction to those described in model 1.  
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Excluding data from 2012 from the model did not alter the associations with regard to effect 
size or direction (model 3).   
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Table 9.7 Poisson regression of factors associated with all-cause mortality 
 Univariable analysis Multivariable model 1 Multivariable model 2 – excluding 
IDU 
Multivariable model 3 – 
excluding 2012 
RR 95% CI P value ARR 95% CI P value ARR 95% CI P value ARR 95% CI P value 
Age (per 10 
years) 
1.57 1.67-5.30 <0.0001 1.66 1.56-1.77 <0.0001 1.70 1.60-1.81 <0.0001 1.68 1.58-1.79 <0.0001 
Ethnicity             
White 1 - - - - - - - - - - - 
Black African 0.82 0.70-0.97 0.02 - - - - - - - - - 
Other/unknown 0.86 
 
0.72-1.03 0.11 - - - - - - - - - 
HIV Exposure 
group 
            
MSM 1 - - 1 - - 1 - - 1 - - 
IDU 4.45 3.66-5.41 <0.0001 2.51 1.96-3.21 <0.0001 - - - 2.47 1.92-3.17 <0.0001 
Male 
heterosexual 
1.56 1.30-1.86 <0.0001 1.04 0.87-1.25 0.66 1.03 0.86-1.25 0.71 1.05 0.87-1.27 0.58 
Female 
heterosexual 
0.87 0.72-1.04 0.13 0.92 0.76-1.12 0.42 0.92 0.76-1.12 0.42 0.91 0.75-1.11 0.37 
Other/unknown 1.99 1.53-2.57 <0.0001 1.88 1.42-2.47 <0.0001 1.89 1.43-2.48 <0.0001 1.91 1.45-2.52 <0.0001 
CD4 count (per 
100 cells/mm3) 
0.68 0.65-0.70 <0.0001 0.72 0.69-0.75 <0.0001 0.71 0.69-0.74 <0.0001 0.71 0.69-0.74 <0.0001 
  
 
3
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 Univariable analysis Multivariable model 1 Multivariable model 2 – excluding 
IDU 
Multivariable model 3 – 
excluding 2012 
RR 95% CI P value ARR 95% CI P value ARR 95% CI P value ARR 95% CI P value 
HIV viral load 
(copies/ml) 
            
≤50 1 - - 1 - - 1 - - 1 - - 
51-10000 1.49 1.26-1.76 <0.0001 1.75 1.46-2.08 <0.0001 1.77 1.47-2.14 <0.0001 1.71 1.42-2.04 <0.0001 
>10000 2.52 2.19-2.89 <0.0001 2.91 2.40-3.52 <0.0001 2.96 2.41-3.64 <0.0001 2.86 2.35-3.48 <0.0001 
Calendar year             
2004 0.95 0.75-1.22 0.72 0.74 0.58-0.96 0.02 0.76 0.58-1.00 0.05 0.75 0.58-0.96 0.02 
2005 0.98 0.76-1.26 0.86 0.78 0.60-1.01 0.07 0.81 0.61-1.08 1.15 0.78 0.60-1.01 0.07 
2006 0.92 0.72-1.17 0.50 0.79 0.61-1.02 0.07 0.78 0.59-1.02 0.07 0.79 0.62-1.02 0.07 
2007 1.23 0.99-1.54 0.06 1.06 0.84-1.32 0.64 1.12 0.88-1.43 0.36 1.06 0.84-1.32 0.63 
2008 0.96 0.76-1.21 0.74 0.87 0.69-1.20 0.25 0.87 0.68-1.12 0.29 0.87 0.69-1.10 0.25 
2009 1 - - 1 - - 1 - - 1 - - 
2010 0.96 0.77-1.21 0.73 0.97 0.77-1.21 0.78 1.03 0.81-1.32 0.78 0.97 0.77-1.22 0.77 
2011 1.38 1.09-1.77 0.01 1.40 1.10-1.78 0.01 1.51 1.17-1.95 0.001 1.39 1.09-1.77 0.01 
2012 19.23 13.79-28.83 <0.0001 14.29 10.11-20.19 <0.0001 18.75 13.01-27.02 <0.0001 - - - 
On HIV 
treatment 
            
Yes 0.97 0.85-1.12 0.71 1.42 1.19-1.71 0.0001 1.46 1.20-1.77 0.0002 1.45 1.21-1.74 <0.0001 
No 1 - - 1 - - 1 - - 1 - - 
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 Univariable analysis Multivariable model 1 Multivariable model 2 – excluding 
IDU 
Multivariable model 3 – 
excluding 2012 
RR 95% CI P value ARR 95% CI P value ARR 95% CI P value ARR 95% CI P value 
Hepatitis 
infection status 
            
HIV mono-
infected 
1 - - 1 - - 1 - - 1 - - 
HIV/HBV co-
infected 
1.88 1.52-2.31 <0.0001 1.43 1.15-1.79 0.001 1.37 1.09-1.72 0.01 1.60 1.28-2.00 <0.0001 
HIV/HCV co-
infected 
2.89 1.94-2.70 <0.0001 1.28 1.04-1.57 0.02 1.24 0.98-1.56 0.07 1.43 1.16-1.76 0.001 
HIV/HBV/HCV 
triple-infected 
2.97 2.12-4.14 <0.0001 1.80 1.27-2.54 0.001 1.39 0.88-2.21 0.16 2.29 1.62-3.24 <0.0001 
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Table 9.8 Poisson regression of factors associated with liver-related mortality 
 Univariable analysis Multivariable model 1 Multivariable model 2 – excluding 
IDU 
Multivariable model 3 – 
excluding 2012 
RR 95% CI P value ARR 95% CI P value ARR 95% CI P value ARR 95% CI P value 
Age (per 10 
years) 
1.51 1.24-1.83 <0.0001 1.56 1.23-1.98 0.0002 1.54 1.19-2.00 0.01 1.54 1.21-1.98 0.001 
Ethnicity             
White 1 - - - - - - - - - - - 
Black African 0.42 0.22-0.81 0.01 - - - - - - - - - 
Other/unknown 0.39 0.18-0.85 0.02 - - - - - - - - - 
HIV Exposure 
group 
            
MSM 1 - - 1 - - 1 - - 1 - - 
IDU 11.32 7.04-18.18 <0.0001 2.76 1.54-4.91 0.001 - - - 2.94 1.63-5.33 0.0004 
Male 
heterosexual 
0.84 0.38-1.86 0.67 0.48 0.22-1.08 0.08 0.50 0.22-1.12 0.09 0.51 0.23-1.14 0.10 
Female 
heterosexual 
0.50 0.23-1.11 0.10 0.62 0.28-1.38 0.24 0.60 0.27-1.35 0.22 0.57 0.24-1.35 0.20 
Other/unknown 1.79 0.72-4.50 0.21 1.41 0.50-3.94 0.52 1.42 0.51-3.99 0.51 1.13 0.35-3.67 0.84 
CD4 count (per 
100 cells/mm3) 
0.56 0.50-0.63 <0.0001 0.63 0.56-0.72 <0.0001 0.68 0.59-0.79 <0.0001 0.63 0.55-0.73 <0.0001 
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 Univariable analysis Multivariable model 1 Multivariable model 2 – excluding 
IDU 
Multivariable model 3 – 
excluding 2012 
RR 95% CI P value ARR 95% CI P value ARR 95% CI P value ARR 95% CI P value 
HIV viral load 
(copies/ml) 
            
≤50 1 - - 1 - - 1 - - 1 - - 
51-10000 1.23 0.69-2.18 0.49 1.53 0.85-2.78 0.16 2.27 1.67-4.39 0.02 1.48 0.80-2.74 0.21 
>10000 2.36 1.49-3.75 0.0003 3.64 2.06-6.45 <0.0001 5.53 2.79-10.95 <0.0001 3.36 1.87-6.04 <0.0001 
Calendar year             
2004 0.43 0.17-1.08 0.07 0.32 0.12-0.82 0.02 0.36 0.10-1.38 0.13 3.00 1.15-7.80 0.02 
2005 1.21 0.60-2.43 0.60 0.96 0.48-1.94 0.91 1.51 0.59-3.86 0.39 2.21 0.82-5.99 0.12 
2006 0.81 0.38-1.72 0.59 0.71 0.33-1.51 0.37 1.11 0.41-2.97 0.84 1.45 0.50-4.19 0.49 
2007 0.66 0.31-1.43 0.29 0.47 0.20-1.07 0.07 1.06 0.40-2.85 0.89 1.73 0.62-4.77 0.29 
2008 0.60 0.28-1.29 0.19 0.56 0.26-1.20 0.13 0.88 0.32-2.44 0.81 3.12 1.23-7.91 0.02 
2009 1 - - 1 - - 1 - - 1 - - 
2010 0.83 0.42-1.64 0.59 0.82 0.41-1.62 0.56 1.61 0.67-3.88 0.29 2.55 0.98-6.64 0.06 
2011 0.48 0.18-1.30 0.15 0.43 0.16-1.17 0.10 0.80 0.24-2.66 0.72 1.35 0.41-4.47 0.62 
2012 21.06 8.53-54.18 <0.0001 6.62 2.59-16.93 <0.0001 16.34 5.53-48.35 <0.0001 - - - 
On HIV 
treatment 
            
Yes 3.10 1.61-5.97 0.001 4.49 2.16-9.34 <0.0001 5.56 2.31-13.38 0.0001 4.63 2.15-9.98 <0.0001 
No 1 - - 1 - - 1 - - 1 - - 
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 Univariable analysis Multivariable model 1 Multivariable model 2 – excluding 
IDU 
Multivariable model 3 – 
excluding 2012 
RR 95% CI P value ARR 95% CI P value ARR 95% CI P value ARR 95% CI P value 
Hepatitis 
infection status 
            
HIV mono-
infected 
1 - - 1 - - 1 - - 1 - - 
HIV/HBV co-
infected 
13.21 7.62-22.90 <0.0001 8.97 5.07-15.88 <0.0001 8.83 4.95-15.73 <0.0001 10.43 5.78-18.80 <0.0001 
HIV/HCV co-
infected 
12.75 7.69-21.13 <0.0001 5.70 3.13-10.37 <0.0001 5.14 2.65-9.95 <0.0001 6.19 3.31-11.60 <0.0001 
HIV/HBV/HCV 
triple-infected 
23.22 11.24-47.98 <0.0001 12.35 5.70-26.77 <0.0001 7.98 2.74-23.21 0.0001 15.19 6.94-33.23 <0.0001 
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Table 9.9 Poisson regression of factors associated with AIDS-related mortality 
 Univariable analysis Multivariable model 1 Multivariable model 2 – excluding 
IDU 
Multivariable model 3 – 
excluding 2012 
RR 95% CI P value ARR 95% CI P value ARR 95% CI P value ARR 95% CI P value 
Age (per 10 
years) 
1.31 0.98-1.31 0.09 1.27 1.09-1.49 0.02 1.27 1.09-1.50 0.002 1.32 1.13-1.54 0.001 
Ethnicity             
White 1 - - - - - - - - - - - 
Black African 1.73 1.26-2.37 0.001 - - - - - - - - - 
Other/unknown 1.19 0.80-1.79 0.39 - - - - - - - - - 
HIV Exposure 
group 
            
MSM 1 - - 1 - - 1 - - 1 - - 
IDU 4.35 2.58-7.32 <0.0001 3.16 1.64-6.12 0.001 - - - 3.13 1.61-6.08 0.001 
Male 
heterosexual 
2.69 1.84-3.95 <0.0001 1.13 0.75-1.70 0.60 1.12 0.75-1.69 0.58 1.16 0.77-1.75 0.47 
Female 
heterosexual 
1.82 1.26-2.63 0.001 1.30 0.88-1.91 0.19 1.29 0.88-1.91 0.19 1.25 0.84-1.87 0.27 
Other/unknown 3.17 1.83-5.48 <0.0001 2.02 1.11-3.69 0.02 2.00 1.09-3.67 0.04 2.13 1.16-3.91 0.01 
CD4 count (per 
100 cells/mm3) 
0.38 0.34-0.42 <0.0001 0.42 0.37-0.47 <0.0001 0.42 0.37-0.47 <0.0001 0.42 0.37-0.47 <0.0001 
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 Univariable analysis Multivariable model 1 Multivariable model 2 – excluding 
IDU 
Multivariable model 3 – 
excluding 2012 
RR 95% CI P value ARR 95% CI P value ARR 95% CI P value ARR 95% CI P value 
HIV viral load 
(copies/ml) 
            
≤50 1 - - 1 - - 1 - - 1 - - 
51-10000 2.29 1.54-4.00 <0.0001 1.67 1.10-2.53 0.02 1.73 1.13-2.68 0.01 1.81 1.19-2.74 0.01 
>10000 5.09 3.69-7.02 <0.0001 2.30 1.51-3.50 0.0001 2.48 1.60-3.84 <0.0001 2.48 1.62-3.80 <0.0001 
Calendar year             
2004 1.01 0.60-1.70 0.98 0.58 0.33-1.00 0.05 0.57 0.32-1.01 0.05 0.58 0.33-1.01 0.05 
2005 0.78 0.42-1.42 0.41 0.47 0.25-0.89 0.02 0.44 0.22-0.86 0.02 0.47 0.25-0.89 0.02 
2006 0.91 0.54-1.58 0.75 0.69 0.40-1.20 0.19 0.61 0.34-1.10 0.10 0.69 0.40-1.20 0.19 
2007 1.44 0.90-2.31 0.12 1.03 0.63-1.67 0.91 1.03 0.61-1.70 0.93 1.03 0.63-1.68 0.90 
2008 0.91 0.54-1.52 0.71 0.73 0.43-1.24 0.24 0.76 0.44-1.30 0.31 0.73 0.43-1.24 0.25 
2009 1 - - 1 - - 1 - - 1 - - 
2010 0.47 0.25-0.86 0.01 0.53 0.29-0.98 0.04 0.53 0.28-1.01 0.05 0.53 0.28-0.98 0.04 
2011 0.87 0.48-1.58 0.65 1.03 0.56-1.88 0.92 1.04 0.56-1.94 0.89 1.02 0.56-1.86 0.95 
2012 12.10 5.06-28.94 <0.0001 15.76 6.39-38.85 <0.0001 20.35 8.19-50.61 <0.0001 - - - 
On HIV 
treatment 
            
Yes 0.73 0.54-0.98 0.04 1.23 0.87-1.79 0.29 1.41 0.94-2.10 0.09 1.32 0.90-1.93 0.16 
No 1 - - 1 - - 1 - - 1 - - 
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 Univariable analysis Multivariable model 1 Multivariable model 2 – excluding 
IDU 
Multivariable model 3 – 
excluding 2012 
RR 95% CI P value ARR 95% CI P value ARR 95% CI P value ARR 95% CI P value 
Hepatitis 
infection status 
            
HIV mono-
infected 
1 - - 1 - - 1 - - 1 - - 
HIV/HBV co-
infected 
1.36 0.80-2.31 0.25 0.92 0.53-1.58 0.76 0.85 0.48-1.49 0.57 1.08 0.63-1.84 0.78 
HIV/HCV co-
infected 
0.80 0.46-1.41 0.44 0.34 0.17-0.70 0.003 0.38 0.16-0.95 0.04 0.40 0.20-0.81 0.01 
HIV/HBV/HCV 
triple-infected 
2.29 1.01-5.18 0.05 1.26 0.52-3.02 0.61 0.77 0.19-3.13 0.70 1.54 0.64-3.69 0.33 
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Table 9.10  Rate ratios from Poisson regression showing associations between liver-related 
mortality and composite HAART and HIV viral load covariate 
HAART/HIV viral load 
category 
Univariable analysis Multivariable analysis 
RR 95% CI P value ARR 95% CI P value 
Off HAART & HIV viral 
load ≥50 copies/ml 
1 - - 1 - - 
Off HAART & HIV viral 
load <50 copies/ml 
0.13 0.02-1.02 0.05 0.19 0.02-1.51 0.12 
On HAART & HIV viral 
load <50 copies/ml 
1.13 0.56-2.31 0.73 1.13 0.54-2.36 0.74 
On HAART & HIV viral 
load 50-10000 copies/ml 
2.70 1.17-6.25 0.02 1.78 0.77-4.15 0.19 
On HAART & HIV viral 
load >10000 copies/ml 
10.25 4.64-22.67 <0.0001 3.91 1.75-8.78 0.001 
 
 
9.3.2 Predictors of mortality among HIV/HBV co-infected individuals 
A total of 1679 HIV/HBV co-infected individuals were included in the analysis, of whom 132 
died.  Median follow-up time for the group, from first recorded positive HBsAg test, was 5.7 
years (IQR 2.6, 7.8):  5.9 years (IQR 2.8, 7.9) for individuals who did not die; and 3.3 years (IQR 
1.4, 5.8) for those who died.  Probability of survival over time is shown in Figure 9.1.  At 2 
years, 3% of HIV/HBV co-infected individuals had died, at 4 years, 5% of HIV/HBV co-infected 
individuals had died and by 6 years, 8% of HIV/HBV co-infected individuals had died.
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Years 1 2 3 4 5 6 7 8 
Number at risk 1494 1366 1213 1078 946 791 618 325 
 
Results of the univariable and three multivariable Cox regression models are shown in Table 
9.11. Model 1 includes all HIV/HBV co-infected individuals, model 2 includes only those 
individuals who have known HBeAg status during follow up and model 3 includes only those 
who have known liver disease status (cirrhotic or not cirrhotic) during follow-up.   
 
In model 1, individuals who were older at baseline were more likely to die (AHR, 95% CI: 1.73, 
1.41-2.11 per additional 10 years of age).  Compared to MSM, IDU were 3.56 times more likely 
to die (95% CI 1.98-5.69) and individuals of other or unknown exposure category were 2.29 
times more likely to die than MSM (95% CI 1.09-4.79).  Individuals with higher CD4 counts 
were less likely to die (AHR, 95% CI: 0.84, 0.77-0.92 per 100 cells/mm3) as were individuals 
with undetectable HIV viral load.  Being on HBV treatment was protective in univariable 
analysis and in the in multivariable analysis (AHR, 95% CI: 0.56, 0.35-0.89). 
Figure 9.1 Kaplan Meier estimations of probability of survival from first evidence of HIV/HBV co-
infection 
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In model 2, including those individuals who had HBeAg results available, individuals who were 
HBeAg-positive were significantly more likely to die than those who were HBeAg-negative 
(AHR, 95% CI: 1.79, 1.16-2.76).  All other associations remained the same.  In model 3, 
including those individuals who had measures of cirrhosis available, individuals who had 
confirmed cirrhosis were almost 5 times more likely to die than those who were not cirrhotic 
(AHR, 95% CI: 4.77, 2.39-9.51).  In this model there was no significant association between HBV 
treatment and survival.  The association seen between higher CD4 counts and survival was also 
lost after adjusting for cirrhosis status.  Baseline age, IDU and high HIV viral loads remained 
associated with increased likelihood of dying, even after adjusting for cirrhosis.   
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Table 9.11 Cox regression models of factors associated with mortality among HIV/HBV co-infected individuals 
 Univariable analysis Multivariable model 1 Multivariable Model 2 – 
including HBeAg status 
Multivariable model 3 – including 
cirrhosis 
HR 95% CI P value AHR 95% CI P value AHR 95% CI P value AHR 95% CI P value 
Baseline age 
(per 10 years) 
1.67 1.38-2.02 <0.0001 1.73 1.41-2.11 <0.0001 1.72 1.38-2.14 <0.0001 1.86 1.28-2.71 0.001 
Ethnicity             
White 1 - - - - - - - - - - - 
Black African 0.66 0.42-1.04 0.07 - - - - - - - - - 
Other/unknown 0.66 0.40-1.10 0.10 - - - - - - - - - 
HIV exposure 
group 
            
MSM 1 - - 1 - - 1 - - 1 - - 
IDU 4.71 2.87-7.71 <0.0001 3.56 1.98-5.69 <0.0001 2.90 1.53-5.48 0.001 2.48 0.96-6.41 0.06 
Male 
heterosexual 
0.95 0.56-1.61 0.85 0.64 0.35-1.17 0.15 0.60 0.30-1.21 0.15 0.18 0.02-1.39 0.10 
Female 
heterosexual 
0.61 0.31-1.22 0.16 0.53 0.24-1.17 0.11 0.64 0.27-1.54 0.32 0.36 0.05-2.67 0.31 
Other/unknown 2.38 1.19-4.76 0.01 2.29 1.09-4.79 0.03 2.58 1.21-5.49 0.01 2.13 0.62-7.30 0.23 
CD4 count (per 
100 cells/mm3) 
0.62 0.56-0.67 <0.0001 0.84 0.77-0.92 <0.0001 0.87 0.79-0.97 0.01 0.99 0.86-1.13 0.82 
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 Univariable analysis Multivariable model 1 Multivariable Model 2 – 
including HBeAg status 
Multivariable model 3 – including 
cirrhosis 
HR 95% CI P value AHR 95% CI P value AHR 95% CI P value AHR 95% CI P value 
HIV viral load 
(copies/ml) 
            
≤50 1 - - 1 - - 1 - - 1 - - 
50-10000 3.63 2.38-5.53 <0.0001 2.99 1.85-4.82 <0.0001 2.87 1.64-5.01 0.0002 3.04 1.36-6.78 0.01 
>10000 6.85 4.45-10.53 <0.0001 5.27 3.11-8.93 <0.0001 5.64 3.09-10.29 <0.0001 7.16 2.57-19.96 0.0002 
On HAART             
Yes 0.03 0.02-0.04 <0.0001 - - - - - - - - - 
No 1 - - - - - - - - - - - 
On HBV 
treatment 
            
Yes 0.28 0.19-0.41 <0.0001 0.56 0.35-0.89 0.02 0.49 0.29-0.84 0.01 0.69 0.27-1.79 0.45 
No 1 - - 1 - - 1 - - 1 - - 
HCV co-infected             
Yes 1.20 0.82-1.76 0.36 - - - - - - - - - 
No 1 - - - - - - - - - - - 
HBeAg             
Negative 1 - - - - - 1 - - - - - 
Positive 2.15 1.47-3.15 0.0001 - - - 1.79 1.16-2.76 0.01 - - - 
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 Univariable analysis Multivariable model 1 Multivariable Model 2 – 
including HBeAg status 
Multivariable model 3 – including 
cirrhosis 
HR 95% CI P value AHR 95% CI P value AHR 95% CI P value AHR 95% CI P value 
Liver Disease             
Cirrhotic 5.59 2.96-10.57 <0.0001 - - - - - - 4.77 2.39-9.51 <0.0001 
Not cirrhotic 1 - - - - - - - -    
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9.3.3 Predictors of mortality among HIV/HCV co-infected individuals 
A total of 2651 HIV/HCV co-infected individuals were included in the analysis, of whom 208 
died during follow-up.  Median follow-up time was 4.3 years (IQR 2.0, 7.1 years):  4.5 years 
(IQR 2.1, 7.3) for individuals who did not die; and 2.8 years (IQR 1.4, 4.9) for individuals who 
died.  The probability of survival over time is shown in Figure 9.2.  At 2 years after first HCV-
positive test 3% of individuals had died, at 4 years 6% of individuals had died and by 8 years 
13% of HIV/HCV co-infected individuals had died. 
 
 
 
Years 1 2 3 4 5 6 7 8 
Number at risk 2310 2000 1713 1410 1154 957 712 315 
 
Results of the univariable and three multivariable Cox regression models are shown in Table 
9.12.  Model 1 includes all individuals, model 2 includes only those individuals with an HCV-
RNA test result during follow-up and model 3 includes only those individuals with a measure of 
liver disease (cirrhotic or not) during follow-up.  
Figure 9.2 Kaplan Meier estimations of probability of survival from first evidence of HCV co-
infection 
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In univariable analysis, individuals who were older at baseline were more likely to die. 
However in model 1, after adjusting for other variables age was no longer associated with 
mortality among HIV/HCV co-infected individuals (AHR, 95% CI: 1.19, 0.98-1.44).  After 
adjusting for all other factors there was no significant difference in survival of individuals from 
different HIV exposure categories. Individuals with higher CD4 counts were less likely to die 
(AHR, 95% CI: 0.78, 0.73-0.83 per additional 100 cells/mm3) as were those on HAART 
compared to those who were not (AHR, 95% CI: 0.07, 0.04-0.08).  Compared to individuals who 
had not received treatment for HCV infection, those who had successful treatment were less 
likely to die (AHR, 95% CI: 0.11, 0.02-0.78).  There was no significant difference in survival 
among individuals infected with different HCV genotypes.  While acute HCV appeared to be 
protective in univariable analysis, this association was lost after adjusting for other factors, in 
particular after adjusting for HCV treatment (AHR, 95% CI: 0.71, 0.40-1.25).   
 
When only those individuals with HCV-RNA test results were included (model 2), those who 
were known to be HCV-RNA positive were significantly more likely to die than those who were 
HCV-RNA negative (AHR, 95% CI: 1.52, 1.09-2.12).  All other associations remained unchanged.  
In model 3, including only those individuals who had a measurement of liver disease, cirrhotic 
individuals were 2.5 times more likely to die than those individuals who were not cirrhotic 
(95% CI 1.52-4.10).  After adjusting for cirrhosis, the association between HCV treatment and 
survival was lost.  All other associations remained the same. 
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Table 9.12 Cox regression models of factors associated with mortality among HIV/HCV co-infected individuals 
 Univariable analysis Multivariable model 1 Multivariable model 2 – 
including HCV-RNA test results 
Multivariable model 3 – 
including cirrhosis 
HR 95% CI P value AHR 95% CI P value AHR 95% CI P value AHR 95% CI P value 
Baseline age 
(per 10 years) 
1.31 1.10-1.57 0.002 1.19 0.98-1.44 0.08 1.23 0.99-1.53 0.06 1.13 0.80-1.58 0.50 
Ethnicity             
White 1 - - - - - - - - - - - 
Black African 0.68 0.32-1.44 0.31 - - - - - - - - - 
Other/unknown 0.85 0.54-1.33 0.47 - - - - - - - - - 
HIV exposure 
group 
            
MSM 1 - - 1 - - 1 - - 1 - - 
IDU 3.12 2.33-4.18 <0.0001 1.20 0.86-1.66 0.28 1.19 0.82-1.73 0.35 0.99 0.60-1.66 0.98 
Male 
heterosexual 
1.34 0.71-2.52 0.36 0.84 0.44-1.60 0.59 1.06 0.55-2.07 0.86 1.81 0.69-4.72 0.23 
Female 
heterosexual 
0.97 0.47-2.01 0.94 0.72 0.34-1.50 0.38 0.52 0.19-1.44 0.21 0.58 0.17-1.95 0.38 
Other/unknown 1.14 0.50-2.63 0.75 0.82 0.35-1.90 0.64 0.68 0.24-1.88 0.46 0.42 0.06-3.08 0.39 
CD4 count (per 
100 cells/mm3) 
0.67 0.62-0.71 <0.0001 0.78 0.73-0.83 <0.0001 0.78 0.72-0.84 <0.0001 0.79 0.70-0.88 <0.0001 
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 Univariable analysis Multivariable model 1 Multivariable model 2 – 
including HCV-RNA test results 
Multivariable model 3 – 
including cirrhosis 
HR 95% CI P value AHR 95% CI P value AHR 95% CI P value AHR 95% CI P value 
HIV viral load 
(copies/ml) 
            
≤50 1 - - 1 - - 1 - - 1 - - 
50-10000 2.70 1.89-3.76 <0.0001 0.95 0.66-1.38 0.79 0.83 0.53-1.29 0.41 1.31 0.71-2.43 0.39 
>10000 4.60 3.29-6.44 <0.0001 0.80 0.55-1.17 0.25 0.86 0.56-1.33 0.50 0.98 0.49-1.95 0.95 
On HAART             
Yes 0.05 0.04-0.08 <0.0001 0.07 0.05-0.10 <0.0001 0.08 0.05-0.11 <0.0001 0.09 0.05-0.16 <0.0001 
No 1 - - 1 - - 1 - - 1 - - 
HCV treatment             
Untreated 1 - - 1 - - 1 - - 1 - - 
Successful  0.04 0.01-0.31 0.002 0.11 0.02-0.78 0.03 0.15 0.02-1.07 0.06 0.24 0.03-1.76 0.16 
Failed  0.21 0.07-0.65 0.01 0.39 0.12-1.24 0.11 0.41 0.13-1.32 0.14 0.32 0.04-2.36 0.26 
Unknown 
outcome 
0.31 0.17-0.59 0.0003 0.55 0.29-1.07 0.07 0.64 0.33-1.25 0.19 0.69 0.24-1.99 0.49 
HCV genotype             
1 or 4 1 - - 1 - - 1 - - 1 - - 
2 or 3 1.06 0.62-1.82 0.83 0.66 0.37-1.15 0.14 0.66 0.36-1.17 0.16 0.73 0.31-1.72 0.48 
Unknown 2.12 1.56-2.87 <0.0001 1.31 0.95-1.80 0.11 1.30 0.90-1.87 0.16 1.48 0.90-2.42 0.12 
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 Univariable analysis Multivariable model 1 Multivariable model 2 – 
including HCV-RNA test results 
Multivariable model 3 – 
including cirrhosis 
HR 95% CI P value AHR 95% CI P value AHR 95% CI P value AHR 95% CI P value 
Acute HCV             
Yes 0.29 0.17-0.48 <0.0001 0.71 0.40-1.25 0.23 0.85 0.47-1.53 0.59 0.64 0.24-1.74 0.64 
No 1 - - 1 - - 1 - - 1 - - 
HCV-RNA             
Negative 1 - - - - - 1 - - - - - 
Positive 1.80 1.32-2.45 0.0002 - - - 1.52 1.09-2.12 0.01 - - - 
Liver disease             
Cirrhotic 4.83 3.10-7.54 <0.0001 - - - - - - 2.50 1.52-4.10 0.0003 
Not Cirrhotic 1 - - - - - - - - 1 - - 
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9.3.4 Predictors of cirrhosis among hepatitis co-infected individuals 
Among 658 HIV/HBV co-infected individuals and 1418 HIV/HCV co-infected individuals who 
had any measurement of cirrhosis, 178 (27.1%) and 411 (29.0%) respectively had a confirmed 
diagnosis of cirrhosis through APRI score, biopsy or FibroScan®.  Baseline characteristics of 
individuals who ever had a diagnosis of cirrhosis compared to those who did not and the 
results of a logistic regression of baseline characteristics associated with ever having a 
diagnosis of cirrhosis are shown in Table 9.13 and Table 9.14. 
 
Among HIV/HBV co-infected individuals, there was no association between age at first HBsAg 
test, ethnicity or HIV exposure group and the development of cirrhosis.  Those individuals with 
higher baseline CD4 counts were significantly less likely to have a confirmed diagnosis of 
cirrhosis in univariable analysis and this association was maintained after adjusting for HBeAg 
and HCV infection (AOR, 95% CI: 0.89, 0.82-0.96 per 100 cells/mm3).  Individuals who were 
HIV/HBV/HCV triple-infected were 52% more likely to develop cirrhosis than those who did not 
have HCV infection.  Compared to individuals who were HBeAg-negative, those with unknown 
HBeAg status were more likely to have a diagnosis of cirrhosis (AOR, 95% CI: 2.48, 1.43-4.31), 
but there was no significant difference in the likelihood of having cirrhosis between HBeAg-
negative and HBeAg-positive individuals (AOR, 95% CI: 1.65, 0.91-3.01).  
 
Among HIV/HCV co-infected individuals, there was no association with developing cirrhosis 
and baseline age or ethnicity.  However, compared to MSM, IDU and male heterosexuals were 
significantly more likely to have cirrhosis:  AOR 1.78 (95% CI 1.29-2.45); and 2.18 (95% CI 1.30-
3.65) respectively.  Individuals who were not on HAART at baseline were significantly more 
likely to have cirrhosis than those who were on HAART at baseline (AOR 1.36, 95% CI: 1.07-
1.75), as were those with unknown HCV genotype (AOR, 95% CI: 1.67, 1.29-2.16) and those 
who were diagnosed with acute HCV infection (AOR, 95% CI: 2.35, 1.75-3.15). 
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Table 9.13 Characteristics of individuals at first positive HBsAg test and logistic regression of factors associated with ever having a confirmed diagnosis of 
cirrhosis among HIV/HBV co-infected individuals 
 No cirrhosis Cirrhosis Univariable analysis Multivariable analysis 
N % N % OR 95% CI P value AOR 95% CI P value 
Median age (years) 
(IQR) 1 
39 (34,45) 38 (32, 43) 1.18 0.97-1.44 0.09 - - - 
Ethnicity           
White 278 57.9 117 65.7 1 - - - - - 
Black African 107 22.3 30 16.9 0.67 0.42-1.05 0.08 - - - 
Other/unknown 95 19.8 31 17.4 0.78 0.49-1.23 0.28 - - - 
HIV exposure group           
MSM 303 63.1 117 65.7 1 - - - - - 
IDU 23 4.8 9 5.1 1.01 0.46-2.25 0.97 - - - 
Male heterosexual 70 14.6 31 17.4 1.15 0.71-1.84 0.57 - - - 
Female heterosexual 60 12.5 14 7.9 0.6 0.33-1.12 0.11 - - - 
Other/unknown 24 5.0 7 3.9 0.76 0.33-1.80 0.53 - - - 
Median CD4 count 
(cells/mm3) (IQR) 2,3 
385 (210, 556) 313 (209, 480) 0.92 0.86-1.00 0.04 0.89 0.82-0.96 0.003 
HIV viral load 
(copies/ml) 
          
<50 148 30.8 58 32.6 1 - - - - - 
>50 238 49.6 94 52.8 1.01 0.69-1.48 0.97 - - - 
Unknown 94 19.6 26 14.6 0.71 0.42-1.20 0.2 - - - 
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 No cirrhosis Cirrhosis Univariable analysis Multivariable analysis 
N % N % OR 95% CI P value AOR 95% CI P value 
On HAART           
Yes 321 66.9 123 69.1 1 - - - - - 
No 159 33.1 55 30.9 0.91 0.63-1.31 0.59 - - - 
HBV treatment           
Yes 140 29.2 43 24.2 1 - - - - - 
No 340 70.8 135 75.8 1.29 0.87-1.92 0.2 - - - 
HBeAg status           
Negative 126 26.3 25 14.0 1 - - 1 - - 
Positive 149 31.0 47 26.4 1.59 0.93-2.73 0.1 1.65 0.91-3.01 0.1 
Unknown 205 42.7 106 59.6 2.61 1.60-4.25 0.0001 2.48 1.43-4.31 0.001 
Ever HCV-infected           
No 343 71.5 111 62.4 1 - - 1 - - 
Yes 137 28.5 67 37.6 1.51 1.05-2.17 0.03 1.52 1.02-2.26 0.04 
 
1 Odds ratios per 10 years 
2 Baseline CD4 count was unknown for 73 individuals with no cirrhosis and 10 individuals with cirrhosis. 
3 Odds ratios per 100 cells/mm3 
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Table 9.14 Characteristics of individuals at first positive HCV test and odds ratios from logistic regression of factors associated with ever having a 
confirmed diagnosis of cirrhosis among HIV/HCV co-infected individuals 
 No cirrhosis Cirrhosis Univariable analysis Multivariable analysis 
N % N % OR 95% CI P value AOR 95% CI P value 
Median age (years) 
(IQR) 1 
38 (32, 44) 39 (33,43) 1.11 0.97-1.28 0.14 - - - 
Ethnicity           
White 837 83.1 350 85.2 1 - - - - - 
Black African 42 4.2 13 3.2 0.74 0.39-1.40 0.35 - - - 
Other/unknown 128 12.7 48 11.7 0.89 0.63-1.28 0.54 - - - 
HIV exposure group           
MSM 649 64.4 242 58.9 1 - - 1 - - 
IDU 194 19.3 103 25.1 1.42 1.08-1.89 0.01 1.78 1.29-2.45 0.0004 
Male heterosexual 45 4.5 28 6.8 1.67 1.02-2.74 0.04 2.18 1.30-3.65 0.003 
Female heterosexual 54 5.4 22 5.4 1.09 0.65-1.83 0.74 1.45 0.85-2.49 0.18 
Other/unknown 65 6.5 16 3.9 0.66 0.38-1.16 0.15 0.72 0.41-1.29 0.27 
Median CD4 count 
(cells/mm3) (IQR) 2,3 
430 (300, 601) 423 (260, 611) 1 0.95-1.04 0.81 - - - 
HIV viral load 
(copies/ml) 
          
<50 400 39.7 133 32.4 1 - - - - - 
>50 486 48.3 194 47.2 1.2 0.93-1.55 0.16 - - - 
Unknown 121 12.0 84 20.4 2.09 1.49-2.94 <0.0001 - - - 
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 No cirrhosis Cirrhosis Univariable analysis Multivariable analysis 
N % N % OR 95% CI P value AOR 95% CI P value 
HAART           
Yes 671 66.6 243 59.1 1 - - 1 - - 
No 336 33.4 168 40.9 1.38 1.09-1.75 0.01 1.36 1.07-1.75 0.01 
HCV-RNA status           
Negative 196 19.5 70 17.0 1 - - - - - 
Positive 536 53.2 211 51.3 1.1 0.80-1.51 0.55 - - - 
Unknown 275 27.3 130 31.6 1.32 0.94-1.87 0.11 - - - 
HCV genotype           
1 or 4 596 59.2 200 48.7 1 - - 1 - - 
2 or 3 107 10.6 50 12.2 1.39 0.96-2.02 0.08 1.4 0.95-2.07 0.09 
Unknown 304 30.2 161 39.2 1.58 1.23-2.03 0.0003 1.67 1.29-2.16 0.0001 
Diagnosed with acute 
HCV infection 
          
No 765 76.0 274 66.7 1 - - 1 - - 
Yes 242 24.0 137 33.3 1.58 1.23-3.03 0.0003 2.35 1.75-3.15 <0.0001 
Ever HBV-positive           
No 870 86.4 344 83.7 1 - - - - - 
Yes 137 13.6 67 16.3 1.24 0.90-1.70 0.19 - - - 
1 Odds ratios per 10 years 
2 Baseline CD4 count was unknown for 81 individuals with no cirrhosis and 29 individuals with cirrhosis. 
3 Odds ratios per 100 cells/mm3 
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9.3.5 Complications of liver disease 
Among 1689 HIV/HBV co-infected individuals, 71 individuals (4.2%) had evidence of 
complications of liver disease.  Among 2657 HIV/HCV co-infected individuals, 89 individuals 
(3.3%)had evidence of complications of liver disease.  The large majority of these 
complications occurred among cirrhotic individuals.  In both HIV/HBV and HIV/HCV co-infected 
groups the most commonly reported complication was gastroesophageal varices (Table 9.15). 
Baseline characteristics of HIV/HBV co-infected and HIV/HCV co-infected individuals with any 
evidence of complicated liver disease are shown in Table 9.16 and Table 9.17. 
 
Table 9.15 Reported complications of liver disease 
Reported complication HIV/HBV co-infected 
individuals  
(% of total) 
HIV/HCV co-infected 
individuals  
(% of total) 
Individuals with evidence of cirrhosis 62 (87.3) 86 (62.9) 
Ascites 25 (35.2) 43 (48.3) 
Portal hypertension 42 (59.2) 62 (69.7) 
Hematemesis 3 (4.2) 3 (3.4) 
Gastroesophageal varices 46 (64.8) 64 (71.9) 
Hepatic encephalopathy 3 (4.2) 3 (3.4) 
Hepatocellular carcinoma 15 (21.1) 9 (10.1) 
Transplant 1 (1.4) 4 (4.5) 
Individuals without evidence of cirrhosis   
Hepatocellular carcinoma 7 (9.9) 3 (3.4) 
Transplant 2 (2.8) 0 (0.0) 
Total  71 (100.0) 89 (100.0) 
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Table 9.16 Baseline characteristics of HIV/HBV co-infected individuals who do and do not 
have evidence of complicated liver disease 
 No  complications Reported complications P-value 
N % N %  
Total 1618  71   
Median age (years) 
(IQR) 
39  (33, 44) 
 
44  
 
(39, 47) <0.0001 
Ethnicity      
White 883 54.6 48 67.6 0.07 
Black African 418 25.8 11 15.5  
Other/unknown 317 19.6 12 16.9  
HIV exposure group      
MSM 962 59.5 41 57.7 0.04 
IDU 68 4.2 8 11.3  
Male heterosexual 277 17.1 11 15.5  
Female heterosexual 229 14.2 6 8.5  
Other/unknown 82 5.1 5 7.0  
Median CD4 count 
(cells/mm3) (IQR) 1  
370  
 
(230, 556) 280  
 
(160, 415) 0.01 
HIV viral load 
(copies/ml) 
     
<50 670 41.4 29 40.8 0.36 
>50 800 49.4 32 45.1  
Unknown 148 9.1 10 14.1  
On HAART      
Yes 1191 73.6 57 80.3 0.21 
No 427 26.4 14 19.7  
HBV treatment      
Yes 637 39.4 28 39.4 0.99 
No 981 60.6 43 60.6  
HBeAg status      
Negative 526 32.5 25 35.2 0.27 
Positive 535 33.1 28 39.4  
Unknown 557 34.4 18 25.4  
Ever HCV-positive      
No 1192 73.7 46 64.8 0.10 
Yes 426 26.3 25 35.2  
1 Baseline CD4 was unknown for 135 individuals with no evidence of complicated liver disease 
and 9 individuals with complicated liver disease 
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Table 9.17 Baseline characteristics of HIV/HCV co-infected individuals who do and do not 
have evidence of complicated liver disease 
 No  complications Reported complications P-value 
N % N %  
Total 2568  89   
Median age (years) (IQR) 39 (24, 44) 43 (39, 48) <0.0001 
Ethnicity      
White 2095 81.5 77 86.5 0.49 
Black African 128 5.0 3 3.4  
Other/unknown 245 9.5 9 10.1  
HIV exposure group      
MSM 1560 60.7 33 37.1 <0.0001 
IDU 540 21.0 39 43.8  
Male heterosexual 164 6.4 7 7.9  
Female heterosexual 151 5.9 6 6.7  
Other/unknown 153 6.0 4 4.5  
Median CD4 count 
(cells/mm3)  (IQR)1 
440 (300, 605) 350 (210, 495) <0.0001 
HIV viral load (copies/ml)      
<50 1161 45.2 51 57.3 0.07 
>50 1265 49.3 33 37.1  
Unknown 142 5.5 5 5.6  
On HAART      
Yes 1804 70.2 78 87.6 0.0004 
No 764 29.8 11 12.4  
HCV-RNA status      
Negative 605 23.6 12 13.5 0.02 
Positive 1311 51.1 58 65.2  
Unknown 652 25.4 19 21.3  
HCV genotype      
1 or 4 1133 44.1 33 37.1 0.23 
2 or 3 254 9.9 13 14.6  
Unknown 1181 46.0 43 48.3  
Diagnosed with acute HCV 
infection 
     
No 1915 74.6 81 91.0 0.0004 
Yes 653 25.4 8 9.0  
Ever HBV-positive      
No 2142 83.4 64 71.9 0.005 
Yes 426 16.6 25 28.1  
 1 Baseline CD4 was unknown for 126 individuals with no evidence of complicated liver disease 
and 4 individuals with complicated liver disease 
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To investigate predictors of developing complicated liver disease, individuals were excluded 
from the analyses if their final follow-up date or first evidence of complication was on or 
before the date that they were first entered into the co-infected group.  Among those 
individuals, with evidence of liver disease complication prior to evidence of co-infection, it was 
assumed that liver disease in these had aetiology other than viral hepatitis infection.  A total of 
1665 HIV/HBV co-infected individuals contributed a total of 8485 person-years of follow-up 
and 56 individuals experienced complications giving an overall rate of complications of liver 
disease of 0.66 per 100 person-years follow-up.  Among 2633 HIV/HCV co-infected individuals 
(contributing 11679 person-years of follow-up), 71 individuals experienced a complication, 
giving an overall complication rate of 0.61 per 100 years of follow-up 
 
Among HIV/HBV co-infected individuals, older age, black African ethnicity, having acquired HIV 
through IDU exposure category, lower CD4 count and higher HIV viral load were associated 
with greater probability of complications in univariable analysis.  However, in multivariable 
analysis, the association between developing complications of liver disease and baseline age 
was lost as was the association between developing complications and HIV viral load (Table 
9.18).  Other associations remained.  IDU were more likely than MSM to develop complications 
of liver disease (AHR, 95% CI: 3.06, 1.30-7.20).  There was no significant difference in the rate 
of developing complications among any other risk group, compared to MSM.  Individuals with 
higher CD4 counts were less likely to experience complications of liver disease (AHR, 95% CI: 
0.78, 0.68-0.90). 
 
There were 44 HIV/HBV co-infected individuals who had further follow-up after their first 
complication of liver disease and who had no evidence of having received a liver transplant.  
Median follow for these individuals after first reported complication was 2.0 years (IQR 1.0, 
4.1).  Of these 44 individuals, 19 were known to have died, giving a mortality rate of 17.4 per 
100 person-years.  Survival after first liver disease complication is shown in Figure 9.3.
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Among HCV co-infected individuals, older age, HIV exposure group, a higher CD4 count, higher 
HIV viral load, being HCV-RNA positive, HCV genotype, not being diagnosed with acute 
infection and HBV triple-infection were all associated with increased rates of developing 
complications in univariable analysis (Table 9.19).  In multivariable analysis, older individuals 
had significantly higher rates of first complication than younger individuals (ARR, 95% CI: 1.81, 
1.91-2.53).  Individuals with higher CD4 counts were less likely to develop complications than 
those with lower CD4 counts (ARR, 95% CI: 0.71, 0.61-0.82 per 100 cells/mm3).  However, the 
association between complications and HIV viral load was not maintained in the multivariable 
model.  Compared to individuals who were HCV-RNA negative, those who were HCV-RNA 
positive were significantly more likely to develop complications (AHR, 95% CI: 2.12, 1.22-3.69).  
There was no significant difference in the development of complications when comparing 
those who were infected with genotype 1/4 and those infected with genotype 2/3.  However, 
being infected with an unknown HCV genotype was associated with a higher likelihood of 
developing complications.  Those individuals who were triple infected with HBV were more 
Years 1 2 3 4 5 6 7 
Number at risk 32 20 15 12 4 2 1 
Figure 9.3 Kaplan Meier graph of survival after first recorded complication of liver 
disease among HIV/HBV co-infected individuals 
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likely to develop complications than those who were not HBV-infected (ARR, 95% CI: 2.13, 
1.15-3.97).   
 
There were 54 HIV/HCV co-infected individuals who had further follow-up after their first 
complication of liver disease and who had no evidence of undergoing a liver transplant.  
Median follow-up time for these individuals was 1.9 years (IQR 0.5, 3.6).  Of these individuals, 
25 were known to have died; a mortality rate of 20.6 per 100 person-years.  Survival after first 
liver disease complication is shown in Figure 9.4.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Years 1 2 3 4 5 6 7 
Number at 
risk 
35 27 20 9 4 1 0 
Figure 9.4 Kaplan Meier graph of survival after first reported complication of liver 
disease among HIV/HCV co-infected individuals 
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Table 9.18 Cox regression of time-updated and fixed covariates associated with first recorded complication of liver disease among HIV/HBV co-infected 
individuals 
 Univariable analysis Multivariable analysis 
HR 95% CI P value AHR 95% CI P value 
Baseline age (per 10 years) 1.45 1.07-1.95 0.02 1.36 0.98-1.90 0.07 
Ethnicity       
White 1 - - 1 - - 
Black African 0.40 0.18-0.90 0.03 0.29 0.08-1.00 0.05 
Other/unknown 0.67 0.31-1.43 0.27 0.54 0.21-1.37 0.19 
HIV exposure group       
MSM 1 - - 1 - - 
IDU 4.00 1.76-9.08 0.001 3.06 1.30-7.20 0.01 
Male heterosexual 0.96 0.44-2.09 0.91 1.33 0.45-3.98 0.61 
Female heterosexual 0.61 0.22-1.73 0.36 1.75 0.46-6.66 0.41 
Other/unknown 1.93 0.59-6.33 0.28 1.95 0.45-8.43 0.37 
CD4 count (cells/mm3) (per 100 
cells) 
0.76 0.67-0.86 <0.0001 0.78 0.68-0.90 0.001 
HIV viral load (copies/ml)       
<50 1 - - 1 - - 
51-10000 1.13 0.48-2.70 0.78 0.99 0.40-2.47 0.99 
>10000 2.62 1.16-5.94 0.02 1.24 0.51-2.01 0.63 
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 Univariable analysis Multivariable analysis 
HR 95% CI P value AHR 95% CI P value 
On HAART       
Yes 1 - - - - - 
No 0.59 0.30-1.16 0.13 - - - 
On HBV treatment       
Yes 1 - - - - - 
No 2.25 0.69-7.36 0.18 - - - 
HBeAg status       
Negative 1 - - - - - 
Positive 1.81 0.98-3.33 0.06 - - - 
HCV-infected       
No 1 - - - - - 
Yes 1.62 0.92-2.86 0.10 - - - 
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Table 9.19 Cox regression of time updated and fixed covariates associated with first recorded complication of liver disease among HIV/HCV co-infected 
individuals 
 Univariable analysis Multivariable analysis 
HR 95% CI P value AHR 95% CI P value 
Age (per 10 years)  1.72 1.28-2.31 0.0003 1.81 1.29-2.53 0.001 
Ethnicity       
White 1 - - - - - 
Black African 0.30 0.04-2.16 0.23 - - - 
Other/unknown 0.61 0.26-1.43 0.26 - - - 
HIV exposure group       
MSM 1 - - 1 - - 
IDU 2.40 1.42-4.07 0.001 1.23 0.64-2.37 0.53 
Male heterosexual 2.22 0.91-5.37 0.08 0.90 0.30-2.71 0.86 
Female heterosexual 1.77 0.68-4.61 0.24 1.33 0.44-3.99 0.61 
Other/unknown 1.22 0.29-5.13 0.79 1.23 0.29-5.29 0.78 
CD4 count (cells/mm3) (per 100 
cells) 
0.70 0.62-0.79 <0.0001 0.71 0.61-0.82 <0.0001 
HIV viral load (copies/ml)       
<50 1 - - 1 - - 
51-10000 0.68 0.27-1.72 0.42 0.53 0.20-1.27 0.19 
>10000 2.17 1.09-4.29 0.03 1.23 0.54-2.80 0.63 
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 Univariable analysis Multivariable analysis 
HR 95% CI P value AHR 95% CI P value 
On HAART       
Yes 1 - - - - - 
No 0.95 0.51-1.74 0.85 - - - 
HCV-RNA status       
Negative 1 - - 1 - - 
Positive 1.84 1.11-3.09 0.02 2.12 1.22-3.69 0.01 
HCV genotype       
1 or 4 1 - - 1 - - 
2 or 3 2.20 1.07-4.51 0.03 1.52 0.67-3.46 0.32 
Unknown 1.85 1.08-3.19 0.03 2.03 1.11-3.73 0.02 
Diagnosed with acute HCV 
infection 
      
No 1 - - 1 - - 
Yes 0.45 0.21-0.99 0.05 0.99 0.42-2.36 0.98 
HBV-positive       
No 1 - - 1 - - 
Yes 1.92 1.12-3.29 0.02 2.13 1.15-3.97 0.02 
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9.4 Discussion 
9.4.1 Summary of results 
In this chapter I have compared mortality rates among HIV mono-infected individuals to those 
among hepatitis co-infected individuals and identified independent predictors of liver disease 
progression and mortality among co-infected individuals.  
 
In the UK CHIC study, among patients under follow-up in an era of effective treatment for HIV 
infection, co-infection with HBV or HCV was significantly associated with increased all-cause 
mortality even after adjusting for other known predictors of mortality.  Compared to HIV 
mono-infected individuals, HIV/HBV co-infected individuals were 1.4 times more likely to die, 
HIV/HCV co-infected individuals were 1.3 times more likely to die and triple-infected 
individuals were 1.8 times more likely to die after adjusting for confounding variables.  The 
association between liver-related mortality and co-infection was even more striking:  HIV/HBV 
co-infected individuals were 9.0 times more likely to die, HIV/HCV co-infected individuals were 
5.7 times more likely and HIV/HBV/HCV triple-infected individuals were 12.4 times more likely 
to die of liver disease than HIV mono-infected individuals.  In contrast, co-infection was not 
associated with AIDS-related deaths in this cohort.     
 
A diagnosis of cirrhosis was a strong predictor of mortality among both HIV/HBV and HIV/HCV 
co-infected individuals.  Among HIV/HBV co-infected individuals, cirrhosis was significantly 
more likely to be diagnosed among those with lower baseline CD4 cell counts than those with 
higher baseline CD4 cell counts, and among those who were HIV/HBV/HCV triple-infected 
compared to HIV/HBV co-infected individuals.  Among HIV/HCV co-infected individuals, 
cirrhosis was significantly more likely to be diagnosed among IDU, male heterosexuals, those 
not on HAART at baseline, those with unknown genotype and those who were diagnosed in 
the acute phase of infection. 
 
Although reported complications of liver disease in the co-infected groups were rare (reported 
for 4.2% of HIV/HBV co-infected and 3.3% of HIV/HCV co-infected individuals), mortality 
among the individuals who had experienced complications of liver disease was high with only 
60% of co-infected individuals surviving up to 2 years after their first reported complication of 
liver disease. 
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9.4.2 Interpretation of results 
The very high adjusted rate ratios for liver-related mortality in co-infected individuals 
compared to HIV mono-infected individuals, combined with the lack of association between 
co-infection and AIDS-related mortality indicate that the increase in all-cause mortality among 
co-infected individuals compared to mono-infected individuals is a result of liver disease rather 
than increased progression of HIV disease among co-infected individuals.   
 
In assessing the association of hepatitis co-infection with all-cause, liver-related and AIDS-
related mortality, some other associations were also observed.  A number of these 
associations were as expected.  For example, IDU and older age were significantly associated 
with increased all-cause, liver-related and AIDS-related mortality.  Lower CD4 count and higher 
HIV viral load were also associated with each of the three types of mortality investigated.  Low 
CD4 count and high HIV viral load are markers of HIV disease progression and therefore the 
association with all-cause mortality is expected since individuals with advanced HIV disease are 
more likely to die.  Both are known to be associated with mortality (537).   
 
The observed association between all-cause mortality and being on HAART, and the even 
stronger association between liver-related mortality and being on HAART is less intuitive.  
While a previous study has shown that HAART is associated with adverse liver events (291), the 
size of the effect in the present analysis was not expected.  On further investigation this 
association was found to be closely related to HIV viral load and after repeating the analysis 
using a composite measure of HAART and HIV viral load, comparing to those individuals who 
were not on HAART and had detectable HIV viral loads, only those individuals who were on 
HAART but also had very high HIV viral loads were found to have significantly higher rates of 
liver-related mortality.  Being on HAART and having a high HIV viral load is likely to be a sign of 
treatment failure and therefore these individuals could be expected to be very unwell 
compared to individuals in the other HAART/viral load categories.  This additional analysis 
indicates that the observed association of HAART and liver-related mortality may not be as a 
result of HAART.  Instead the observed association is due to a group of individuals who are on 
HAART and are very unwell (as indicated by their high HIV viral loads) prior to dying.   
 
Another reason for being on HAART and having high HIV viral load may be poor adherence to 
treatment.  HIV and HBV are treated with common agents and therefore those individuals who 
are poorly adherent to HIV treatment could also be considered to be poorly adherent to their 
HBV treatment.  Therefore the finding that HBV/HIV co-infected individuals have a higher rate 
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of mortality than HIV mono-infected individuals  may be driven by a group of individuals who 
are not adherent to treatment and therefore have uncontrolled HIV and HBV infections.  
 
In addition, the association between mortality and year of follow-up was unexpected.  Being 
under follow-up in 2004 was associated with significantly lower all-cause mortality when 
taking 2009 as a reference year, while 2011 had significantly higher all-cause mortality. 
Similarly, being under follow-up in 2004 was associated with significantly lower liver-related 
mortality when compared to 2009, and being followed-up in 2005 was associated with 
significantly lower AIDS-related mortality.  Given the efforts that have been made to improve 
the quality of death data within UK CHIC, these findings may be due to under-reporting of 
deaths in 2004.  In particular, linkage to PHE data was first conducted in 2011 using a dataset 
that contained data up to the end of 2010.  Therefore it is likely that from 2010 onwards a 
higher proportion of individuals who had died would have information recorded in UK CHIC. 
 
The results of the Cox models used to identify predictors of mortality and the logistic model 
used to identify predictors of cirrhosis further illustrate the important role of liver disease in 
mortality among HIV/HBV co-infected individuals.  The addition of cirrhosis to the model of 
mortality, among HIV/HBV co-infected individuals removed the previously seen association 
between mortality and lower CD4 counts.  In addition, HIV/HBV co-infected individuals with 
lower baseline CD4 counts were more likely to ever have a diagnosis of cirrhosis in logistic 
regression and were more likely to develop complications of liver disease than individuals with 
higher CD4 counts.  Therefore it appears that although CD4 count and liver disease are 
associated, once an individual has established liver disease, CD4 count no longer predicts 
mortality.  It is not possible from these data to assess whether CD4 count impacts 
development of cirrhosis or cirrhosis impacts CD4 count. 
 
Among HIV/HCV co-infected individuals, the addition of cirrhosis to the model of predictors of 
mortality did not remove the previously seen associations between mortality and lower CD4 
count or mortality and not being on HAART, indicating that even if an individual has developed 
cirrhosis, HIV treatment and immune system function are important determinants of survival 
of HIV/HCV co-infected individuals.  In the logistic model of predictors of cirrhosis among 
HIV/HCV co-infected individuals, not being on HAART at baseline was associated with an 
increased likelihood of ever being diagnosed with cirrhosis, again indicating that HAART is an 
important protective factor for HIV/HCV co-infected individuals.  The addition of cirrhosis to 
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the model of mortality among HIV/HCV co-infected individuals did remove the association 
between successful HCV treatment and mortality indicating that the observed reduced 
mortality among individuals successfully treated for HCV may be a result of lower rates of 
cirrhosis among these individuals.  HCV treatment was not included in the logistic regression 
model of predictors of cirrhosis (see section 9.2.6), however, so this cannot be confirmed.  The 
finding that having an unknown HCV genotype is associated with ever having a confirmed 
diagnosis of cirrhosis may be explained by the fact that individuals would likely have a 
genotype test before undergoing HCV treatment.  Therefore those with unknown genotype are 
likely to include a higher proportion of individuals who have not been treated.   
 
The very high mortality rates observed following first report of complications of liver disease, 
in both HIV/HBV and HIV/HCV co-infected individuals, confirms the importance of liver disease 
in mortality of co-infected individuals.     
 
9.4.3 Comparisons with the literature 
The association of HIV/HBV co-infection with increased all-cause mortality and the even larger 
effect of HBV infection on the risk of liver-related mortality has been seen in other cohorts 
(257, 258, 261, 290, 291, 303).  The degree to which HBV co-infection increases the risk of all-
cause mortality is also in line with other studies.  The analyses presented in this chapter 
indicate that HIV/HBV co-infected individuals are 1.4 times more likely to die than HIV mono-
infected individuals.  In the largest previously published study comparing mortality among 
HIV/HBV co-infected and HIV mono-infected individuals, in the EuroSida cohort, individuals 
who were HIV/HBV co-infected were 1.54 times more likely to die than HIV mono-infected 
individuals (258).  The magnitude of increased risk of liver-related mortality among HIV/HBV 
co-infected individuals compared to HIV mono-infected individuals in this UK cohort is higher 
than previously reported.  For example, in EuroSida the risk of liver-related mortality among 
HIV/HBV co-infected individuals was 3.3 times more likely than among HIV mono-infected 
individuals (258).  Similarly, in another Pan-European study (D:A:D) the risk of liver-related 
mortality was 3.7 times higher among HIV/HBV co-infected compared to HIV mono-infected 
individuals.  In the present analysis the risk of liver-related mortality was 8.9 times higher 
among HIV/HBV co-infected compared to HIV mono-infected individuals.  This difference in 
effect size may be due to different levels of liver-related mortality in the mono-infected 
individuals in each cohort. As UK CHIC has lower proportions of IDU than other cohorts, the 
rate of liver deaths in the mono-infected group is likely to be lower within UK CHIC, and 
therefore the additional risk of liver-related mortality among the co-infected group will be 
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greater.  Finally, the finding that HIV/HBV co-infection is strongly associated with liver-related 
mortality but not with AIDS-related mortality is in line with research which has shown that, in 
the era of HAART, HBV co-infection is not associated with an increased progression of HIV to 
AIDS (258, 302, 303).  
 
The association between increased mortality and HIV/HCV co-infection has also been shown in 
other cohorts (252, 253, 274, 284-286, 288, 289, 291, 295, 538).  In the present analysis, the 
risk of all-cause mortality was 1.28 times higher among HIV/HCV co-infected individuals 
compared to HIV mono-infected individuals. This is similar to the effect size seen in a meta-
analysis of 20 studies comparing mortality in HIV/HCV co-infected to that in HIV mono-infected 
individuals.  In the meta-analysis HIV/HCV co-infected individuals had a risk of mortality which 
was 1.35 times higher than HIV mono-infected individuals (275).  Other cohort studies which 
have shown an increased risk of all-cause mortality among co-infected individuals have also 
shown effect sizes of between 1.2 and 2.5 (Chapter 2, Table 2.3).  The analyses presented in 
this chapter indicate that HIV/HCV co-infection leads to a greater increase in risk of liver-
related death than the increase seen for all-cause mortality:  the risk of liver-related mortality 
was 5.7 times higher among HIV/HCV co-infected than among HIV mono-infected individuals. 
This magnitude of increased risk for liver-related mortality among HIV/HCV co-infected 
compared to HIV mono-infected individuals was smaller than that seen in other cohorts (as 
described for HBV co-infection).  For example, in the EuroSida cohort the risk of liver-related 
mortality was 11.7 times higher among HIV/HCV co-infected individuals than among HIV 
mono-infected individuals (252).  Similarly, among a cohort of Danish patients the risk of liver-
related mortality was 15 times higher among HIV/HCV co-infected individuals than among HIV 
mono-infected individuals (253).  As described for HBV, this difference is likely due to higher 
liver-related mortality in the mono-infected group, possibly as a result of the higher proportion 
of IDU in other cohorts compared to in UK CHIC.  As with HIV/HBV co-infection, HIV/HCV co-
infection was not associated with AIDS-related mortality.  This supports the hypothesis that 
HIV/HCV co-infection does not alter progression of HIV to AIDS in the era of HAART (246, 252).  
 
Importantly, in addition to the association between liver-related mortality and HIV hepatitis 
co-infection, the analyses presented in this chapter show a strong association between liver-
related mortality and CD4 count.  Those individuals who had good immune function (higher 
CD4 counts) were less likely to have liver-related mortality.  In this cohort a 100 cell/mm3 
increase in CD4 count was associated with a 37% reduction in risk of mortality.  This finding is 
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in agreement with the study by Weber et al, which also showed a strong association of 
immune function with liver-related death:  for every 2-fold increase in CD4 cell count, the risk 
of liver-related death decreased by 23% (291).  The same study found an increased risk of liver-
related mortality with cumulative exposure to HAART after adjusting for most recent CD4 
count.  The authors postulated that the modest increase in liver-related deaths may be due to 
an increased risk of hepatotoxicity and that the protective effect of increased CD4 count, to 
some extent counteracts this increased risk.  The analyses presented in this chapter indicate 
that although HAART is associated with increased liver-related death, this association occurs 
only among those individuals who have high HIV viral loads and could be considered to be 
failing HIV treatment.   
 
Among HIV/HBV co-infected individuals in this cohort, lower CD4 count and higher HIV viral 
load were associated with mortality.  However, after adjusting for liver disease in the analysis, 
HIV-related parameters were no longer associated with increased mortality among co-infected 
individuals.  A slightly different result was seen among HIV/HCV co-infected individuals where 
lower CD4 count and not being on HAART were associated with an increased risk of mortality 
even after adjusting for liver disease.   Although previous studies have shown that higher CD4 
counts and HAART use are associated with decreased mortality among co-infected individuals, 
these studies have not adjusted for liver disease.  For example, Bonacini et al, found that 
among co-infected individuals, initial CD4 count was associated with liver-related mortality, 
though in their analysis co-infection was considered together and was not split by specific 
hepatitis virus and no  markers of the stage of liver disease were included in the analysis (290).  
The analysis presented in this chapter, however, also found a strong association between 
lower CD4 cell count and cirrhosis.  Other researchers have also reported the association 
between low CD4 counts and cirrhosis (386, 387) which support our findings.  The finding that 
not being on HAART is significantly associated with cirrhosis is supported by previous research 
comparing the progression of liver disease in the pre-HAART and post-HAART eras (332). 
 
A previous study investigating complications of liver disease in HIV-positive individuals has 
shown that one third of all cirrhotic patients have decompensated liver disease.  However, this 
study does not break this prevalence down by aetiology of cirrhosis (336).  Among a small 
Spanish cohort of patients receiving treatment for HBV the rate of liver decompensation was 
2.9 per 100 person-years.  Among HCV co-infected patients the proportion of individuals who 
have liver decompensation events has been reported as 5.8% - 10% among all co-infected 
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(287, 539) and 23% among cirrhotic individuals (540).  It is difficult to compare these results 
with those from the UK CHIC co-infected groups given the varying follow-up times.   However, 
it is clear from these studies as well as the results presented in this chapter that mortality 
following liver disease complications is high (541).  
 
9.4.4 Strengths and weaknesses 
The analyses presented in this chapter provide the first estimations of mortality among 
hepatitis co-infected HIV-positive individuals in the UK.  The links made between the UK CHIC 
dataset and data from ONS and PHE have resulted in very reliable data on the number of 
individuals who have died.  However, accurately establishing cause of death is difficult and 
obtaining reliable causes of death is an ongoing project in UK CHIC.  Therefore it is possible 
that the number of AIDS-related and liver-related deaths are underestimated as cause of death 
data remains incomplete.     
 
Given the potential for under ascertainment of cause of death and the methods used to code 
the deaths within the dataset, it was not possible to examine mortality rates for non-AIDS, 
non-liver related causes of death as part of this analysis.  This additional analysis would be 
useful since it is possible that co-infected individuals may have higher mortality rates due to 
reasons which are not related direction to their hepatitis infection.  For example, IDU might be 
more likely to die than individuals of other exposure categories for reasons such as of suicide 
or drug overdose.  However, as it is not possible to assess the non-AIDS non-liver-related 
causes of death in this dataset, it is not possible to examine the impact of other causes of 
death on mortality rates in each co-infection group.  
 
Conversely, it is also possible that the number of liver-related deaths is overestimated in co-
infected individuals since a known hepatitis diagnosis may influence how a death is reported.  
In this analysis, the impact of this was minimised by not coding a death as liver-related purely 
on the basis of a mention of viral hepatitis infection and by coding the deaths without 
knowledge of the individual’s hepatitis status.  However, some bias in reporting deaths as liver-
related among co-infected individuals may exist.   
 
Measurements of cirrhosis were only available for 39% of HIV/HBV co-infected individuals and 
53% of HIV/HCV co-infected individuals.  It is likely that individuals are only investigated for 
cirrhosis where there is clinical suspicion of liver damage.  Therefore the prevalence of 
cirrhosis may be over-estimated.  In addition, the bias towards investigating liver damage 
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among individuals with clinical signs of liver damage means that it is not possible to accurately 
estimate the point at which an individual becomes cirrhotic.  Therefore, using these data it was 
not possible to investigate rates of progression to cirrhosis and predictors of cirrhosis could 
only be investigated using “ever cirrhotic” as an outcome.  Investigating progression to 
cirrhosis would require active follow-up of individuals known to be non-cirrhotic with regular 
measurements of liver damage.   
 
Individuals who develop complications of liver disease may become very seriously unwell and 
require hospital treatment.  This may or may not occur within the same facility where they 
receive their HIV care.  Data on complications of liver disease were gathered from the centres 
where individuals receive their HIV care.  Therefore, where individuals received care for liver 
disease away from their HIV clinic, it may not be possible to gather these data.  Even where 
care for liver disease is received at the same facility as HIV care, different communication 
systems between departments may mean that some information on liver disease 
complications was not obtained.  Therefore the number of individuals who have recorded 
complications may be an underestimate of the true number of co-infected individuals who 
experience complicated liver disease.  However, this underestimate does not affect the 
findings of high mortality results among individuals with reported complications.   
 
Finally, using the data from UK CHIC it is not possible to determine the date of infection with 
HBV or HCV since individuals may have been infected for some time before their first positive 
result in the dataset.  Therefore it is not possible to examine the effect of timing of hepatitis 
infection compared to HIV infection on the clinical outcomes.     
   
9.4.5 Conclusions 
These analyses represent the first in-depth description of mortality among HIV and hepatitis 
co-infected individuals in a UK setting.  The results of the analyses presented in this chapter 
have shown that compared to HIV mono-infected individuals, hepatitis co-infected individuals 
have increased mortality and that development of liver damage in the form of cirrhosis and 
the complications caused by cirrhosis are important factors in this increased mortality.  The 
association between CD4 cell count and liver disease demonstrates the impact of HIV on the 
progression of damage as a result of viral hepatitis infection.  The strong association between 
cirrhosis and mortality illustrates the importance of preventing liver damage as a result of 
hepatitis infection.  Therefore, in an era where HIV-positive individuals can expect successful 
suppression of HIV infection, identifying hepatitis co-infected individuals early in their hepatitis 
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infection and ensuring their successful treatment in order to prevent the development of 
cirrhosis is vital in improving outcomes for co-infected individuals.
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Chapter 10  Concluding remarks 
 
10.1 Summary of main findings 
Since the introduction of HAART, the rate of AIDS-related morbidity and mortality has fallen 
and with prompt access to treatment, HIV-positive individuals can be expected to live a near 
normal life-span.  Treatment and management of non-AIDS morbidity such has viral hepatitis 
has, therefore, become an increasingly important component of HIV care.  
 
I began my research by conducting a literature review, presented in chapter 2, through which I 
assessed the current knowledge on the burden of HBV/HCV co-infection among HIV-positive 
populations and clinical outcomes for co-infected individuals.  Both HBV and HCV have been 
shown to be prevalent in HIV-positive populations, with 4.5-8.7% of individuals being HBV-
infected in European cohorts.   A wider range in prevalence of HCV has been reported: 8.9-
69%; the prevalence is higher where IDU make up a higher proportion of the HIV-positive 
population.  The published research shows that HBV and/or HCV co-infection has an important 
impact on the clinical outcomes of HIV-positive individuals.  Firstly, HIV-positive individuals are 
more likely to develop chronic hepatitis infection (rather than clearing infection) than HIV-
negative individuals.  Secondly, those who are co-infected with HIV and HBV and/or HCV have 
higher rates of liver disease progression than individuals who are infected with HBV or HCV 
alone.  In addition, while hepatitis co-infection does not appear to affect the progression of 
HIV to AIDS, there is some evidence to suggest that compared to HIV mono-infected 
individuals, hepatitis co-infected individuals may have decreased responses to HAART.  Higher 
mortality rates are observed among HIV-positive individuals co-infected with HBV and/or HCV 
than among individuals who are infected with HIV alone and liver disease appears particularly 
important in as a cause of death.  In the context of these detrimental effects of HBV/HCV co-
infection on HIV-positive individuals, understanding who is at the greatest risk of co-infection, 
the effectiveness of treatment outside of clinical trials and the determinants of disease 
progression is particularly important.   
 
Given the findings of the literature review, the aim of this thesis was to investigate clinical 
outcomes for HIV/HBV and HIV/HCV co-infected individuals in the UK.  The UK CHIC study is 
the largest clinical cohort of HIV-positive individuals in the UK.  However, prior to commencing 
my research, the study collected limited information on hepatitis co-infection.  Dates and 
results of hepatitis laboratory test results were available, but lower than expected proportions 
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of individuals were recorded as ever having had a test for HBV or HCV (as reported in chapter 
3).  In addition, no information was available regarding liver disease among individuals who 
were HBV and/or HCV co-infected or treatment for HBV or HCV infections.  Therefore, as 
described in chapter 4, I undertook a process of data collection during which I identified a 
subset of individuals from 11 UK CHIC centres who were confirmed as being HBV and/or HCV 
co-infected.  For this group, I then collected additional data on liver disease and treatment for 
hepatitis infection.  The information was gathered from a range of sources including electronic 
patient records, hard copy clinical notes and downloads from specific databases such as 
laboratory records, FibroScan® machines and radiology records.  The resulting dataset was 
then standardised, pseudonymised, cleaned and merged with the UK CHIC dataset.  This 
process resulted in a cohort of 1637 individuals who were confirmed as HBV co-infected and 
3299 individuals who were confirmed as HCV-co-infected.   
 
In order to assess the value of routinely recorded laboratory test results in defining an 
individual as HBV or HCV co-infected, I conducted a detailed examination of the available 
results within UK CHIC.  This work is presented in chapter 5.  Specifically, for HBV I focussed on 
the results of tests for HBsAg, anti-HBs and anti-HBc and for HCV I focussed on anti-HCV tests.  
With clinical input I developed algorithms for making decisions about erroneous results and 
defining an individual’s true HBV or HCV infection status.  An important finding from this 
chapter was that for a high proportion of individuals it was not possible to assign a definitive 
HBV-infection status.  Therefore whilst I have been able to confidently define a cohort of HBV 
co-infected individuals as a result of the data collection, the proportion of individuals who are 
immune to HBV-infection (either through vaccination or previous cleared infection) and the 
proportion who have never been exposed to HBV remain uncertain. 
 
In the context of this newly collected data, in chapter 6 I investigated the proportion of 
individuals who had been tested for HBV and/or HCV co-infection and the prevalence and 
incidence of these infections within UK CHIC.  A key finding from this chapter is that from 2004 
to 2011, the proportion of individuals who have ever had a test for HBsAg or anti-HCV has 
significantly increased.  In addition the proportion of individuals not known to be infected who 
test within each calendar year has also increased.  Testing has increased differentially among 
subgroups.  For example, the probability of having a first HBsAg test has increased more 
among white individuals than among black African individuals and the probability of having a 
first anti-HCV test has increased more among MSM than among IDU.  The prevalence of HBV-
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infection in this cohort was 6.7% and the incidence of newly identified infection was estimated 
as 1.2 per 1000 person years.  Prevalence of HCV was 10.7% in this cohort with incidence 
estimated as 0.91 per 1000 person years.  Prevalence of HBV appears to have decreased from 
2004 to 2011 while that of HCV has remained stable.  However, changes in prevalence and 
incidence may be impacted by increasing testing.  Another key finding from this chapter is that 
although prevalence of HCV has remained stable for the cohort as a whole the prevalence 
among MSM has increased.   
 
In chapter 7 I present an analysis investigating receipt of treatment for HCV-infection and 
responses to treatment.  More than a third of HCV-infected individuals in UK CHIC had 
received treatment with those individuals who were diagnosed with acute infection being 
more likely to receive treatment than those not diagnosed in the acute stage.  MSM were 
more likely than IDU and heterosexuals to receive treatment.  A particularly important, but 
disappointing, finding reported in this chapter was that with the data available in UK CHIC it 
was not possible to define SVR to HCV treatment.  Therefore in order to identify predictors of 
treatment failure I investigated time to treatment failure among all individuals who had an 
HCV-RNA test available within a year of stopping treatment.  I reported that 33% of these 
individuals had evidence of failing treatment.  Those factors shown to be associated with 
treatment failure in other studies were also identified as independent predictors of treatment 
failure in this cohort particularly higher baseline HCV viral load, shorter time on treatment, not 
being treated in acute infection and being infected with genotype 1 or 4 HCV.  Of particular 
importance is the finding that there is a large group of HCV co-infected individuals who are in 
need of HCV treatment, either because they have never received treatment or because they 
have failed treatment.  These individuals are at risk of developing liver disease and a small 
proportion already have evidence of cirrhosis.   
 
In chapter 8 I report on the strategies in use within UK CHIC to treat HBV-infection and I assess 
response to treatment with regard to suppression of viral replication (evidenced by loss of 
detectable HBV-DNA), loss of HBeAg and seroconversion to anti-HBe positivity.  In this cohort, 
the majority of HBV co-infected individuals received treatment.  In addition, the most 
commonly used treatment was with two NRTIs.  Whilst the majority of individuals suppressed 
HBV replication, less than half lost HBeAg and of those even fewer (57.7%) were known to 
develop anti-HBe.  These individuals remain at risk of developing cirrhosis.  The analysis of 
treatment response identified some important independent predictors of treatment response:  
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being on 2 or more drugs was significantly associated with loss of HBeAg; and higher CD4 
count and being HBeAg negative was associated with suppression of HBV replication.   
 
Finally, in chapter 9 I examined the impact of HBV and/or HCV co-infection on clinical 
outcomes of HIV-positive individuals.  Like a number of other studies I reported a strong 
association between hepatitis co-infection and increased all-cause mortality.  HBV and/or HCV 
co-infection had an even greater effect on the rate of liver-related mortality in this cohort.  
Among HBV co-infected individuals the analyses showed the importance of treatment as those 
who received HBV active treatment were significantly less likely to die than those who did not.  
In addition, those with higher CD4 counts were less likely to die than those with lower CD4 
counts.  I reported similar findings among HCV co-infected individuals; individuals with higher 
CD4 counts were less likely to die than those with lower CD4 counts as were individuals on 
HAART compared to those not on HAART.  Importantly, those individuals who had evidence of 
successful or failed HCV-treatment were less likely to die than those who were untreated. 
 
In addition, among the co-infected groups evidence of cirrhosis was a strong predictor of 
mortality when added to the model.  Therefore predictors of cirrhosis were also assessed.   
Among HBV co-infected individuals CD4 count was a predictor of cirrhosis.  Among HCV co-
infected individuals, cirrhosis was associated with injecting drug use.  Another important 
finding is that not being on HAART was associated with cirrhosis among HCV co-infected 
individuals.   
 
The consequences of developing cirrhosis can be serious.  I only identified small proportions of 
HBV and/or HCV co-infected individuals who had experienced complications of liver disease.  
However, the survival curves for individuals who experience complications of liver disease  and 
mortality rates following first recorded complication indicate the importance of preventing 
liver disease from progressing. 
 
10.2 Relevance of findings and limitations 
As shown in the literature review HIV and HBV/HCV co-infection has previously been studied 
within a number of different cohorts.  However, the range of results indicates the importance 
of having locally applicable data on which to base clinical guidelines.  This work has resulted in 
the creation of the largest research cohort of HIV and HBV and/or HCV co-infected individuals 
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in the UK.  The results will be particularly important in guiding decisions about treatment and 
management of co-infected individuals in the UK. 
 
Although estimates of the prevalence of HBV and HCV in this cohort had been published 
previously, these newer estimates are important for two reasons. Firstly, the work which I 
have undertaken to confirm the status of individuals means that the data can be considered to 
be more complete than that used in previously published estimates.  Secondly, these estimates 
provide a more up-to-date picture of co-infection at a time where there are a number of new 
treatments for HCV becoming available.  The estimates of incidence and prevalence of co-
infection as well as the estimates of treatment uptake and response can be used to predict 
future requirements for treatment and to estimate the potential impact of any new 
interventions   Indeed, the results of the HCV analyses are currently being used to inform a 
model predicting the impact of new DAAs on the HCV epidemic among MSM in the UK (542).   
 
The ongoing incidence of both HBV and HCV highlights the need for ongoing prevention of 
these infections.  An effective vaccine is available to protect against HBV-infection.  A 
limitation of the work presented here is that a high proportion of individuals have an unknown 
HBV-infection status.  Therefore it was not possible for me to assess the proportion of 
individuals in this cohort who have received HBV vaccination.  No vaccine against HCV exists.  
However, I have shown that MSM are significantly more likely than heterosexuals to have 
incident HCV-infection.  Prevention efforts should therefore be particularly targeted to this 
group. A further limitation of this work is that there were limited test results available which 
allowed me to assess whether infected individuals have cleared HBV or HCV infection.  I 
estimated the proportion of individuals with resolved HBV infection as well as the proportion 
of individuals known to have acute HCV infection who spontaneously cleared infection.  
However, these calculations included only a subset of the infected groups who had the 
necessary data available. 
 
The development of DAAs for treatment of HCV in the last 3 years has changed the outlook for 
HCV-infected individuals. Since conducting the expanded data collection in 2012-13, three new 
DAAs have been licensed for use against HCV (sofosbuvir, simeprevir and daclatasvir).  As 
described in section 1.3.4, these newer drugs result in SVR in up to 90% of HCV mono-infected 
individuals in clinical trials.  However, phase III trials of these drugs excluded HIV-positive 
individuals.  Subsequent studies have been conducted among HIV-positive populations.  These 
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studies have mainly been small in size but have included both interferon containing regimens 
and interferon free regimens.  A recent systematic review of clinical trials to date compared 
the results in studies including HCV mono-infected with studies including HIV-positive 
individuals and concluded that where assessed the proportion of HIV co-infected individuals 
who achieve SVR with these new drugs is comparable to the SVR rates seen among HCV mono-
infected individuals (543).  Although European treatment guidelines now recommend use of 
DAAs for HIV co-infected individuals, access to these treatments is still limited since 
treatments are costly (499).  The results presented in chapter 7 which show that a high 
proportion of HIV-positive individuals have never been treated or have failed treatment, 
outline the urgent need for access to newer, more effective HCV treatments for HIV-positive 
individuals in particular.   
 
A major limitation of the work presented in chapter 7 is that I was unable to define SVR due to 
the limited number HCV-RNA test results within the dataset.  As newer treatment regimens 
become more easily accessible and are used outside of clinical trials it will be very important to 
monitor their effectiveness.  The UK CHIC dataset, including the additional data collected for 
HCV co-infected individuals presents an excellent opportunity for this monitoring.  However, in 
order to compare findings in this cohort with others, it will be vital to calculate SVR rates.  
Therefore a key aim of further rounds of data collection will be to ensure that treatment 
response is recorded in the dataset.   
 
Although the effectiveness of NRTIs to treat HIV/HBV co-infected individuals has been 
previously reported, studies have been small.  Therefore the findings in chapter 8, which 
assess predictors of viral suppression and HBeAg clearance, are of great relevance in ensuring 
effective treatment for this co-infected group.  In particular, these data provide additional 
evidence that use of two HBV active drugs is preferable over use of monotherapy. 
 
I believe that the results presented in chapter 9 are especially important since they quantify 
the effect of HBV and/or HCV co-infection with regard to mortality among HIV-positive 
populations and therefore add additional weight to the importance of ensuring that the most 
effective treatment options are used.  The very high rates of mortality after the first liver 
decompensation event raise the question of how to manage end-stage liver disease in HIV-
positive individuals with HBV and/or HCV co-infection.  Research has shown that survival after 
liver transplant is comparable among HIV-positive and HIV-negative individuals and therefore 
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HIV should not be considered a contraindication for liver transplant (Chapter 2, section 2.9).   
As part of the expanded data collection, I aimed to collect information on whether an 
individual had been referred for or received a liver transplant.  However, the number of 
individuals reported as having been referred for liver transplant in this cohort was very low.  As 
an extension to this research, work is ongoing to obtain information from transplant centres 
on all liver transplants carried out among HIV-positive individuals.  This information will be 
linked back into UK CHIC so that it is possible to assess whether HIV-positive individuals are 
being appropriately referred for liver transplant and how transplant affects survival.   A final 
limitation of the work on mortality is the number of individuals for whom a cause of death is 
not reported in UK CHIC.  Further work to obtain additional causes of death is ongoing and this 
work is part of one of the major research themes conducted in the UK CHIC study. 
 
10.3 Future work 
Data collected for this thesis included individuals seen from 2004-2012.  The additional data 
does not form part of the standard UK CHIC data submission.  Since the data collected came 
from a range of sources and was not recorded in a standardised manner within HIV clinics the 
process of gathering the data was very time consuming.  Prospective data collection will be 
necessary in order to assess the frequency of the use of new drugs, responses to new drugs 
and the development of resistance to HBV/HCV treatments.  In addition, the impact of new 
drugs on the burden of disease, the potential for HCV re-infection and any effects which new 
drugs may have on response to HAART could be monitored.  
 
It is clear from the limitations described above that the main priority for future data collection 
should be ensuring that all treated individuals have full serological data recorded during and 
after their treatment.  The experience of the first round of data collection has shown that a 
number of the variables which we aimed to collect were not easily accessible or were not 
available in a form which could easily be used in analyses.  For example, alcohol consumption 
was recorded at different points in an individual’s diagnosis and a person’s use of alcohol may 
change over time.  Therefore it was not possible to record this is a meaningful manner which 
could be easily included as a covariate in analyses.  The lessons learned throughout the initial 
round of data collection which I conducted will be used to inform the refinement of the 
dataset collected in subsequent rounds of data collection.  If the hepatitis data collection is to 
continue prospectively, given the importance of country of birth in the epidemiology of 
hepatitis infection, consideration should be given to including country of birth as an additional 
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data item.  This would allow more meaningful comparisons between this research data and 
national surveillance data.  In addition to monitoring the impact of treatment, there are a 
number of other areas of research questions which can be addressed using information from 
the expanded dataset.  In particular, questions around the rate of progression of liver disease, 
the development of HCC and monitoring of HIV and HBV/HCV co-infected individuals. Some of 
these topics are already being addressed. 
 
10.4 Final comments 
For individuals living with HIV in the UK, access to HAART means a normal length life 
expectancy which can be spent in good health.  However, this means that HIV-positive 
individuals are at risk of suffering the ill-effects of other co-morbidities such as HBV and HCV.  
These two infections, both serious in their own right, have increased rates of progression 
among HIV-positive individuals and I have shown that HIV-positive individuals in the UK, who 
are co-infected with HBV and HCV, are at increased risk of mortality as a result of their 
hepatitis infection.  Despite the limitations in the data, I have shown that HBV treatment in the 
form of two active agents successfully supresses the virus whereas currently used treatments 
for HCV are less effective.  I have shown that IDU are less likely to have received treatment 
than other groups and that a high proportion of individuals failed treatment.  Some of these 
individuals already have evidence of cirrhosis.  Therefore it is hoped that the results presented 
in this thesis can be used to help prioritise those most at need of new treatments as they 
become available, thus preventing serious complications of liver disease.     
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Appendix I Commonly used scoring systems in use for assessing 
the stages of liver disease 
 
Table I.1 Ishak scoring for assessing the degree of liver damage 
Description Score 
Necro-inflammatory scores 
A. Periportal or periseptal interface hepatitis (piecemeal necrosis) 
Absent 
Mild 
Mild/moderate  
Moderate 
Severe 
 
0 
1 
2 
3 
4 
 
B. Confluent necrosis 
Absent 
Focal 
Zone 3 necrosis in some areas 
Zone 3 necrosis in most areas 
Zone 3 necrosis and occasional portal-central bridging 
Zone 3 necrosis and multiple portal-central bridging 
Panacinar or multi acinar necrosis 
 
0 
1 
2 
3 
4 
5 
6 
C. Focal lytic necrosis, apoptosis and focal inflammation 
Absent 
One focus or less per 10X objective 
Two to four foci per 10X objective 
Five to ten foci per 10X objective 
More than ten foci per 10X objective 
 
 
0 
1 
2 
3 
4 
D. Portal inflammation 
None 
Mild, some or all portal areas 
Moderate, some or all portal areas 
Moderate/marked, all portal areas 
Marked, all portal areas 
 
 
0 
1 
2 
3 
4 
Architectural change, fibrosis  and cirrhosis 
No fibrosis 
Fibrous expansion of some portal areas with or without short fibrous 
septa 
Fibrous expansion of most portal areas with or without short fibrous 
septa 
Fibrous expansion of most portal areas  with occasional portal to 
portal bridging 
Fibrous expansion of portal areas  with marked portal to portal and 
portal to central bridging 
Marked bridging  with occasional nodules (incomplete cirrhosis) 
Cirrhosis probable or definite 
0 
1 
 
2 
 
3 
 
4 
 
5 
6 
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Table I.2 METAVIR scoring for assessing the degree of liver damage among individuals with 
chronic viral hepatitis 
Fibrosis Score Description 
F0 No fibrosis 
F1 Portal fibrosis without septa 
F2 Portal fibrosis with few septa 
F3 Numerous septa without cirrhosis 
F4 Cirrhosis 
Activity score Description 
A0 No activity 
A1 Mild activity 
A2 Moderate activity 
A3 Severe activity 
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Appendix II UK CHIC study organisation 
 
II.1 UK CHIC coordinating group 
Caroline Sabin (Principle Investigator), Andrew Phillips, Teresa Hill (study coordinator), Sophie 
Jose (research statistician), Susie Huntington (PhD student), Alicia Thornton (PhD student); UCL 
Research Department of Infection and Population Health. 
David Dunn, Adam Glaby; Medical Research Council Clinical Trials Unit (MRC CTU at UCL) 
 
II.2 UK CHIC Steering Committee 
Jonathan Ainsworth, Sris Allan, Jane Anderson, Abdel Babiker, David Chadwick, Valerie 
Delpech, David Dunn, Martin Fisher, Brian Gazzard, Richard Gilson, Mark Gompels, Phillip Hay, 
Teresa Hill, Margaret Johnson, Sophie Jose, Stephen Kegg, Clifford Leen, Fabiola Martin, Mark 
Nelson, Chloe Orkin, Adrian Palfreeman, Andrew Phillips, Deenan Pillay, Frank Post, Jillian 
Pritchard, Caroline Sabin (PI), Roy Trevelion, Achim Schwenk, Anjum Tariq, John Walsh. 
 
II.3 Hepatitis subgroup of the UK CHIC steering committee 
Sanjay Bhagani, Andrew Burroughs, David Chadwick, David Dunn, Martin Fisher, Richard 
Gilson, Janice Main, Mark Nelson, Alison Rodger, Chris Taylor 
II.4 UK CHIC centres 
Brighton and Sussex University Hospitals NHS Trust, Brighton 
Chelsea & Westminster Healthcare NHS Trust, London 
Kings College Hospital NHS Foundation Trust, London 
Mortimer Market Centre, Royal Free and University College Medical School, London 
Royal Free NHS Trust and Royal Free University College Medical School, London 
St. Mary's Hospital, Imperial College Healthcare NHS Trust, London 
Bart’s and The London NHS Trust, London 
North Middlesex University Hospital NHS Trust, London 
Homerton University Hospital NHS Trust, London 
The Lothian University Hospitals NHS Trust, Edinburgh 
North Bristol NHS Trust, Bristol 
University Hospitals of Leicester NHS Trust 
South Tees Hospitals NHS Foundation Trust, Middlesbrough 
South London Healthcare NHS Trust 
 404 
 
St. George's Healthcare NHS Trust, London 
York Teaching Hospitals NHS Foundation Trust 
Coventry & Warwickshire NHS Trust 
The Royal Wolverhampton NHS Trust 
Ashford & St. Peter’s Hospitals NHS Foundation Trust 
 
II.5 UK CHIC centres contributing to expanded hepatitis data 
collection and key contacts within centres 
Brighton (M Fisher, E Youssef, Elton John Centre Staff) 
St Mary’s (N Mackie, G Cooke, J Main, S Reeves, Wharfside clinic staff)  
Chelsea and Westminster (M Nelson, C Fletcher, A Moyes, L Phillips, E Seah) 
Mortimer Market (R Gilson, P Muniina, N Brima) 
Kings (F Post, L Campbell, K Childs, C Taylor) 
Royal Free (A Rodger, S Bhagani, C Chaloner, K Singh)  
Edinburgh (C Leen, S Morris, A Wilson) 
North Middlesex (A Schwenk, A Waters, S Miller)  
Bristol (M Gompels, S Allen, H Wilson) 
Middlesbrough (D Chadwick, J Gibson)  
Woolwich (S Kegg, T Leitao) 
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Appendix III  Timelines for the preparation of an annual UK CHIC dataset 
 
Data collection and processing stage Time for completion     Deadline 
Data specification and request 
 Distribution of data specifications including new variables, as agreed by the steering committee and request for data 
sent to centres: data for all patients ever seen, not just those seen since 01/01/1996.   
 Data submitted via FTP server. 
 
6 weeks Request data 
beginning of 
November to be 
sent by end of 
December 
General checks on integrity of data from sites (not checking of individual records) 
 Identify obvious errors by cross tabulating all variables and  check new data against previous data submission for 
each centre and resolve and problems with the local data manager 
 Manipulate centre-specific data so that conforms with data specification  
 
3.5 months Mid-April 
Import of data into UK CHIC database 
 Prepare all data for one centre as tab delimited text file and import into MRC database 
 
4 weeks Mid-May 
Data cleaning of individual records 
 Run within-centre data queries and consistency checks and resolve errors with local data managers and clinicians 
 Edit to the CHIC database and ask centres to update local databases as necessary 
 Send centres a summary of data cleaning for example, how many inconsistencies identified and resolved  
 
3 months Mid-August 
De-duplication  
 Run de-duplication process and manually resolve ambiguous matches 
 Merge data from matched records 
6 weeks End of September 
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Data collection and processing stage Time for completion     Deadline 
 
Preparation of final dataset 
 Export merged data tables to text files 
 Resolve outstanding data quirks using SAS program (study statistician)   
 
1 month End of October 
  
 
4
07
 
Appendix IV Changes over time in the characteristics of individuals under follow-up in UK CHIC 
Year of follow-up 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
Total number of 
individuals in follow-up 
14475 15989 17713 19377 21575 23447 24953 26270 27352 28271 29326 27670 
Median age at entry 
(IQR) 
33  
(29, 38) 
33  
(28, 38) 
33  
(28, 39) 
33  
(28, 39) 
33  
(28, 39) 
33  
(28, 39) 
33  
(28, 39) 
33  
(28, 39) 
34  
(28, 40) 
34  
(28, 40) 
34  
(28, 40) 
34  
(28, 
40) 
Male (%) 11640 
(80.4) 
12587 
(78.7) 
13700 
(77.3) 
14730 
(76.0) 
16169 
(74.9) 
17374 
(74.1) 
18382 
(73.7) 
19366 
(73.7) 
20176 
(73.8) 
20925 
(74.0) 
21638 
(73.8) 
20421 
(73.8) 
Ethnicity             
White (%) 9511 
(65.7) 
10130 
(63.4) 
10853 
(61.3) 
11550 
(59.6) 
12519 
(58.0) 
13428 
(57.2) 
10780 
(43.2) 
11411 
(43.4) 
15473 
(56.6) 
16050 
(56.8) 
16541 
(56.4) 
15532 
(56.1) 
Black African (%) 2533 
(17.5) 
3161 
(19.8) 
3900 
(22.0) 
4672 
(24.1) 
5518 
(25.6) 
6119 
(26.1) 
6623 
(26.5) 
7009 
(26.7) 
7402 
(27.1) 
7566 
(26.8) 
7868 
(26.8) 
7423 
(26.8) 
Black other (%) 612  
(4.2) 
722 
(4.5) 
868 
(4.9) 
953 
(4.9) 
1101 
(5.1) 
1209 
(5.2) 
1305 
(5.2) 
1409 
(5.4) 
1511 
(5.5) 
1576 
(5.6) 
1644 
(5.6) 
1596 
(5.8) 
Other/unknown (%) 1819 
(12.6) 
1976 
(12.4) 
2092 
(11.8) 
2202 
(11.4) 
2437 
(11.3) 
2691 
(11.5) 
2852 
(11.4) 
2993 
(11.4) 
2966 
(10.8) 
3079 
(10.9) 
3273 
(11.2) 
3119 
(11.3) 
HIV exposure group             
MSM (%) 9187 
(63.5) 
9872 
(61.7) 
10603 
(59.9) 
11315 
(58.4) 
12321 
(57.1) 
13181 
(56.2) 
13841 
(55.5) 
14484 
(55.1) 
14962 
(54.7) 
15477 
(54.8) 
16058 
(54.8) 
15082 
(54.5) 
IDU (%) 715  
(4.9) 
712 
(4.5) 
709 
(4.0) 
703 
(3.6) 
721 
(3.3) 
738 
(3.2) 
769 
(3.1) 
767 
(2.9) 
765 
(2.8) 
753 
(2.7) 
741 
(2.5) 
670 
(2.4) 
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Year of follow-up 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
Male heterosexual (%) 1412 
(9.8) 
1673 
(10.5) 
2017 
(11.4) 
2309 
(11.9) 
2703 
(12.5) 
3007 
(12.8) 
3237 
(13.0) 
3440 
(13.1) 
3617 
(13.2) 
3713 
(13.1) 
3798 
(13.0) 
3523 
(12.7) 
Female heterosexual (%) 2363 
(16.3) 
2891 
(18.1) 
3499 
(19.8) 
4153 
(21.4) 
4870 
(22.6) 
5467 
(23.3) 
5919 
(23.7) 
6202 
(23.6) 
6518 
(23.8) 
6657 
(23.6) 
6896 
(23.5) 
6445 
(23.3) 
Other/unknown (%) 798  
(5.5) 
841 
(5.3) 
885 
(5.0) 
897 
(4.6) 
960 
(4.5) 
1054 
(4.5) 
1187 
(4.8) 
1377 
(5.2) 
1490 
(5.5) 
1671 
(5.9) 
1833 
(6.3) 
1950 
(7.1) 
CD4 <200 cells/mm3 (%)             
Within year (%) 3087 
(21.3) 
3161 
(19.8) 
3490 
(19.7) 
3716 
(19.2) 
3734 
(17.3) 
3828 
(16.3) 
3577 
(14.3) 
3231 
(12.3) 
3058 
(11.2) 
2670 
(9.4) 
2487 
(8.5) 
2007 
(7.3) 
By the end of the year (%) 6085 
(42.0) 
6889 
(43.1) 
7987 
(45.1) 
9016 
(46.5) 
10179 
(47.2) 
11272 
(48.1) 
12154 
(48.7) 
12878 
(49.0) 
13531 
(49.5) 
13897 
(49.2) 
14201 
(48.4) 
13287 
(48.0) 
Undetectable viral  load 
(< 50 copies/ml) 
            
Within year (%) 5551 
(38.4) 
6764 
(42.3) 
7969 
(45.0) 
9494 
(49.0) 
11725 
(54.4) 
13129 
(56.0) 
14684 
(58.9) 
15939 
(60.7) 
18220 
(66.6) 
20290 
(71.8) 
21678 
(73.9) 
21165 
(76.5) 
By the end of year (%) 12224 
(84.5) 
13666 
(85.5) 
15234 
(86.0) 
16805 
(86.7) 
18756 
(86.9) 
20376 
(86.9) 
21715 
(87.0) 
22852 
(87.0) 
23930 
(87.5) 
24679 
(87.3) 
25246 
(86.1) 
23231 
(84.0) 
HAART experienced (%) 8277 
(57.2) 
9506 
(59.5) 
10897 
(61.5) 
12392 
(64.0) 
14157 
(65.6) 
15897 
(67.8) 
17434 
(69.9) 
13124 
(72.8) 
21034 
(76.9) 
22621 
(80.0) 
24169 
(82.4) 
23400 
(84.6) 
Initial HAART regimen             
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Year of follow-up 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 
PI based 
(% of HAART 
experienced) 
4914 
(34.0) 
5155 
(32.2) 
5448 
(30.8) 
5696 
(29.4) 
6186 
(28.7) 
6699 
(28.6) 
7152 
(28.7) 
7486 
(28.5) 
7793 
(28.5) 
8049 
(28.5) 
8252 
(28.1) 
7414 
(26.8) 
NNRTI based  
(% of HAART 
experienced) 
6372 
(44.0) 
7401 
(46.3) 
8502 
(48.0) 
9692 
(50.0) 
11050 
(51.2) 
12150 
(51.8) 
13006 
(52.1) 
13778 
(52.5) 
14495 
(52.0) 
14928 
(52.8) 
15343 
(52.3) 
14543 
(52.6) 
Other regimen 
(% of HAART 
experienced) 
3189 
(22.0) 
3433 
(21.5) 
3763 
(21.2) 
3989 
(20.6) 
4339 
(20.1) 
4598 
(19.6) 
4795 
(19.2) 
5006 
(19.1) 
5064 
(18.5) 
5294 
(18.7) 
5731 
(19.5)  
5713 
(20.7) 
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Appendix V Tables produced from expanded data collection for merging into UK CHIC 
Table V.1 Hepatitis co-infection lists 
Includes all potentially HBV and/or HCV co-infected individuals identified either through the UK CHIC 2011 dataset or though centre specific lists of co-
infected individuals. 
Field name Data Type Description Relevant Coding 
CLINIC_ID Text ID number used within HIV clinics to 
identify individual 
N/A 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC database 
N/A 
CHIC_HBV Numeric  
(1 or 0) 
Whether the individual is identified as 
HBV-positive in UK CHIC  
1 = Patient identified as HBV -
positive in CHIC list 
 
0= Patient not identified as HBV-
positive in CHIC list 
CENTRE_HBV Numeric   
(1 or 0) 
Whether the individual is identified as 
HBV-positive by the centre 
1 = Patient identified as HBV-
positive  in centre list 
 
0 = Patient no identified as HBV-
positive in centre list 
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Table V.2 Not Co-infected according to clinical data 
Field name Data Type Description Relevant coding 
CLINIC_ID Text ID number used within HIV clinics to 
identify individual 
N/A 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC database. 
N/A 
NOT_HBV_COINF Numeric After reviewing patient notes and 
electronic records at the centre it was 
ascertained that this individual was 
not HBV co-infected 
1 = Not HBV co-infected 
NOT_HCV_COINF Numeric After reviewing patient notes and 
electronic records at the centre it was 
ascertained that this individual was 
not HCV co-infected 
1 = Not HCV co-infected 
CHIC_HCV Numeric   
(1 or 0) 
Whether the individual is identified as 
HCV-positive in UK CHIC 
1 = Patient identified as HCV-
positive in CHIC list 
 
0 = Patient not identified as 
HCV-positive in CHIC list 
CENTRE_HCV Numeric   
(1 or 0) 
Whether the individual is identified as 
HCV-positive by the centre 
1 = Patient identified as HCV-
positive in centre list 
 
0 = Patient not identified as 
HCV-positive in centre list 
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Table V.3 Demographics 
Field Name Data Type Description Relevant coding 
CLINIC_ID Text ID number used within HIV clinics to 
identify individual 
N/A 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC database. 
N/A 
N_SEX Number Gender of individual 1 = Male 
2 = Female 
N_SEXORI Number Sexual orientation at time of 
hepatitis diagnosis.  This may or may 
not also be the individual’s HIV risk 
factor 
 
1 = homosexual 
2 = heterosexual 
3 = bisexual 
99 = unknown 
N_ETHNICITY Number Ethnic group to which individual 
belongs 
1 = White 
2 = Black Caribbean 
3 =  Black African 
4 = Black other/ unspecified 
5 = Indian/ Pakistani/ 
Bangladeshi 
6 = Other Asian/ Oriental 
7 = Other/ mixed 
98 = Other 
99 = Not known 
DRUGS Text Has the individual ever injected 
drugs? 
0 = No 
1 = Yes 
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Field Name Data Type Description Relevant coding 
DRUGS_ YEAR Numeric If the individual has injected drugs 
the year in which they first did so 
N/A 
AL_DX_TXT Text In words N/A 
AL_DX_VAL Numeric Number of stated units N/A 
AL_DX_UNIT Text The unit in which alcohol 
consumption at hepatitis diagnosis 
was measured 
 
AL_CURR_TXT Text As recorded in the clinical notes N/A 
AL_CURR_VAL Numeric Current amount of alcohol 
consumption  
N/A 
AL_CURR_UNITS Text The unit in which current alcohol 
consumption was measured 
N/A 
 
 
 
 
 
Table V.4 Hepatitis serology 
Field Name Data Type Description Relevant coding 
CLINIC_ID Text ID number used within HIV clinics to 
identify individual 
N/A 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC database. 
N/A 
N_HEPTEST Numeric  The specific hepatitis test which was 1= Hep A antibody (total) 
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Field Name Data Type Description Relevant coding 
(1-14) conducted 2= Hepatitis B surface antigen 
3= Hepatitis B surface antibody 
4= Hepatitis B core antibody 
(total) 
5= Hepatitis B e antigen 
6= Hepatitis B e antibody 
7= Hepatitis C antibody 
8= Hepatitis C RNA 
9 = Hepatitis B core antibody 
(IgM) 
10 = Hepatitis A antibody (IgM) 
11 = Hepatitis B DNA 
12 = Hepatitis D antibody (total) 
13 = Hepatitis B surface antigen 
titre 
14 = Hepatitis D antibody (IgM) 
98 = Other 
99= Unknown 
N_HEPDATE Date Date on which hepatitis test was 
conducted 
N/A 
N_HEPRESULT Numeric Result of hepatitis test 
 
0=negative 
1= positive 
2=indeterminate/weakly 
reactive/equivocal 
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Field Name Data Type Description Relevant coding 
N_HVAL Numeric The value of quantitative tests for 
HBV-DNA and HCV-RNA 
N/A 
N_HVAL_UNIT Text The unit used for measuring 
quantitative DNA and RNA tests. 
N/A 
 
Table V.5 Hepatitis C virus genotype 
Field Name Data Type Description Relevant coding 
CLINIC_ID Text ID number used within HIV clinics to 
identify individual 
N/A 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC database. 
N/A 
D_GENO Date/Time Date genotype reported.  N/A 
HCV_GENO Text Genotype N/A 
HCV_SUBGENO Text Subtype N/A 
 
Table V.6 Acute HCV 
Field Name Data Type Description Relevant coding 
CLINIC_ID Text ID number used within HIV clinics to 
identify individual 
N/A 
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Field Name Data Type Description Relevant coding 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC database. 
N/A 
ACUTE_HCV Numeric Mention in clinical notes that an 
individual was diagnosed with acute 
HCV infection 
1 = diagnosed with acute 
infection 
 
 
Table V.7 Alpha-feto protein tests 
Field Name Data Type Description Relevant coding 
CLINIC_ID Text ID number used within HIV clinics to 
identify individual 
N/A 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC database. 
N/A 
AFP_DATE Date Date of AFP test N/A 
AFP_RESULT Numeric Result of test (quantitative) N/A 
AFP_UNIT Text Units of measurement N/A 
 
Table V.8 Prothrombin time tests 
Field Name Data Type Description Relevant coding 
Clinic_ID Text ID number used within HIV clinics to 
identify individual 
N/A 
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Field Name Data Type Description Relevant coding 
Centre Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC database. 
N/A 
PT_DATE Date Date of prothrombin time test N/A 
PT_RESULT Numeric Result of test in seconds N/A 
 
Table V.9 International Normalised Ratio (INR) tests 
Field Name Data Type Description Relevant coding 
CLINIC_ID Text ID number used within HIV clinics to 
identify individual 
N/A 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC database. 
N/A 
INR_DATE Date Date of INR test N/A 
INR_RESULT Numeric Result of INR test  N/A 
 
Table V.10 Results of liver imaging 
Field Name Data Type Description Relevant coding 
CLINIC_ID Text ID number used within HIV clinics to 
identify individual 
N/A 
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Field Name Data Type Description Relevant coding 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC database. 
N/A 
SCAN Numeric The technique used to assess the 
liver 
1 = US scan 
2 = CT scan 
3 = MRI scan 
4 = ultrasound elastography 
SCAN_DATE Date Date of scan N/A 
SCAN_RESULT Text Result of scan N/A 
 
Table V.11 Liver biopsies 
Field Name Data Type Description Relevant coding 
CLINIC_ID Text ID number used within HIV clinics to 
identify individual 
N/A 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC database. 
N/A 
BIOPSY_DATE Date Date if biopsy N/A 
BIOPSY_RESULT Text Result of biopsy N/A 
Table V.12 FibroScans® 
Field Name Data Type Description Relevant coding 
CLINIC_ID Text ID number used within HIV clinics to 
identify individual 
N/A 
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Field Name Data Type Description Relevant coding 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC database 
N/A 
FIBROSCAN_DATE Date Date of FibroScan® N/A 
FIBROSCAN_RESULT Numeric Result of FibroScan® (KPa) N/A 
FIBROSCAN_IQR Numeric IQR of FibroScan® result N/A 
FIBROSCAN_SR Numeric Success rate for FibroScan® (%) N/A 
 
Table V.13 Hepatitis specific treatment 
Field Name Data Type Description Relevant coding 
CLINIC_ID Text ID number used within HIV clinics to 
identify individual 
N/A 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC database 
N/A 
HEPDRUG Numeric The specific drug used to treat 
hepatitis infection 
1 = Pegylated-interferon 
2 = Ribavirin 
3 = Adefovir 
4 = Entecavir 
5 = IFN 
6 = Telaprevir 
7 = Sofosbuvir 
8 = Boceprevir 
10 = Any other directly acting 
agent 
HEPDRUG_DOSE Text Dose of drug given N/A 
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Field Name Data Type Description Relevant coding 
HEPDRUG_FREQ Text Weekly, daily, twice daily N/A 
HEPDRUG_START Date Date of starting drug N/A 
HEPDRUG_STOP Date Date of Stopping drug N/A 
HEPDRUG_STOP_REASON Numeric Coded reason for stopping 
See codes ion data cleaning notes 
1 =  Completed course of 
treatment 
2 =  Lack of efficacy (relapse) 
3 =  Lack of efficacy(non-
response) 
4 = Side effects 
5 = Unable to adhere to regimen 
6 = Patient lost to follow-up 
7 = Patient choice 
8 = Drug interaction 
9 = Early response 
10 = Other illness 
11 = Patient died 
12 = Treatment break 
REASON_STOP_SIDEEFFECT Text Where the reason for stopping was 
a side effect, the specific side effect 
which was stated 
N/A 
HEP_RX_NOTES Text Any additional information on 
treatment, time of treatment or 
treatment response  
N/A 
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Table V.14 Complications of liver disease 
Field Name Data Type Description Relevant coding 
CLINIC_ID Text ID number used within HIV clinics 
to identify individual 
N/A 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC 
database. 
N/A 
COMPLICATION Numeric Complications of liver disease 
which were mentioned in clinical 
notes 
 
1 = Ascites 
2 = Portal Hypertension 
3 = Hematemesis 
4 = Endoscopy with varices 
5 = Encephalopathy 
6 = Hepatoma 
COMPLICATION_DATE Date Date when complication was 
diagnosed 
N/A 
 
Table V.15 Liver transplants 
Field Name Data Type Description Relevant coding 
CLINIC_ID Text ID number used within HIV clinics 
to identify individual 
N/A 
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Field Name Data Type Description Relevant coding 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC 
database. 
N/A 
TRANSPLANT_REFER Numeric Evidence in the clinical notes that 
the patient has been referred for a 
liver transplant assessment 
1 = Patient has been referred for 
a liver transplant 
TRANSPLANT_REFER_DATE Date Date patient was referred for liver 
transplant 
N/A 
TRANSPLANT Numeric Evidence in the clinical notes that 
the patient has received a liver 
transplant 
1 = patient has received a liver 
transplant 
TRANSPLANT_DATE Date Date liver transplant occurred N/A 
 
Table V.16 Deaths 
Field Name Data Type Description Relevant coding 
CLINIC_ID Text ID number used within HIV clinics 
to identify individual 
N/A 
CENTRE Numeric  
(3 digits) 
Centre where data was collected.  
Using same codes as MRC 
database. 
N/A 
DIED Numeric Evidence in the clinical notes that 
patient has died 
1 = patient is known to have died 
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Field Name Data Type Description Relevant coding 
DEATH_DATE Date Date patient died N/A 
DEATH_CAUSE Text Cause of death as reported in 
clinical notes  
N/A 
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Appendix VI  Independent predictors of HBsAg using three methods of defining HBsAg status 
 
 AOR and 95 % CI from multivariable model1 
Ever positive Most recent test is positive Positive according to algorithm 
OR (95% CI) P value OR (95%CI) P value OR (95% CI) P value 
Age (per 10 years) 1.01 (0.96-1.07) 0.73 1.01 (0.95-1.07) 0.75 1.00 (0.95-1.06) 0.89 
HIV exposure group       
MSM 1 - 1 - 1 - 
IDU 0.64 (0.50-0.81) 0.0002 0.79 (0.62-1.02) 0.08 0.78 (0.61-1.00) 0.05 
Male heterosexual 1.06 (0.90-1.25) 0.48 1.13 (0.95-1.34) 0.18 1.09 (0.92-1.30) 0.33 
Female heterosexual 0.49 (0.41-0.58) <0.0001 0.52 (0.43-0.62) <0.0001 0.50 (0.42-0.60) <0.0001 
Other/ unknown 0.90 (0.73-1.11) 0.34 0.99 (0.80-1.23) 0.95 0.95 (0.77-1.18) 0.64 
Ethnicity       
White 1 - 1 - 1 - 
Black African 2.24 (1.93-2.67) <0.0001 2.45 (2.07-2.90) <0.0001 2.52 (2.13-2.99) <0.0001 
Other black  1.56 (1.26-1.94) <0.0001 1.55 (1.23-1.96) 0.0002 1.57 (1.24-1.98) 0.0001 
Other/ Unknown 1.53 (1.33-1.76) <0.0001 1.53 (1.31-1.78) <0.0001 1.58 (1.36-1.84) <0.0001 
Year of entry into cohort       
1996-1998 1 - 1 - 1 - 
1999-2001 0.82 (0.70-0.95) 0.01 0.84 (0.71-0.99) 0.04 0.82 (0.69-0.96) 0.01 
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 AOR and 95 % CI from multivariable model1 
Ever positive Most recent test is positive Positive according to algorithm 
OR (95% CI) P value OR (95%CI) P value OR (95% CI) P value 
2002-2004 0.72 (0.62-0.82) <0.0001 0.80 (0.69-0.93) 0.004 0.79 (0.68-0.92) 0.002 
2005-2007 0.71 (0.61-0.81) <0.0001 0.73 (0.62-0.85) <0.0001 0.73 (0.62-0.95) <0.0001 
2008-2011 0.63 (0.54-0.73) <0.0001 0.84 (0.72-0.99) 0.03 0.84 (0.72-0.98) 0.03 
Nadir CD4 (per 100cells/mm3) 0.89 (0.87-0.93) <0.0001 0.90 (0.87-0.94) <0.0001 0.90 (0.87-0.94) <0.0001 
HCV co-infection       
Not infected 1 - 1 - 1 - 
Infected 3.44 (3.03-3.90) <0.0001 3.02 (2.62-3.47) <0.0001 3.19 (2.78-3.66) <0.0001 
Not tested 1.71 (1.38-2.11) <0.0001 2.09 (1.69-2.57) <0.0001 2.04 (1.65-2.52) <0.0001 
On HBV active ARVs 1.25 (1.12-1.41) 0.0001 1.25 (1.11-1.42) 0.0004 1.25 (1.11-1.42) 0.0004 
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Appendix VII Conference presentations arising from this work 
 
1. Thornton A, Gilson R and Sabin C on behalf of the UK Collaborative HIV cohort study.    
A Method for ascertaining hepatitis B infection status in HIV cohorts in the presence of 
missing and/or inconsistent data: An example from the UK CHIC study.  Poster 
presentation.  International Workshop on HIV Observational Databases (IWHOD), 
2013.  Cavtat, Croatia. 
 
2. Thornton A, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Gilson R, Jose S, 
Main J, Nelson M, Rodger A, Taylor C and Sabin C.  Viral hepatitis testing patterns 
among HIV-positive individuals in the UK Collaborative HIV cohort (UK CHIC) study.  
Poster presentation.  Third Joint conference of the British HIV Association (BHIVA) with 
the British Association for Sexual Health and HIV (BASHH), 2014, Liverpool, UK. 
 
3. Thornton A, Bhagani S, Burroughs A, Chadwick D, Dunn D, Fisher M, Gilson R, Jose S, 
Main J, , Rodger A, Sabin C, Taylor C and Nelson M.  Hepatitis B infection among 
individuals attending for care in the UK Collaborative HIV cohort (CHIC) study.  Poster 
presentation.  Third Joint conference of the British HIV Association (BHIVA) with the 
British Association for Sexual Health and HIV (BASHH), 2014, Liverpool, UK. 
 
4. Thornton A, Sabin C, Jose S, Bhagani S, Chadwick D, Dunn D, Fisher M, Gilson R, Main J, 
Rodger A, Taylor C, Nelson M.  Treatment for hepatitis C infection in the UK 
Collaborative HIV cohort (UK CHIC) study.  Oral presentation.  Highly Commended.  21st 
Annual Conference of the British HIV Association (BHIVA), 2015.  Brighton, UK.   
 
5. Martin N, Hickman M, Nelson M, Thornton A, Sabin S, Lattimore S, Martin T, Cooke G, 
Delpech V, Ruf M, Thomson E and Vickerman P.  Understanding and preventing the 
HCV epidemic among men who have sex with men in the UK: a mathematical 
modelling analysis.  Oral presentation. 50th Annual Meeting of the European 
Association for the Study of the Liver (EASL), 2015.  Vienna, Austria.  
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